Please type a plus sign (+) inside this box → [+]

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	TPI-350C1
First Inventor	Örn Almarsson
Title	Pharmaceutical Co-Crystal Compositions
Express Mail Label No.	EU082848285US

03916 U.S. PTO 10/660202 09/11/03

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

1. [X] Fee Transmittal Form (e.g. PTO/SB/17) *(Submit an original and a duplicate for fee processing)*
2. [X] Applicant claims small entity status. See 37 CFR 1.27
3. [X] Specification [Total Pages 437] *(preferred arrangement set forth below)*
   - Descriptive title of the invention
   - Cross Reference to Related Applications
   - Statement Regarding Fed Sponsored R & D
   - Reference to sequence listing, a table, or a computer program listing appendix
   - Background of the Invention
   - Brief Summary of the Invention
   - Brief Description of the Drawings *(if filed)*
   - Detailed Description
   - Claim(s)
   - Abstract of the Disclosure
4. [X] Drawing(s) (35 U.S.C. 113) [Total Sheets 66]
5. Oath or Declaration [Total Pages 2]
   a. [X] Newly executed (original or copy) (unsigned)
   b. [ ] Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional with Box 18 completed)*
      i. [ ] DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, 37 CFR 1.63(d)(2) and 1.33(b).
6. [X] Application Data Sheet. See 37 CFR 1.76
7. [ ] CD-ROM or CD-R in duplicate, large table or Computer Program *(Appendix)*
8. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
   a. [ ] Computer Readable Form (CRF)
   b. Specification Sequence Listing on:
      i. [ ] CD-ROM or CD-R (2 copies); or
      ii. [ ] paper
   c. [ ] Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. [ ] Assignment Papers (cover sheet & document(s))
10. [ ] 37 CFR 3.73(b) Statement [X] Power of Attorney *(when there is an assignee)*
11. [ ] English Translation Document *(if applicable)*
12. [ ] Information Disclosure Statement (IDS)/PTO-1449 [ ] Copies of IDS Citations
13. [ ] Preliminary Amendment
14. [X] Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
15. [ ] Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. [ ] Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. [X] Other: Cert. Of Express Mailing

18. If a CONTINUING APPLICATION, *check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:*

[ ] Continuation [ ] Divisional [ ] Continuation-in-Part (CIP) of prior application No.: _____

Prior application information: *Examiner:* _____ *Group Art Unit:* _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

[X] Customer Number or Bar Code Label 23557 or [ ] Correspondence address below

Name					
Address					
City		State		Zip Code	
Country		Telephone		Fax	

Name (Print/Type)	Frank C. Eisenschenk, Ph.D.	Registration No. (Attorney/Agent)	45,332
Signature		Date	September 11, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313.

DOCKET NO. TPI-350C1

FEE TRANSMITTAL FORM

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Sir:

Transmitted herewith for filing is the patent application of:

Inventors: Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

Entitled: Pharmaceutical Co-Crystal Compositions

☒ A Utility Patent Application Transmittal Form accompanies this Fee Transmittal Form.
☒ The Filing Fee is calculated below:

CLAIMS AS FILED

	Number filed	Number Extra	Rate	Fee
Basic Fee			$375.00	$ 375.00
Total Claims	37 – 20 =	17	x $9	$ 153.00
Independent Claims	20 – 3 =	17	x $84	$ 1,680.00
Presentation of Multiple Dependent Claim(s) ($140)				$ 0.00
			Total Filing Fee	$2,208.00

☒ Please charge $2,208.00 to Deposit Account No. 19-0065. Two copies of this sheet are enclosed.
☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required, or credit any overpayment, to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.
☒ This application is being mailed by Express Mail under 37 CFR 1.10 and the required certificate appears below.

September 11, 2003
Date

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D.

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR 1.10)

Express Mail No.: EU 082848285 US
EU082848285

Date of Deposit: September 11, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313.

Betty Audette
Name of person mailing paper

Betty Audette
Signature

Pharmaceutical Co-Crystal Compositions

INCORPORATION BY REFERENCE

This application claims the benefit of US Provisional Patent Application No. 60/451,213 filed on February 28, 2003; U.S. Provisional Patent Application No. 60/463,962, filed on April 18, 2003; and U.S. Provisional Application No. 60/487,064, filed on July 11, 2003 each of which incorporated herein by reference in its entirety. This application is also a continuation-in-part of PCT US03/XXXXX, filed on September 4, 2003 which is a continuation-in-part of U.S. Patent Application No. 10/378,956, filed March 1, 2003, which claims the benefit of U.S. Provisional Application No. 60/360,768, filed March 1, 2002; said PCT US03/XXXXX also claims the benefit of US Provisional Patent Application No. 60/451,213 filed on February 28, 2003; U.S. Provisional Patent Application No. 60/463,962, filed on April 18, 2003; and U.S. Provisional Application No. 60/487,064, filed on July 11, 2003. This application is also a continucation-in-part of U.S. Patent Application No. 10/637,829, filed August 8, 2003, which is a divisional of U.S. Patent Application No. 10/295,995, filed November 18, 2002, which is a continuation of U.S. Patent Application No.10/232,589, filed September 3, 2002, which claims the benefit of US Provisional Patent Application No. 60/406,974, filed August 30, 2002 and US Provisional Patent Application No.60/380,288, filed May 15, 2002 and US Provisional Patent Application No. 60/356,764, filed February 15, 2002. This application is also a continuation-in-part of US Patent Application No. 10/449,307, filed May 30, 2003 which claims the benefit of US Provisional Patent Application No. 60/463,962 filed April 18, 2003 and US Provisional Patent Application No. 60/444,315, filed January 31, 2003 and US Provisional Patent Application No. 60/439,282 filed January 10, 2003 and US Provisional Patent Application No. 60/384,152, filed May 31, 2002. This application is also a continuation-in-part of US Patent Application No. 10/601,092, filed June 20, 2003, which claims the benefit of US Provisional Patent Application No. 60/451,213, filed February 28, 2003. Each of these applications is hereby incorporated by reference in their entireties, including all figures, tables and formulae.

FIELD OF THE INVENTION

The present invention relates to co-crystal API-containing compositions, pharmaceutical compositions comprising such APIs, and methods for preparing the same.

BACKGROUND OF THE INVENTION

Active pharmaceutical ingredients (API or APIs (plural)) in pharmaceutical compositions can be prepared in a variety of different forms. Such APIs can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such APIs can also be prepared to have different physical forms. For example, the APIs may be amorphous, may have different crystalline polymorphs, or may exist in different solvation or hydration states. By varying the form of an API, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapour pressure, density, colour, and compressibility. Accordingly, variation of the crystalline state of an API is one of many ways in which to modulate the physical properties thereof.

It would be advantageous to have new forms of these APIs that have improved properties, in particular, as oral formulations. Specifically, it is desirable to identify improved forms of APIs that exhibit significantly improved properties including increased aqueous solubility and stability. Further, it is desirable to improve the processability, or preparation of pharmaceutical formulations. For example, needle-like crystal forms or habits of APIs can cause aggregation, even in compositions where the API is mixed with other substances, such that a non-uniform mixture is obtained. It is also desirable to increase the dissolution rate of API-containing pharmaceutical compositions in water, increase the bioavailability of orally-administered compositions, and provide a more rapid onset to therapeutic effect. It is also desirable to have a form of the API which, when administered to a subject, reaches a peak plasma level faster, has a longer lasting therapeutic plasma concentration, and higher overall exposure when compared to equivalent amounts of the API in its presently-known form.

NPC-UNIV-000004382
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 4 of 1101

SUMMARY OF THE INVENTION

It has now been found that new co-crystalline forms of APIs can be obtained which improve the properties of APIs as compared to such APIs in a non-co-crystalline state (free acid, free base, zwitter ions, salts, etc.).

Accordingly, in a first aspect, the present invention provides a co-crystal pharmaceutical composition comprising an API compound and a co-crystal former, such that the API and co-crystal former are capable of co-crystallizing from a solid or solution phase under crystallization conditions.

Another aspect of the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

(1) providing an API which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(2) providing a co-crystal former which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(3) grinding, heating or contacting in solution the API with the co-crystal former under crystallization conditions;

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition.

A further aspect of the present invention provides a process for the production of a pharmaceutical composition, which comprises:

(1) grinding, heating or contacting in solution an API compound with a co-crystal former, under crystallization conditions, so as to form a solid phase;

(2) isolating co-crystals comprising the API and the co-crystal former; and

NPC-UNIV-000004383
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 5 of 1101

(3) incorporating the co-crystals into a pharmaceutical composition.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which comprises:

(1) providing (*i*) an API or a plurality of different APIs, and (*ii*) a co-crystal former or a plurality of different co-crystal formers, wherein at least one of the APIs and the co-crystal formers is provided as a plurality thereof;

(2) isolating co-crystals comprising the API and the co-crystal former; and

(3) incorporating the co-crystals into a pharmaceutical composition.

Solubility Modulation

In a further aspect, the present invention provides a process for modulating the solubility of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dissolution Modulation

In a further aspect, the present invention provides a process for modulating the dissolution of an API, whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased or decreased, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In one embodiment, the dissolution of the API is increased.

Bioavailability Modulation

In a further aspect, the present invention provides a process for modulating the bioavailability of an API, whereby the AUC is increased, the time to T_{max} is reduced, the

length of time the concentration of the API is above ½ T_{max} is increased, or C_{max} is increased, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dose Response Modulation

In a further aspect the present invention provides a process for improving the linearity of a dose response of an API, which process comprises:

(1) grinding, heating, or contacting in solution an API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Increased Stability

In a still further aspect the present invention provides a process for improving the stability of a pharmaceutical salt, which process comprises:

(1) grinding, heating or contacting in solution the pharmaceutical salt with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Difficult to Salt or Unsaltable Compounds

In a still further aspect the present invention provides a process for making co-crystals of difficult to salt or unsaltable APIs, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Decreasing Hygroscopicity

In a still further aspect the present invention provides a method for decreasing the hygroscopicity of an API, which method comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Crystallizing Amorphous Compounds

In a still further embodiment aspect the present invention provides a process for crystallizing an amorphous compound, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Decreasing Form Diversity

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Morphology Modulation

In a still further embodiment aspect the present invention provides a process for modifying the morphology of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In a further aspect, the present invention provides a co-crystal composition comprising a co-crystal, wherein said co-crystal comprises an API compound and a co-crystal former. In further embodiments the co-crystal has an improved property as compared to the free form (including a free acid, free base, zwitter ion, hydrate, solvate, etc.) or a salt (which includes salt hydrates and solvates). In further embodiments, the improved property is

selected from the group consisting of: increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a crystalline form of a normally amorphous compound, a crystalline form of a difficult to salt or unsaltable compound, decreased form diversity, more desired morphology, or other property described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 PXRD pattern for a co-crystal of carbamazepine and saccharin (Form I).

Fig. 2 DSC thermogram for a co-crystal of carbamazepine and saccharin (Form I).

Fig. 3 PXRD pattern for a co-crystal of carbamazepine and nicotinamide (Form I).

Fig. 4 DSC thermogram for a co-crystal of carbamazepine and nicotinamide (Form I).

Fig. 5 PXRD pattern for a co-crystal of carbamazepine and trimesic acid (Form I).

Fig. 6 PXRD pattern for a co-crystal of topiramate and 18-crown-6.

Fig. 7 DSC thermogram for a co-crystal of topiramate and 18-crown-6.

Fig. 8 PXRD pattern for a co-crystal of olanzapine and nicotinamide (Form I).

Fig. 9 DSC thermogram for a co-crystal of olanzapine and nicotinamide (Form I).

Fig. 10 PXRD pattern for a co-crystal of celecoxib and 18-crown-6.

Fig. 11 DSC thermogram for a co-crystal of celecoxib and 18-crown-6.

Fig. 12 PXRD pattern for a co-crystal of itraconazole and succinic acid.

Fig. 13 DSC thermogram for a co-crystal of itraconazole and succinic acid.

Fig. 14 PXRD pattern for a co-crystal of itraconazole and fumaric acid.

Fig. 15 DSC thermogram for a co-crystal of itraconazole and fumaric acid.

Fig. 16 PXRD pattern for a co-crystal of itraconazole and tartaric acid

Fig. 17 DSC thermogram for a co-crystal of itraconazole and tartaric acid.

Fig. 18 PXRD pattern for a co-crystal of itraconazole and malic acid.

Fig. 19 DSC thermogram for a co-crystal of itraconazole and malic acid.

Fig. 20 PXRD pattern for a co-crystal of itraconazoleHCl and tartaric acid.

Fig. 21 DSC thermogram for a co-crystal of itraconazoleHCl and tartaric acid.

NPC-UNIV-000004387
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 9 of 1101

Fig. 22 PXRD pattern for a co-crystal of modafinil and malonic acid.

Fig. 23 PXRD pattern for a co-crystal of modafinil and benzamide.

Fig. 24 PXRD pattern for a co-crystal of modafinil and mandelic acid.

Fig. 25 PXRD pattern for a co-crystal of modafinil and glycolic acid.

Fig. 26 PXRD pattern for a co-crystal of modafinil and fumaric acid.

Fig. 27 Dissolution profile for a co-crystal of celecoxib:nicotinamide vs. celecoxib free acid.

Fig. 28 Dissolution profile for co-crystals of itraconazole:succinic acid, itraconazle:tartaric acid and itraconazole:malic acid vs. itraconazole free base.

Fig. 29 Hygroscopicity profile for a co-crystal of celecoxib:nicotinamide vs. celecoxib sodium.

Fig. 30 PXRD pattern for a co-crystal of olanzapine and nicotinamide (Form II).

Fig. 31 PXRD pattern for a co-crystal of olanzapine and nicotinamide (Form III).

Fig. 32A-D Packing diagrams and crystal structure of olanzapine and nicotinamide (Form III). Figure 32A depicts the molecular structure of the olanzapine-nicotinamide-H_2O-IPOAc crystal. In Figure 32C, the olanzapine molecules occupy the spaces shown and are hydrogen bonded to the water molecules. The arrangement of the olanzapine molecules is similar to that observed from the methanol solvate and the published structures for the hydrates; the water molecules bridge the olanzapine moieties resulting in hydrogen-bonded zigzag sheets (see Figure 32D).

Fig. 33 DSC thermogram for a co-crystal of 5-fluorouracil and urea.

Fig. 34 TGA thermogram for a co-crystal of 5-fluorouracil and urea.

Fig. 35 Raman spectrum for a co-crystal of 5-fluorouracil and urea.

Fig. 36 PXRD pattern for a co-crystal of 5-fluorouracil and urea.

Fig. 37 PXRD pattern for a co-crystal of hydrochlorothiazide and nicotinic acid.

Fig. 38 PXRD pattern for a co-crystal of hydrochlorothiazide and 18-crown-6.

Fig. 39 PXRD pattern for a co-crystal of hydrochlorothiazide and piperazine.

Fig. 40 DSC thermogram for a co-crystal of modafinil and malonic acid.

Fig. 41 TGA thermogram for a co-crystal of modafinil and malonic acid.

Fig. 42 Raman spectrum for a co-crystal of modafinil and malonic acid.

Fig. 43 PXRD pattern for a co-crystal of modafinil and maleic acid.

Fig. 44A–B An acetaminophen 1-D polymeric chain and a co-crystal of acetaminophen and 4,4'-bipyridine, respectively.

NPC-UNIV-000004388

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 10 of 1101

Fig. 45A-B Pure phenytoin and a co-crystal with phenytoin and pyridone, respectively.

Fig. 46A-D Pure aspirin and the corresponding crystal structure are shown in Figures 46A and 46B, respectively. Figures 46C and 46D show the supramolecular entity containing the synthon and corresponding co-crystal of aspirin and 4,4'-bipyridine, respectively.

Fig. 47A-D Pure ibuprofen and the corresponding crystal structure are shown in Figures 7A and 7B, respectively. Figures 7C and 7D show the supramolecular entity containing the synthon and corresponding co-crystal of ibuprofen and 4,4'-bipyridine, respectively.

Fig. 48A-D Pure flurbiprofen and the corresponding crystal structure are shown in Figures 48A and 48B, respectively. Figures 5C and 5D show the supramolecular synthon and corresponding co-crystal of flurbiprofen and 4,4'-bipyridine, respectively.

Fig. 49A-B The supramolecular entity containing the synthon and the corresponding co-crystal structure of flurbiprofen and trans-1,2-bis(4-pyridyl)ethylene, respectively.

Fig. 50A-B The crystal structure of pure carbamazepine and the co-crystal structure of carbamazepine and *p*-phthalaldehyde, respectively.

Fig. 51 The co-crystal structure of carbamazepine and nicotinamide (Form II).

Fig. 52 The co-crystal structure of carbamazepine and saccharin (Form II).

Fig. 53A-C The chemical structures of ibuprofen, flurbiprofen, and aspirin, respectively.

Fig. 54A-B The crystal structure of carbamazepine and the co-crystal structure of carbamazepine and 2,6-pyridinedicarboxylic acid, respectively.

Fig. 55A-B The crystal structure of carbamazepine and the co-crystal structure of carbamazepine and 5-nitroisophthalic acid, respectively.

Fig. 56A-B The crystal structure of carbamazepine and the co-crystal structure of carbamazepine and 1,3,5,7-adamantanetetracarboxylic acid, respectively.

Fig. 57A-B The crystal structure of carbamazepine and the co-crystal structure of carbamazepine and benzoquinone, respectively.

Fig. 58A-B The crystal structure of carbamazepine and the co-crystal structure of carbamazepine and trimesic acid (Form II), respectively.

Fig. 59 PXRD diffractogram for a co-crystal of celecoxib and nicotinamide.

Fig. 60 DSC thermogram for a co-crystal of celecoxib and nicotinamide.

NPC-UNIV-000004389

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 11 of 1101

Fig. 61 TGA thermogram for a co-crystal of celecoxib and nicotinamide.

Fig. 62 Raman spectrum for a co-crystal of celecoxib and nicotinamide.

Fig. 63 Hydrogen-bonding motifs observed in co-crystals.

DETAILED DESCRIPTION OF THE INVENTION

The term "co-crystal" as used herein means a crystalline material comprised of two or more unique solids at room temperature, each containing distinctive physical characteristics, such as structure, melting point and heats of fusion, with the exception that, if specifically stated, the API may be a liquid at room temperature. The co-crystals of the present invention comprise a co-crystal former H-bonded to an API. The co-crystal former may be H-bonded directly to the API or may be H-bonded to an additional molecule which is bound to the API. The additional molecule may be H-bonded to the API or bound ionically or covalently to the API. The additional molecule could also be a different API. Solvates of API compounds that do not further comprise a co-crystal former are not co-crystals according to the present invention. The co-crystals may however, include one or more solvate molecules in the crystalline lattice. That is, solvates of co-crystals, or a co-crystal further comprising a solvent or compound that is a liquid at room temperature, is included in the present invention, but crystalline material comprised of only one solid and one or more liquids (at room temperature) are not included in the present invention, with the previously noted exception of specifically stated liquid APIs. The co-crystals may also be a co-crystal between a co-crystal former and a salt of an API, but the API and the co-crystal former of the present invention are constructed or bonded together through hydrogen bonds. Other modes of molecular recognition may also be present including, pi-stacking, guest-host complexation and van der Waals interactions. Of the interactions listed above, hydrogen-bonding is the dominant interaction in the formation of the co-crystal, (and a required interaction according to the present invention) whereby a non-covalent bond is formed between a hydrogen bond donor of one of the moieties and a hydrogen bond acceptor of the other. Hydrogen bonding can result in several different intermolecular configurations. For example, hydrogen bonds can result in the formation of dimers, linear chains, or cyclic structures. These configurations can further include extended (two-dimensional) hydrogen bond networks and isolated triads (Fig. 63). An alternative embodiment provides for a co-crystal wherein the co-crystal former is a second API. In another embodiment, the co-crystal former is not an API. In another embodiment the co-crystal

comprises two co-crystal formers. For purposes of the present invention, the chemical and physical properties of an API in the form of a co-crystal may be compared to a reference compound that is the same API in a different form. The reference compound may be specified as a free form, or more specifically, a free acid, free base, or zwitter ion; a salt, or more specifically for example, an inorganic base addition salt such as sodium, potassium, lithium, calcium, magnesium, ammonium, aluminum salts or organic base addition salts, or an inorganic acid addition salts such as HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts or an organic acid addition salt such as acetic, proprionic, pyruvic, malanic, succinic, malic, maleic, fumaric, tartaric, citric, benzoic, methanesulfonic, ethanesulforic, stearic or lactic acid addition salt; an anhydrate or hydrate of a free form or salt, or more specifically, for example, a hemihydrate, monohydrate, dihydrate, trihydrate, quadrahydrate, pentahydrate; or a solvate of a free form or salt. For example, the reference compound for an API in salt form co-crystallized with a co-crystal former can be the API salt form. Similarly, the reference compound for a free acid API co-crystallized with a co-crystal former can be the free acid API. The reference compound may also be specified as crystalline or amorphous.

According to the present invention, the co-crystals can include an acid addition salt or base addition salt of an API. Acid addition salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartatic acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, madelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutaric acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. Base addition salts include, but are not limited to, inorganic bases such as sodium, potassium, lithium, ammonium, calcium and magnesium salts, and organic bases such as primary, secondary and tertiary amines (e.g. isopropylamine, trimethyl amine, diethyl amine,

NPC-UNIV-000004391
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 13 of 1101

tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, and N-ethylpiperidine).

The ratio of API to co-crystal former may be stoichiometric or non-stoichiometric according to the present invention. For example, 1:1, 1:1.5 and 1:2 ratios of API:co-crystal former are acceptable.

It has surprisingly been found that when an API and a selected co-crystal former are allowed to form co-crystals, the resulting co-crystals give rise to improved properties of the API, as compared to the API in a free form (including free acids, free bases, and zwitter ions, hydrates, solvates, etc.), or an acid or base salt thereof particularly with respect to: solubility, dissolution, bioavailability, stability, Cmax, Tmax, processability, longer lasting therapeutic plasma concentration, hygroscopicity, crystallization of amorphous compounds, decrease in form diversity (including polymorphism and crystal habit), change in morphology or crystal habit, etc. For example, a co-crystal form of an API is particularly advantageous where the original API is insoluble or sparingly soluble in water. Additionally, the co-crystal properties conferred upon the API are also useful because the bioavailability of the API can be improved and the plasma concentration and/or serum concentration of the API can be improved. This is particularly advantageous for orally-administrable formulations. Moreover, the dose response of the API can be improved, for example by increasing the maximum attainable response and/or increasing the potency of the API by increasing the biological activity per dosing equivalent.

Accordingly, in a first aspect, the present invention provides a pharmaceutical composition comprising a co-crystal of an API and a co-crystal former, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions or from the solid-state, for example, through grinding or heating. In another aspect, the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine anda co-crystal

NPC-UNIV-000004392
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 14 of 1101

former which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, or a functional group in a Table herein, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

The co-crystals of the present invention are formed where the API and co-crystal former are bonded together through hydrogen bonds. Other non-covalent interactions, including pi-stacking and van der Waals interactions, may also be present.

In one embodiment, the co-crystal former is selected from the co-crystal formers of Table I and Table II. In other embodiments, the co-crystal former of Table I is specified as a Class 1, Class 2, or Class 3 co-crystal former (see column labeled "class" Table I). In another embodiment, the difference in pK_a value of the co-crystal former and the API is less than 2. In other embodiments, the difference in pK_a values of the co-crystal former and API is less than 3, less than 4, less than 5, between 2 and 3, between 3 and –4, or between 4 and 5. Table I lists multiple pK_a values for co-crystal formers having multiple functionalities. It is readily apparent to one skilled in the art the particular functional group corresponding to a particular pK_a value.

In another embodiment the particular functional group of a co-crystal former interacting with the API is specified (see for example Table I, columns labeled "Functionality" and "Molecular Structure" and the column of Table II labeled "Co-Crystal Former Functional Group"). In a further embodiment the functional group of the API interacting with the co-crystal former functional group is specified (see, for example, Tables II and III).

In another embodiment, the co-crystal comprises more than one co-crystal former. For example, two, three, four, five, or more co-crystal formers can be incorporated in a co-crystal with an API. Co-crystals which comprise two or more co-crystal formers and an API are bound together via hydrogen bonds. In one embodiment, incorporated co-crystal formers are hydrogen bonded to the API molecules. In another embodiment, co-crystal formers are hydrogen bonded to either the API molecules or the incorporated co-crystal formers.

NPC-UNIV-000004393
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 15 of 1101

In a further embodiment, several co-crystal formers can be contained in a single compartment, or kit, for ease in screening an API for potential co-crystal species. The co-crystal kit can comprise 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or more of the co-crystal formers in Tables I and II. The co-crystal formers are in solid form and in an array of individual reaction vials such that individual co-crystal formers can be tested with one or more APIs by one or more crystallization methods or multiple co-crystal formers can be easily tested against one or more compounds by one or more crystallization methods. The crystallization methods include, but are not limited to, melt recrystallization, grinding, milling, standing, co-crystal formation from solution by evaporation, thermally driven crystallization from solution, co-crystal formation from solution by addition of anti-solvent, co-crystal formation from solution by vapor-diffusion, co-crystal formation from solution by drown-out, co-crystal formation from solution by any combination of the above mentioned techniques, co-crystal formation by co-sublimation, co-crystal formation by sublimation using a Knudsen cell apparatus, co-crystal formation by standing the desired components of the co-crystal in the presence of solvent vapor, co-crystal formation by slurry conversion of the desired components of the co-crystal in a solvent or mixtures of solvents, or co-crystal formation by any combination of the above techniques in the presence of additives, nucleates, crystallization enhancers, precipitants, chemical stabilizers, or anti-oxidants. The co-crystallization kits can be used alone or as part of larger crystallization experiments. For example, kits can be constructed as single co-crystal former single well kits, single co-crystal former multi-well kits, multi-co-crystal former single well kits, or multi-co-crystal former multi-well kits.

In a further embodiment, the API is selected from an API of Table IV or elsewhere herein. For pharmaceuticals listed in Table IV, co-crystals can comprise such APIs in free form (i.e. free acid, free base, zwitter ion), salts, solvates, hydrates, or the like. For APIs in Table IV listed as salts, solvates, hydrates, and the like, the API can either be of the form listed in Table IV or its corresponding free form, or of another form that is not listed. Table IV includes the CAS number, chemical name, or a PCT or patent reference (each incorporated herein in their entireties). In further embodiments, the functional group of the particular API interacting with the co-crystal former is specified. A specific functional group of a co-crystal former, a specific co-crystal former, or a specified functional group or a specific co-crystal former interacting with the particular API may also be specified. It is noted that for Table II, the co-crystal

NPC-UNIV-000004394
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 16 of 1101

former, and optionally the specific functionality, and each of the listed corresponding interacting groups are included as individual species of the present invention. Thus, each specific combination of a co-crystal former and one of the interacting groups in the same row may be specified as a species of the present invention. The same is true for other combinations as discussed in the Tables and elsewhere herein.

In each process according to the invention, there is a need to contact the API with the co-crystal former. This may involve grinding the two solids together or melting one or both components and allowing them to recrystallize. This may also involve either solubilizing the API and adding the co-crystal former, or solubilizing the co-crystal former and adding the API. Crystallization conditions are applied to the API and co-crystal former. This may entail altering a property of the solution, such as pH or temperature and may require concentration of the solute, usually by removal of the solvent, typically by drying the solution. Solvent removal results in the concentration of both API and co-crystal former increasing over time so as to facilitate crystallization. Once the solid phase comprising any crystals is formed, this may be tested as described herein.

The co-crystals obtained as a result of such process steps may be readily incorporated into a pharmaceutical composition by conventional means. Pharmaceutical compositions in general are discussed in further detail below and may further comprise a pharmaceutically-acceptable diluent, excipient or carrier.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

(1) providing an API which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine or of Table II or III;

(2) providing a co-crystal former which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile,

NPC-UNIV-000004395
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 17 of 1101

diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine or of Table I, II, or III;

(3) grinding, heating or contacting in solution the API with the co-crystal former under crystallization conditions;

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition.

In a still further aspect the present invention provides a process for the production of a pharmaceutical composition, which comprises:

(1) grinding, heating or contacting in solution an API with a co-crystal former, under crystallization conditions, so as to form a solid phase;

(2) isolating co-crystals comprising the API and the co-crystal former; and

(3) incorporating the co-crystals into a pharmaceutical composition.

Assaying the solid phase for the presence of co-crystals of the API and the co-crystal former may be carried out by conventional methods known in the art. For example, it is convenient and routine to use powder X-ray diffraction techniques to assess the presence of co-crystals. This may be affected by comparing the spectra of the API, the crystal former and putative co-crystals in order to establish whether or not true co-crystals had been formed. Other techniques, used in an analogous fashion, include differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and Raman spectroscopy. Single crystal X-ray diffraction is especially useful in identifying co-crystal structures.

In a further aspect, the present invention therefore provides a process of screening for co-crystal compounds, which comprises:

(1) providing (*i*) an API compound, and (*ii*) a co-crystal former; and

(2) screening for co-crystals of APIs with co-crystal formers by subjecting each combination of API and co-crystal former to a step comprising:

(a) grinding, heating or contacting in solution the API with the co-crystal former under crystallization conditions so as to form a solid phase; and

(b) isolating co-crystals comprising the API and the co-crystal former.

NPC-UNIV-000004396
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 18 of 1101

An alternative embodiment is drawn to a process of screening for co-crystal compounds, which comprises:

(1) providing (*i*) an API or a plurality of different APIs, and (*ii*) a co-crystal former or a plurality of different co-crystal formers, wherein at least one of the API and the co-crystal former is provided as a plurality thereof; and

(2) screening for co-crystals of APIs with co-crystal formers by subjecting each combination of API and co-crystal former to a step comprising

(a) grinding, heating or contacting in solution the API with the co-crystal former under crystallization conditions so as to form a solid phase; and

(b) isolating co-crystals comprising the API and the co-crystal former.

Solubility Modulation

In a further aspect, the present invention provides a process for modulating the solubility of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In one embodiment, the solubility of the API is modulated such that the aqueous solubility is increased. Solubility of APIs may be measured by any conventional means such as chromatography (e.g., HPLC) or spectroscopic determination of the amount of API in a saturated solution of the API, such as UV-spectroscopy, IR-spectroscopy, Raman spectroscopy, quantitative mass spectroscopy, or gas chromatography.

In another aspect of the invention, the API may have low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to 10 mg/mL, when measured at 37 degrees C, and preferably less than or equal to 5 mg/mL or 1 mg/mL. Low aqueous solubility can further be specifically defined as less than or equal to 900, 800, 700, 600, 500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20 micrograms/mL, or further 10, 5 or 1 micrograms/mL, or further 900, 800, 700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or 10 ng/mL, or less than 10 ng/mL when measured at 37 degrees C. Aqueous solubility can also be specified as less than 500, 400, 300, 200, 150, 100, 75, 50 or 25 mg/mL. As embodiments of the present invention, solubility can

NPC-UNIV-000004397
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 19 of 1101

be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100, 200, 300, 500, 750, 1000, 5000, or 10,000 times by making a co-crystal of the reference form (e.g., crystalline or amorphous free acid, free base or zwitter ion, hydrate or solvate), or a salt thereof. Further aqueous solubility can be measured in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) rather than water. SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 20 mM HCl to obtain a solution with a final pH=1.7 (SIF is 0.68% monobasic potassium phosphate, 1% pancreatin, and sodium hydroxide where the pH of the final solution is 7.5). The pH of the solvent used may also be specified as 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12, or any pH in between successive values.

Examples of embodiments includes: co-crystal compositions with an aqueous solubility, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the reference form, co-crystal compositions with a solubility in SGF that is increased at least 5 fold over the reference form, co-crystal compositions with a solubility in SIF that is increased at least 5 fold over the reference form.

Dissolution Modulation

In another aspect of the present invention, the dissolution profile of the API is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which API solids dissolve in a dissolution medium. For APIs whose absorption rates are faster than the dissolution rates (e.g., steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, APIs that are not dissolved before they are removed from intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of APIs that are poorly soluble. Because of this factor, the dissolution rate of APIs in solid dosage forms is an important, routine, quality control parameter used in the API manufacturing process.

Dissolution rate = $K S (C_s-C)$

NPC-UNIV-000004398
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 20 of 1101

where K is dissolution rate constant, S is the surface area, C_s is the apparent solubility, and C is the concentration of API in the dissolution medium.

For rapid API absorption, C_s-C is approximately equal to C_s

The dissolution rate of APIs may be measured by conventional means known in the art.

The increase in the dissolution rate of a co-crystal, as compared to the reference form (e.g., free form or salt), may be specified, such as by 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 2, 3, 4, 5 ,6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the reference form (e.g., free form or salt form) in the same solution. Conditions under which the dissolution rate is measured is the same as discussed above The increase in dissolution may be further specified by the time the composition remains supersaturated before reaching equilibrium solubility.

Examples of above embodiments include: co-crystal compositions with a dissolution rate in aqueous solution, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the reference form, co-crystal compositions with a dissolution rate in SGF that is increased at least 5 fold over the reference form, co-crystal compositions with a dissolution rate in SIF that is increased at least 5 fold over the reference form.

Bioavailability Modulation

The methods of the present invention are used to make a pharmaceutical API formulation with greater solubility, dissolution, and bioavailability. Bioavailability can be improved via an increase in AUC, reduced time to T_{max}, (the time to reach peak blood serum levels), or increased $C_{max,}$. The present invention can result in higher plasma concentrations of API when compared to the neutral form or salt alone (reference form).

AUC is the area under the plot of plasma concentration of API (not logarithm of the concentration) against time after API administration. The area is conveniently determined by the "trapezoidal rule": The data points are connected by straight line segments, perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last

NPC-UNIV-000004399
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 21 of 1101

measured concentration (C_n, at time t_n) is not zero, the AUC from t_n to infinite time is estimated by C_n/k_{el}.

The AUC is of particular use in estimating bioavailability of APIs, and in estimating total clearance of APIs (Cl_T). Following single intravenous doses, AUC = D/Cl_T, for single compartment systems obeying first-order elimination kinetics, where D is the dose; alternatively, AUC = C_0/k_{el}, where k_{el} is the API elimination rate constant. With routes other than the intravenous, for such systems, AUC = $F \cdot D/Cl_T$, where F is the absolute bioavailability of the API.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an API when administered in its normal and effective dose range as a co-crystal, whereby the AUC is increased, the time to T_{max} is reduced, or C_{max} is increased, as compared to a reference form, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Examples of the above embodiments include: co-crystal compositions with a time to T_{max} that is reduced by at least 10% as compared to the reference form, co-crystal compositions with a time to T_{max} that is reduced by at least 20% over the reference form, co-crystal compositions with a time to T_{max} that is reduced by at least 40% over the reference form, co-crystal compositions with a time to T_{max} that is reduced by at least 50% over the reference form, co-crystal compositions with a T_{max} that is reduced by at least 60% over the reference form, co-crystal compositions with a T_{max} that is reduced by at least 70% over the reference form, co-crystal compositions with a T_{max} that is reduced by at least 80% over the reference form, co-crystal compositions with a T_{max} that is reduced by at least 90% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 20% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 30% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 40% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 50% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 60% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 70% over the reference form, co-crystal compositions with a C_{max} that is increased by at least 80% over the reference form, co-crystal compositions with a Cmax that is

NPC-UNIV-000004400
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 22 of 1101

increased by at least 2 fold, 3 fold, 5 fold, 7.5 fold, 10 fold, 25 fold, 50 fold or 100 fold, co-crystal compositions with an AUC that is increased by at least 10% over the reference form, co-crystal compositions with an AUC that is increased by at least 20% over the reference form, co-crystal compositions with an AUC that is increased by at least 30% over the reference form, co-crystal compositions with an AUC that is increased by at least 40% over the reference form, co-crystal compositions with an AUC that is increased by at least 50% over the reference form, co-crystal compositions with an AUC that is increased by at least 60% over the reference form, co-crystal compositions with an AUC that is increased by at least 70% over the reference form, co-crystal compositions with an AUC that is increased by at least 80% over the reference form or co-crystal compositions with an AUC that is increased by at least 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, or 10 fold. Other examples include wherein the reference form is crystalline, wherein the reference form is amorphous, wherein the reference form is an anhydrous crystalline sodium salt, or wherein the reference form is an anhydrous crystalline HCl salt.

Dose Response Modulation

In a further aspect the present invention provides a process for improving the dose response of an API, which process comprises:

(1) contacting in solution an API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art. The curve relating effect (as the dependent variable) to dose (as the independent variable) for an API-cell system is the "dose-response curve". Typically, the dose-response curve is the measured response to an API plotted against the dose of the API (mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the API given.

NPC-UNIV-000004401
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 23 of 1101

In an embodiment of the present invention, a co-crystal of the present invention has an increased dose response curve or a more linear dose response curve than the corresponding reference compound.

Increased Stability

In a still further aspect the present invention provides a process for improving the stability of an API (as compared to a reference form such as its free form or a salt thereof), which process comprises:

(1) grinding, heating or contacting in solution the pharmaceutical salt with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In a preferred embodiment, the compositions of the present invention, including the API or active pharmaceutical ingredient (API) and formulations comprising the API, are suitably stable for pharmaceutical use. Preferably, the API or formulations thereof of the present invention are stable such that when stored at 30 degrees C for 2 years, less than 0.2 % of any one degradant is formed. The term degradant refers herein to product(s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 degrees C for 2 years, less than 0.2 % of any one degradant is formed. Alternatively, when stored at 30 degrees C for 3 months, less than 0.2% or 0.15 %, or 0.1 % of any one degradant is formed, or when stored at 40 degrees C for 3 months, less than 0.2 % or 0.15 %, or 0.1 % of any one degradant is formed. Further alternatively, when stored at 60 degrees C for 4 weeks, less than 0.2 % or 0.15 %, or 0.1 % of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75 % (RH), or as any single integer between 1 to 99 %.

Difficult to Salt or Unsaltable Compounds

In a still further aspect the present invention provides a process for making co-crystals of unsaltable or difficult to salt APIs which process comprises:

NPC-UNIV-000004402
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 24 of 1101

(1) grinding, heating or contacting in solution an API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Difficult to salt compounds include bases with a pKa < 3 or acids with a pKa > 10. Zwitter ions are also difficult to salt or unsaltable compounds according to the present invention.

Decreasing Hygroscopicity

In a still further aspect, the present invention provides a method for decreasing the hygroscopicity of an API, which method comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

An aspect of the present invention provides a pharmaceutical composition comprising a co-crystal of an API that is less hygroscopic than amorphous or crystalline, free form or salt (including metal salts such as sodium, potassium, lithium, calcium, magnesium) or another reference compound. Hygroscopicity can be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (%RH) is flowed until eqilibrium criteria are met. Typical equilibrium criteria include weight changes of less than 0.01 % over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40 degrees C unless doing so would de-solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 %

NPC-UNIV-000004403
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 25 of 1101

in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in % RH. If the compound deliquesces or becomes amorphous above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH, instead of 5-95 %RH. If the sample cannot be dried prior to testing due to lack of form stability, than the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0 %, or more preferably, 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0 %, or more preferably, 0.5 % weight when cycled between 5 and 95 % RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., "Equilibrium moisture content of pharmaceutical excipients", in Api Dev. Ind. Pharm., Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic	Essentially no moisture increases occur at relative humidities below 90 %.
Class 2: Slightly hygroscopic	Essentially no moisture increases occur at relative humidities below 80%.
Class 3: Moderately hygroscopic	Moisture content does not increase more than 5 % after storage for 1 week at relative humidities below 60 %.
Class 4: Very hygroscopic	Moisture content increase may occur at relative humidities as low as 40 to 50 %.

NPC-UNIV-000004404
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 26 of 1101

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygrospocity, based on the static method, after storage at 25 degrees C for 24 hours at 80 % RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very Hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

Co-crystals of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very Hygroscopic. Co-crystals of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred co-crystals of the present invention are less hygroscopic than a reference compound. The reference compound can be specified as the API in free form (free acid, free base, hydrate, solvate, etc.) or salt (e.g., especially metal salts such as sodium, potassium, lithium, calcium, or magnesium). Further included in the present invention are co-crystals that do not gain or lose more than 1.0 % weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0 % weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5 % or more than 1.0 % weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 1.0 % weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0 % weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5 % weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the

NPC-UNIV-000004405
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 27 of 1101

reference compound gains or loses more than 0.5 % or more than 1.0 % weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.25 % weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5 % or more than 1.0 % weight under the same conditions.

Further included in the present invention are co-crystals that have a hygroscopicity (according to Callaghan et al.) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Included are a Class 1 co-crystal of a Class 2 reference compound, a Class 2 co-crystal of a Class 3 reference compound, a Class 3 co-crystal of a Class 4 reference compound, a Class 1 co-crystal of a Class 3 reference compound, a Class 1 co-crystal of a Class 4 reference compound, or a Class 2 co-crystal of a Class 4 reference compound.

Further included in the present invention are co-crystals that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a slightly hygroscopic co-crystal of a hygroscopic reference compound, a hygroscopic co-crystal of a very hygroscopic reference compound, a very hygroscopic co-crystal of a deliquescent reference compound, a slightly hygroscopic co-crystal of a very hygroscopic reference compound, a slightly hygroscopic co-crystal of a deliquescent reference compound, and a hygroscopic co-crystal of a deliquescent reference compound.

Crystallizing Amorphous Compounds

In a further aspect, the present invention provides a process for crystallizing an amorphous compound, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

An amorphous compound includes compounds that do not crystallize using routine methods in the art.

Decreasing Form Diversity

NPC-UNIV-000004406
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 28 of 1101

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

For purposes of the present invention, the number of forms of a co-crystal is compared to the number of forms of a reference compound (e.g. the free form or a salt of the API) that can be made using routine methods in the art.

Morphology Modulation

In a still further aspect the present invention provides a process for modifying the morphology of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with a co-crystal former under crystallization conditions, so as to form a co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In an embodiment the co-crystal comprises or consists of a co-crystal former and a pharmaceutical wherein the interaction between the two, e.g., H-bonding, occurs between a functional group of Table III of an API with a corresponding interacting group of Table III. In a further embodiment, the co-crystal comprises a co-crystal former of Table I or II and an API with a corresponding interacting group of Table III. In a further embodiment the co-crystal comprises an API from Table IV and a co-crystal former with a functional group of Table III. In a further embodiment, the co-crystal is from Table I or II. In an aspect of the invention, only co-crystals having an H-bond acceptor on the first molecule and an H-bond donor on the second molecule, where the first and second molecules are either co-crystal former and API respectively or API and co-crystal former respectively, are included in the present invention. Table IV includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). Thus, whether a particular API contains an H-bond donor, acceptor or both is readily apparent.

In another embodiment, the co-crystal former and API each have only one H-bond donor/acceptor. In another aspect, the molecular weight of the API is less than 2000, 1500, 1000, 750, 500, 350, 200, or 150 Daltons. In another embodiment, the molecular weight of the API is between 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, or 1800-2000. APIs with the above molecular weights may also be specifically excluded from the present invention.

In another embodiment, peptides, proteins, nucleic acids or other biological APIs are excluded from the present invention. In another embodiment, all non-pharmaceutically acceptable co-crystal formers are excluded from the present invention. In another embodiment, organometalic APIs are excluded from the present invention. In another embodiment, a co-crystal former comprising any one or more of the functional groups of Table III may be specifically excluded from the present invention. In another embodiment, any one or more of the co-crystal formers of Table I or II may be specifically excluded from the present invention. Any APIs currently known in the art may also be specifically excluded from the present invention. For example, carbanazepine, itraconazole, nabumetone, fluoxetine, acetaminophen and theophylline can each be specifically excluded from the present invention. In another embodiment, the API is not a salt, is not a non-metal salt, or is not a metal salt, e.g., sodium, potassium, lithium, calcium or magnesium. In another embodiment, the API is a salt, is a non-metal salt, or is a metal salt, e.g., sodium, potassium, lithium, calcium, magnesium. In one embodiment, the API does not contain a halogen. In one embodiment, the API does contain a halogen.

In another embodiment, any one or more of the APIs of Table IV may be specifically excluded from the present invention. Any APIs currently known in the art may also be specifically excluded from the present invention. For example, nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile,

NPC-UNIV-000004408
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 30 of 1101

sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamidine:maleic acid, diglycine hydrochloride ($C_2H_5NO_2$:$C_2H_6NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-ylium)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine) succinate:succinic acid, bis(p-cyanophenyl)imidazolylmethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI_3, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid, barbital:N'-(p-cyanophenyl)-N-(p-iodophenyl)melamine, barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(p-chlorophenyl)melamine, N,N'-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(p-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(p-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-chlorophenyl)melamine, N,N'-Bis(m-methylphenyl)melamine:barbital, N,N'-bis(m-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(t-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(t-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-

NPC-UNIV-000004409
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 31 of 1101

carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-t-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(m-fluorophenyl)melamine:barbital, N,N'-bis(m-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(m-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF_3CSO_3, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid, 4,4'-bipyridyl:tricaballylic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N^{ε}-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid, isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester, isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid, isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid, isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline: 1,3,5-cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid, pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid, pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoic acid, diammine-(deoxy-quanyl-quanyl-N^7,N^7)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-phenylenediacetic acid, bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid, 2-aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic acid, 2-aminopyrimidine:thiophen-2-

NPC-UNIV-000004410
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 32 of 1101

carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid, 2,4,6-Trinitrobenzoic acid: 2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic acid, 2-hexeneoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic acid:4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid, oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N',N'-dimethylhydrazino)-4-thiazolylmethylthio]-N^2-sulfamoylpropionamidine:maleic acid, 5-fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{[4-(1-imidazolylmethyl)cyclohexyl]methyl}imidazole:succinic acid, CGS18320B:succinic acid, sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-dinitrobenzoic acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid, isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid, benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol, betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of

NPC-UNIV-000004411
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 33 of 1101

itraconazole, and co-crystals of topiramate are specifically excluded from the present invention.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Preferably, excipients are solids. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with an API or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of API per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. If intended for parenteral administration, it can be in the form, for example, of a suspension or transdermal patch. If intended for rectal administration, it can be in the form, for example, of a suppository. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the API, such as tablets or capsules.

In another embodiment, APIs with an inappropriate pH for transdermal patches can be co-crystallized with an appropriate co-crystal former, thereby adjusting its pH to an appropriate level for use as a transdermal patch. In another embodiment, an APIs pH level can be optimized for use in a transdermal patch via co-crystallization with an appropriate co-crystal former.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., Celutab™ and Emdex™); mannitol; sorbitol; xylitol; dextrose (e.g., Cerelose™ 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., RexcelJ), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium

NPC-UNIV-000004412
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 34 of 1101

carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with many co-crystals described herein. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of co-crystals, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e.g., Explotab™ of PenWest) and pregelatinized corn starches (e.g., National™ 1551 of National Starch and Chemical Company, National™ 1550, and Colorcon™ 1500), clays (e.g., Veegum™ HV of R.T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e.g., Ac-Di-Sol™ of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%, preferably about 0.2% to about 10%, and more preferably about 0.2% to about 5%, of the total weight of the composition.

NPC-UNIV-000004413
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 35 of 1101

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2% to about 10%, more preferably about 0.2% to about 7%, and still more preferably about 0.2% to about 5%, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a co-crsytal of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., National™ 1511 and National™ 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., Tylose™); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., Klucel™ of Aqualon); and ethylcellulose (e.g., Ethocel™ of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5% to about 25%, preferably about 0.75% to about 15%, and more preferably about 1% to about 10%, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

NPC-UNIV-000004414
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 36 of 1101

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Such wetting agents are preferably selected to maintain the co-crystal in close association with water, a condition that is believed to improve bioavailability of the composition. Such wetting agents can also be useful in solubilizing or increasing the solubility of co-crystals.

Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and degrees Ctoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., Labrasol™ of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e.g., Tween™ 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., Lauroglycol™ of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about 0.25% to about 15%, preferably about 0.4% to about 10%, and more preferably about 0.5% to about 5%, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. Sodium lauryl sulfate is a particularly preferred wetting agent. Sodium lauryl sulfate, if present, constitutes about 0.25% to about 7%, more preferably about 0.4% to about 4%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e.g., Compritol™ 888 of Gattefosse); stearic acid and

NPC-UNIV-000004415
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 37 of 1101

salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., Sterotex™ of Abitec); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., Carbowax™ 4000 and Carbowax™ 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0. 1% to about 10%, preferably about 0.2% to about 8%, and more preferably about 0.25% to about 5%, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1% to about 10%, more preferably about 0.25% to about 5%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention. When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30% to about 75%, and preferably about 45% to about 70%, for example about 60%, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the API

NPC-UNIV-000004416
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 38 of 1101

in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the API from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastrointestinal dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1% to about 20%, more preferably about 2.5% to about 15%, and still more preferably about 5% to about 10%, by weight of the pharmaceutical composition.

An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid (as D-, L-, or DL-malic acid), maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1:100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1:10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize APIs typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene

NPC-UNIV-000004417
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 39 of 1101

glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhyride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkyene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d-alpha-tocopherol polyethylene glycol-1000 succinate), and macrogolglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearoyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Pharmaceutical compositions of the present invention can comprise about 10 % to about 50 %, about 25 % to about 50 %, about 30 % to about 45 %, or about 30 % to about 35 % by weight of a co-crystal; about 10 % to about 50 %, about 25 % to about 50 %, about 30 % to about 45 %, or about 30 % to about 35 % by weight of an excipient which inhibits crystallization in aqueous solution, in simulated gastric fluid, or in simulated intestinal fluid; and about 5 % to about 50 %, about 10 % to about 40 %, about 15 % to about 35 %, or about 30 % to about 35 % by weight of a binding agent. In one example, the weight ratio of the co-crystal to the excipient which inhibits crystallization to binding agent is about 1 to 1 to 1.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending an API of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a co-crystal of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably

NPC-UNIV-000004418
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 40 of 1101

added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniform in API content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein an API is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

Pharmaceutically acceptable co-crystals can be administered by controlled- or delayed-release means. Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include: 1) extended activity of the drug; 2) reduced dosage frequency; 3) increased patient compliance; 4) usage of less total drug; 5) reduction in local or systemic side effects; 6) minimization of drug accumulation; 7) reduction in blood level fluctuations; 8) improvement in efficacy of treatment; 9) reduction of potentiation or loss of drug activity; and 10) improvement in speed of control of diseases or conditions. Kim, Cherng-ju, Controlled Release Dosage Form Design, 2 (Technomic Publishing, Lancaster, Pa.: 2000).

NPC-UNIV-000004419
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 41 of 1101

Conventional dosage forms generally provide rapid or immediate drug release from the formulation. Depending on the pharmacology and pharmacokinetics of the drug, use of conventional dosage forms can lead to wide fluctuations in the concentrations of the drug in a patient's blood and other tissues. These fluctuations can impact a number of parameters, such as dose frequency, onset of action, duration of efficacy, maintenance of therapeutic blood levels, toxicity, side effects, and the like. Advantageously, controlled-release formulations can be used to control a drug's onset of action, duration of action, plasma levels within the therapeutic window, and peak blood levels. In particular, controlled- or extended-release dosage forms or formulations can be used to ensure that the maximum effectiveness of a drug is achieved while minimizing potential adverse effects and safety concerns, which can occur both from under dosing a drug (i.e., going below the minimum therapeutic levels) as well as exceeding the toxicity level for the drug.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.

A variety of known controlled- or extended-release dosage forms, formulations, and devices can be adapted for use with the co-crystals and compositions of the invention. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,733,566; and 6,365,185 B1; each of which is incorporated herein by reference. These dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS® (Alza Corporation, Mountain View, Calif. USA)), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Additionally, ion exchange

NPC-UNIV-000004420
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 42 of 1101

materials can be used to prepare immobilized, adsorbed co-crystals and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite® A568 and Duolite® AP143 (Rohm & Haas, Spring House, PA. USA).

One embodiment of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable co-crystal, or a solvate, hydrate, dehydrate, anhydrous, or amorphous form thereof, and one or more pharmaceutically acceptable excipients or diluents, wherein the pharmaceutical composition or dosage form is formulated for controlled-release. Specific dosage forms utilize an osmotic drug delivery system.

A particular and well-known osmotic drug delivery system is referred to as OROS® (Alza Corporation, Mountain View, Calif. USA). This technology can readily be adapted for the delivery of compounds and compositions of the invention. Various aspects of the technology are disclosed in U.S. Pat. Nos. 6,375,978 B1; 6,368,626 B1; 6,342,249 B1; 6,333,050 B2; 6,287,295 B1; 6,283,953 B1; 6,270,787 B1; 6,245,357 B1; and 6,132,420; each of which is incorporated herein by reference. Specific adaptations of OROS® that can be used to administer compounds and compositions of the invention include, but are not limited to, the OROS® Push-Pull™, Delayed Push-Pull™, Multi-Layer Push-Pull™, and Push-Stick™ Systems, all of which are well known. See, e.g., http://www.alza.com. Additional OROS® systems that can be used for the controlled oral delivery of compounds and compositions of the invention include OROS®-CT and L-OROS®. Id.; see also, Delivery Times, vol. II, issue II (Alza Corporation).

Conventional OROS® oral dosage forms are made by compressing a drug powder (e.g. co-crystal) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e.g., with a laser). Kim, Cherng-ju, Controlled Release Dosage Form Design, 231-238 (Technomic Publishing, Lancaster, Pa.: 2000). The advantage of such dosage forms is that the delivery rate of the drug is not influenced by physiological or experimental conditions. Even a drug with a pH-dependent solubility can be delivered at a constant rate regardless of the pH of the delivery medium. But because these advantages are provided by a build-up of osmotic pressure within the dosage form after administration, conventional OROS® drug delivery systems cannot be used to effectively deliver drugs with low water solubility. Id. at 234. Because co-crystals of this invention can be far

NPC-UNIV-000004421
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 43 of 1101

more soluble in water than the API itself, they are well suited for osmotic-based delivery to patients. This invention does, however, encompass the incorporation of conventional crystalline API (e.g. pure API without co-crystal former), and non-salt isomers and isomeric mixtures thereof, into OROS® dosage forms.

A specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a co-crystal, or a solvate, hydrate, dehydrate, anhydrous, or amorphous form thereof. See U.S. Pat. No. 6,368,626, the entirety of which is incorporated herein by reference.

Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer, wherein the active agent formulation comprises a co-crystal, or a solvate, hydrate, dehydrate, anhydrous, or amorphous form thereof. See U.S. Pat. No. 6,342,249, the entirety of which is incorporated herein by reference.

The invention will now be described in further detail, by way of example, with reference to the accompanying drawings.

EXEMPLIFICATION

NPC-UNIV-000004422
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 44 of 1101

General Methods for the Preparation of Co-Crystals

a) High Throughput crystallization using the CrystalMax platform

CrystalMax™ comprises a sequence of automated, integrated high throughput robotic stations capable of rapid generation, identification and characterization of polymorphs, salts, and co-crystals of APIs and API candidates. Worksheet generation and combinatorial mixture design is carried out using proprietary design software InForm™. Typically, an API or an API candidate is dispensed from an organic solvent into tubes and dried under a stream of nitrogen. Salts and/or co-crystal formers may also be dispensed and dried in the same fashion. Water and organic solvents may be combinatorially dispensed into the tubes using a multi-channel dispenser. Each tube in a 96-tube array is then sealed within 15 seconds of combinatorial dispensing to avoid solvent evaporation. The mixtures are then rendered supersaturated by heating to 70 degrees C for 2 hours followed by a 1 degree C/minute cooling ramp to 5 degrees C. Optical checks are then conducted to detect crystals and/or solid material. Once a solid has been identified in a tube, it is isolated through aspiration and drying. Raman spectra are then obtained on the solids and cluster classification of the spectral patterns is performed using proprietary software (QForm™).

b) Crystallization from solution

Co-crystals may be obtained by dissolving the separate components in a solvent and adding one to the other. The co-crystal may then precipitate or crystallize as the solvent mixture is evaporated slowly. The co-crystal may also be obtained by dissolving the two components in the same solvent or a mixture of solvents.

c) Crystallization from the melt

A co-crystal may be obtained by melting the two components together and allowing recrystallization to occur. In some cases, an anti-solvent may be added to facilitate crystallization.

d) Thermal microscopy

A co-crystal may be obtained by melting the higher melting component on a glass slide and allowing it to recrystallize. The second component is then melted and is also allowed to recrystallize. The co-crystal may form as a separated phase/band in between the eutectic bands of the two original components.

e) Mixing and/or grinding

NPC-UNIV-000004423
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 45 of 1101

A co-crystal may be obtained by mixing or grinding two components together in the solid state.

Analytical Methods

Procedure for DSC analysis

DSC analysis of the samples was performed using a Q1000 Differential Scanning Calorimeter (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (©2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (©2001 TA Instruments-Water LLC).

For the DSC analysis, the purge gas used was dry nitrogen, the reference material was an empty aluminum pan that was crimped, and the sample purge was 50 mL/minute.

DSC analysis of the sample was performed by placing ≤ 2 mg of sample in an aluminum pan with a crimped pan closure. The starting temperature was typically 20 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 300 degrees C. Unless otherwise indicated, all reported transitions are as stated +/- 1.0 degrees C.

Procedure for TGA analysis

TGA analysis of samples was performed using a Q500 Thermogravimetric Analyzer (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (©2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (©2001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, the balance purge was 40 mL/minute N_2, and the sample purge was 60 mL/minute N_2.

NPC-UNIV-000004424
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 46 of 1101

TGA of the sample was performed by placing ≤ 2 mg of sample in a platinum pan. The starting temperature was typically 20 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 300 degrees C.

Procedure for PXRD analysis

A powder X-ray diffraction pattern for the samples was obtained using a D/Max Rapid, Contact (Rigaku/MSC, The Woodlands, TX, U.S.A.), which uses as its control software RINT Rapid Control software, Rigaku Rapid/XRD, version 1.0.0 (©1999 Rigaku Co.). In addition, the analysis software used were RINT Rapid display software, version 1.18 (Rigaku/MSC), and JADE XRD Pattern Processing, versions 5.0 and 6.0 ((©1995-2002, Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows: source was Cu with a K line at 1.5406Å; x-y stage was manual; collimator size was 0.3 or 0.8 mm; capillary tube (Charles Supper Company, Natick, MA, U.S.A.) was 0.3 mm ID; reflection mode was used; the power to the X-ray tube was 46 kV; the current to the X-ray tube was 40 mA; the omega-axis was oscillating in a range of 0-5 degrees at a speed of 1 degree/minute; the phi-axis was spinning at an angle of 360 degrees at a speed of 2 degrees/second; 0.3 or 0.8 mm collimator; the collection time was 60 minutes; the temperature was room temperature; and the heater was not used. The sample was presented to the X-ray source in a boron rich glass capillary.

In addition, the analysis parameters were as follows: the integration 2-theta range was 2-40 or 60 degrees; the integration chi range was 0-360 degrees; the number of chi segments was 1; the step size used was 0.02; the integration utility was cylint; normalization was used; dark counts were 8; omega offset was 180; and chi and phi offsets were 0.

The relative intensity of peaks in a diffractogram is not necessarily a limitation of the PXRD pattern because peak intensity can vary from sample to sample, e.g., due to crystalline impurities. Further, the angles of each peak can vary by about +/- 0.1 degrees, preferably +/-0.05. The entire pattern or most of the pattern peaks may also shift by about +/- 0.1 degree due to differences in calibration, settings, and other variations from instrument to instrument and from operator to operator.

NPC-UNIV-000004425
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 47 of 1101

Procedure for Raman Acquisition, Filtering and Binning

Acquisition

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega™ Dispersive Raman (Almega™ Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table A. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

Filtering and Binning

Each spectrum in a set was filtered using a matched filter of feature size 25 to remove background signals, including glass contributions and sample fluorescence. This is particularly important as large background signal or fluorescence limit the ability to accurately pick and assign peak positions in the subsequent steps of the binning process. Filtered spectra were binned using the peak pick and bin algorithm with the parameters given in Table B. The sorted cluster diagrams for each sample set and the corresponding cluster assignments for each spectral file were used to identify groups of samples with similar spectra, which was used to identify samples for secondary analyses.

NPC-UNIV-000004426
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 48 of 1101

Table A. Raman Spectral acquisition parameters

Parameter	Setting Used
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (um)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition (degrees C)	24.0

Table B. Raman Filtering and Binning Parameters

Parameter	Setting Used
Filtering Parameters	
Filter type	Matched
Filter size	25
QC Parameters	
Peak Height Threshold	1000
Region for noise test (cm^{-1})	0-10000
RMS noise threshold	10000
Automatically eliminate failed spectra	Yes
Region of Interest	
Include (cm^{-1})	104-3428
Exclude region I (cm^{-1})	
Exclude region II (cm^{-1})	
Exclude region III (cm^{-1})	
Exclude region IV (cm^{-1})	
Peak Pick Parameters	
Peak Pick Sensitivity	Variable
Peak Pick Threshold	100
Peak Comparison Parameters	
Peak Window (cm^{-1})	2
Analysis Parameters	
Number of clusters	Variable

Procedure for Single Crystal X-Ray Diffraction

Single crystal x-ray data were collected on a Bruker SMART-APEX CCD diffractometer (M. J. Zawarotko, Department of Chemistry, University of South Florida). Lattice parameters were determined from least squares analysis. Reflection

NPC-UNIV-000004427
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 49 of 1101

data was integrated using the program SAINT. The structure was solved by direct methods and refined by full matrix least squares using the program SHELXTL (Sheldrick, G. M. SHELXTL, Release 5.03; Siemans Analytical X-ray Instruments Inc.: Madison, WI).

The co-crystals of the present invention can be characterized, e.g., by the TGA or DSC data or by any one, any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, or any single integer number of PXRD 2-theta angle peaks or Raman shift peaks listed herein or disclosed in a figure, or by single crystal x-ray diffraction data.

Example 1

1:1 carbamazepine:saccharin co-crystals (Form I) were prepared. A 12-block experiment was designed with 12 solvents. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from a mixture of isopropyl acetate and heptane. Detailed characterization of the co-crystal is listed in Table V. (See Figs. 1 and 2)

Example 2

1:1 carbamazepine:nicotinamide co-crystals (Form I) were prepared. A 12-block experiment was designed with 12 solvents. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from samples containing toluene, acetone, or isopropyl acetate. Detailed characterization of the co-crystal is listed in Table V. (See Figs. 3 and 4)

Example 3

1:1 carbamazepine:trimesic acid co-crystals (Form I) were prepared. A 9-block experiment was designed with 10 solvents. 864 crystallization experiments with 8 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from samples containing methanol. Detailed characterization of the co-crystal is listed in Table V. (See Fig. 5)

NPC-UNIV-000004428
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 50 of 1101

Example 4

1:1 celecoxib:nicotinamide co-crystals were prepared. Celecoxib (100 mg, 0.26 mmol) and nicotinamide (32.0 mg, 0.26 mmol) were each dissolved in acetone (2 mL). The two solutions were mixed and the resulting mixture was allowed to evaporate slowly overnight. The precipitated solid was collected and characterized. Detailed characterization of the co-crystal is listed in Table V.

Example 5

Co-crystals of topiramate and 18-crown-6 were prepared. An equimolar amount of topiramate and 18-crown-6 were dissolved in ether separately. The solution containing topiramate was then added to the solution containing 18-crown-6. A white solid precipitated after minor agitation and was collected and dried. Detailed characterization of the co-crystal is listed in Table V. (See Figs. 6 and 7)

Example 6

Co-crystals of olanzapine and nicotinamide (Form I and II) were prepared. A 9-block experiment was designed with 12 solvents. 864 crystallization experiments with 10 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from tubes containing isopropyl acetate. PXRD and DSC characterization of the co-crystal (Form I and II) is listed in Table V. (See Figs. 8, 9, and 30)

Example 7

Co-crystals of celecoxib and 18-crown-6 were prepared. A solution of celecoxib (157.8 mg, 0.4138 mmol) in Et_2O (10.0 mL) was added to 18-crown-6 (118.1 mg, 0.447 mmol). The opaque solid dissolves immediately and a white solid subsequently began to crystallize very rapidly. The solid was collected via filtration and was washed with additional Et_2O (5 mL). Detailed characterization of the co-crystal is listed in Table V. (See Figs. 10 and 11)

Example 8

Co-crystals of itraconazole and succinic acid were prepared. Approximately 51.1 mg of *cis*-itraconazole free base, 0.75 mL of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw

NPC-UNIV-000004429

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 51 of 1101

cap and placed on top of a hot plate maintained at a temperature between 60 and 75 degrees C. A solution of 77.7 mg of succinic acid in 1.58 mL of THF was prepared. 0.20 mL of the succinic acid solution was added to the cis-itraconazole solution and the solution remained clear. 0.75 mL of iso-propylacetate was added and the solution was seeded with <1 mg of the L-tartaric acid co-crystal salt from Example 10 below. The heat was turned off and the sample crystallized as it cooled to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 mL of THF. The filter cake was broken-up and allowed to air-dry for 1 hour prior to analysis. (See Figs. 12 and 13)

Example 9

Co-crystals of itraconazole and fumaric acid were prepared. Approximately 500 mg of *cis*-itraconazole free base was placed in a 50 mL screw top bottle along with 33.33 mL of tetrahydrofuran (THF). 3.0887 mL of fumaric acid stock solution (prepared in Example 1) was then added to the beaker (resulting in a 1.05:1 ratio of salt former to free base). The cap was screwed on to seal the bottle and the bottle was placed in a 70 degrees C oven (Model # 1400E, VWR Scientific) and heated for approximately 1 hour. Thereafter, the bottle was removed from the oven, the cap from the bottle was removed, and the sample was allowed to evaporate under flowing air under ambient conditions. When all but about 5 mL of the solvent had evaporated, the remaining solvent was removed by decantation and the solid was isolated by filtering over a Whatman filter using suction. This solid was returned back into the 50 mL bottle with the remaining solid and the bottle was placed into the vacuum oven at approximately 25 mm Hg and the solid was allowed to dry for 4 days prior to analysis. (See Figs. 14 and 15)

Example 10

Co-crystals of itraconazole and tartaric acid were prepared. Approximately 100.4 mg of *cis*-itraconazole free base, 0.90 mL of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw cap and placed in an oil bath maintained at 70 degrees C. A solution of 138.5 mg of L(+) tartaric acid in 1.15 mL of THF was prepared. 0.21 mL of the L(+)tartaric acid solution was added to the cis-itraconazole solution and the solution

NPC-UNIV-000004430
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 52 of 1101

remained clear. 0.90 mL of iso-propylacetate was added and the solution was seeded with <1 mg of the salt from a preparation of DL-tartaric acid co-crystal. The sample was allowed to crystallize over about 5 minutes in the 70 degrees C oil bath before it was removed and allowed to cool to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 mL of THF. The filter cake was broken-up and allowed to air-dry for 4 hours prior to analysis. (See Figs. 16 and 17)

Example 11

Co-crystals of itraconazole and malic acid were prepared. To prepare the L-malic acid co-crystal salt of *cis*-itraconazole, 100.4 mg of *cis*-itraconazole free base, 0.50 mL of THF, and a magnetic stir bar were charged into a screw cap vial. A solution of 191.3 mg of L(-)malic acid in 5.0 mL of THF was prepared. 0.50 mL of the L-malic acid solution was added to the vial containing cis-itraconazole and the solution was heated with a heat gun to dissolve. The solution was allowed to cool and was then seeded with <1 mg of the salt from *cis*-itraconazole-L-tartaric acid co-crystal. The cooled crystals were filtered in a centrifuge filter tube. The filter cake was broken-up and allowed to air-dry prior to analysis. (See Figs. 18 and 19)

Example 12

Co-crystals of itraconazole HCl and tartaric acid were prepared. Approximately 212.7mg of L-tartaric acid and 118 microL of 37% HCl were dissolved in 25 mL of hot dioxane. This solution was added to 1.0 g of *cis*-itraconazole dissolved in 50 mL of hot dioxane with stirring. The mixture was heated until a clear solution formed and was then allowed to cool to room temperature. Upon cooling, 50 mL tert-butyl methyl ether was added and the crystals were harvested by vacuum filtration on a Buchner funnel with #4 Whatman filter paper. The crystals were washed 3 times with 5 mL aliquots of cold tert-butyl methyl ether and left to air dry. Approximately 573 mg of a crystalline form of cis-itraconazole HCl-tartaric acid (1:1:0.5) co-crystal were obtained. (See Figs. 20 and 21)

NPC-UNIV-000004431
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 53 of 1101

Example 13

Co-crystals of modafinil and malonic acid were prepared. Using a 250 mg/ml modafinil-acetic acid solution, malonic acid was dissolved on a hotplate (about 67 degrees C) at a 1:2 modafinil to malonic acid ratio. The mixture was dried under flowing nitrogen overnight. A powdery white solid was produced. After further drying for 1 day, acetic acid is removed (as determined by TGA) and the crystal structure, as determined by PXRD, remains the same. (See Fig. 22)

Example 14

Co-crystals of modafinil and benzamide were prepared. Modafinil (1 mg, 0.0037mmol) and benzamide (0.45 mg, 0.0037 mmol) were dissolved in 1,2-dichloroethane (400 microL). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table V. (See Fig. 23)

Example 15

Co-crystals of modafinil and mandelic acid were prepared. Modafinil (1 mg, 0.0037mmol) and mandelic acid (0.55 mg, 0.0037 mmol) were dissolved in acetone (400 microL). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table V. (See Fig. 24)

Example 16

Co-crystals of modafinil and glycolic acid were prepared. Modafinil (1 mg, 0.0037mmol) and glycolic acid (0.30 mg, 0.0037 mmol) were dissolved in acetone (400 microL). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table V. (See Fig. 25)

Example 17

Co-crystals of modafinil and fumaric acid were prepared. Modafinil (1 mg, 0.0037mmol) and fumaric acid (0.42 mg, 0.0037 mmol) were dissolved in 1,2-dichloroethane (400 microL). The solution was allowed to evaporate to dryness and the

NPC-UNIV-000004432
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 54 of 1101

resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table V. (See Fig. 26)

Example 18

Co-crystals of modafinil and maleic acid were prepared. Using a 250 mg/ml modafinil-acetic acid solution, maleic acid was dissolved on a hotplate (about 67 degrees C) at a 2:1 modafinil to maleic ratio. The mixture was dried under flowing nitrogen overnight. A clear amorphous material remained. Solids began to grow after 2 days stored in a sealed vial at room temperature. (See Fig. 43)

Example 19

Co-crystals of olanzapine and nicotinamide (Form III) were prepared. Olanzapine (40 μL of 25 mg/mL stock solution in tetrahydrofuran) and nicotinamide (37.6 μL of 20 mg/mL stock solution in methanol) were added to a glass vial and dried under a flow of nitrogen. To the solid mixture was added isopropyl acetate (100 μL) and the vial was sealed with an aluminum cap. The suspension was then heated at 70 degrees C for two hours in order to dissolve all of the solid material. The solution was then cooled to 5 degrees C and maintained at that temperature for 24 hours. After 24 hours the vial was uncapped and the mixture was concentrated to 50 μL of total volume. The vial was then resealed with an aluminum cap and was maintained at 5 degrees C for an additional 24 hours. Large, yellow plates were observed and were collected (Form III). The solid was characterized with single crystal x-ray diffraction and powder x-ray diffraction. PXRD characterization of the co-crystal is listed in Table V. (See Fig. 31 and 32A-D)

Single crystal x-ray analysis reveals that the olanzapine:nicotinamide (Form III) co-crystal is made up of a ternary system containing olanzapine, nicotinamide, water and isopropyl acetate in the unit cell. The co-crystal crystallizes in the monoclinic space group $P2_1/c$ and contains one olanzapine, one nicotinamide, 4 waters and one isopropyl acetate solvate in the asymmetric unit. The packing diagram is made up of a two-dimensional hydrogen-bonded network with the water molecules connecting the olanzapine and nicotinamide moieties. The packing diagram is also comprised of alternating olanzapine and nicotinamide layers connected through hydrogen bonding via the water and isopropyl acetate molecules, as shown in Figure 32B. The olanzapine layer propagates along the b axis at c/4 and 3c/4. The nicotinamide layer propagates along the b axis at c/2. The top of Figure 32C illustrates the nicotinamide

NPC-UNIV-000004433
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 55 of 1101

superstructure. The nicotinamide molecules form dimers which hydrogen bond to chains of 4 water molecules. The water chains terminate with isopropyl acetate molecules on each side.

Crystal data: $C_{45}H_{64}N_{10}O_7S_2$, M = 921.18, monoclinic P21/c; a = 14.0961(12) Å, b = 12.5984(10) Å, c = 27.219(2) Å, $\alpha = 90°$, $\beta = 97.396(2)°$, $\gamma = 90°$, T = 100(2) K, Z = 4, $D_c = 1.276$ Mg/m^3,U = 4793.6(7) Å^3, $\lambda = 0.71073$ Å; 24952 reflections measured, 8457 unique ($R_{int} = 0.0882$). Final residuals were $R_1 = 0.0676$, $wR_2 = 0.1461$ for $I>2\sigma(I)$, and $R_1 = 0.1187$, $wR_2 = 0.1687$ for all 8457 data.

Example 20

Co-crystals of 5-fluorouracil and urea were prepared. To 5-fluorouracil (1g, 7.69 mmol) and urea (0.46g, 7.69 mmol) was added methanol (100 mL). The solution was heated at 65 degrees C and sonicated until all the material dissolved. The solution was then cooled to 5 degrees C and maintained at that temperature overnight. After about 3 days a white precipitate was observed and collected. The solid was characterized by DSC, PXRD, Raman spectroscopy, and TGA. Characterization data are listed in Table V. (See Figs. 33- 36)

Example 21

Co-crystals of hydrochlorothiazide and nicotinic acid were prepared. Hydrochlorothiazide (12.2 mg, 0.041 mmol) and nicotinic acid (5 mg, 0.041 mmol) were dissolved in methanol (1 mL). The solution was then cooled to 5 degrees C and maintained at that temperature for 12 hours. A white solid precipitated and was collected and characterized using PXRD. (See Fig. 37)

Example 22

Co-crystals of hydrochlorothiazide and 18-crown-6 were prepared. Hydrochlorothiazide (100 mg, 0.33 mmol) was dissolved in diethyl ether (15 mL) and was added to a solution of 18-crown-6 (87.2 mg, 0.33 mmol) in diethyl ether (15 mL). A white precipitate immediately began to form and was collected and characterized as the hydrochlorothiazide:18-crown-6 co-crystal using PXRD. (See Fig. 38)

NPC-UNIV-000004434
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 56 of 1101

Example 23

Co-crystals of hydrochlorothiazide and piperazine were prepared. Hydrochlorothiazide (17.3 mg, 0.058 mmol) and piperazine (5 mg, 0.058 mmol) were dissolved in a 1:1 mixture of ethyl acetate and acetonitirle (1 mL). The solution was then cooled to 5 degrees C and maintained at that temperature for 12 hours. A white solid precipitated and was collected and characterized using PXRD. (See Fig. 39)

Example 24

Acetaminophen:4,4'-bipyridine:water (1:1:1 stoichiometry)

50 mg (0.3307 mmol) acetaminophen and 52 mg (0.3329 mmol) 4,4'-bipyridine were dissolved in hot water and allowed to stand. Slow evaporation yielded colorless needles of a 1:1:1 acetaminophen/4,4'-bipyridine/water co-crystal, as shown in Figure 44A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{36}H_{44}N_2O_4$, M=339.84, triclinic, space group $P\bar{1}$; a = 7.0534(8), b = 9.5955(12), c = 19.3649(2) Å, α = 86.326(2), β = 80.291(2), γ = 88.880(2)°, U = 1308.1(3) Å^3, T = 200(2) K, Z = 2, μ(Mo-Kα) = 0.090 mm^{-1}, D_c = 1.294 Mg/m^3, λ = 0.71073 Å, F(000) = 537, $2\theta_{max}$ = 25.02°; 6289 reflections measured, 4481 unique (R_{int} = 0.0261). Final residuals for 344 parameters were R_1 = 0.0751, wR_2 = 0.2082 for I>2σ(I), and R_1 = 0.1119, wR_2 = 0.2377 for all 4481data.

Crystal packing: The co-crystals contain bilayered sheets in which water molecules act as a hydrogen bonded bridge between the network bipyridine moieties and the acetaminophen. Bipyridine guests are sustained by π-π stacking interactions between two network bipyridines. The layers stack via π-π interactions between the phenyl groups of the acetaminophen moieties.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 57.77 degrees C (endotherm); m.p. = 58-60 degrees C (MEL-TEMP); (acetaminophen m.p. = 169 degrees C, 4,4'-bipyridine m.p. = 111-114 degrees C).

Example 25

Phenytoin:Pyridone (1:1 stoichiometry)

28 mg (0.1109 mmol) phenytoin and 11 mg (0.1156 mmol) 4-hydroxypyridone were dissolved in 2 mL acetone and 1 mL ethanol with heating and stirring. Slow

NPC-UNIV-000004435
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 57 of 1101

evaporation yielded colorless needles of a 1:1 phenytoin/pyridone co-crystal, as shown in Figure 45A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{20}H_{17}N_3O_3$, M = 347.37, monoclinic $P2_1/c$; a = 16.6583(19), b = 8.8478(10), c = 11.9546(14) Å, β = 96.618(2)°, U = 1750.2(3) Å^3, T = 200(2) K, Z = 4, μ(Mo-Kα) = 0.091 mm^{-1}, D_c = 1.318 Mg/m^3, λ = 0.71073 Å, F(000) = 728, $2\theta_{max}$ = 56.60°; 10605 reflections measured, 4154 unique (R_{int} = 0.0313). Final residuals for 247 parameters were R_1 = 0.0560, wR_2 = 0.1356 for I>2σ(I), and R_1 = 0.0816, wR_2 = 0.1559 for all 4154 data.

Crystal packing: The co-crystal is sustained by hydrogen bonding of adjacent phentoin molecules between the carbonyl and the amine closest to the tetrahedral carbon, and by hydrogen bonding between pyridone carbonyl functionalities and the amine not involved in phenytoin-phenytoin interactions. The pyridone carbonyl also hydrogen bonds with adjacent pyridone molecules forming a one-dimensional network.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), characteristic peaks for the co-crystal were identified as: 2° amine found at 3311cm^{-1}, carbonyl (ketone) found at 1711cm^{-1}, olephin peak found at 1390cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 233.39 degrees C (endotherm) and 271.33 degrees C (endotherm); m.p. = 231-233 degrees C (MEL-TEMP); (phenytoin m.p. = 295 degrees C, pyridone m.p. = 148 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), a 29.09% weight loss starting at 192.80 degrees C, 48.72% weight loss starting at 238.27 degrees C, and 18.38% loss starting at 260.17 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD: Showed analogous peaks to the simulated PXRD derived from the single crystal data. In all cases of recrystallization and solid state reaction, experimental (calculated): 5.2 (5.3); 11.1 (11.3); 15.1 (15.2); 16.2 (16.4); 16.7 (17.0); 17.8 (17.9); 19.4 (19.4); 19.8 (19.7); 20.3 (20.1); 21.2 (21.4); 23.3 (23.7); 26.1 (26.4); 26.4 (26.6); 27.3 (27.6); 29.5 (29.9).

Example 26

NPC-UNIV-000004436
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 58 of 1101

Aspirin (acetylsalicylic acid):4,4'-bipyridine (2:1 stoichiometry)

50 mg (0.2775 mmol) aspirin and 22 mg (0.1388 mmol) 4,4'-bipyridine were dissolved in 4 mL hexane. 8 mL ether was added to the solution and allowed to stand for one hour, yielding colorless needles of a 2:1 aspirin/4,4'-bipyridine co-crystal, as shown in Figure 46A-D. Alternatively, aspirin/4,4'-bipyridine (2:1 stoichiometry) can be made by grinding the solid ingredients in a pestle and mortar.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{28}H_{24}N_2O_8$, M = 516.49, orthorhombic *Pbcn*; a = 28.831(3), b = 11.3861(12), c = 8.4144(9) Å, U = 2762.2(5) Å^3, T = 173(2) K, Z = 4, μ(Mo-Kα) = 0.092 mm^{-1}, D_c = 1.242 Mg/m^3, λ = 0.71073 Å, F(000) = 1080, $2\theta_{max}$ = 25.02°; 12431 reflections measured, 2433 unique (R_{int} = 0.0419). Final residuals for 202 parameters were R_1 = 0.0419, wR_2 = 0.1358 for I>2σ(I), and R_1 = 0.0541, wR_2 = 0.1482 for all 2433 data.

Crystal packing: The co-crystal contains the carboxylic acid-pyridine heterodimer that crystallizes in the *Pbcn* space group. The structure is an inclusion compound containing disordered solvent in the channels. In addition to the dominant hydrogen bonding interaction of the heterodimer, π-π stacking of the bipyridine and phenyl groups of the aspirin and hydrophobic interactions contribute to the overall packing interactions.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), characteristic (-COOH) peak at 1679 cm^{-1} was shifted up and less intense at 1694cm^{-1}, where as the lactone peak is shifted down slightly from 1750cm^{-1} to 1744cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 95.14 degrees C (endotherm); m.p. = 91-96 degrees C (MEL-TEMP); (aspirin m.p. = 1345 degrees C, 4,4'-bipyridine m.p. = 111-114 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), weight loss of 9% starting at 22.62 degrees C, 49.06% weight loss starting at 102.97 degrees C followed by complete decomposition starting at 209.37 degrees C.

Example 27

Ibuprofen:4,4'-Bipyridine (2:1 stoichiometry)

50 mg (0.242 mmol) racemic ibuprofen and 18mg (0.0960 mmol) 4,4'-bipyridine were dissolved in 5 mL acetone. Slow evaporation of the solvent yielded colorless needles of a 2:1 ibuprofen/4,4'-bipyridine co-crystal, as shown in Figure 47A-D.

NPC-UNIV-000004437
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 59 of 1101

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{36}H_{44}N_2O_4$, M = 568.73, triclinic, space group *P-1*; a = 5.759(3), b = 11.683(6), c = 24.705(11) Å, α = 93.674(11), β = 90.880(10), γ = 104.045(7)°, *U* = 1608.3(13) $Å^3$, T= 200(2) K, Z = 2, μ(Mo-Kα) = 0.076 mm^{-1}, D_c = 1.174 Mg/m^3, λ = 0.71073 Å, F(000) = 612, $2\theta_{max}$ = 23.29°; 5208 reflections measured, 3362 unique (R_{int} = 0.0826). Final residuals for 399 parameters were R_1 = 0.0964, wR_2 = 0.2510 for I>2σ(I), and R_1 = 0.1775, wR_2 = 0.2987 for all 3362 data.

Crystal packing: The co-crystal contains ibuprofen/bipyridine heterodimers, sustained by two hydrogen bonded carboxylic acidpyridine supramolecular synthons, arranged in a herringbone motif that packs in the space group *P-1*. The heterodimer is an extended version of the homodimer and packs to form a two-dimensional network sustained by π-π stacking of the bipyridine and phenyl groups of the ibuprofen and hydrophobic interactions from the ibuprofen tails.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Analysis observed stretching of aromatic C-H at 2899 cm^{-1}; N--H bending and scissoring at 1886 cm_{-1}; C=O stretching at 1679 cm^{-1}; C-H out-of-plane bending for both 4,4'-bipyridine and ibuprofen at 808 cm^{-1} and 628 cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 64.85 degrees C (endotherm) and 118.79 degrees C (endotherm); m.p. = 113-120 degrees C (MEL-TEMP); (ibuprofen m.p. = 75-77 degrees C, 4,4'-bipyridine m.p. = 111-114 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 13.28% weight loss between room temperature and 100.02 degrees C immediately followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from the single crystal data, experimental (calculated): 3.4 (3.6); 6.9 (7.2); 10.4 (10.8); 17.3 (17.5); 19.1 (19.7).

NPC-UNIV-000004438
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 60 of 1101

Example 28

Flurbiprofen:4,4'-bipyridine (2:1 stoichiometry)

50 mg (0.2046 mmol) flurbiprofen and 15 mg (0.0960 mmol) 4,4'-bipyridine were dissolved in 3 mL acetone. Slow evaporation of the solvent yielded colorless needles of a 2:1 flurbiprofen/4,4'-bipyridine co-crystal, as shown in Figure 48A-D.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{40}H_{34}F_2N_2O_4$, M = 644.69, monoclinic $P2_1/n$; a = 5.860(4), b = 47.49(3), c = 5.928(4) Å, β = 107.382 (8)°, U = 1574.3(19) Å^3, T = 200(2) K, Z = 2, μ(Mo-Kα) = 0.096 mm^{-1}, D_c = 1.360 Mg/m^3, λ = 0.71073 Å, F(000) = 676, $2\theta_{max}$ = 21.69°; 4246 reflections measured, 1634 unique (R_{int} = 0.0677). Final residuals for 226 parameters were R_1 = 0.0908, wR_2 = 0.2065 for I>2σ(I), and R_1 = 0.1084, wR_2 = 0.2209 for all 1634 data.

Crystal packing: The co-crystal contains flurbiprofen/bipyridine heterodimers, sustained by two hydrogen bonded carboxylic acidpyridine supramolecular synthon, arranged in a herringbone motif that packs in the space group $P2_1/n$. The heterodimer is an extended version of the homodimer and packs to form a two-dimensional network sustained by π-π stacking and hydrophobic interactions of the bipyridine and phenyl groups of the flurbiprofen.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic C-H stretching at 3057 cm^{-1} and 2981 cm^{-1}; N--H bending and scissoring at 1886 cm^{-1}; C=O stretching at 1690 cm^{-1}; C=C and C=N ring stretching at 1418 cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 162.47 degrees C (endotherm); m.p. = 155-160 degrees C (MEL-TEMP); (flurbiprofen m.p. = 110-111 degrees C, 4,4'-bipyridine m.p. = 111-114 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 30.93% weight loss starting at 31.13 degrees C and a 46.26% weight loss starting at 168.74 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA), the powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from the single crystal data: experimental (calculated): 16.8 (16.8); 17.1 (17.5); 18.1 (18.4); 19.0 (19.0); 20.0 (20.4); 21.3 (21.7); 22.7 (23.0); 25.0 (25.6); 26.0 (26.1); 26.0 (26.6); 26.1 (27.5); 28.2 (28.7); 29.1 (29.7).

Example 29

NPC-UNIV-000004439

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 61 of 1101

Flurbiprofen:trans-1,2-bis (4-pyridyl) ethylene (2:1 stoichiometry)

25 mg (0.1023 mmol) flurbiprofen and 10 mg (0.0548 mmol) trans-1, 2-bis (4-pyridyl) ethylene were dissolved in 3 mL acetone. Slow evaporation of the solvent yielded colorless needles of a 2:1 flurbiprofen/1,2-bis (4-pyridyl) ethylene co-crystal, as shown in Figure 49A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{42}H_{36}F_2N_2O_4$, M = 670.73, monoclinic $P2_1/n$; a = 5.8697(9), b = 47.357(7), c = 6.3587(10) Å, β = 109.492(3)°, U = 1666.2(4) Å^3, T = 200(2) K, Z = 2, μ(Mo-Kα) = 0.093 mm^{-1}, D_c = 1.337 Mg/m^3, λ = 0.71073 Å, F(000) = 704, $2\theta_{max}$ = 21.69°, 6977 reflections measured, 2383 unique (R_{int} = 0.0383). Final residuals for 238 parameters were R_1 = 0.0686, wR_2 = 0.1395 for I>2σ(I), and R_1 = 0.1403, wR_2 = 0.1709 for all 2383 data.

Crystal packing: The co-crystal contains flurbiprofen/1,2-bis (4-pyridyl) ethylene heterodimers, sustained by two hydrogen bonded carboxylic acid-pyridine supramolecular synthons, arranged in a herringbone motif that packs in the space group $P2_1/n$. The heterodimer from 1,2-bis (4-pyridyl) ethylene further extends the homodimer relative to example 28 and packs to form a two-dimensional network sustained by π-π stacking and hydrophobic interactions of the bipyridine and phenyl groups of the flurbiprofen.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic C-H stretching at 2927 cm^{-1} and 2850 cm^{-1}; N--H bending and scissoring at 1875 cm^{-1}; C=O stretching at 1707 cm^{-1}; C=C and C=N ring stretching at 1483 cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 100.01 degrees C, 125.59 degrees C and 163.54 degrees C (endotherms); m.p. = 153-158 degrees C (MEL-TEMP); (flurbiprofen m.p. = 110-111 degrees C, trans-1, 2-bis (4-pyridyl) ethylene m.p. = 150-153 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 91.79% weight loss starting at 133.18 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA), the powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from the single crystal data, experimental (calculated): 3.6 (3.7); 17.3 (17.7); 18.1 (18.6); 18.4 (18.6); 19.1 (19.3); 22.3 (22.5); 23.8 (23.9); 25.9 (26.4); 28.1 (28.5).

NPC-UNIV-000004440
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 62 of 1101

Example 30

Carbamazepine:*p*-Phthalaldehyde (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 7 mg (0.0521 mmol) *p*-phthalaldehyde were dissolved in approximately 3 mL methanol. Slow evaporation of the solvent yielded colorless needles of a 1:1 carbamazepine/*p*-phthalaldehyde co-crystal, as shown in Figure 50A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{38}H_{30}N_4O_4$, M = 606.66, monoclinic *C2/c*; a = 29.191(16), b = 4.962(3), c = 20.316(11) Å, $\beta = 92.105(8)°$, *U* = 2941(3) $Å^3$, T= 200(2) K, Z = 4, μ(Mo-Kα) = 0.090 mm^{-1}, $D_c = 1.370$ Mg/m^3, $\lambda = 0.71073$ Å, F(000) = 1272, $2\theta_{max} = 43.66°$, 3831 reflections measured, 1559 unique ($R_{int} = 0.0510$). Final residuals for 268 parameters were $R_1 = 0.0332$, $wR_2 = 0.0801$ for $I>2\sigma(I)$, and $R_1 = 0.0403$, $wR_2 = 0.0831$ for all 1559 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamide homodimers that crystallize in the space group *C2/c*. The 1° amines of the homodimer are bifurcated to the carbonyl of the *p*-phthalaldehyde forming a chain with an adjacent homodimer. The chains pack in a crinkled tape motif sustained by π-π interactions between phenyl rings of the CBZ.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). The 1° amine unsymmetrical and symmetrical stretching was shifted down to 3418 cm^{-1}; aliphatic aldehyde and 1° amide C=O stretching was shifted up to 1690 cm^{-1}; N-H in-plane bending at 1669 cm^{-1}; C-H aldehyde stretching at 2861 cm^{-1} and H-C=O bending at 1391 cm^{-1}.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 128.46 degrees C (endotherm), m.p. = 121-124 degrees C (MEL-TEMP), (carbamazepine m.p. = 190.2 degrees C, *p*-phthalaldehyde m.p. = 116 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 17.66% weight loss starting at 30.33 degrees C then a 17.57% weight loss starting at 100.14 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα ($\lambda = 1.540562$), 30kV, 15mA). The powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from the single crystal data, experimental (calculated): 8.5

NPC-UNIV-000004441
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 63 of 1101

(8.7); 10.6 (10.8); 11.9 (12.1); 14.4 (14.7) 15.1 (15.2); 18.0 (18.1); 18.5 (18.2); 19.8 (18.7); 23.7 (24.0); 24.2 (24.2); 26.4 (26.7); 27.6 (27.9); 27.8 (28.2); 28.7 (29.1); 29.3 (29.6); 29.4 (29.8).

Example 31

Carbamazepine:nicotinamide (Form II) (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 12 mg (0.0982 mmol) nicotinamide were dissolved in 4 mL of DMSO, methanol or ethanol. Slow evaporation of the solvent yielded colorless needles of a 1:1 carbamazepine/nicotinamide co-crystal, as shown in Figure 51.

Using a separate method, 25 mg (0.1058 mmol) carbamazepine and 12 mg (0.0982mmol) nicotinamide were ground together with mortar and pestle. The solid was determined to be 1:1 carbamazepine/nicotinamide microcrystals (PXRD).

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{21}H_{18}N_4O_2$, M = 358.39, monoclinic $P2_1/n$; a = 5.0961(8), b = 17.595(3), c = 19.647(3) Å, β = 90.917(3)°, U = 1761.5(5) Å^3, T = 200(2) K, Z = 4, μ(Mo-Kα) = 0.090 mm^{-1}, D_c = 1.351 Mg/m^3, λ = 0.71073 Å, F(000) = 752, $2\theta_{max}$ = 56.60°, 10919 reflections measured, 4041 unique (R_{int} = 0.0514). Final residuals for 248 parameters were R_1 = 0.0732, wR_2 = 0.1268 for I>2σ(I), and R_1 = 0.1161, wR_2 = 0.1430 for all 4041 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamide homodimers. The 1° amines are bifurcated to the carbonyl of the nicotinamide on each side of the dimer. The 1° amines of each nicotinamide are hydrogen bonded to the carbonyl of the adjoining dimer. The dimers form chains with π-π interactions from the phenyl groups of the CBZ.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), unsymmetrical and symmetrical stretching shifts down to 3443 cm^{-1} and 3388 cm^{-1} accounting for 1° amines; 1° amide C=O stretching at 1690 cm^{-1}; N-H in-plane bending at 1614 cm^{-1}; C=C stretching shifted down to 1579 cm^{-1}; aromatic H's from 800 cm^{-1} to 500 cm^{-1} are present.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 74.49 degrees C (endotherm) and 159.05 degrees C (endotherm), m.p. = 153-158 degrees C (MEL-TEMP), (carbamazepine m.p. = 190.2 degrees C, nicotinamide m.p. = 150-160 degrees C).

NPC-UNIV-000004442
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 64 of 1101

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 57.94% weight loss starting at 205.43 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD: Showed analogous peaks to the simulated PXRD derived from the single crystal data. PXRD analysis experimental (calculated): 6.5 (6.7); 8.8 (9.0); 10.1 (10.3); 13.2 (13.5); 15.6 (15.8); 17.7 (17.9); 17.8 (18.1); 18.3 (18.6); 19.8 (20.1); 20.4 (20.7); 21.6 (22.); 22.6 (22.8); 22.9 (23.2); 26.4 (26.7); 26.7 (27.0); 28.0 (28.4).

Example 32

Carbamazepine:saccharin (Form II) (1:1 stoichiometry)

25 mg (0.1058mmol) carbamazepine and 19 mg (0.1037 mmol) saccharin were dissolved in approximately 4 mL ethanol. Slow evaporation of the solvent yielded colorless needles of a 1:1 carbamazepine/saccharin cocrystal, as shown in Figure 52. Solubility measurements indicate that this multiple-component crystal of carbamazepine has improved solubility over previously known forms of carbamazepine (*e.g.*, increased molar solubility and longer solubility in aqueous solutions).

Crystal data: (Bruker SMART-APEX CCD Diffractometer), $C_{22}H_{17}N_3O_4S_1$, M = 419.45, triclinic *P-1*; a = 7.5140(11), b = 10.4538(15), c = 12.6826(18) Å, α = 83.642(2)°, β = 85.697(2) °, γ = 75.411(2) °, U = 957.0(2) Å^3, T = 200(2) K, Z = 2, μ(Mo-Kα) = 0.206 mm^{-1}, D_c = 1.456 Mg/m^3, λ = 0.71073 Å, F(000) = 436, $2\theta_{max}$ = 56.20°; 8426 reflections measured, 4372 unique (R_{int} = 0.0305). Final residuals for 283 parameters were R_1 = 0.0458, wR_2 = 0.1142 for I>2σ(I), and R_1 = 0.0562, wR_2 = 0.1204 for all 4372 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamide homodimers. The 2° amines of the saccharin are hydrogen bonded to the carbonyl of the CBZ on each side forming a tetramer. The crystal has a space group of *P-1* with π-π interactions between the phenyl groups of the CBZ and the saccharin phenyl groups.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), unsymmetrical and symmetrical stretching shifts up to 3495 cm^{-1} accounting for 1° amines; C=O aliphatic stretching was shifted up to 1726 cm^{-1}; N-H in-plane bending at 1649 cm^{-1}; C=C stretching shifted down to 1561 cm^{-1}; (O=S=O) sulfonyl peak at 1330 cm^{-1} C-N aliphatic stretching 1175 cm^{-1}.

NPC-UNIV-000004443
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 65 of 1101

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 75.31 degrees C (endotherm) and 177.32 degrees C (endotherm), m.p. = 148-155 degrees C (MEL-TEMP); (carbamazepine m.p. = 190.2 degrees C, saccharin m.p. = 228.8 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), 3.342% weight loss starting at 67.03 degrees C and a 55.09% weight loss starting at 118.71 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα (λ = 1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from the single crystal data, experimental (calculated): 6.9 (7.0); 12.2 (12.2); 13.6 (13.8); 14.0 (14.1); 14.1 (14.4); 15.3 (15.6); 15.9 (15.9); 18.1 (18.2); 18.7 (18.8); 20.2 (20.3); 21.3 (21.5); 23.7 (23.9); 26.3 (26.4); 28.3 (28.3).

Example 33

Carbamazepine:2,6-pyridinedicarboxylic acid (2:3 stoichiometry)

36 mg (0.1524 mmol) carbamazepine and 26 mg (0.1556 mmol) 2,6-pyridinedicarboxylic acid were dissolved in approximately 2 mL ethanol. Slow evaporation of the solvent yielded clear needles of a 1:1 carbamazepine/2,6-pyridinedicarboxylic acid co-crystal, as shown in Figure 54A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{22}H_{17}N_3O_5$, M=403.39, orthorhombic P2(1)2(1)2(1); a=7.2122, b=14.6491, c=17.5864 Å,α=90°, β=90°, γ=90°, V=1858.0(2) $Å^3$, T=100 K, Z=4, μ(MO-Kα)=0.104 mm^{-1}, D_c=1.442 Mg/m^3, λ=0.71073Å , F(000)840, $2\theta_{max}$=28.3. 16641 reflections measured, 4466 unique (R_{int}=0.093). Final residuals for 271 parameters were R_1=0.0425 and wR_2=0.0944 for I>2σ(I).

Crystal packing: Each hydrogen on the CBZ 1° amine is hydrogen bonded to a carbonyl group of a different 2,6-pyridinedicarboxylic acid moiety. The carbonyl of the CBZ carboxamide is hydrogen bonded to two hydroxide groups of one 2,6-pyridinedicarboxylic acid moitey.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3439 cm^{-1}, (N-H stretch, 1° amine, CBZ); 1734 cm^{-1}, (C=O); 1649 cm^{-1} , (C=C).

Melting Point: 214-216 degrees C (MEL-TEMP). (carbamazepine m.p. = 191-192 degrees C, 2,6-pyridinedicarboxylic acid m.p. = 248-250 degrees C).

NPC-UNIV-000004444
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 66 of 1101

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 69% weight loss starting at 215 degrees C and a 17% weight loss starting at 392 degrees C followed by complete decomposition.

Example 34

Carbamazepine:5-nitroisophthalic acid (1:1 stoichiometry)

40 mg (0.1693 mmol) carbamazepine and 30 mg (0.1421 mmol) 5-nitroisophthalic acid were dissolved in approximately 3 mL methanol or ethanol. Slow evaporation of the solvent yielded yellow needles of a 1:1 carbamazepine/5-nitroisophthalic acid co-crystal, as shown in Figure 55A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{47}H_{40}N_6O_{16}$, M=944.85, monoclinic C2/c; a=34.355(8), b=5.3795(13), c=23.654(6) Å,α=90°, β=93.952(6)°, γ=90°, V=4361.2(18)Å^3, T=200(2) K, Z=4, μ(MO-Kα)=0.110 mm^{-1}, D_c=1.439 Mg/m^3, λ=0.71073Å, F(000)1968, $2\theta_{max}$=26.43°. 11581 reflections measured, 4459 unique (R_{int}=0.0611). Final residuals for 311 parameters were R_1=0.0725, wR_2=0.1801 for I>2σ(I), and R_1=0.1441, wR_2=0.1204 for all 4459 data.

Crystal packing: The co-crystals are sustained by hydrogen bonded carboxylic acid homodimers between the two 5-nitroisophthalic acid moieties and hydrogen bonded carboxy-amide heterodimers between the carbamazepine and 5-nitroisophthalic acid moiety. There is solvent hydrogen bonded to an additional N-H donor from the carbamazepine moiety.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3470 cm^{-1}, (N-H stretch, 1° amine, CBZ); 3178 cm^{-1}, (C-H stretch, alkene); 1688 cm^{-1}, (C=O); 1602 cm^{-1}, (C=C).

Differential Scanning Calorimetry: (TA Instruments 2920 DSC). 190.51 degrees C (endotherm). m.p. = NA (decomposes at 197-200 degrees C) (MEL-TEMP). (carbamazepine m.p. = 191-192 degrees C, 5-nitroisophthalic acid m.p. = 260-261 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 32.02% weight loss starting at 202 degrees C, a 12.12% weight loss starting at 224 degrees C and a 17.94% weight loss starting at 285 degrees C followed by complete decomposition.

NPC-UNIV-000004445
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 67 of 1101

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3 to 40 2 in continuous scan mode using a step size of 0.02 2 and a scan speed of 2.0 /min. PXRD: Showed analogous peaks to the simulated PXRD derived from the single crystal data. PXRD analysis experimental (calculated): 10.138 (10.283), 15.291 (15.607), 17.438 (17.791), 21.166 (21.685), 31.407 (31.738), 32.650 (32.729).

Example 35

Carbamazepine:1,3,5,7-adamantane tetracarboxylic acid (1:1 stoichiometry)

15 mg (0.1524 mmol) carbamazepine and 20 mg (0.1556 mmol) 1,3,5,7-adamantanetetracarboxylic acid were dissolved in approximately 1 mL methanol or 1 mL ethanol. Slow evaporation of the solvent yields clear plates of a 2:1 carbamazepine/1,3,5,7-adamantanetetracarboxylic acid co-crystal, as shown in Figure 56A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{44}H_{40}N_2O_{10}$, M=784.80, monoclinicC2/c; a=18.388(4), b=12.682(3), c=16.429(3) Å, β=100.491(6)°, V=3767.1(14) $Å^3$, T=100(2) K, Z=4, μ(MO-Kα)=0.099 mm^{-1}, D_c=1.384 Mg/m^3, λ=0.71073Å , F(000)1648, $2\theta_{max}$=28.20°. 16499 reflections measured, 4481 unique (R_{int}=0.052). Final residuals for 263 parameters were R_1=0.0433 and wR_2=0.0913 for I>2σ(I).

Crystal packing: The co-crystals form a single 3D network of four tetrahedron, linked by square planes similar to the *PtS* topology. The crystals are sustained by hydrogen bonding.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3431 cm^{-1}, (N-H stretch, 1° amine, CBZ); 3123 cm^{-1}, (C-H stretch, alkene); 1723 cm^{-1}, (C=O); 1649 cm^{-1}, (C=C).

Melting Point: (MEL-TEMP). 258-260 degrees C (carbamazepine m.p. = 191-192 degrees C, adamantanetetracarboxylic acid m.p. = >390 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 9% weight loss starting at 189 degrees C, a 52% weight loss starting at 251 degrees C and a 31% weight loss starting at 374 degrees C followed by complete decomposition.

Example 36

NPC-UNIV-000004446
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 68 of 1101

Carbamazepine:benzoquinone (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 11 mg (0.1018 mmol) benzoquinone was dissolved in 2 mL methanol or THF. Slow evaporation of the solvent produced an average yield of yellow crystals of a 1:1 carbamazepine/benzoquinone co-crystal, as shown in Figure 57A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{21}H_{16}N_2O_3$, M=344.36, monoclinic P2(1)/c; a=10.3335(18), b=27.611(5), c=4.9960(9) Å, β=102.275(3)°, V=1392.9(4) $Å^3$, T=100(2) K, Z=3, D_c=1.232 Mg/m^3, μ(MO-Kα)=0.084 mm^{-1}, λ=0.71073Å , F(000)540, $2\theta_{max}$=28.24°. 8392 reflections measured, 3223 unique (R_{int}=0.1136). Final residuals for 199 parameters were R_1=0.0545 and wR_2=0.1358 for I>2σ(I), and R_1=0.0659 and wR_2=0.1427 for all 3223 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamide homodimers. Each 1° amine on the CBZ is bifurcated to a carbonyl group of a benzoquinone moiety. The dimers form infinite chains.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3420 cm^{-1}, (N-H stretch, 1° amine, CBZ); 2750 cm^{-1}, (aldehyde stretch); 1672 cm^{-1}, (C=O); 1637 cm^{-1}, (C=C, CBZ).

Melting Point: 170 degrees C (MEL-TEMP). (carbamazepine m.p. = 191-192 degrees C, benzoquinone m.p. = 115.7 degrees C).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 20.62% weight loss starting at 168 degrees C and a 78% weight loss starting at 223 degrees C followed by complete decomposition.

Example 37

Carbamazepine:trimesic acid (Form II) (1:1 stoichiometry)

36 mg (0.1524 mmol) carbamazepine and 31 mg (0.1475 mmol) trimesic acid were dissolved in a solvent mixture of approximately 2 mL methanol and 2 mL dichloromethane. Slow evaporation of the solvent mixture yielded white starbursts of a 1:1 carbamazepine/trimesic acid co-crystal, as shown in Figure 58A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). $C_{24}H_{18}N_2O_7$, M=446.26, monoclinic C2/c; a=32.5312(50), b=5.2697(8), c=24.1594(37) Å,α=90°, β=98.191(3)°, γ=90°, V=4099.39(37) $Å^3$, T=-173 K, Z=8, μ(MO-Kα)=0.110 mm^{-1}, D_c=1.439 Mg/m^3, λ=0.71073Å, F(000)1968, $2\theta_{max}$=26.43°. 11581 reflections

NPC-UNIV-000004447
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 69 of 1101

measured, 4459 unique (R_{int}=0.0611). Final residuals for 2777 parameters were R_1=0.1563, wR_2=0.1887 for I>2σ(I), and R_1=0.1441, wR_2=0.1204 for all 3601 data.

Crystal packing: The co-crystals are sustained by hydrogen bonded carboxylic acid homodimers between carbamazepine and trimesic acid moieties and hydrogen bonded carboxylic acid-amine heterodimers between two trimesic acid moieties arranged in a stacked ladder formation.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3486 cm^{-1}(N-H stretch, 1° amine, CBZ); 1688 cm^{-1} (C=O, 1° amide stretch, CBZ); 1602 cm^{-1} (C=C, CBZ).

Differential Scanning Calorimetry: (TA Instruments 2920 DSC). 273 degrees C (endotherm). m.p. = NA, decomposes at 278 degrees C (MEL-TEMP). (carbamazepine m.p. = 191-192 degrees C, trimesic acid m.p. = 380 degrees C)

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 62.83% weight loss starting at 253 degrees C and a 30.20% weight loss starting at 278 degrees C followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using CuKα (λ=1.540562), 30kV, 15mA). The powder data were collected over an angular range of 3 to 40 2 in continuous scan mode using a step size of 0.02 2 and a scan speed of 2.0 /min. PXRD analysis experimental: 10.736, 12.087, 16.857, 24.857, 27.857.

NPC-UNIV-000004448
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 70 of 1101

Table V. Detailed Characterization of Co-Crystals All PXRD peaks are in units of degrees 2-theta All Raman shifts are in units of cm^{-1}
Carbamazepine: Saccharin PXRD (Form I): 7.01, 12.07, 14.09, 15.41, 18.47, 20.13, 22.01, 23.57, 24.41, 28.31 (Fig. 1) PXRD (Form II): 6.9, 12.2, 13.6, 14.0, 14.1, 15.3, 15.9, 18.1, 18.7, 20.2, 21.3, 23.7, 26.3, 28.3 DSC (Form I): Broad endotherm at 161.9 degrees C (Fig. 2) TGA (Form I): Decomposition above 200 degrees CDSC (Form II): Endothermic transitions at 75.31 and 177.32 degrees C TGA (Form II): 3.342 percent weight loss starting at 67.03 degrees C, 55.09 percent weight loss starting at 118.71 degrees C, followed by decomposition Method: CMAX
Carbamazepine: Nicotinamide PXRD (Form I): 4.97, 6.67, 8.75, 10.25, 13.25, 17.91, 18.49, 19.95, 20.49, 22.73, 24.39, 26.49 (Fig. 3) PXRD (Form II): 6.5, 8.8, 10.1, 13.2, 15.6, 17.7, 17.8, 18.3, 19.8, 20.4, 21.6, 22.6, 22.9, 26.4, 26.7, 28.0 DSC (Form I): Sharp endotherm at 156.9 degrees C (Fig. 4) TGA (Form I): Decomposition beginning at ~150 degrees CDSC (Form II): Endothermic transitions at 74.49 and 159.05 degrees C TGA (Form II): 57.94 percent weight loss starting at 205.43 degrees C, followed by decomposition Method: CMAX
Carbamazepine: Trimesic acid PXRD (Form I): 10.89, 12.23, 14.83, 16.25, 17.05, 18.13, 18.47, 21.47, 21.95, 24.57, 25.11, 27.99 (Fig. 5) PXRD (Form II): 10.74, 12.09, 16.86, 24.86, 27.86 DSC (Form II): Endothermic transition at 273 degrees C TGA (Form II): 62.83 percent weight loss starting at 253 degrees C, 30.20 percent weight loss starting at 278 degrees C, followed by decomposition Method: CMAX
Celecoxib: Nicotinamide PXRD: 3.77, 7.56, 9.63, 14.76, 15.21, 16.01, 17.78, 18.68, 19.31, 20.44, 21.19, 22.10 DSC: Two endothermic transitions at 117.2 and 118.8 degrees C and a sharp endotherm at 129.7 degrees C TGA: Decomposition beginning at ~150 degrees C Raman: 1617.5, 1598.7, 1452.1, 1370.3, 1162.5, 1044.3, 972.9, 796.4, 631.8, 392.5, 205.9 Method: Slow evaporation of a 1:1 solution from acetone

NPC-UNIV-000004449
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 71 of 1101

Table V (Continued)
Topiramate: 18-Crown-6 PXRD: 10.79, 11.07, 12.17, 13.83, 16.13, 18.03, 18.51, 18.79, 19.21, 21.43, 22.25, 24.11 (Fig. 6) DSC: Sharp endotherm at 134.7 degrees C, followed by an exotherm at 203 degrees C (Fig. 7) TGA: Rapid decomposition beginning at ~ 135 degrees C and leveling off slightly after 200 degrees C Raman: 2994.5, 2942.7, 1471.6, 1427.4, 1261.7, 849.4, 804.5, 745.1, 629.2, 280.4, 225.9 Method: Addition of an ether solution containing 1 equivalent of topiramate to an ether solution containing 18-crown-6. Product precipitated following minor agitation of the combined mixture and was collected.
Olanzapine: Nicotinamide PXRD (Form I): 4.89, 8.65, 12.51, 14.19, 15.59, 17.15, 19.71, 21.05, 23.95, 24.59, 25.53, 26.71 (Fig. 8) PXRD (Form II): 6.41, 12.85, 18.67, 21.85, 24.37 (Fig.30) PXRD (Form III): 6.41, 12.85, 14.91, 18.67, 21.85, 24.37 (Fig. 31) DSC (Form I): Slightly broad endotherm at 126.1 degrees C (Fig. 9) Method: See above
Celecoxib: 18-Crown-6 PXRD: 8.73, 11.89, 12.57, 13.13, 15.01, 16.37, 17.03, 17.75, 18.45, 20.75, 22.37, 23.11, 24.33, 24.97, 26.61, 28.15 (Fig. 10) DSC: Sharp endotherm at 189.6 degrees C (Fig. 11) TGA: Decomposition above 200 degrees C with a 25% weight loss between ~190-210 degrees C Method: A solution containing one equivalent of celecoxib in ether was added to a solution containing 18-crown-6. A white solid formed immediately and was collected.
Itraconazole: Succinic Acid PXRD: 3.0, 6.0, 8.1, 9.0, 17.1, 24.5 (Fig. 12) DSC: Single endothermic transition at 160.1 degrees C ± 1.0 degrees C (Fig. 13) TGA: Less than 0.1 % volatile components by weight Method: See above
Itraconazole: Fumaric Acid PXRD: 4.6, 5.9, 9.2, 10.6, 19.1, 20.8 (Fig. 14) DSC: The material had a weak endothermic transition at 141.7 degrees C and a strong endothermic transition at 179.58 degrees C (Fig. 15) TGA: The sample loses 0.5 % of its weight on the TGA between room temperature and 100 degrees C Method:
Itraconazole: Tartaric Acid PXRD: 4.1, 6.2, 8.3, 20.7, 25.6, 26.3 (Fig. 16) DSC: An endothermic transition at 180.74 degrees C (Fig. 17) TGA: Less than 0.1 % volatile components by weight by TGA. Method: See above

NPC-UNIV-000004450
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 72 of 1101

Table V (Continued)
Itraconazole: Malic acid PXRD: 4.4, 5.9, 8.8, 17.7, 20.0, 21.1, 22.6 (Fig. 18) DSC: The sample has a strong endothermic transition at 154.36 degrees C (Fig.19) TGA: The sample contained less than 0.1% volatile components by weight Method: See above
ItraconazoleHCl: Tartaric acid PXRD: 3.7, 11.0, 13.8, 16.5, 17.8 (Fig. 20) DSC: The sample has a peak endothermic transition at 161degrees C (Fig. 21) TGA: The sample contained less than 0.1 % volatile components by weight Method: See above
Modafinil: Malonic acid PXRD: 5.00, 9.17, 16.81, 18.26, 19.43, 21.36, 21.94, 22.77, 24.49, 25.63, 28.45 (Fig. 22) DSC: Endothermic transition at 106.23 degrees C (Fig. 40) Raman: 1601, 1183, 1032, 1004, 814, 633, 265, 222 (Fig. 42) Method: See above
Modafinil: Benzamide PXRD: 5.11, 9.35, 10.25, 10.79, 14.07, 16.87, 18.33, 19.53, 21.38, 22.05, 22.89, 23.57, 24.73, 25.19, 25.81, 26.51, 28.60 (Fig. 23) Method: Slow evaporation from a 1:1 solution in 1,2-dichoroethane
Modafinil: Mandelic acid PXRD: 6.11, 6.75, 9.53, 10.31, 14.77, 15.77, 16.99, 18.03, 20.01, 21.61, 22.47, 23.27, 25.27, 25.75, 27.23 (Fig. 24) Method: Slow evaporation from a 1:1 solution in acetone
Modafinil: Glycolic acid PXRD: 6.09, 9.51, 14.91, 15.97, 19.01, 20.03, 21.59, 22.43, 22.75, 23.75, 25.03, 25.71 (Fig. 25) Method: Slow evaporation from a 1:1 solution in acetone
Modafinil: Fumaric acid PXRD: 5.87, 7.19, 8.95, 12.49, 13.99, 16.13, 17.09, 18.19, 19.99, 21.57, 23.48, 25.01, 25.79, 28.17, 28.87, 29.69, 32.19 (Fig. 26) Method: Slow evaporation from a 1:1 solution in 1,2-dichoroethane
Modafinil: Maleic acid PXRD: 4.69, 6.15, 9.61, 10.23, 15.65, 16.53, 17.19, 18.01, 19.27, 19.53, 19.97, 21.83, 22.45, 25.65 (Fig. 43) Method: See above
5-fluorouracil: Urea PXRD: 11.23, 12.69, 13.27, 15.93, 16.93, 20.37, 23.65, 25.55, 26.87, 32.49 (Fig. 36) DSC: Sharp endotherm at 207.6 degrees C (Fig. 33) TGA: 32 percent weight loss between 150 and 220 degrees C (Fig. 34) Raman: 1347.1, 1024.4, 756.9, 643.7, 545.3 (Fig. 35) Method: See above
Hydroclorothiazide: Nicotinic acid PXRD: 8.57, 13.23, 14.31, 16.27, 17.89, 18.75, 21.13, 21.45, 24.41, 25.73, 26.57, 27.43 (Fig. 37) Method: See above

NPC-UNIV-000004451
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 73 of 1101

Table V (Continued)
Hydrochlorothiazide: 18-crown-6 PXRD: 9.97, 10.43, 11.57, 11.81, 12.83, 14.53, 15.67, 16.61, 19.05, 20.31, 20.65, 21.09, 21.85, 22.45, 23.63, 24.21, 25.33, 26.73 (Fig. 38) Method: See above
Hydrochlorothiazide: piperazine PXRD: 6.85, 13.75, 15.93, 18.71, 20.67, 20.93, 23.27, 24.17, 28.33, 28.87, 30.89 (Fig. 39) Method: See above
Acetaminophen: 4,4'-bipyridine:water DSC: Endothermic transition at 57.77 degrees C Method: See above
Phenytoin: Pyridone PXRD: 5.2, 11.1, 15.1, 16.2, 16.7, 17.8, 19.4, 19.8, 20.3, 21.2, 23.3, 26.1, 26.4, 27.3, 29.5 DSC: Endothermic transitions at 233.39 and 271.33 degrees C TGA: 29.09 percent weight loss starting at 192.8 degrees C, 48.72 percent weight loss starting at 238.27 degrees C, 18.38 percent weight loss starting at 260.17 degrees C, followed by decomposition Method: See above
Aspirin: 4,4'-bipyridine DSC: Endothermic transition at 95.14 degrees C TGA: 9 percent weight loss starting at 22.62 degrees C, 49.06 percent weight loss starting at 102.97 degrees C, decomposition starting at 209.37 degrees C Method: See above
Ibuprofen: 4,4'-bipyridine PXRD: 3.4, 6.9, 10.4, 17.3, 19.1 DSC: Endothermic transitions at 64.85 and 118.79 degrees C TGA: 13.28 percent weight loss between room temperature and 100.02 degrees C followed by decomposition Method: See above
Flurbiprofen: 4,4'-bipyridine PXRD: 16.8, 17.1, 18.1, 19.0, 20.0, 21.3, 22.7, 25.0, 26.0, 26.0, 26.1, 28.2, 29.1 DSC: Endothermic transition at 162.47 degrees C TGA: 30.93 percent weight loss starting at 31.13 degrees C, 46.26 percent weight loss starting at 168.74 degrees C, followed by decomposition Method: See above
Flurbiprofen:trans-1,2-bis (4-pyridyl) ethylene PXRD: 3.6, 17.3, 18.1, 18.4, 19.1, 22.3, 23.8, 25.9, 28.1 DSC: Endothermic transitions at 100.01, 125.59, and 163.54 degrees C TGA: 91.79 percent weight loss starting at 133.18 degrees C followed by decomposition Method: See above

NPC-UNIV-000004452
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 74 of 1101

Table V (Continued)
Carbamazepine: p-phthalaldehyde PXRD: 8.5, 10.6, 11.9, 14.4, 15.1, 18.0, 18.5, 19.8, 23.7, 24.2, 26.4, 27.6, 27.8, 28.7, 29.3, 29.4 DSC: Endothermic transition at 128.46 degrees C TGA: 17.66 percent weight loss starting at 30.33 degrees C, 17.57 percent weight loss starting at 100.14 degrees C, followed by decomposition Method: See above
Carbamazepine: 2,6-pyridinecarboxylic acid TGA: 69 percent weight loss starting at 215 degrees C, 17 percent weight loss starting at 392 degrees C, followed by decomposition Method: See above
Carbamazepine: 5-nitroisophthalic acid PXRD: 10.14, 15.29, 17.44, 21.17, 31.41, 32.65 TGA: 32.02 percent weight loss starting at 202 degrees C, 12.12 percent weight loss starting at 224 degrees C, 17.94 percent weight loss starting at 285 degrees C, followed by decomposition Method: See above
Carbamazepine: 1,3,5,7-adamantane tetracarboxylic acid TGA: 9 percent weight loss starting at 189 degrees C, 52 percent weight loss starting at 251 degrees C, 31 percent weight loss starting at 374 degrees C, followed by decomposition Method: See above
Carbamazepine: Benzoquinone TGA: 20.62 percent weight loss starting at 168 degrees C, 78 percent weight loss starting at 223 degrees C, followed by decomposition Method: See above

Example 38

A co-crystal with a modulated dissolution profile has been prepared. Celecoxib: nicotinamide co-crystals were prepared via methods shown in example 4. (See Fig. 27)

Example 39

A co-crystal with a modulated dissolution profile has been prepared. Itraconazole: succinic acid, itraconazole:tartaric acid and itraconazole:malic acid co-crystals were prepared via methods shown in examples 8, 10 and 11. (See Fig. 28)

NPC-UNIV-000004453
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 75 of 1101

Example 40

A co-crystal of an unsaltable or difficult to salt API has been prepared. Celecoxib: nicotinamide co-crystals were prepared via methods shown in example 4.

Example 41

A co-crystal with an improved hygroscopicity profile has been prepared. Celecoxib: nicotinamide co-crystals were prepared via methods shown in example 4. (See Fig. 29)







Example 42

A co-crystal with reduced form diversity as compared to the API has been prepared. Co-crystals of carbamazepine and saccharin have been prepared via method shown in example 1.

NPC-UNIV-000004454

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 76 of 1101






TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
1-Hydroxy-2-naphthoic acid	188.18	191-192	2	Carboxylic acid, alcohol	1	2		2.7, 13.5
4-aminobenzoic acid	137.14	187-188	2	Amine, carboxylic acid	1	3		4.7, 4.8
4-aminopyridine	94.11	158-159	3	Amine, pyridine	1	2		10
4-Chlorobenzene-sulfonic acid	192.63	67	1	SO_3H	3	1		0-1
4-ethoxyphenyl urea	180.2	173-174	3	Amide, NH	2	3		~7-9
7-oxo-DHEA	303	190-192	1	Alcohol, Ketone	3	1		

NPC-UNIV-000004455

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 77 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Acesulfame	163.15	123-124	3	SO_2, Amide	4	1		~5-7
Acetohydroxamic acid	75.07	89-92	3	Amide, NH, OH	2	2		8.7
Adenine	135.13	220 (sub.)	1	Amine, NH	3	3		3.8
Adipic Acid	146.14	152	1	Carboxylic acid	2	2	$HOOC(CH_2)_4COOH$	4.44, 5.44
Alanine	89.09	289-291	1	Amine, carboxillic acid	1	3		2.35, 9.87
Allopurinaol	136.11	> 350	3	OH, NH	4	2		10.2

NPC-UNIV-000004456

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 78 of 1101






TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Arginine	174.2	244 (dec.)	1	Amine, COOH	2	7		2.18, 9.09, 13.2
Ascorbic acid	176.12	190-192	1	C=O, OH	6	4		4.17, 11.57
Asparagine	132.12	234-235	1	Amine, amide, COOH	3	5		2.02, 8.5
Aspartic acid	133.1	270-271	1	Amine, COOH	2	4		1.88, 3.65, 9.60
Benzenesulfonic Acid	158.18	43-44	1	SO_3H	2	1		0.70, 1.58
Benzoic acid*	122.12	122-123	2	COOH	1	1		4.19

NPC-UNIV-000004457

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 79 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Caffeine	194.19	238	3	C=O	3	0		
Camphoric acid	200.23	186-189	2	Carboxylic acid	2	2		4.72, 5.83
Capric acid	172.27	31.4	1	Carboxylic acid	1	1	$CH_3(CH_2)_8COOH$	4.9
Chrysin	254.24	285	1	Phenol, ether, ketone	2	2		
Cinnamic acid	144.2	133	3	Carboxylic acid	1	1		4.4
Citric Acid	192.12	153	1	OH, COOH	4	4		3.13, 4.76, 6.40

NPC-UNIV-000004458

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 80 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Clemizole	325.84	167	1	Pyrrolidine	3	0		
Cyclamic acid	179.24	169-170	3	NH, SO_3H	2	2		-2
Cysteine	121.15	---	1	Amine, COOH, SH	2	4		1.71, 8.33, 10.78
Dimethylglycine	103.1	178-192	1	Amine, Carboxylic acid	2	1		2.5
D-Ribose	150.13	87	1	Alcohol, ether	1	4		
Fumaric acid	116.07	287	1	COOH	2	2		3.03, 4.38

NPC-UNIV-000004459

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 81 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Galactaric acid	210.14	255 (dec)	1	Carboxylic acid, alcohol	2	6		3.08, 3.63
Genistein	270.24	297-298	1	Alcohol, Phenol, ether, ketone	2	3		
Gentisic acid	154.12	199-200 form I, 205 form II	2	Carboxylic acid, alcohol, phenol	1	3		2.93
Glucamine, N-Methyl	195.22	128-129	1	Alcohol, Amine	5	6		8.03(B)
Gluconic acid	196.15	131	1	OH, COOH	6	6		3.76
Glucosamine	179.17	88	1	OH	5	6		6.91

NPC-UNIV-000004460

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 82 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Glucuronic acid	194.14	165	1	Carboxylic acid, alcohol, aldehyde	2	5		3.18
Glutamic acid	147.13	160	1	Amine, COOH	2	4		2.19, 4.25, 9.67
Glutamine	146.15	185-186	1	Amine, Amide, COOH	2	5		2.17, 9.13
Glutaric acid	132.11	98-98	1	COOH	2	2		2.7, 4.5
Glycine	75.07	182	1	Amine, COOH	2	3		2.34, 9.6
Glycolic acid	76.05	80	1	OH, COOH	2	2		3.82

NPC-UNIV-000004461

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 83 of 1101






TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Hippuric acid	179.17	187-188	1	Amide, NH, COOH	2	2		3.55
Histidine	155.16	287 (dec.)	1	Amine, COOH, Imidazole	2	4		1.78, 5.97, 8.97
Hydroquinone*	110.11	170-171	2	OH, Phenol	2	2		~10
Imidazole	68.08	90-91	1	NH	1	1		6.92
Ipriflavone	280.32	115-117	1	Ketone, ether	3	0		
Isoleucine	131.17	168-170 (sub.)	1	Amine, COOH	1	3		2.32, 9.76

NPC-UNIV-000004462

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 84 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Lactobionic acid	358.3	128-130	2	Alcohol, carboxylic acid, ether	1	9		3.2
Lauric acid	200.32	44-48	1	Carboxylic acid	1	1	$CH_3(CH_2)_{10}COOH$	~4.5
Leucine	131.17	145-148 (sub.)	1	Carboxylic acid, amine	1	3		2.36, 9.6
Lysine	146.19	225 (dec.)	1	Amine, COOH	1	5		2.2, 8.9, 10.28
Maleic	116.07	138-139	1	COOH	2	2		1.92, 6.23
Malic acid	134.09	131-132	1	OH, COOH	3	3		3.46, 5.1

NPC-UNIV-000004463

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 85 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Malonic	104.06	135	1	COOH	2	2		2.83, 5.70
Mandelic acid	152.15	119	1	OH, COOH	2	2		3.37
Methionine	149.21	280-282 (dec.)	1	Amine, COOH, S-Me	2	3		2-3, 9
Nicotinamide	122.12	128-131	1	Pyridine, amide	2	2		3.3
Nicotinic acid	123.11	236-237	2	Carboxylic acid, pyridine	2	1		2.07(B), 4.85
Orotic acid	156.1	345-346	2	Carboxilic acid, lactam	3	3		5.85, 8.95

NPC-UNIV-000004464

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 86 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Oxalic acid	90.04	189 (dec)	2	Carboxilic acid	2	2		1.27, 4.27
Palmitic acid	256.43	63-64	1	Carboxylic acid	1	1	$CH_3(CH_2)_{14}COOH$	4.9
Pamoic	388.38	280 (dec)	2	Carboxylic acid, phenol	2	4		2.51, 3.1
Phenylalanine	165.19	283 (dec.)	1	Amine, COOH	1	3		~2, ~9
Piperazine	86.14	106	1	NH	0	2		9.82(B)
Procaine	236.31	61	1	Amine, C=O	2	2		8.9(B)
Proline	115.13	220-222 (dec.)	1	COOH, NH	1	2		1.99, 10.6

NPC-UNIV-000004465

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 87 of 1101






TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
p-Toluenesulfonic acid	172.2	106-107	2	Sulfonic acid	2	1		-1.34
Pyridoxamine	168	193-194	2	OH, Amine, Pyridine	3	4		~9
Pyridoxine	170	160	2	Alcohol, Pyridine	3	3		~9
Pyroglutamic acid	129.12	162	2	Carboxylic acid, Lactam	2	2		3.32
Quercetin	302.24	314 dec.	1	Phenol, ether, ketone	2	5		
Resveratrol	228.24	253-255	1	Phenol	0	3		

NPC-UNIV-000004466

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 88 of 1101







TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Saccharin	183.19	228-230	1	Amide, C=O, S=O, N-H	3	1		2
Salicylic acid, 4-amino	153.14	150-151	3	COOH, OH, Analine	1	4		3.25, 10, 3.5(B)
Salicylic acid	138.12	159	3	COOH, OH	2	2		2.98, 13.82
Sebacic acid	202.25	134.5	1	Carboxylic acid	2	2	$HOOC(CH_2)_8COOH$	4.59, 5.59
Serine	105.09	228 (dec.)	1	Carboxylic acid, amine, OH	2	3		2.21, 9.15
Stearic acid	284.47	70-71	1	Carboxylic acid	1	1	$CH_3(CH_2)_{16}COOH$	4.9
Succinic acid	118.09	185-187	1	Carboxylic acid	2	2		4.21, 5.64

NPC-UNIV-000004467

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 89 of 1101




TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Tartaric acid	150.09	205-206	1	Carboxylic acid	4	4		3.02, 4.36
Threonine	119.12	255-257 (dec.)	1	Amine, COOH, OH	2	4		2.15, 9.12
TRIS	121.13	171-172	2	Amine, OH	3	5		5.91, 8.3
Tryptophan	204.23	289 (dec.)	1	Amine, COOH, Indole	1	4		2.38, 9.39
Tyrosine	181.19	342-344	1	Amine, COOH, OH	2	3		2.2, 9.11, 10.07
Urea	60.06	Dec.	1	C=O, NH2	1	4		~8

NPC-UNIV-000004468

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 90 of 1101

TABLE I

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	pKa Values
Valine	117.15	315	1	Amine, COOH	1	3		~4.5, ~9
Vitamin K5	209.68	280-282 (dec.)	3	Amine, OH	1	3		~9
Xylitol	152.15	93-95 (I)	2	OH	5	5		~9

NPC-UNIV-000004469

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 91 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
1,5-Napthalene-disulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
1-Hydroxy-2-naphthoic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
1-Hydroxy-2-naphthoic acid	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
4-Aminobenzoic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
4-Aminobenzoic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
4-aminopyridine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
4-aminopyridine	Pyridine	*alcohol	pyridinium	*	*amide	nitro	*amine	*Carboxylic Acid
4-Chlorobenzene-Sulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
4-ethoxyphenyl Urea	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
4-ethoxyphenyl Urea	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
7-oxo-DHEA	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
7-oxo-DHEA	Ketone	alcohol		thiol	amide	amine	analine	phenol
Acesulfame	Sulfone	pyridine	ketone	aldehyde	ether	ester	amide	carboxilic acid
Acesulfame	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Acetohydroxamic Acid	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Acetohydroxamic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Acetohydroxamic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Adenine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Adenine	N	*alcohol	pyridinium	*	*amide	nitro	*amine	*carboxilic acid
Adipic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Alanine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Alanine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Allopurinaol	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Allopurinaol	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Arginine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Arginine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Ascorbic Acid	Ketone	alcohol		thiol	amide	amine	analine	phenol
Ascorbic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Ascorbic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol

NPC-UNIV-000004470

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 92 of 1101

TABLE II

Co-crystal Former								
1,5-Napthalene-disulfonic Acid	amine	metals	thioether		sulfate	alcohol		
1-Hydroxy-2-naphthoic acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
1-Hydroxy-2-naphthoic acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
4-Aminobenzoic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
4-Aminobenzoic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
4-aminopyridine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
4-aminopyridine	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
4-Chlorobenzene-Sulfonic Acid	amine	metals	thioether		sulfate	alcohol		
4-ethoxyphenyl Urea	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
4-ethoxyphenyl Urea	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
7-oxo-DHEA	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
7-oxo-DHEA	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Acesulfame	amine	metals	thioether		sulfate	alcohol		
Acesulfame	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Acetohydroxamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Acetohydroxamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Acetohydroxamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Adenine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Adenine	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Adipic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Alanine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Alanine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Allopurinaol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Allopurinaol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Arginine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Arginine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Ascorbic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Ascorbic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Ascorbic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals

NPC-UNIV-000004471

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 93 of 1101

TABLE II

Co-crystal Former								
1,5-Napthalene-disulfonic Acid								
1-Hydroxy-2-naphthoic acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
1-Hydroxy-2-naphthoic acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
4-Aminobenzoic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
4-Aminobenzoic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
4-aminopyridine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
4-aminopyridine		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
4-Chlorobenzene-Sulfonic Acid								
4-ethoxyphenyl Urea	aldehyde	ester	ether	cyano		furan	bromine	chlorine
4-ethoxyphenyl Urea	aldehyde	ester	ether	cyano		furan	bromine	chlorine
7-oxo-DHEA	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
7-oxo-DHEA	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Acesulfame								
Acesulfame	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Acetohydroxamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Acetohydroxamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Acetohydroxamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Adenine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Adenine		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Adipic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Alanine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Alanine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Allopurinaol	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Allopurinaol	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Arginine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Arginine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Ascorbic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Ascorbic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Ascorbic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine

NPC-UNIV-000004472

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 94 of 1101

TABLE II

Co-crystal Former							
1,5-Napthalene-disulfonic Acid							
1-Hydroxy-2-naphthoic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
1-Hydroxy-2-naphthoic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
4-Aminobenzoic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
4-Aminobenzoic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
4-aminopyridine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
4-aminopyridine	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
4-Chlorobenzene-Sulfonic Acid							
4-ethoxyphenyl Urea	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
4-ethoxyphenyl Urea	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
7-oxo-DHEA	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
7-oxo-DHEA	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Acesulfame							
Acesulfame	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Acetohydroxamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Acetohydroxamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Acetohydroxamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Adenine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Adenine	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Adipic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Alanine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Alanine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Allopurinaol	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Allopurinaol	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Arginine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Arginine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Ascorbic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Ascorbic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Ascorbic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	

NPC-UNIV-000004473

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 95 of 1101

TABLE II

Co-crystal Former								
1,5-Napthalene-disulfonic Acid								
1-Hydroxy-2-naphthoic acid	carbamate	imidazole	BF4					
1-Hydroxy-2-naphthoic acid	carbamate	imidazole	BF4					
4-Aminobenzoic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
4-Aminobenzoic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
4-aminopyridine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
4-aminopyridine	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
4-Chlorobenzene-Sulfonic Acid								
4-ethoxyphenyl Urea	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
4-ethoxyphenyl Urea	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
7-oxo-DHEA	carbamate	imidazole	BF4					
7-oxo-DHEA	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Acesulfame								
Acesulfame	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Acetohydroxamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Acetohydroxamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Acetohydroxamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Adenine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Adenine	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Adipic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Alanine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Alanine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Allopurinaol	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Allopurinaol	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Arginine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Arginine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Ascorbic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Ascorbic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Ascorbic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea

NPC-UNIV-000004474

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 96 of 1101

TABLE II

Co-crystal Former			
1,5-Napthalene-disulfonic Acid			
1-Hydroxy-2-naphthoic acid			
1-Hydroxy-2-naphthoic acid			
4-Aminobenzoic Acid	iodine		
4-Aminobenzoic Acid	iodine		
4-aminopyridine	iodine		
4-aminopyridine			
4-Chlorobenzene-Sulfonic Acid			
4-ethoxyphenyl Urea	iodine	epoxide	peroxide
4-ethoxyphenyl Urea	iodine		
7-oxo-DHEA			
7-oxo-DHEA	iodine		
Acesulfame			
Acesulfame	iodine	epoxide	peroxide
Acetohydroxamic Acid	iodine	epoxide	peroxide
Acetohydroxamic Acid	iodine		
Acetohydroxamic Acid	iodine	epoxide	
Adenine	iodine		
Adenine			
Adipic acid	iodine		
Alanine	iodine		
Alanine	iodine		
Allopurinaol	iodine	epoxide	
Allopurinaol	iodine		
Arginine	iodine		
Arginine	iodine		
Ascorbic Acid	iodine		
Ascorbic Acid	iodine	epoxide	
Ascorbic Acid	iodine		

NPC-UNIV-000004475

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 97 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
Asparagine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Asparagine	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Asparagine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Aspartic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Aspartic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Benzenesulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
Benzoic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Caffeine	Ketone	alcohol		thiol	amide	amine	analine	phenol
Camphoric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Capric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Genistein	Ketone	alcohol		thiol	amide	amine	analine	phenol
Genistein	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Genistein	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
Cinnamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Citric Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Citric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Clemizole	Pyrrolidine	*alcohol	pyridinium	*	*amide	nitro	*amine	*carboxilic acid
Cyclamic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Cyclamic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
Cysteine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Cysteine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Cysteine	Thiol	carboxylic acid	sodium	aldehyde	ketone	-N	cadmium	
Dimethylglycine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Dimethylglycine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
D-ribose	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
D-ribose	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Fumaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Galactaric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Galactaric acid	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Chrysin	Ketone	alcohol		thiol	amide	amine	analine	phenol

NPC-UNIV-000004476

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 98 of 1101

TABLE II

Co-crystal Former								
Asparagine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Asparagine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Asparagine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Aspartic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Aspartic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Benzenesulfonic Acid	amine	metals	thioether		sulfate	alcohol		
Benzoic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Caffeine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Camphoric acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Capric acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Genistein	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Genistein		alchohol		ester	ether	n-oxide	chlorine	fluorine
Genistein	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Cinnamic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Citric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Citric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Clemizole	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Cyclamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Cyclamic Acid	amine	metals	thioether		sulfate	alcohol		
Cysteine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Cysteine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Cysteine	arsenic	chlorine	alcohol	potassium	Ru		Rb	Sb
Dimethylglycine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Dimethylglycine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
D-ribose	chlorine		cyano	ester	amine	nitro	nitrate	bromine
D-ribose	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Fumaric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Galactaric acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Galactaric acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Chrysin	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals

NPC-UNIV-000004477

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 99 of 1101

TABLE II

Co-crystal Former								
Asparagine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Asparagine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Asparagine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Aspartic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Aspartic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Benzenesulfonic Acid								
Benzoic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Caffeine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Camphoric acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Capric acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Genistein	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Genistein	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Genistein	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
Cinnamic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Citric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Citric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Clemizole		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Cyclamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Cyclamic Acid								
Cysteine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Cysteine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Cysteine								
Dimethylglycine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Dimethylglycine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
D-ribose	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
D-ribose	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Fumaric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Galactaric acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Galactaric acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Chrysin	aldehyde	ester	ether	cyano		furan	bromine	chlorine

NPC-UNIV-000004478

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 100 of 1101

TABLE II

Co-crystal Former							
Asparagine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Asparagine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Asparagine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Aspartic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Aspartic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Benzenesulfonic Acid							
Benzoic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Caffeine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Camphoric acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Capric acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Genistein	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Genistein	nitro	sulfone	analine				
Genistein	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Cinnamic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Citric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Citric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Clemizole	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Cyclamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Cyclamic Acid							
Cysteine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Cysteine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Cysteine							
Dimethylglycine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Dimethylglycine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
D-ribose	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
D-ribose	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Fumaric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Galactaric acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Galactaric acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Chrysin	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	

NPC-UNIV-000004479

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 101 of 1101

TABLE II

Co-crystal Former								
Asparagine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Asparagine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Asparagine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Aspartic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Aspartic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Benzenesulfonic Acid								
Benzoic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Caffeine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Camphoric acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Capric acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Genistein	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Genistein								
Genistein		phospphate	cyanamide					
Cinnamic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Citric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Citric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Clemizole	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Cyclamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Cyclamic Acid								
Cysteine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Cysteine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Cysteine								
Dimethylglycine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Dimethylglycine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
D-ribose		phospphate	cyanamide					
D-ribose	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Fumaric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Galactaric acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Galactaric acid	carbamate	imidazole	BF4					
Chrysin	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea

NPC-UNIV-000004480

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 102 of 1101

TABLE II

Co-crystal Former			
Asparagine	iodine		
Asparagine	iodine	epoxide	peroxide
Asparagine	iodine		
Aspartic Acid	iodine		
Aspartic Acid	iodine		
Benzenesulfonic Acid			
Benzoic Acid	iodine		
Caffeine	iodine		
Camphoric acid	iodine		
Capric acid	iodine		
Genistein	iodine		
Genistein			
Genistein			
Cinnamic acid	iodine		
Citric Acid	iodine	epoxide	
Citric Acid	iodine		
Clemizole			
Cyclamic Acid	iodine		
Cyclamic Acid			
Cysteine	iodine		
Cysteine	iodine		
Cysteine			
Dimethylglycine	iodine		
Dimethylglycine	iodine		
D-ribose			
D-ribose	iodine	epoxide	
Fumaric Acid	iodine		
Galactaric acid	iodine		
Galactaric acid			
Chrysin	iodine		

NPC-UNIV-000004481

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 103 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
Chrysin	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Chrysin	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
Gentisic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Gentisic acid	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Glucamine, N-methyl	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Glucamine, N-methyl	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Gluconic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Gluconic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glucosamine	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Glucuronic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glucuronic acid	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Glucuronic acid	Aldehyde	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutamic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutamic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutamine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutamine	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutamine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glutaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glycine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Glycine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Glycolic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Glycolic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Hippuric Acid	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Hippuric Acid	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Hippuric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Histidine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Histidine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Histidine	Imidazole	imidazole	chlorine	acetamide	carboxylate		thione	nitro
Hydroquinone	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Hydroquinone	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Imidazole	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol

NPC-UNIV-000004482

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 104 of 1101

TABLE II

Co-crystal Former								
Chrysin		alchohol		ester	ether	n-oxide	chlorine	fluorine
Chrysin	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Gentisic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Gentisic acid		alchohol		ester	ether	n-oxide	chlorine	fluorine
Glucamine, N-methyl	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Glucamine, N-methyl	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Gluconic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Gluconic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glucosamine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Glucuronic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glucuronic acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Glucuronic acid	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Glutamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glutamic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glutamine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glutamine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Glutamine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glutaric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glycine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glycine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Glycolic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Glycolic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Hippuric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Hippuric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Hippuric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Histidine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Histidine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Histidine	cyanamide	ketone	cyano	Carboxylic Acid	alcohol		thiol	amine
Hydroquinone	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Hydroquinone		alchohol		ester	ether	n-oxide	chlorine	fluorine
Imidazole	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals

NPC-UNIV-000004483

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 105 of 1101

TABLE II

Co-crystal Former								
Chrysin	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Chrysin	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
Gentisic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Gentisic acid	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Glucamine, N-methyl	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Glucamine, N-methyl	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Gluconic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Gluconic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glucosamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glucuronic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glucuronic acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Glucuronic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutamic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glutaric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glycine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glycine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glycolic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glycolic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Hippuric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Hippuric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Hippuric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Histidine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Histidine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Histidine	phosphinic acid hemihydrate	chlorine	sulfonyl	sulfoxide	amide	fluorine	sulfonate ester	
Hydroquinone	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Hydroquinone	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Imidazole	aldehyde	ester	ether	cyano		furan	bromine	chlorine

NPC-UNIV-000004484

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 106 of 1101

TABLE II

Co-crystal Former							
Chrysin	nitro	sulfone	analine				
Chrysin	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Gentisic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Gentisic acid	nitro	sulfone	analine				
Glucamine, N-methyl	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Glucamine, N-methyl	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Gluconic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Gluconic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glucosamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glucuronic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glucuronic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Glucuronic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutamic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glutaric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glycine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glycine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glycolic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Glycolic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Hippuric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Hippuric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Hippuric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Histidine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Histidine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Histidine							
Hydroquinone	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Hydroquinone	nitro	sulfone	analine				
Imidazole	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	

NPC-UNIV-000004485

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 107 of 1101

TABLE II

Co-crystal Former								
Chrysin								
Chrysin		phospphate	cyanamide					
Gentisic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Gentisic acid								
Glucamine, N-methyl	carbamate	imidazole	BF4					
Glucamine, N-methyl	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Gluconic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Gluconic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glucosamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glucuronic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glucuronic acid	carbamate	imidazole	BF4					
Glucuronic acid	fluorine	carbamate	imidazole	BF4	alkane	aromatic	N-SO2	thiourea
Glutamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glutamic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glutamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glutamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glutamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glutaric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glycine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glycine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glycolic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Glycolic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Hippuric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Hippuric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Hippuric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Histidine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Histidine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Histidine								
Hydroquinone	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Hydroquinone								
Imidazole	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea

NPC-UNIV-000004486

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 108 of 1101

TABLE II

Co-crystal Former			
Chrysin			
Chrysin			
Gentisic acid	iodine		
Gentisic acid			
Glucamine, N-methyl			
Glucamine, N-methyl	iodine		
Gluconic Acid	iodine	epoxide	
Gluconic Acid	iodine		
Glucosamine	iodine	epoxide	
Glucuronic acid	iodine		
Glucuronic acid			
Glucuronic acid	iodine	epoxide	
Glutamic Acid	iodine		
Glutamic Acid	iodine		
Glutamine	iodine		
Glutamine	iodine	epoxide	peroxide
Glutamine	iodine		
Glutaric Acid	iodine		
Glycine	iodine		
Glycine	iodine		
Glycolic Acid	iodine	epoxide	
Glycolic Acid	iodine		
Hippuric Acid	iodine	epoxide	peroxide
Hippuric Acid	iodine		
Hippuric Acid	iodine		
Histidine	iodine		
Histidine	iodine		
Histidine			
Hydroquinone	iodine	epoxide	
Hydroquinone			
Imidazole	iodine		

NPC-UNIV-000004487

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 109 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
Ipriflavone	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
Ipriflavone	Ketone	alcohol		thiol	amide	amine	analine	phenol
Isoleucine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Isoleucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
lactobionic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Lactobionic acid	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Lactobionic acid	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
Lauric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Leucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Leucine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Lysine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Lysine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Maleic	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Malic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Malic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Malonic	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Mandelic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Mandelic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Methionine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Methionine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Methionine	Thioether	-N	amide	amine	_s	Sp2 amine	sulfoxide	chlorate
Nicotinamide	Pyridine	*alcohol		*	*amide	nitro	*amine	*Carboxylic Acid
Nicotinamide	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Nicotinic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Nicotinic Acid	Pyridine	*alcohol		*	*amide	nitro	*amine	*Carboxylic Acid
Orotic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Orotic acid	Lactam	alcohol	ketone	thiol	amide	amine	analine	phenol
Oxalic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Palmitic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Pamoic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Pamoic acid	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Pamoic acid	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde

NPC-UNIV-000004488

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 110 of 1101

TABLE II

Co-crystal Former								
Ipriflavone	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Ipriflavone	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Isoleucine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Isoleucine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
lactobionic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Lactobionic acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Lactobionic acid	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Lauric acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Leucine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Leucine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Lysine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Lysine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Maleic	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Malic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Malic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Malonic	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Mandelic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Mandelic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Methionine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Methionine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Methionine	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Nicotinamide	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Nicotinamide	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Nicotinic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Nicotinic Acid	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Orotic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Orotic acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Oxalic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Palmitic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Pamoic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Pamoic acid	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Pamoic acid		alchohol		ester	ether	n-oxide	chlorine	fluorine

NPC-UNIV-000004489

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 111 of 1101

TABLE II

Co-crystal Former								
Ipriflavone	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
Ipriflavone	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Isoleucine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Isoleucine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
lactobionic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Lactobionic acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Lactobionic acid	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
Lauric acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Leucine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Leucine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Lysine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Lysine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Maleic	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Malic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Malic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Malonic	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Mandelic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Mandelic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Methionine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Methionine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Methionine	aldehyde	ketone	peroxide	epoxide	Ag	Se	heterocyclic-S	iodine
Nicotinamide		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Nicotinamide	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Nicotinic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Nicotinic Acid		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Orotic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Orotic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Oxalic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Palmitic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pamoic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pamoic acid	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Pamoic acid	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid

NPC-UNIV-000004490

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 112 of 1101

TABLE II

Co-crystal Former							
Ipriflavone	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Ipriflavone	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Isoleucine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Isoleucine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
lactobionic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Lactobionic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Lactobionic acid	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Lauric acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Leucine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Leucine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Lysine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Lysine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Maleic	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Malic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Malic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Malonic	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Mandelic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Mandelic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Methionine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Methionine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Methionine	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Nicotinamide	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Nicotinamide	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Nicotinic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Nicotinic Acid	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Orotic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Orotic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Oxalic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Palmitic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pamoic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pamoic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Pamoic acid	nitro	sulfone	analine				

NPC-UNIV-000004491

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 113 of 1101

TABLE II

Co-crystal Former								
Ipriflavone		phospphate	cyanamide					
Ipriflavone	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Isoleucine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Isoleucine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
lactobionic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Lactobionic acid	carbamate	imidazole	BF4					
Lactobionic acid		phospphate	cyanamide					
Lauric acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Leucine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Leucine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Lysine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Lysine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Maleic	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Malic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Malic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Malonic	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Mandelic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Mandelic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Methionine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Methionine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Methionine		phospphate						
Nicotinamide	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Nicotinamide	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Nicotinic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Nicotinic Acid	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Orotic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Orotic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Oxalic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Palmitic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pamoic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pamoic acid	carbamate	imidazole	BF4					
Pamoic acid								

NPC-UNIV-000004492

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 114 of 1101

TABLE II

Co-crystal Former			
Ipriflavone			
Ipriflavone	iodine		
Isoleucine	iodine		
Isoleucine	iodine		
lactobionic acid	iodine		
Lactobionic acid			
Lactobionic acid			
Lauric acid	iodine		
Leucine	iodine		
Leucine	iodine		
Lysine	iodine		
Lysine	iodine		
Maleic	iodine		
Malic Acid	iodine	epoxide	
Malic Acid	iodine		
Malonic	iodine		
Mandelic Acid	iodine	epoxide	
Mandelic Acid	iodine		
Methionine	iodine		
Methionine	iodine		
Methionine			
Nicotinamide			
Nicotinamide	iodine	epoxide	peroxide
Nicotinic Acid	iodine		
Nicotinic Acid			
Orotic acid	iodine		
Orotic acid	iodine	epoxide	peroxide
Oxalic acid	iodine		
Palmitic acid	iodine		
Pamoic acid	iodine		
Pamoic acid			
Pamoic acid			

NPC-UNIV-000004493

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 115 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
Phenylalanine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Phenylalanine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Piperazine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Procaine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Procaine	Ketone	alcohol		thiol	amide	amine	analine	phenol
Proline	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Proline	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
p-Toluenesulfonic acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
Pyridoxamine	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Pyridoxamine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Pyridoxamine	Pyridine	*alcohol		*	*amide	nitro	*amine	*Carboxylic Acid
Pyridoxine (4-Pyridoxic Acid)	Pyridine	*alcohol	pyridinium	*	*amide	nitro	*amine	*Carboxylic Acid
Pyridoxine (4-Pyridoxic Acid)	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Pyroglutamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Pyroglutamic acid	Lactam	alcohol	ketone	thiol	amide	amine	analine	phenol
Quercetin	Ketone	alcohol		thiol	amide	amine	analine	phenol
Quercetin	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Quercetin	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide	chlorate
Resveratrol	Ketone	alcohol		thiol	amide	amine	analine	phenol
Resveratrol	Phenol	amine	amide	sulfoxide	n	pyridine	cyano	aldehyde
Saccharin	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Saccharin	Ketone	alcohol		thiol	amide	amine	analine	phenol
Saccharin	Sulfoxide	pyridine	ketone	aldehyde	ether	ester	amide	Carboxylic Acid
Saccharin	Amine	alcohol	ketone	thiol	amide		analine	phenol
Salicylic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Salicylic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Salicylic Acid, 4-amino	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Salicylic Acid, 4-amino	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Salicylic Acid, 4-amino	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol

NPC-UNIV-000004494

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 116 of 1101

TABLE II

Co-crystal Former								
Phenylalanine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Phenylalanine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Piperazine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Procaine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Procaine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Proline	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Proline	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
p-Toluenesulfonic acid	amine	metals	thioether		sulfate	alcohol		
Pyridoxamine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Pyridoxamine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Pyridoxamine	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Pyridoxine (4-Pyridoxic Acid)	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Pyridoxine (4-Pyridoxic Acid)	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Pyroglutamic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Pyroglutamic acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Quercetin	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Quercetin		alchohol		ester	ether	n-oxide	chlorine	fluorine
Quercetin	chlorine		cyano	ester	amine	nitro	nitrate	bromine
Resveratrol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Resveratrol		alchohol		ester	ether	n-oxide	chlorine	fluorine
Saccharin	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Saccharin	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Saccharin	amine	metals	thioether		sulfate	alcohol		
Saccharin	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Salicylic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Salicylic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Salicylic Acid, 4-amino	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Salicylic Acid, 4-amino	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid	metals	aldehyde
Salicylic Acid, 4-amino	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals

NPC-UNIV-000004495

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 117 of 1101

TABLE II

Co-crystal Former								
Phenylalanine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Phenylalanine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Piperazine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Procaine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Procaine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Proline	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Proline	aldehyde	ester	ether	cyano		furan	bromine	chlorine
p-Toluenesulfonic acid								
Pyridoxamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pyridoxamine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pyridoxamine		thiol	n-heterocyclic ring	thionedisulfide		iodine	hydrazone	thiocyanate
Pyridoxine (4-Pyridoxic Acid)		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Pyridoxine (4-Pyridoxic Acid)	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pyroglutamic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Pyroglutamic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Quercetin	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Quercetin	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Quercetin	aldehyde	ketone	peroxide	epoxide			heterocyclic-S	iodine
Resveratrol	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Resveratrol	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid	carboxylic acid
Saccharin	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Saccharin	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Saccharin								
Saccharin	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Salicylic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Salicylic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Salicylic Acid, 4-amino	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Salicylic Acid, 4-amino	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Salicylic Acid, 4-amino	aldehyde	ester	ether	cyano		furan	bromine	chlorine

NPC-UNIV-000004496

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 118 of 1101

TABLE II

Co-crystal Former							
Phenylalanine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Phenylalanine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Piperazine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Procaine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Procaine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Proline	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Proline	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
p-Toluenesulfonic acid							
Pyridoxamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pyridoxamine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pyridoxamine	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Pyridoxine (4-Pyridoxic Acid)	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Pyridoxine (4-Pyridoxic Acid)	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pyroglutamic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Pyroglutamic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Quercetin	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Quercetin	nitro	sulfone	analine				
Quercetin	ester	ether	carboxylic acid	sulfate	sulfone		alcohol
Resveratrol	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Resveratrol	nitro	sulfone	analine				
Saccharin	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Saccharin	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Saccharin							
Saccharin	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Salicylic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Salicylic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Salicylic Acid, 4-amino	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Salicylic Acid, 4-amino	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine
Salicylic Acid, 4-amino	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	

NPC-UNIV-000004497

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 119 of 1101

TABLE II

Co-crystal Former								
Phenylalanine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Phenylalanine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Piperazine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Procaine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Procaine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Proline	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Proline	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
p-Toluenesulfonic acid								
Pyridoxamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pyridoxamine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pyridoxamine	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Pyridoxine (4-Pyridoxic Acid)	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Pyridoxine (4-Pyridoxic Acid)	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pyroglutamic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Pyroglutamic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Quercetin	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Quercetin								
Quercetin		phospphate	cyanamide					
Resveratrol	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Resveratrol								
Saccharin	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Saccharin	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Saccharin								
Saccharin	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Salicylic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Salicylic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Salicylic Acid, 4-amino	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Salicylic Acid, 4-amino	carbamate	imidazole	BF4					
Salicylic Acid, 4-amino	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea

NPC-UNIV-000004498

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 120 of 1101

TABLE II

Co-crystal Former			
Phenylalanine	iodine		
Phenylalanine	iodine		
Piperazine	iodine		
Procaine	iodine		
Procaine	iodine		
Proline	iodine		
Proline	iodine		
p-Toluenesulfonic acid			
Pyridoxamine	iodine	epoxide	
Pyridoxamine	iodine		
Pyridoxamine			
Pyridoxine (4-Pyridoxic Acid)			
Pyridoxine (4-Pyridoxic Acid)	iodine	epoxide	
Pyroglutamic acid	iodine		
Pyroglutamic acid	iodine	epoxide	peroxide
Quercetin	iodine		
Quercetin			
Quercetin			
Resveratrol	iodine		
Resveratrol			
Saccharin	iodine	epoxide	peroxide
Saccharin	iodine		
Saccharin			
Saccharin	iodine		
Salicylic Acid	iodine		
Salicylic Acid	iodine	epoxide	
Salicylic Acid, 4-amino	iodine		
Salicylic Acid, 4-amino			
Salicylic Acid, 4-amino	iodine		

NPC-UNIV-000004499

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 121 of 1101

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group						
Sebacic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Serine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Serine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Serine	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Stearic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Succinic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Tartaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Threonine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Threonine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Threonine	alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Tris	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Tris	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Tryptophan	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Tryptophan	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Tryptophan	Indole	*alcohol	pyridinium	*	*amide	nitro	*amine	*carboxilic acid
Tyrosine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Tyrosine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Tyrosine	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Urea	Ketone	alcohol		thiol	amide	amine	analine	phenol
Urea	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Urea	Amide	alcohol	ketone	thiol	amide	amine	analine	phenol
Valine	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Valine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine	phenol
Vitamin K5	Amine	alcohol	ketone	thiol	amide	amine	analine	phenol
Vitamin K5	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol
Xylitol	Alcohol	alcohol	ketone	thiol	amide	amine	analine	phenol

NPC-UNIV-000004500

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 122 of 1101

TABLE II

Co-crystal Former								
Sebacic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Serine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Serine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Serine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Stearic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Succinic Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Tartaric Acid	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Threonine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Threonine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Threonine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Tris	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Tris	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Tryptophan	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Tryptophan	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Tryptophan	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	*chlorine
Tyrosine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Tyrosine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Tyrosine	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Urea	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Urea	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Urea	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Valine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Valine	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Vitamin K5	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	metals
Vitamin K5	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals
Xylitol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	metals

NPC-UNIV-000004501

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 123 of 1101

TABLE II

Co-crystal Former								
Sebacic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Serine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Serine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Serine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Stearic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Succinic Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tartaric Acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Threonine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Threonine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Threonine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tris	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tris	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tryptophan	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tryptophan	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tryptophan		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate
Tyrosine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tyrosine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Tyrosine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Urea	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Urea	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Urea	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Valine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Valine	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Vitamin K5	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Vitamin K5	aldehyde	ester	ether	cyano		furan	bromine	chlorine
Xylitol	aldehyde	ester	ether	cyano		furan	bromine	chlorine

NPC-UNIV-000004502

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 124 of 1101

TABLE II

Co-crystal Former							
Sebacic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Serine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Serine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Serine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Stearic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Succinic Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tartaric Acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Threonine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Threonine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Threonine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tris	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tris	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tryptophan	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tryptophan	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tryptophan	*bromine		hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid
Tyrosine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tyrosine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Tyrosine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Urea	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Urea	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Urea	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Valine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Valine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Vitamin K5	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Vitamin K5	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	
Xylitol	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	

NPC-UNIV-000004503

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 125 of 1101

TABLE II

Co-crystal Former								
Sebacic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Serine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Serine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Serine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Stearic acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Succinic Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tartaric Acid	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Threonine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Threonine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Threonine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tris	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tris	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tryptophan	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tryptophan	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tryptophan	N-oxide	ester	ether	fluorine	acetate	thione	dithiadiazocyclopentadienyl	
Tyrosine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tyrosine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Tyrosine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Urea	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Urea	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Urea	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Valine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Valine	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Vitamin K5	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Vitamin K5	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea
Xylitol	fluorine	carbamate	imidazole	BF4			N-SO2	thiourea

NPC-UNIV-000004504

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 126 of 1101







TABLE II

Co-crystal Former			
Sebacic acid	iodine		
Serine	iodine		
Serine	iodine		
Serine	iodine	epoxide	
Stearic acid	iodine		
Succinic Acid	iodine		
Tartaric Acid	iodine		
Threonine	iodine		
Threonine	iodine		
Threonine	iodine	epoxide	
Tris	iodine		
Tris	iodine	epoxide	
Tryptophan	iodine		
Tryptophan	iodine		
Tryptophan			
Tyrosine	iodine		
Tyrosine	iodine		
Tyrosine	iodine	epoxide	
Urea	iodine		
Urea	iodine		
Urea	iodine	epoxide	peroxide
Valine	iodine		
Valine	iodine		
Vitamin K5	iodine		
Vitamin K5	iodine	epoxide	
Xylitol	iodine	epoxide	

NPC-UNIV-000004505

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 127 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
pyridine		*alcohol	pyridinium	*amide	nitro	*amine	*carboxilic acid
imidazol		imidazole	chlorine	acetamide	carboxylate	thione	nitro
Hydroxamic acid		hydroxamic acid	alcohol	phosphinic ester	alkane	pyridine	amide
peroxide		ester	peroxide	amide	ether	alkane	N-heterocycle
epoxide		alkane	bromine	alcohol	ester	epoxide	amide
thioester		aromatic	thioester	alkane	sulfamide	hydroxy	bromine
thioketone		alkane	thioketone	ketone	SULFAMIDE	AMINE	thiol

NPC-UNIV-000004506

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 128 of 1101

TABLE III

Functional Group									
pyridine	*sulfonamide	*ketone	ether	triazole	alkane	ammonium	oxime	*chlorine	alkyne
imidazole	cyanamide	ketone	cyano	carboxilic acid	alcohol	alkane	thiol	amine	phosphinic acid hemihydrate
Hydroxamic acid	sulfonamide	carboxylate	phosphine	amine	aromatic				
peroxide	aromatic	alcohol	pyrimidinedione	analine	thiazole	peroxy acid	ketone	carboxilic acid	azide
epoxide	alkene	hydrazone	aromatic	thioether	ketone	aldehyde	chlorine	carboxilic acid	alkyne
thioester	iodine	amine	cyano	thioketone	amide		chlorine	nitro	
thioketone	sulfoxide	oxo	chlorine	bromine	AROMATIC	alkene	sulfone	iodine	AZOXY

NPC-UNIV-000004507

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 129 of 1101

TABLE III

Functional Group									
pyridin	thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate	*bromine	aromatic
imidazole	chlorine	sulfonyl	sulfoxide	amide	fluorine	sulfonate ester			
Hydroxamic acid									
peroxide	phosphine oxide	sulfonamide	analine						
epoxide		ammonium	fluorine	nitro	amine	cyano			
thio ster									
thioketone	potassium	epoxide	n-oxide	cyano	iron	cobalt	amine	sulfate	

NPC-UNIV-000004508

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 130 of 1101

TABLE III

Functional Group											
pyridine	hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
imidazole											
Hydroxamic acid											
peroxide											
epoxide											
thioester											
thioketone											

NPC-UNIV-000004509

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 131 of 1101








TABLE III

Functional Group						
pyridine	dithiadiazocyclopentadienyl					
imidazole						
Hydroxamic acid						
peroxide						
epoxide						
thioester						
thioketone						

NPC-UNIV-000004510

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 132 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
nitrate ester		aromatic	amide	alkane	chlorine	nitrate ester	bromine
Thiophosphate ester-O		amine	imidazole	cyclic amide			
Phosphate ester		aromatic	alcohol	phosphate ester	aromatic N-ring	pyridine	analine
Ketone		alcohol	ketone	thiol	amide	amine	analine
Aldehyde		alcohol	ketone	thiol	amide	amine	analine
Thiol		carboxylic acid	sodium	aldehyde	ketone	aromatic-N	cadmium
Alcohol		alcohol	ketone	thiol	amide	amine	analine

NPC-UNIV-000004511

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 133 of 1101

TABLE III

Functional Group									
nitrate est r	alcohol	ether	acetate						
Thiophosphate ester-O									
Phosphate ester	amine		sodium	potassium	lithium	carboxylic acid	amide	alkane	
Ketone	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Aldehyde	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Thiol	alkane	arsenic	chlorine	alcohol	potassium	Ru	aromatic	Rb	Sb
Alcohol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals

NPC-UNIV-000004512

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 134 of 1101

TABLE III

Functional Group									
nitrate ester									
Thiophosphate ester-O									
Phosphate ester									
Ketone	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Aldehyde	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Thiol									
Alcohol	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic

NPC-UNIV-000004513

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 135 of 1101

TABLE III

Functional Group											
nitrate ester											
Thiophosphate ester-O											
Phosphate ester											
Ketone	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane
Aldehyde	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane
Thiol											
Alcohol	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane

NPC-UNIV-000004514

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 136 of 1101







TABLE III

Functional Group						
nitrat ester						
Thiophosphate st r-O						
Phosphate ester						
Ketone	aromatic	N-SO2	thiourea	iodine		
Aldehyde	aromatic	N-SO2	thiourea	iodine	epoxide	
Thiol						
Alcohol	aromatic	N-SO2	thiourea	iodine	epoxide	

NPC-UNIV-000004515

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 137 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
Thioether		aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Ether		aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Cyanamide		cyano	amine	potassium	aromatic-N	bromine	sodium
Thiocyanate		aromatic-S	ester	ether			
sP2 amine		thioether	ether	metals	MoOCl4	BF4	bromine
Amine primary		alcohol	ketone	thiol	amide	amine	analine
Amine secondary		alcohol	ketone	thiol	amide	amine	analine

NPC-UNIV-000004516

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 138 of 1101

TABLE III

Functional Group									
Thioether	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate	bromine
Ether	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate	bromine
Cyanamide	imidazole	ether	n-heterocyclic	alcohol	cesium	Ag			
Thiocyanate									
sP2 amine	chlorine		Sp2 amine	sulfate	Osmium				
Amin primary	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Amine secondary	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals

NPC-UNIV-000004517

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 139 of 1101

TABLE III

Functional Group									
Thioether	aldehyde	ketone	peroxide	epoxide	Ag	Se	heterocyclic-S	iodine	ester
Ether	aldehyde	ketone	peroxide	epoxide	Ag	Se	heterocyclic-S	iodine	ester
Cyanamide									
Thiocyanate									
sP2 amine									
Amine primary	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Amine secondary	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic

NPC-UNIV-000004518

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 140 of 1101

TABLE III

Functional Group											
Thioether	ether	carboxylic acid	sulfate	sulfone	alkane	alcohol		phospphate			
Ether	ether	carboxylic acid	sulfate	sulfone	alkane	alcohol		phospphate	cyanamide		
Cyanamide											
Thiocyanate											
sP2 amine											
Amine primary	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane
Amine secondary	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane

NPC-UNIV-000004519

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 141 of 1101







TABLE III

Functional Group						
Thioether						
Ether						
Cyanamide						
Thiocyanate						
sP2 amine						
Amine primary	aromatic	N-SO2	thiourea	iodine		
Amine secondary	aromatic	N-SO2	thiourea	iodine		

NPC-UNIV-000004520

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 142 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
Amin t rtiary		alcohol	ketone	thiol	amide	amine	analine
Amide		alcohol	ketone	thiol	amide	amine	analine
Sulfonic acid		pyridine	ketone	aldehyde	ether	ester	amide
Phosphinic acid		alkane	potassium	lithium	n-heterocyclic	oxime	amide
Phosphonic acid		alkane	potassium	lithium	n-heterocyclic	oxime	amide
Carboxylic acid		alcohol	ketone	thiol	amide	amine	analine

NPC-UNIV-000004521

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 143 of 1101

TABLE III

Functional Group									
Amine tertiary	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Amide	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals
Sulfonic acid	carboxilic acid	amine	metals	thioether		sulfate	alcohol		
Phosphinic acid	phenol	aromatic	amine	alcohol		metals			
Phosphonic acid	phenol	aromatic	amine	alcohol		metals	carboxylic acid	Sp2 amine	analine
Carboxylic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid	metals

NPC-UNIV-000004522

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 144 of 1101

TABLE III

Functional Group									
Amine tertiary	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Amide	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic
Sulfonic acid									
Phosphinic acid									
Phosphonic acid	ether	phosphonic acid	aromatic-N	ketone	aldehyde	imidazole			
Carboxylic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine	s-heterocyclic

NPC-UNIV-000004523

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 145 of 1101

TABLE III

Functional Group											
Amine tertiary	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane
Amide	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane
Sulfonic acid											
Phosphinic acid											
Phosphonic acid											
Carboxylic acid	pyridine	cyano	n-heterocyclic	ketone	phosphate ester		fluorine	carbamate	imidazole	BF4	alkane

NPC-UNIV-000004524

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 146 of 1101







TABLE III

Functional Group						
Amine tertiary	aromatic	N-SO2	thiourea	iodine		
Amide	aromatic	N-SO2	thiourea	iodine	epoxide	peroxide
Sulfonic acid						
Phosphinic acid						
Phosphonic acid						
Carboxylic acid	aromatic	N-SO2	thiourea	iodine		

NPC-UNIV-000004525

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 147 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
Sulfate ester		pyridine	ketone	aldehyde	ether	ester	amide
Oxime		alcohol	alkane	amine	amide	ether	ester
Nitrile		metal	ketone	phenol	alcohol		cyano
Diazo		Oxime					
Nitro	NO_2	pyridine	ketone	aldehyde	ether	ester	amide
S-heterocyclic ring		alcohol	thioketone	thioether	s-heterocyclic	ketone	aromatic
Thiophene		chlorine	fluorine	amide	ketone	NO	SO

NPC-UNIV-000004526

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 148 of 1101

TABLE III

Functional Group									
Sulfate ester	carboxilic acid	amine	metals	thioether	sulfate	alcohol			
Oxime	pyridine	n-aromatic	chlorate	chlorine	Sp2-N	diazo	thioketone	cyano	n-oxide
Nitrile	amine	analine	bromine	amide	alkane	carboxylic acid	chlorine	n-heterocyclic	aromatic
Diazo									
Nitro	carboxilic acid	amine	metals	thioether	sulfate	alcohol			
S-heterocyclic ring	alkene	amine	chlorine	BF4	sulfate	ester	NO	ether	amide
Thiophene	CO								

NPC-UNIV-000004527

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 149 of 1101

TABLE III

Functional Group									
Sulfate ester									
Oxime	ketone	aldehyde	carboxylic acid	bromine	aromatic	pyridine	BF4		
Nitrile	potassium	aldehyde	thioether	pyridine	n-aromatic	bromine	ether	s-aromatic	thiophene
Diazo									
Nitro									
S-heterocyclic ring	iodine	carboxylic acid	sodium	cyano	chloride	furan			
Thiophene									

NPC-UNIV-000004528

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 150 of 1101

TABLE III

Functional Group											
Sulfate ester											
Oxime											
Nitrile											
Diazo											
Nitro											
S-heterocyclic ring											
Thiophene											

NPC-UNIV-000004529

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 151 of 1101




TABLE III

Functional Group						
Sulfate ester						
Oxime						
Nitrile						
Diazo						
Nitro						
S-heterocyclic ring						
Thiophene						

NPC-UNIV-000004530

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 152 of 1101

TABLE III

Functional Group	Functional Group Structure	Interacting Group					
N-heterocyclic ring		alcohol	thioketone	thioether	s-heterocyclic	ketone	aromatic
O-heterocyclic ring		alcohol	thioketone	thioether	s-heterocyclic	ketone	aromatic
Pyrrole		chlorine	fluorine	amide	ketone	NO	SO
Furan		s-heterocyclic					

NPC-UNIV-000004531

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 153 of 1101

TABLE III

Functional Group									
N-heterocyclic ring	alkene	amine	chlorine	BF4	sulfate	ester	NO	ether	amide
O-heterocyclic ring	alkene	amine	chlorine	BF4	sulfate	ester	NO	ether	amide
Pyrrole	CO	imidazole	pyridine	n-aromatic	aldehyde	carboxylic acid	sulfate	chlorine	bromine
Furan									

NPC-UNIV-000004532

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 154 of 1101

TABLE III

Functional Group									
N-heterocyclic ring	iodine	carboxylic acid	sodium	cyano	chloride	aldehyde			
O-heterocyclic ring	iodine	carboxylic acid	sodium	cyano	chloride	aldehyde			
Pyrrole	oxime	alcohol	phenol	ester	ether				
Furan									

NPC-UNIV-000004533

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 155 of 1101

TABLE III

Functional Group											
N-heterocyclic ring											
O-heterocyclic ring											
Pyrrole											
Furan											

NPC-UNIV-000004534

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 156 of 1101

TABLE III

Functional Group						
N-heterocyclic ring						
O-heterocyclic ring						
Pyrrol						
Furan						

NPC-UNIV-000004535

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 157 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
(-)-amlodipine	3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, (S)- [CAS]	103129-82-4	WO	9310779	Antihypertensive, other	Hypertension, general
(-)-halofenate	(-)-Benzeneacetic acid, 4-chloro-Alpha-[3-(trifluoromethyl)-phenoxy]-, 2-(acetylamino)ethyl ester		US	6262118	Antidiabetic	Diabetes, Type II
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimithylethyl)amino)methyl)-4-hydroxy- [CAS]				Formulation, modified-release, <=24hr	Asthma
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy- [CAS]	34391-04-3	US	5547994	Antiasthma	Asthma
(R,R)-formoterol	Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)- (R-(R*,R*))- [CAS]	67346-49-0	US	5795564	Antiasthma	Asthma
(S)-doxazosin	(S)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-yl carbonyl)piperazine	70918-18-2	WO	9409785	Prostate disorders	Benign prostatic hyperplasia
(S)-fluoxetine	Benzenepropanamide, N-methyl-Gamma-(4-(trifluoromethyl)phenoxy)- (S)				Antimigraine	Migraine
(S)-oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester, (S)- [CAS]	119618-22-3			Urological	Incontinence
1,2-Naphthoquinone		524-42-5				
17α-Hydroxyprogesterone		68-96-2				
17-Methyltestosterone		58-18-4				
195mPt-cisplatin	Platinum-195m, diamminedichloro, (SP-4-2)-		US	6074626	Anticancer, alkylating	Cancer, liver
1α-Hydroxycholecalciferol		41294-56-8				

NPC-UNIV-000004536

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 158 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
1-Naphthyl Salicylate		550-97-0				
1-Naphthylamine-4-sulfonic Acid		84-86-6				
1-Theobromineacetic Acid		5614-56-2				
2,4,6-Tribromo-m-cresol		4619-74-3				
2,6-Diamino-2′-butyloxy-3,5′-azopyridine		617-19-6				
21-Acetoxypregnenolone		566-78-9				
2-Amino-4-picoline		695-34-1				
2-Aminothiazole		96-50-4				
2-ethoxybenzoic acid	2-Ethoxybenzoic acid		DE	5134001	Analgesic, NSAID	Pain, general
2-Naphthol		135-19-3				
2-Naphthyl Benzoate		93-44-7				
2-Naphthyl Lactate		93-43-6				
2-Naphthyl Salicylate		613-78-5				
2-p-Sulfanilylanilinoethanol		80-02-4				
2-Thiouracil		141-90-2				
3′,3″,5′,5″-T trabromophenolphthalein		76-62-0				
3-Amino-4-hydroxybutyric Acid		589-44-6				
3-Bromo-d-camphor		76-29-9				
3-Hydroxycamphor		10373-81-6				
3-O-Lauroylpyridoxol Diacetate		1562-13-6				
3-Pentadecylcatechol		492-89-7				

NPC-UNIV-000004537

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 159 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
3-Quinuclidinol		1619-34-7				
4,4'-Oxydi-2-butanol		821-33-0				
4,4'-Sulfinyldianiline		119-59-5				
4-Amino-3-hydroxybutyric Acid		352-21-6				
4-Amino-3-phenylbutyric Acid		1078-21-3				
4-aminosalicylic acid	Benzoic acid, 4-amino-2-hydroxy- [CAS]	65-49-6			GI inflammatory/bowel disorders	Inflammatory bowel disease
4-Chloro-m-cresol		59-50-7				
4-Hexylresorcinol		136-77-6				
4-Salicyloylmorpholine		3202-84-4				
5'-Nitro-2'-propoxyacetanilide		553-20-8				
5-aminolevulinic acid,	Pentanoic acid, 5-amino-4-oxo- [CAS]	106-60-5			Dermatological	Keratosis
5-azacitidine	1,3,5-Triazin-2(1H)-one, 4-amino-1-ß-D-ribofuranosyl- [CAS]	320-67-2			Anticancer, antimetabolite	Myelodysplastic syndrome
5-Bromosalicylhydroxamic Acid		5798-94-7				
5F-DF-203	2-(4-Amino-3-methylphenyl)-6-hydroxybenzothiazole				Anticancer, other	Cancer, breast
5-FU	2,4(1H,3H)-Pyrimidinedione, 5-fluoro [CAS]	51-21-8			Formulation, parenteral, targeted	Cancer, general
5-HT3 antagonists			US	6037360	Male sexual dysfunction	Premature ejaculation
6-Azauridine		54-25-1				
6-Mercaptopurine		50-44-2				
8-Hydroxyquinoline		148-24-3				
9-Aminocamptothecin		91421-43-1				
A-151892	N-[2-(2,2,2-Trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl] amide				Urological	Overactive bladder
α_1-Antitrypsin		9041-92-3				

NPC-UNIV-000004538

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 160 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
A-5021	6H-Purin-6-one, 2-amino-9-(((1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl)methyl)-1,9-dihydro- [CAS]	145512-85-2			Antiviral, other	Infection, varicella zoster virus
abacavir	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)- [CAS]	136470-78-5 188062-50-2	EP	434450	Antiviral, anti-HIV	Infection, HIV/AIDS
abaperidone	7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one	183849-43-6	WO	9632389	Neuroleptic	Schizophrenia
abarelix	D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	183552-38-7	US	5843902	Anticancer, hormonal	Cancer, prostate
Abciximab		143653-53-6				
Abecarnil		111841-85-1				
abetimus		169147-32-4	US	5552391	Immunosuppressant	Lupus erythematosus, systemic
abiraterone	Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3ß)- [CAS]	154229-18-2	GB	2265624	Anticancer, hormonal	Cancer, prostate
α-Bisabolol		515-69-5				
ABLC	Amphotericin B [CAS]	1397-89-3 30652-87-0			Formulation, conjugate, carbohydrate	Infection, Candida, general
ABT-751	Benzenesulfonamide, N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy- [CAS]	141430-65-1	EP	472053	Anticancer, other	Cancer, general
AC-5216	N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide				Anxiolytic	Anxiety, general
Acadesine		2627-69-2				
acamprosate	1-Propanesulfonic acid, 3-(acetylamino)- [CAS]	77337-76-9	GB	2051789	Dependence treatment	Addiction, alcohol
Acamprosate		77337-73-6				
Acarbose		56180-94-0				

NPC-UNIV-000004539

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 161 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
acebrophylline	7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-,compd. with trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol (1:1) [CAS]	96989-76-3	DE	3425007	Antiasthma	Asthma
acebutolol	Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (+/-)- [CAS]	34381-68-5 37517-30-9	US	3726919	Antihypertensive, adrenergic	
Acecainide		32795-44-1				
Ac carbromal		77-66-7				
aceclofenac	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester [CAS]	89796-99-6	EP	119932	Anti-inflammatory	Pain, musculoskeletal
Acedapsone		77-46-3				
Acediasulfone		80-03-5				
Acefylline		652-37-9				
Aceglutamide		2490-97-3				
aceglutamide	Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]	12607-92-0	DE	2127176	Antiulcer	Ulcer, GI, general
acemetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester [CAS]	53164-05-9	US	3910952	Anti-inflammatory	
Acenocoumarol		152-72-7				
Acetal		105-57-7				
Acetamidoeugenol		305-13-5				
Acetaminophen		103-90-2				
Acetaminosalol		118-57-0				
Acetanilide		103-84-4				
Acetarsone		97-44-9				
Acetazolamide		59-66-5				
Acetiamine		299-89-8				
Acetohexamide		968-81-0				
Acetohydroxamic Acid		546-88-3				
Ac tophenazine		2751-68-0				
Acetoph none		98-86-2				

NPC-UNIV-000004540

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 162 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Acetosulfone		128-12-1				
acetoxolone	Olean-12-en-30-oic acid, 3ß-hydroxy-11-oxo-acetate, aluminium salt [CAS]	29728-34-5 6277-14-1	US	3764618	Antiulcer	
Acetrizoat		129-63-5				
Acetyl Sulfamethoxypyrazine		3590-05-4				
Acetylcarnitine		14992-62-2				
Acetylcholine		66-23-9				
Acetylcholine		60-31-1				
Acetylcysteine		616-91-1				
Acetylleucine Monoethanolamine		149-90-6				
Acetylpheneturide		13402-08-9				
acetylsalicylic acid	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2 530 75-6			Formulation, optimized, microencapsulate	Pain, general
α-Chloralose		15879-93-3				
aciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- [CAS]	59277-89-3			Formulation, dermal, topical	Infection, herpes simplex virus
Acifran		72420-38-3				
acipimox	Pyrazinecarboxylic acid, 5-methyl-, 4-oxide [CAS]	51037-30-0	GB	1361967	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
acitazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]- [CAS]	114607-46-4	EP	256507	Ophthalmological	Conjunctivitis
acitretin	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)- [CAS]	55079-83-9	GB	1468401	Antipsoriasis	Psoriasis
aclarubicin		57576-44-0 75443-99-1	US	3988315	Anticancer, antibiotic	
Aclatonium Napadisilate		55077-30-0				
Aconitine		302-27-2				
Acranil®		1684-42-0				
Acriflavine		8048-52-0				
Acrisorcin		7527-91-5				

NPC-UNIV-000004541

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 163 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
acrivastine	2-Propenoic acid, 3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)- [CAS]	87848-99-5	EP	85959	Antipruritic/inflamm, allergic	Rhinitis, allergic, general
acrivastine + pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)]-, mixtwith 2-Propenoic acid, 3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)-				Antiallergic, non-asthma	Rhinitis, allergic, seasonal
actagardine derivative	3,3-dimethyl-1-propylamide HCl monocarboxamide actagardine				Peptide antibiotic	Infection, general
Actarit		18699-02-0				
ACTH		9002-60-2				
Acyclovir		59277-89-3				
adapalene	2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)- [CAS]	106685-40-9	EP	199636	Antiacne	Acne
ADCON-L	GL 402 [CAS]	137802-74-5			Formulation, other	Fibrosis, epidural
Ad fovir		106941-25-7				
adefovir dipivoxil	Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene)ester- [CAS]	142340-99-6	EP	205826	Antiviral, other	Infection, hepatitis-B virus
Adenoscan	6-Amino-9-ß-D-ribofuranosyl-9H-purine [CAS]	58-61-7			Imaging agent	Diagnosis, coronary
Adenosine Triphosphate		56-65-5				
ADEPT		156079-88-8			Immunoconjugate, other	Cancer, colorectal
Adinazolam		37115-32-5				
Adiphenine		64-95-9				
ADL-10-0101			WO	9732857	Analgesic, other	Pain, general
Adrafinil		63547-13-7				
Adrenalone		99-45-6				
Adrenochrome		54-06-8				
adrogolide	Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride (5aR-trans)- [CAS]	166591-11-3 171752-56-0	US	5597832	Dependence treatment	Addiction, cocaine

NPC-UNIV-000004542

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 164 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
AEOL-10150			US	6103714	Neuroprotective	Unspecified
AET		56-10-0				
α-Ethylbenzyl Alcohol		93-54-9				
AF-2259	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-methoxyphenyl ester [CAS]	66332-77-2	DE	2726435	Anti-inflammatory	Inflammation, general
Afloqualone		56287-74-2				
AG-041R	1H-Indole-3-acetamide, 1-(2,2-diethoxyethyl)-2,3-dihydro-N-(4-methylphenyl)-3-((((4-methylphenyl)amino)carbonyl)amino)-2-oxo-, (3R)- [CAS]	199800-49-2	WO	9419322	Alimentary/Metabolic, other	Unspecified
AG-2037	N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethy]-4-methylthieno-2-yl)glutamic acid				Anticancer, antimetabolite	Cancer, general
α-Glucose-1-phosphate		59-56-3				
AGN-194310	Benzoic acid, 4-((4-(4-ethylphenyl)-2,2-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)- [CAS]	229961-45-9	WO	9709297	Dermatological	Psoriasis
agomelatine	Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)- [CAS]	138112-76-2	EP	447285	Antidepressant	Sleep disorder, general
Ahistan		518-61-6				
AHL-157			US	5411972	Hypolipaemic/Antiatherosclerosis	Atherosclerosis
AIT-034	9H-Purine-9-propanamide, 1,6-dihydro-6-oxo-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- [CAS]	138117-48-3	US	5447939	Cognition enhancer	Dementia, senile, general
AIT-202	N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-3-(6-oxo-6,9-dihydro-1H-purin-9-yl)propionamide		WO	9957120	Antidepressant	Unspecified

NPC-UNIV-000004543

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 165 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
AJ-9677	Acetic acid, ((3-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)- [CAS]	244081-42-3			Antidiabetic	Diabetes, Type II
AJG-049			WO	9733885	Gastroprokinetic	Motility dysfunction, GI, general
Ajmaline		12/07/4360				
Alacepril		74258-86-9				
albaconazole	4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]	187949-02-6	WO	9705131	Antifungal	Infection, Candida, general
albendazole	Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester [CAS]	54029-12-8 54965-21-8	GB	1464326	Anthelmintic	Infection, helminth, general
Albuterol		18559-94-9				
Albutoin		830-89-7				
alclofenac	Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- [CAS]	22131-79-9	GB	1174535	Anti-inflammatory	
alclometasone	Pregna-1,4-diene-3,20-dione, 7-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (7Alpha,11ß,16Alpha)- [CAS]	66734-13-2 67452-97-5	US	4124707	Antipruritic/inflamm, allergic	Inflammation, dermal
Alcuronium		23214-96-2				
Aldioxa		5579-81-7				
Aldol		107-89-1				
Aldosterone		52-39-1				
alendronate	Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-[CAS]	121268-17-5 129318-43-0	GB	2118042	Osteoporosis treatment	Osteoporosis
Al ndronic Acid		66376-36-1				
Alexidine		22573-93-9				
alfacalcidol	9,10-Secocholesta-5,7,10(19)-triene-1,3-diol, (1Alpha,3ß,5Z,7E)- [CAS]	41294-56-8			Osteoporosis treatment	Osteodystrophy
Alfadolone		23930-37-2				
Alfaxalone		23930-19-0				
Alfentanil		71195-58-9				
alfimeprase		259074-76-5			Fibrinolytic	Peripheral vascular disease

NPC-UNIV-000004544

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 166 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
alfuzosin	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- [CAS]	81403-68-1 81403-80-7	GB	2013679	Prostate disorders	Benign prostatic hyperplasia
alfuzosin	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- [CAS]	81403-68-1 81403-80-7			Formulation, modified-release, other	Benign prostatic hyperplasia
Algestone		595-77-7				
Algestone Acetophenide		24356-94-3				
Algin		9005-38-3				
Alglucerase		143003-46-7				
Alibendol		26750-81-2				
aliskiren	(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide	173334-57-1			Antihypertensive, renin system	Hypertension, general
alitretinoin	9-cis retinoic acid	03/08/5300			Antipruritic/inflamm, allergic	Eczema, general
alizapride	1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]- [CAS]	59338-93-1	GB	1475234	Antiemetic	Nausea and vomiting, general
Alkannin		517-88-4				
Alkofanone		7527-94-8				
Allantoin		97-59-6				
Allobarbital		52-43-7				
Allopurinol		315-30-0				
Allyl Isothiocyanate		57-06-7				
Allylestrenol		432-60-0				
almagate	Magnesium, [carbonato(2-)]heptahydroxy(aluminum)tri-, dihydrate [CAS]	66827-12-1 72526-11-5	US	4447417	Antacid/Antiflatulent	
alminoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-methyl-2-propenyl)amino]- [CAS]	39718-89-3	US	3957850	Analgesic, NSAID	

NPC-UNIV-000004545

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 167 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
almitrine	1,3,5-Triazine-2,4-diamine, 6-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-N,N'-di-2-propenyl-, dimethanesulfonate [CAS]	27469-53-0 29608-49-9	GB	1256513	Respiratory	Bronchitis, chronic
almotriptan	Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)- [CAS]	154323-57-6	WO	9402460	Antimigraine	Migraine
Aloe-Emodin		481-72-1				
Aloin		5133-19-7				
alosetron	2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one [CAS]	122852-42-0 122852-69-1 132414-02-9	EP	306323	GI inflammatory/bowel disorders	Irritable bowel syndrome
alovudine	Thymidine, 3'-deoxy-3'-fluoro- [CAS]	25526-93-6	EP	470355	Antiviral, anti-HIV	Infection, HIV/AIDS
Aloxiprin		9014-67-9				
Alpha-1 protease inhibitor			US	5780014	Formulation, inhalable, topical	Emphysema, alpha-1 antitrypsin deficiency
Alpha-dihydroergocryptine	Ergocryptine, 9,10-dihydro-methanesulfonate (salt)- [CAS]	29261-93-6			Formulation, other	Parkinson's disease
Alphaprodine		77-20-3				
Alpidem		82626-01-5				
Alpiropride		81982-32-3				
alprazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-[CAS]	28981-97-7	US	3987052	Anxiolytic	Anxiety, general
Alprenolol		13655-52-2				
alsactide	Alpha1-17-Corticotropin, 1-ß-alanine-17-[N-(4-aminobutyl)-L-lysinamide]- [CAS]	34765-96-3	US	3749704	ACTH	Arthritis, rheumatoid
ALT-711	Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide [CAS]	181069-80-7	WO	9622095	Symptomatic antidiabetic	Hypertension, general
Althiazid		5588-16-9				
altinicline	Pyridine, 3-ethynyl-5-((2S)-1-methyl-2-pyrrolidinyl)- [CAS]	179120-92-4	US	5594011	Antiparkinsonian	Parkinson's disease
altretamine	1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl- [CAS]	645-05-6	US	3424752	Anticancer, alkylating	Cancer, ovarian
aluminium chloride hexahydrate	Aluminium chloride, hexahydrate	7446-70-0 7784-13-6			Dermatological	Hyperhidrosis

NPC-UNIV-000004546

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 168 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Aluminon		569-58-4				
Aluminum Acetate Solution		8006-13-1				
Aluminum Chlorate		15477-33-5				
Aluminum Hydroxychloride		1327-41-9				
Aluminum Potassium Sulfate		10043-67-1				
Aluminum Sodium Sulfate		10102-71-3				
alusulf	Aluminum hydroxide sulfate (Al7(OH)17(SO4)2), dodecahydrate [CAS]	61115-28-4	DE	2510663	Urological	Hyperphosphataemia
Alverine		150-59-4				
alvimopan	Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- [CAS]	156053-89-3	EP	657428	GI inflammatory/bowel disorders	Ileus
alvocidib	4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-)- [CAS]	131740-09-5 146426-40-6			Anticancer, other	Cancer, renal
ALX-0646			WO	9506638	Antimigraine	Migraine
AM-24	2,4,6-Triiodophenol	609-23-4			GI inflammatory/bowel disorders	Crohn's disease
AM-36	1-Piperazineethanol, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-Alpha-(4-chlorophenyl)- [CAS]	199467-52-2			Neuroprotective	Unspecified
AM-477	2-Methoxyoestradiol				Antiasthma	Asthma
Amantadine		768-94-5				
amantanium	1-Decanaminium, N,N-dimethyl-N-[2-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)oxy]ethyl]-, bromide [CAS]	58158-77-3	US	4288609	Antifungal	Infection, general
Ambazon		539-21-9				
Ambenonium		115-79-7				

NPC-UNIV-000004547

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 169 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ambrisentan	(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid	177036-94-1			Vasodilator, peripheral	Heart failure
ambroxol	Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, trans- [CAS]	18683-91-5 23828-92-4	GB	1178034	COPD treatment	Bronchitis, chronic
Ambucaine		119-29-9				
Ambuphylline		5634-34-4				
Ambusid		3754-19-6				
Ambutonium Bromide		115-51-5				
amcinonide	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11ß,16Alpha)- [CAS]	51022-69-6	DE	2437847	Antipsoriasis	
AMD-3100	1,4,8,11-Tetraazacyclotetradecane, 1,11-(1,4-phenylenebis(methylene))bis-, octahydrochloride [CAS]	155148-31-5	US	5612478	Haematological	Chemotherapy-induced injury, bone marrow, leucopenia
Amdinocillin		32887-01-7				
Amdinocillin Pivoxil		32886-97-8				
amdoxovir	1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)- (2R-cis)- [CAS]	145514-04-1	EP	656778	Antiviral, anti-HIV	Infection, HIV/AIDS
amelubant	Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)- ethyl ester [CAS]	346735-24-8	DE	10000907	COPD treatment	Chronic obstructive pulmonary disease
Americaine	Benzenemethanaminium, N,N-dimethyl-N-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]-, chloride, mixt. with ethyl 4-aminobenzoate [CAS]	129128-13-8			Formulation, inhalable, other	Pain, general
Amezinium		30578-37-1				
Amfenac		51579-82-9				
Amid phrine		3354-67-4				
Amidinomycin		3572-60-9				

NPC-UNIV-000004548

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 170 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
amifostine	Ethanethiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester)- [CAS]	20537-88-6 63717-27-1	EP	131500	Radio/chemoprotective	Chemotherapy-induced injury, renal
amiglumide	Pentanoic acid, 5-(dipentylamino)-4-((2-naphthalenylcarbonyl)amino)-5-oxo- (R)- [CAS]	119363-62-1	WO	8805774	GI inflammatory/bowel disorders	Pancreatitis
amikacin		37517-28-5 39831-55-5			Formulation, optimized, microencapsulate	Infection, general
Amiloride		2609-46-3				
Aminacrine		90-45-9				
amineptine	Heptanoic acid, 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]- [CAS]	30272-08-3 57574-09-1	US	3758528	Antidepressant	
Aminitrozole		140-40-9				
Amino Acid Preparations						
Aminocaproic Acid						
aminoglutethimide	2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl- [CAS]	125-84-8	US	3944671	Anticancer, hormonal	Cancer, breast
Aminoguanidine		79-17-4				
Aminohippurate						
Aminometradine		642-44-4				
Aminopentamide		60-46-8				
aminophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1) [CAS]	317-34-0			Formulation, modified-release, other	Asthma
Aminopromazine		58-37-7				
Aminopyrine		58-15-1				
Aminoquinuride		3811-56-1				
Aminorex		2207-50-3				
amiodarone	Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]- [CAS]	1951-25-3 19774-82-4	US	3248401	Antiarrhythmic	Arrhythmia, general
Amiphenazole		490-55-1				
Amiprilose		56824-20-5				

NPC-UNIV-000004549

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 171 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
amisulpride	Benzamide, 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy- [CAS]	71675-85-9	US	4401822	Neuroleptic	Schizophrenia
Amitriptyline		50-48-6				
amitriptyline+ketamine	1-Propanamine,3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl + cyclohexanone,2-(2-chlorophenyl)-2-(methylamino)				Formulation, fixed-dose combinations	Pain, neuropathic
Amitriptylinoxide		4317-14-0				
amlexanox	5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- [CAS]	68302-57-8	US	4299963	Antiasthma	Asthma
amlodipine	3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester [CAS]	111470-99-6 88150-42-9 88150-47-4	EP	89167	Antianginal	Hypertension, general
Ammoniacum		03/07/9000				
Ammonium Benzoate		1863-63-4				
Ammonium Mandelate		530-31-4				
Ammonium Salicylate		528-94-9				
Ammonium Valerate		42739-38-8				
Amobarbital		57-43-2				
Amocarzine		36590-19-9				
Amodiaquin		86-42-0				
amorolfine	Morpholine, 4-[3-[4-(1,1-dimethylpropyl)phenyl]-2-methylpropyl]-2,6-dimethyl-, cis- [CAS]	78613-35-1 78613-38-4	EP	24334	Antifungal	Infection, fungal, general
Amoscanat		26328-53-0				
amosulalol	Benzenesulfonamide, 5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methyl-, (+/-)- [CAS]	70958-86-0 85320-68-9	EP	136103	Antihypertensive, adrenergic	Hypertension, general
Amotriphene		5585-64-8				
amoxapine	Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)- [CAS]	14028-44-5	GB	1192812	Antidepressant	Depression, general

NPC-UNIV-000004550

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 172 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
amoxicillin	4-Thia-1-azobicyclo[3,2,0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-,[2S-[2Alpha,5Alpha,6ß(S*)]] [CAS]	26787-78-0 61336-70-7			Formulation, modified-release, other	Infection, general
amoxicillin+potassium clavulan		74469-00-4	GB	1508977	Formulation, fixed-dose combinations	Infection, respiratory tract, general
AMPAlex	Piperidine, 1-(6-quinoxalinylcarbonyl)- [CAS]	154235-83-3	US	5650409	Psychostimulant	Attention deficit disorder
Amphetamine		300-62-9				
Amphetaminil		17590-01-1				
amphotericin B	Amphotericin B compd. with (3ß)-cholest-5-en-3-yl hydrogen sulfate (1:1) [CAS]	120895-52-5 1397-89-3	US	4822777	Formulation, optimized, liposomes	Infection, general
ampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6ß(S*)]]	69-53-4 7177-48-2			Formulation, fixed-dose combinations	Infection, general
Ampiroxicam		99464-64-9				
Ampligen		38640-92-5				
amprenavir	Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1R*,2S*)))- [CAS]	161814-49-9	US	5783701	Antiviral, anti-HIV	Infection, HIV/AIDS
amrinone	[3,4'-Bipyridin]-6(1H)-one, 5-amino- [CAS]	60719-84-8 75898-90-7	US	4004012	Cardiostimulant	
amrubicin	5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-ß-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7S-cis)- [CAS]	92395-36-3	EP	107486	Anticancer, antibiotic	Cancer, lung, non-small cell
amsacrine	Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- [CAS]	51264-14-3			Anticancer, other	Cancer, leukaemia, acute lymphocytic

NPC-UNIV-000004551

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 173 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
amtolmetin guacil	Glycine, N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]-, 2-methoxyphenyl ester [CAS]	87344-06-7	GB	2115417	Analgesic, NSAID	Arthritis, rheumatoid
Amylocaine		532-59-2				
AN-152			WO	9719954	Anticancer, antibiotic	Cancer, prostate
anabolic steroids			WO	9848812	Cardiovascular	Heart failure
Anagestone		2740-52-5				
anagrelide	Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride [CAS]	58579-51-4 68475-42-3	GB	1418822	Haematological	Thrombocytosis
anastrozole	1,3-Benzenediacetonitrile, Alpha,Alpha,Alpha,Alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	120511-73-1	EP	296749	Anticancer, hormonal	Cancer, breast
Anazolene		3861-73-2				
Ancitabine		31698-14-3				
Ancrod		9046-56-4				
andolast	N-4'-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)-benzamide	132640-22-3	EP	460083	Antiasthma	Asthma
Androisoxazole		360-66-7				
Androstenediol		521-17-5				
anecortave	21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione	7753-60-8			Ophthalmological	Macular degeneration
Anethole		4180-23-8; 104-46-1 (unspecified)				
Anethole Trithione		532-11-6				
Angiogenix			US	6417205	Cardiovascular	Cardiomyopathy, ischaemic
Angiot nsin		1407-47-2				
anhydrovinblastine	Vincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	38390-45-3	US	6011041	Anticancer, other	Cancer, general
anidulafungin	Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine)- [CAS]	166663-25-8	US	6384013	Antifungal	Infection, Candida, general

NPC-UNIV-000004552

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 174 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Anileridine		144-14-9				
Aniracetam		72432-10-1				
Anisindione		117-37-3				
Anisomycin		22862-76-6				
Anisotropine Methylbromide		80-50-2				
anistreplase	Anistreplase [CAS]	81669-57-0	EP	28489	Fibrinolytic	Infarction, myocardial
Antazoline		91-75-8				
Anthiolimine		305-97-5				
Anthralin		1143-38-0				
Anthramycin		4803-27-4				
Anthrarobin		577-33-3				
anthrax inhibitor			US	6436933	Anti-infective, other	Infection, anthrax
antiangiogenic dendrimers			US	6426067	Anticancer, other	Cancer, general
Anticort	L-Ascorbic acid, mixt with 2-(diethylamino)ethyl 4-aminobenzoate monohydrochloride, disodium hydrogen phosphate, potassium benzoate and zinc sulfate (1:1) [CAS]	186646-39-9	WO	9640038	Anabolic	Cachexia
antidepressants			US	5898036	Antidepressant	Depression, general
anti-invasins			US	6303302	Antifungal	Infection, fungal, general
Antimony Potassium Tartrate		28300-74-5				
Antimony Sodium Thioglycollate		539-54-8				
Antimony Thioglycollamide		6533-78-4				
Antiprogestin	19-Norpregna-4,9-dien-3-one,(acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-(11ß,17Alpha) [CAS]	211254-73-8	DE	19706061	Anticancer, hormonal	Cancer, breast
Antipyrine		60-80-0				
Antipyrine Salicylate		520-07-0				
antithrombin III	Antithrombin, III [CAS]	9000-94-6 90170-80-2			Blood fraction	Antithrombin III deficiency

NPC-UNIV-000004553

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 175 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
anxiolytics			US	5756538	Anxiolytic	Anxiety, general
AP-521	N-Piperonyl-2-amino-1,2,3,4-tetrahydrobenzo(b)thieno(2,3-c)pyridine-3-carbamide	151227-08-6	WO	9321189	Anxiolytic	Anxiety, general
AP-5280			US	5965118	Anticancer, alkylating	Cancer, general
Apalcillin		63469-19-2				
apaziquone	1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)- [CAS]	114560-48-4	WO	8706227	Anticancer, alkylating	Cancer, breast
Apazone		13539-59-8				
α-Phenylbutyramide		90-26-6				
Apocodeine		641-36-1				
apomine	Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis- tetrakis(1-methylethyl) ester [CAS]	126411-13-0			Anticancer, other	Cancer, prostate
apomorphine	4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride	314-19-2 58-00-4			Formulation, transmucosal, nasal	Impotence
apraclonidine	1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	66711-21-5 73218-79-8	US	4517199	Antiglaucoma	Glaucoma
aprepitant	3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]	170729-80-3	US	5719147	Antiemetic	Chemotherapy-induced nausea and vomiting
aprindine	1,3-Propanediamine, N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-[CAS]	33237-74-0 37640-71-4	GB	1321424	Antiarrhythmic	
Aprobarbital		77-02-1				
Apronalide		528-92-7				
Aprotinin		9087-70-1				
Aptiganel		137159-92-3				
AQ4N	9,10-Anthracenedione, 1,4-bis((2-(dimethyloxidoamino)ethyl)amino)-5,8-dihydroxy-[CAS]	136470-65-0	US	5132327	Anticancer, other	Cancer, general
Aquavan			US	6204257	Anaesthetic, injectable	Anaesthesia

NPC-UNIV-000004554

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 176 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
AR-116081			US	6107324	Neuroleptic	Unspecified
AR-A2	(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide				Anxiolytic	Anxiety, general
Arachidonic Acid		506-32-1				
aranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-oxopropyl ester- [CAS]	86780-90-7	GB	2111978	Antihypertensive, other	Hypertension, general
arbekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)- [CAS]	51025-85-5 75282-65-4	US	4001208	Aminoglycoside antibiotic	Infection, general
Arbidol	1H-indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethylester, monohydrochloride [CAS]	131707-23-8	WO	9008135	Immunostimulant, other	Infection, influenza virus
arbutamine	1,2-Benzenediol, 4-[1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-, (R)- [CAS]	128470-16-6	WO	9220324	Diagnostic	Diagnosis, coronary
Arcitumomab		154361-48-5				
ardeparin	Heparin [CAS]	9005-49-6			Anticoagulant	Thrombosis, venous
arecoline	1,2,5,6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester				Formulation, transdermal, patch	Alzheimer's disease
argatroban	2-Piperidinecarboxylic acid, 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl- [CAS]	74863-84-6	EP	8746	Anticoagulant	Thrombosis, arterial
Arginine		74-79-3				
Ariflo®		153259-65-5				
aripiprazole	2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro- [CAS]	129722-12-9	EP	367141	Neuroleptic	Schizophrenia

NPC-UNIV-000004555

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 177 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
arofylline	1H-Purine-2,6-dione, 3-(4-chlorophenyl)-3,7-dihydro-1-propyl- [CAS]	136145-07-8	EP	435811	COPD treatment	Chronic obstructive pulmonary disease
arotinolol	2-Thiophenecarboxamide, 5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-, (±)- [CAS]	104766-23-6 68377-92-4	US	3932400	Antihypertensive, adrenergic	Hypertension, general
Arsacetin		618-22-4				
arsenic trioxide	Arsenic oxide (As2O3) [CAS]	1327-53-3			Anticancer, other	Cancer, leukaemia, acute myelogenous
Arsph namine		139-93-5				
Arsthinol		119-96-0				
Arteether		75887-54-6				
Arteflene		123407-36-3 (Z-form)				
Artemether		71963-77-4				
Artemisinin		63968-64-9				
artemotil	3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, [3R-(3Alpha,5aß,6ß,8aß,9aAlpha,10Alpha,12ß,12aR*)]- [CAS]	75887-54-6			Antimalarial	Infection, malaria
artesunate	Butanedioic acid mono-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]ester	88495-63-0			Formulation, transmucosal, systemic	Infection, malaria
arzoxifene	Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)ethoxy)phenoxy)- [CAS]	182133-27-3	WO	9609041	Anticancer, hormonal	Cancer, breast
AS-3201	Spiro(pyrrolidine-3,4'(1'H)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'H)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)-, (3'R)- [CAS]	147254-64-6	EP	520320	Symptomatic antidiabetic	Diabetic complication, general
ASA	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2 56449-07-1			Formulation, modified-release, other	Pain, general

NPC-UNIV-000004556

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 178 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
α-Santonin		481-06-1				
Ascaridole		512-85-6				
Ascorbic Acid		50-81-7				
asenapine	1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1) [CAS]	85650-56-2	WO	9523600	Neuroleptic	Psychosis, general
asimadoline	Benzeneacetamide, N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-Alpha-phenyl-, [S-(R*,R*)]- [CAS]	153205-46-0	DE	4215213	GI inflammatory/bowel disorders	Irritable bowel syndrome
asoprisnil	11ß-[4-(Hydroxyiminomethyl)phenyl]-17ß-methoxy-17Alpha-(methoxymethyl)estra-4,9-dien-3-one	199396-76-4	EP	0648778	Menstruation disorders	Endometriosis
Asoxime		34433-31-3				
Aspartic Acid		56-84-8				
Aspidin		584-28-1				
Aspidinol		519-40-4				
Aspirin		50-78-2				
Aspirin, Dipyridamole						
aspoxicillin	Glycinamide, N-methyl-D-asparaginyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2Alpha,5Alpha,6ß)]- [CAS]	63358-49-6	GB	1533413	Penicillin, injectable	Infection, respiratory tract, general
AST-120	AST 120 [CAS]	90597-58-3			Urological	Renal failure
Astemizole		68844-77-9				
asulacrine	4-Acridinecarboxamide, 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl- [CAS]	80841-47-0 80841-48-1	EP	39224	Anticancer, other	Cancer, general
AT-1015	(N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperdino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate				Antithrombotic	Thrombosis, general
atamestane	Androsta-1,4-diene-3,17-dione, 1-methyl- [CAS]	96301-34-7	DE	3338212	Anticancer, hormonal	Cancer, breast

NPC-UNIV-000004557

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 179 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
atazanavir	2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)- dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) [CAS]	229975-97-7			Antiviral, anti-HIV	Infection, HIV/AIDS
atenolol	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- [CAS]	29122-68-7 73677-19-7	GB	1285038	Antihypertensive, adrenergic	Hypertension, general
atenolol + chlorthalidone	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, mixt. with 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide [CAS]	73677-19-7	US	3836671	Formulation, fixed-dose combinations	Hypertension, general
atenolol + nifedipine	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- + 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine				Formulation, fixed-dose combinations	Hypertension, general
α-Terpineol		98-55-5				
Atevirdine		136816-75-6				
atipamezole	1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- [CAS]	104054-27-5	EP	183492	Reproductive/gonadal, general	Sexual dysfunction, female
atiprimod dimaleate	2-Azaspivo[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl, dimaleate	130065-61-1	US	5744495	Antiarthritic, immunological	Arthritis, rheumatoid
ATL-146e			US	6232297	Imaging agent	Unspecified
α-Tocopherol		59-02-9				
atomoxetine	Benzenepropanamine, N-methyl-Gamma-(2-methylphenoxy)-, (R)- [CAS]	82248-59-7 83015-26-3	EP	52492	Neurological	Attention deficit disorder
atorvastatin	1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-ß,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]- [CAS]	134523-03-8 134523-00-5	EP	409281	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
atosiban	Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine- [CAS]	90779-69-4	EP	112809	Labour inhibitor	Labour, preterm

NPC-UNIV-000004558

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 180 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
atovaquone	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans-[CAS]	95233-18-4	EP	123238	Antifungal	Infection, Pneumocystis jiroveci
atovaquone + proguanil	1,4-Naphthalenedione,2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-,trans + N-(4-chloro-phenyl)-N-(1-methylethyl)imidiodicarbonimidic diamide				Antimalarial	Infection, malaria
atracurium	Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl- [CAS]	64228-81-5	US	4179557	Muscle relaxant	Surgery adjunct
atrasentan	3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- [CAS]	173937-91-2	WO	9730045	Anticancer, other	Cancer, prostate
Atrial Natriuretic Peptide		85637-73-6				
Atrolactamide		2019-68-3				
Atropine		51-55-8				
Augmentin		74469-00-4			Formulation, modified-release, other	Infection, respiratory tract, general
auranofin	Gold, (1-thio-ß-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-[CAS]	34031-32-8	US	3708579	Antiarthritic, other	Arthritis, rheumatoid
Aurothioglucose		12192-57-3				
avasimibe	Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester [CAS]	166518-60-1	US	5491172	Hypolipaemic/Antiatherosclerosis	Atherosclerosis
Avobenzone		70356-09-1				
AWD-12-281	AWD 12-281 [CAS]	257892-33-4			Antiallergic, non-asthma	Rhinitis, allergic, general
Azacitidine		320-67-2				
Azacyclonol		115-46-8				
azanidazole	2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)ethenyl]-,(E)- [CAS]	62973-76-6	US	3882105	Antibacterial, other	Infection, trichomoniasis

NPC-UNIV-000004559

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 181 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
azapropazone	1H-Pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione, 5-(dimethylamino)-9-methyl-2-propyl- [CAS]	13539-59-8	FR	1440629	Anti-inflammatory	
Azaserine		115-02-6				
azasetron	2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride- [CAS]	123040-16-4 123040-94-8 123040-96-0 123040-69-7	EP	313393	Antiemetic	Nausea and vomiting, general
Azatadine		3964-81-6				
azathioprine	6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine	446-86-6			Formulation, oral, other	Transplant rejection, bone marrow
AZD-4282	glycine				Analgesic, other	Pain, neuropathic
AZD-6140	3,4 Difluorophenylcyclopropylamine				Antithrombotic	Thrombosis, arterial
azelaic acid	Nonanedioic acid [CAS]	123-99-9			Antiacne	Acne
azelastine	1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride [CAS]	58581-89-8 79307-93-0	GB	1377231	Antiasthma	Asthma
azelnidipine	3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl)ester, (+/-)- [CAS]	123524-52-7	EP	266922	Antihypertensive, other	Hypertension, general
Azidamfenicol		13838-08-9				
Azidocillin		17243-38-8				
Azimilide		149908-53-2				
Azintamide		1830-32-6				
azithromycin	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin-A	76801-85-9 83905-01-5 92395-24-9	US	4328334	Macrolide antibiotic	Infection, respiratory tract, lower
azlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, [2S-[2.alpha.,5Alpha,6ß(S*)]]- [CAS]	37091-65-9 37091-66-0	GB	1392849	Penicillin, injectable	Infection, general

NPC-UNIV-000004560

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 182 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Azosemide		27589-33-9				
aztreonam	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-[2Alpha,3ß(Z)]]-[CAS]	104184-69-2 78110-38-0	GB	2071650	Beta-lactam antibiotic	Infection, general
azulene	Sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate	6223-35-4	EP	88958	Formulation, modified-release, other	Inflammation, general
bacampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, 1-[(ethoxycarbonyl)oxy]ethyl ester, [2S-[2Alpha,5Alpha,6ß(S*)]]- [CAS]	37661-08-8 50972-17-3	GB	1363506	Penicillin, oral	Infection, general
Bacitracin		1405-87-4				
baclofen	ß-(Aminomethyl)-4-chlorobenzenepropanoic acid [CAS]	1134-47-0			Formulation, implant	Spastic paralysis
Baicalein		491-67-8				
balofloxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]	127294-70-6	EP	342675	Quinolone antibacterial	Infection, urinary tract
balsalazide	Benzoic acid, 5-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, (E)- [CAS]	80573-04-2	US	4412992	GI inflammatory/bowel disorders	Colitis, ulcerative
bambuterol	Carbamic acid, dimethyl-, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester, monohydrochloride [CAS]	81732-46-9 81732-65-2	EP	43807	Antiasthma	Asthma
Bamethan		3703-79-5				
Bamifylline		2016-63-9				
Bamipine		4945-47-5				
Barbital		57-44-3				
barnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl-1-(phenylmethyl)-3-pyrrolidinyl ester, [S-(R*,R*)]-	104713-75-9 104757-53-1 71863-56-4	US	4220649	Antihypertensive, other	Hypertension, general

NPC-UNIV-000004561

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 183 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
BAS-118	N-Methyl-3-[2-(2-napthyl)acetylamino]benzamide				Antibacterial, other	Infection, Helicobacter pylori
Basic Aluminum Carbonate Gel		1339-92-0				
Basiliximab		179045-86-4				
Batimastat		130370-60-4				
Batroxobin		9039-61-6				
Bay-41-2272	5-cyclopropyl-2-[1(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4ylamine				Male sexual dysfunction	Sexual dysfunction, male, general
Bay-41-8543	2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-mopholinyl)pyrimidine-4,6-diamine				Cardiovascular	Unspecified
BAY-43-9006	N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea				Anticancer, other	Cancer, liver
BAY-57-1293	N-[5(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide				Antiviral, other	Infection, herpes simplex virus
bazedoxifen	TSE 424 [CAS]	198481-33-3	EP	802183	Osteoporosis treatment	Osteoporosis
β-Benzalbutyramide		7236-47-7				
BBR-3464	Platinum(4+), hexaaminedichlorobis(μ-(1,6 hexanediamine-N:N'))tri- stereoisomer, tetranitrate [CAS]	172903-00-3	US	5744497	Anticancer, alkylating	Cancer, lung, non-small cell
BBR-3576			US	5519029	Anticancer, antibiotic	Cancer, prostate
BBR-3610			US	6060616	Anticancer, alkylating	Cancer, general
β-Carotene		7235-40-7				
BCH-1868	(-)-2-R-dihydroxyphosphinyol-5-(S)-(guanin-9'-yl-methyl)tetrahydrofuran				Anticancer, antimetabolite	Cancer, general
Bebeerine		477-60-1				
Beclamide		501-68-8				

NPC-UNIV-000004562

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 184 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
beclometasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11ß,17,21-trihydroxy-16ß-methyl, [CAS]	5534-09-8 4419-39-0	WO	0006132	Formulation, inhalable, solution	Asthma
Befloxatone		134564-82-2				
befunolol	Ethanone, 1-[7-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2-benzofuranyl]-[CAS]	39543-79-8 39552-01-7			Antiglaucoma	
Bemegride		64-65-3				
Benactyzine		302-40-9				
benazepril	1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-[CAS]	86541-74-4 86541-75-5 86541-78-8	EP	72352	Antihypertensive, renin system	Hypertension, general
bencyclane	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyl]oxy]-, (E)-2-butenedioate (1:1) [CAS]	14286-84-1 2179-37-5	WO	9829409	Vasodilator, peripheral	
bendazac	L-Lysine, mono[[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]acetate] [CAS]	81919-14-4 20187-55-7	GB	2081708	Ophthalmological	
Bendroflumethiazide		73-48-3				
Benexate		78718-25-9				
benfluorex	Ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]-, benzoate (ester) [CAS]	23602-78-0 23642-66-2	GB	1175516	Hypolipaemic/Antiatherosclerosis	
Benfotiamine		22457-89-2				
Benfurodil		3447-95-8				
benidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-piperidinyl ester, monohydrochloride (R*,R*)-(+/-)-[CAS]	105979-17-7 91599-74-5	EP	63365	Antihypertensive, other	Hypertension, general
Benorylate		5003-48-5				
Benoxaprofen		67434-14-4				
Benoxinate		99-43-4				
Benperidol		2062-84-2				
Benproperine		2156-27-6				
Benserazide		322-35-0				

NPC-UNIV-000004563

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 185 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
bentazepam	2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-one, 1,3,6,7,8,9-hexahydro-5-phenyl[CAS]	29462-18-8	DE	2005276	Anxiolytic	
B ntiromide		37106-97-1				
Bentoquatam		1340-69-8				
Benzalkonium		8001-54-5				
Benzarone		1477-19-6				
benzbromarone	Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-[CAS]	3562-84-3	US	3012042	Antigout	
Benzethonium		121-54-0				
Benzetimide		14051-33-3				
Benzilonium		1050-48-2				
Benziodarone		68-90-6				
benznidazole	N-benzyl-2-nitroimidazole-1-acetamide	22994-85-0	GB	1138529	Protozoacide	
benzocaine	Benzoic acid, 4-amino-, ethyl ester	94-09-7			Formulation, fixed-dose combinations	Pain, musculoskeletal
Benzoctamine		17243-39-9				
Benzonatate		104-31-4				
Benzoxonium Chloride		19379-90-9				
benzoyl peroxide	Peroxide, dibenzoyl [CAS]	94-36-0			Formulation, other	Acne
Benzoylpas		13898-58-3				
Benzphetamine		156-08-1				
Benzpiperylon		53-89-4				
Benzquinamide		63-12-7				
Benzthiazide		91-33-8				
Benztropine		132-17-2				
benzydamine	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]- [CAS]	132-69-4 642-72-8			Stomatological, reproductive/gonadal, anti-inflammatory	
Benzyl Benzoate		120-51-4				
Benzylhydrochlorothiazide		1824-50-6				
Benzylmorphine		14297-87-1				

NPC-UNIV-000004564

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 186 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bephenium Hydroxynaphthoate		3818-50-6				
bepotastine	1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)-, (S)-, monobenzenesulfonate [CAS]	190786-44-8 190786-43-7	WO	9829409	Antiallergic, non-asthma	Allergy, general
bepridil	1-Pyrrolidineethanamine, ß-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)- [CAS]	64706-54-3 74764-40-2 74764-75-3	EP	146155	Antianginal	Angina, general
beraprost	1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)- [CAS]	88475-69-8 88430-50-6	US	4474802	Prostaglandin	Peripheral vascular disease
Berberine		2086-83-1				
Bergapten		484-20-8				
Bermoprofen		78499-27-1				
Besipirdine		119257-34-0				
betahistine	2-Pyridineethanamine, N-methyl-, dihydrochloride	5579-84-0 5638-76-6			Formulation, modified-release, <=24hr	Meniere's disease
betaine	Betaine- [CAS]	107-43-7			Metabolic and enzyme disorders	Homocystinuria
betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11ß,16ß)- [CAS]	378-44-9			Formulation, dermal, topical	Psoriasis
Betamipron		3440-28-6				
Betasine		3734-24-5				
betaxolol	2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	63659-18-7 63659-19-8	US	4252984	Antihypertensive, adrenergic	Hypertension, general, glaucoma
Betazole		105-20-4				
Bethanechol		590-63-6				
Bethanidine		55-73-2				
Betoxycaine		3818-62-0				
β-Eucaine		500-34-5				
bevantolol	2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-methylphenoxy)- [CAS]	42864-78-8 59170-23-9	US	3857891	Antihypertensive, adrenergic	Hypertension, general
Bevonium		5205-82-3				

NPC-UNIV-000004565

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 187 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
bexarotene	Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)- [CAS]	153559-49-0	WO	9321146	Anticancer, other	Cancer, lymphoma, T-cell
bezafibrate	Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- [CAS]	41859-67-0	GB	1359264	Hypolipaemic/Antiatherosclerosis	
Bezitramide		15301-48-1				
BG-9928		166374-48-7			Cardiostimulant	Heart failure
BIA-2-024	10,11-dihydro-10-hydroxyimino-5H-dibenz/b,f/azepine-5-carboxamide	199997-15-4	WO	9745416	Antiepileptic	Epilepsy, general
BIA-2-093	(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide- [CAS]	236395-14-5			Antiepileptic	Epilepsy, general
BIA-3-202	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone	274925-86-9	EP	1010688	Antiparkinsonian	Parkinson's disease
Bialamicol		493-75-4				
biapenem	5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-[[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-, hydroxide, inner salt, [4R-[4Alpha,5ß,6ß(R*)]]- [CAS]	120410-24-4	EP	289801	Beta-lactam antibiotic	Infection, beta-lactamase resistant
Bibenzonium		15585-70-3				
Bibrocathol		6915-57-7				
bicalutamide	Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-)- [CAS]	90357-06-5	EP	100172	Anticancer, hormonal	Cancer, prostate
bicifadine	3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (+/-)- [CAS]	66504-75-4 71195-57-8	DE	2740562	Analgesic, other	Pain, general
bicyclic monoterpene diols			US	6294585	Dermatological	Unspecified
Bidisomide		116078-65-0				
Bietamiverine		479-81-2				
Bietanautine		6888-11-5				

NPC-UNIV-000004566

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 188 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bietaserpine		53-18-9				
bifemelane	1-Butanamine, N-methyl-4-[2-(phenylmethyl)phenoxy]-, hydrochloride [CAS]	62232-46-6 90293-01-9	GB	1512880	Cognition enhancer	Attention deficit disorder
Bifluranol		34633-34-6				
bifonazole	1H-Imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)- [CAS]	60628-96-8 60629-08-5 60629-09-6	US	4118487	Antifungal	Infection, fungal, general
bimatoprost	5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl (1R-(1Alpha(Z)2ß(1E,3S,3Alpha,5Alpha)) [CAS]	155206-00-1	US	5688819	Prostaglandin	Glaucoma
bimoclomol	N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidoyl chloride, (Z)-2-butanedioate (1:1)	130493-04-8	US	5147874	Symptomatic antidiabetic	Neuropathy, diabetic
bimosiamose	(1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]	187269-40-5	US	5444050	Antiasthma	Asthma
Binifibrate		69047-39-8				
binodenoson	Adenosine, 2-((cyclohexylmethylene)hydrazino)- [CAS]	144348-08-3			Vasodilator, coronary	Diagnosis, coronary
Biomed-101			US	6423744	Anticancer, other	Cancer, renal
Biotin		58-85-5				
Biperiden		514-65-8				
biricodar	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-,4-(3-pyridinyl)-1-(3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS]	174254-13-8 159997-94-1			Radio/chemosensitizer	Cancer, breast
biriperone	1-Butanone, 1-(4-fluorophenyl)-4-(3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-2(1H)-yl)- [CAS]	42021-34-1	DE	2333922	Neuroleptic	
Bisacodyl		603-50-9				
Bisantrene		78186-34-2				

NPC-UNIV-000004567

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 189 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bisbentiamine		2667-89-2				
Bisdequalinium		52951-36-7				
Bismuth Aluminate		12284-76-3				
Bismuth Butylthiolaurate		53897-25-9				
Bismuth Ethyl Camphorate		52951-37-8				
Bismuth Iodosubgallate		138-58-9				
Bismuth Sodium Iodide		53778-50-0				
Bismuth Sodium *Triglycollamate*		5798-43-6				
Bismuth Subcarbonate		5892-10-4				
Bismuth Subgallate		22650-86-8				
Bismuth Subnitrate		1304-85-4				
Bismuth Subsalicylate		14882-18-9				
Bismuth Tribromophenate		5175-83-7				
bisoprolol	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	104344-23-2 66722-44-9	GB	1532380	Antihypertensive, adrenergic	Heart failure
bisoprolol + HCTZ	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino] mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide				Formulation, fixed-dose combinations	Hypertension, general
bisoprolol+trichloromethiazide	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)*amino*] mixt. with 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide				Formulation, fixed-dose combinations	Hypertension, general
Bisoxatin		14008-48-1				

NPC-UNIV-000004568

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 190 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bithionol		97-18-7				
Bitolterol		30392-40-6				
Bitoscanat		4044-65-9				
BL-3875			WO	0218378	Anti-inflammatory	Unspecified
bleomycin	Bleomycin [CAS]	11056-06-7 9041-93-4			Formulation, transdermal, enhanced	Cancer, head and neck
blonanserin	Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro- [CAS]	132810-10-7	EP	385237	Neuroleptic	Schizophrenia
BMS-184476			EP	639577	Anticancer, other	Cancer, breast
BMS-387032	cis-(+/-)-2-(Ethylthio)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one		WO	9742949	Anticancer, other	Cancer, general
BN-82451	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, dihydrochloride				Neuroprotective	Unspecified
BNP-7787	Ethanesulfonic acid, 2,2'-dithiobis-, disodium salt [CAS]	16208-51-8			Radio/chemoprotective	Chemotherapy-induced nausea and vomiting
BO-653	5-Benzofuranol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl- [CAS]	157360-23-1	WO	9408930	Hypolipaemic/Antiatherosclerosis	Atherosclerosis
Bolandiol		19793-20-5				
Bolasterone		1605-89-6				
Bold none		846-48-0				
bopindolol	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-, benzoate (ester), (+/-)- [CAS]	62658-63-3 82857-38-3	US	4340541	Antihypertensive, adrenergic	Hypertension, general
Bornyl Chloride		464-41-5				
Bornyl Salicylate		560-88-3				
bortezomib	Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo 3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- [CAS]	179324-69-7	US	6271199	Anticancer, other	Cancer, myeloma

NPC-UNIV-000004569

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 191 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
bosentan	Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- [CAS]	147536-97-8	EP	633259	Vasodilator, peripheral	Hypertension, pulmonary
BP2.94	Phenol, 2-[[[(1R)-2-(1H-imidazol-4-yl)-1-methylethyl]imino]phenylmethyl]- [CAS]	139191-80-3	WO	9117146	Respiratory	Rhinitis, general
BP4.897	N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]naphthalene-2-carboxamide		EP	779284	Dependence treatment	Addiction, cocaine
β-Propiolactone		57-57-8				
Bradycor		140661-97-8				
Brain Natriuretic Peptide		114471-18-0				
Brallobarbital		561-86-4				
brasofensine	8-Azabicyclo(3.2.1)octane-2-carboxaldehyde, 3-(3,4-dichlorophenyl)-8-methyl-, O-methyloxime, (1R-(1Alpha,2β(E),3Alpha,5Alpha))- [CAS]	171655-91-7	WO	9528401	Antiparkinsonian	Parkinson's disease
Brequinar		96187-53-0				
Bretylium		61-75-6				
Brilliant Green		633-03-4				
brimonidine	6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	59803-98-4	DE	2538620	Antiglaucoma	Glaucoma
brinzolamide	2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)- [CAS]	138890-62-7	US	5378703	Antiglaucoma	Glaucoma
brivudin	Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]	69304-47-8			Antiviral, other	Infection, varicella zoster virus
Brodimoprim		56518-41-3				
Bromazepam		1812-30-2				
bromfenac	Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- [CAS]	91714-93-1 91714-94-2			Formulation, mucosal, topical	Inflammation, ocular
Bromhexine		3572-43-8				
Bromindione		1146-98-1				
Bromisovalum		496-67-3				

NPC-UNIV-000004570

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 192 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bromocriptine		25614-03-3				
Bromodiphenhydramine		118-23-0				
Bromoform		75-25-2				
Bromopride		4093-35-0				
Bromosalicylchloranilide		3679-64-9				
bromperidol	1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- [CAS]	10457-90-6	US	3438991	Neuroleptic	Psychosis, general
Brompheniramine		86-22-6				
Broparoestrol		479-68-5				
Bropirimine		56741-95-8				
brostallicin	4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1'',1'''-tetramethyl-N,4':N',4'':N'',4'''-quater-[pyrrole-2-carboxamide] [CAS]				Anticancer, other	Cancer, general
brotizolam	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl- [CAS]	57801-81-7	US	4094984	Hypnotic/Sedative	
Brovincamine		57475-17-9				
Broxuridine		59-14-3				
Broxyquinoline		521-74-4				
Brucine		357-57-3				
β-Sitosterol		83-46-5				
Bucetin		1083-57-4				
Bucillamine		65002-17-7				
Bucindolol		71119-11-4				
bucladesine	Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate [CAS]	362-74-3	JP	51113896	Cardiostimulant	Wound healing
Buclizine		82-95-1				
Buclosamide		575-74-6				
Bucolome		841-73-6				
bucricaine	9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-, monohydrochloride [CAS]	82636-28-0			Anaesthetic, local	

NPC-UNIV-000004571

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 193 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Bucumolol		58409-59-9				
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11ß,16Alpha)- [CAS]	51333-22-3	GB	1429922	Antiasthma	Asthma
budesonide + formoterol	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-,(11ß,1bAlpha) + formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenol)-1-methylethyl]amino]ethyl]phenyl]-(R*,R*)-(±)				Formulation, fixed-dose combinations	Asthma
budipine	Piperidine, 1-(1,1-dimethylethyl)-4,4-diphenyl- [CAS]	57982-78-2 63661-61-0	DE	2825322	Antiparkinsonian	Parkinson's disease
Budralazine		36798-79-5				
Bufeniode		22103-14-6				
Bufetolol		53684-49-4				
bufexamac	p-butoxyacetohydroxamic acid	2438-72-4	US	3479396	Anti-inflammatory	
buflomedil	1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)- [CAS]	35543-24-9 55837-25-7	GB	1325192	Vasodilator, peripheral	
Buformin		692-13-7				
Bufuralol		54340-62-4				
Bumadizon		3583-64-0				
bumetanide	Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- [CAS]	28395-03-1	US	3806534	Antihypertensive, diuretic	Hypertension, general
bunaftine	1-Naphthalenecarboxamide, N-butyl-N-[2-(diethylamino)ethyl]- [CAS]	32421-46-8	DE	2009894	Antiarrhythmic	
Bunamiodyl Sodium		1923-76-8				
bunazosin	1H-1,4-Diazepine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)hexahydro-4-(1-oxobutyl)- [CAS]	52712-76-2 80755-51-7	GB	1398455	Antihypertensive, adrenergic	Hypertension, general
bunitrolol	Benzonitrile, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- [CAS]	34915-68-9	US	3940489	Antihypertensive, adrenergic	
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]	38396-39-3 2180-92-9			Formulation, modified-release, >24hr	Anaesthesia
Bupranolol		14556-46-8				

NPC-UNIV-000004572

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 194 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
buprenorphine	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]- [CAS]	52485-79-7 53152-21-9	US	3433791	Analgesic, other	
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2	US	4425363	Antidepressant	Depression, general
Buramate		4663-83-6				
buserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57982-77-1 68630-75-1	GB	1523623	Releasing hormones	Cancer, prostate
buspirone	8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-[CAS]	36505-84-7	EP	276536	Anxiolytic	Anxiety, general
busulfan	1,4-Butanediol, dimethanesulfonate [CAS]	55-98-1			Formulation, optimized, microparticles	Cancer, general
busulfan	1,4-Butanediol, dimethanesulfonate- [CAS]	55-98-1			Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Butabarbital		143-81-7				
Butacaine		149-16-6				
Butac tin		2109-73-1				
Butalamine		22131-35-7				
Butalbital		77-26-9				
Butallylonal		1142-70-7				
butamben	4-Aminobenzoic acid butyl ester [CAS]	94-25-7			Formulation, modified-release, other	Pain, cancer
butamirate	Benzeneacetic acid, Alpha-ethyl-, 2-[2-(diethylamino)ethoxy]ethylester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	18109-80-3 18109-81-4			Antitussive	Cough
Butanilicaine		3785-21-5				
Butaperazine		653-03-2				
Butaverine		55837-14-4				
Butazolamide		16790-49-1				
Butedronic Acid		51395-42-7				

NPC-UNIV-000004573

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 195 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
butenafine	1-Naphthalenemethanamine, N-((4-(1,1-dimethylethyl)phenyl)methyl)-N-methyl- [CAS]	101827-46-7 101828-21-1	EP	164697	Antifungal	Infection, dermatological
Butethal		77-28-1				
Butethamate		14007-64-8				
Butethamine		2090-89-3				
Buthalital		510-90-7				
Buthiazide		2043-38-1				
Butibufen		55837-18-8				
Butidrine		1506-12-3				
butobendine	benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediylbis[(methylimino)(2-ethyl-2,1-ethanediyl)] ester, [S-(R*,R*)]- [CAS]	55769-64-7 55769-65-8	US	4021473	Antiarrhythmic	Arrhythmia, general
butoconazole	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)- [CAS]	64872-76-0 64872-77-1	GB	1567431	Antifungal	Infection, Candida, general
Butoctamide		32838-26-9				
Butofilolol		64552-17-6				
butorphanol	Morphinan-3,14-diol, 17-(cyclobutylmethyl)-, [S-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	42408-82-2 58786-99-5	GB	1412129	Analgesic, other	
Butoxycaine		3772-43-8				
Butriptyline		35941-65-2				
Butropium		29025-14-7				
Buzepide		3691-21-2				
BVT-5182			WO	0208178	Anorectic/Antiobesity	Obesity
BXT-51072	2H-1,2-Benzoselenazine, 3,4-dihydro-4,4-dimethyl- [CAS]	173026-17-0			GI inflammatory/bowel disorders	Colitis, ulcerative
C-1311	6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-, 2HCl, 2H2O				Anticancer, other	Cancer, general
cabergoline	Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8ß)- [CAS]	81409-90-7 85329-89-1	GB	2103603	Antiprolactin	Galactorrhoea

NPC-UNIV-000004574

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 196 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Cabergoline		81409-90-7				
Cacodylic Acid		75-60-5				
Cactinomycin		8052-16-2				
cadexomer iodine	Cadexomer iodine [CAS]	94820-09-4			Anti-infective, other	Ulcer, venostasis
Cadmium Salicylate		19010-79-8				
Cadralazine		64241-34-5				
Cafaminol		30924-31-3				
caffeine	1,2,3,-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione [CAS]	69-22-7 58-08-2			Respiratory	Apnoea
Calcifediol		19356-17-3				
Calcipotriene		112965-21-6				
calcipotriol	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-,(1Alpha,3ß,5Z,7E,22E)- [CAS]	112965-21-6	WO	8700834	Antipsoriasis	Psoriasis
calcipotriol+beclometasone	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-,(1Alpha,3ß,5Z,7E,22E) + Pregna-1,4-diene-3,20-dione, 9-chloro-11ß,17,21-trihydroxy-16ß-methyl, 17,21-dipropionate				Formulation, fixed-dose combinations	Psoriasis
calcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1Alpha,3ß,5Z,7E)- [CAS]	32222-06-3			Antipsoriasis	Psoriasis
Calcium 3-Aurothio-2-propanol-1-sulfonate		5743-29-3				
Calcium Acetylsalicylate		69-46-5				
Calcium Bromolactobionate		33659-28-8				
Calcium Carbonate		471-34-1				
Calcium Gluconate		299-28-5				
Calcium Glycerophosphate		27214-00-2				

NPC-UNIV-000004575

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 197 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
calcium hopantothenate	Calcium D-(+)-4-(2,4-dihydroxy-3,3-dimethylbutyramido)butyrate (hemihydrate) [CAS]	17097-76-6	EP	117260	Neurological	Attention deficit disorder
Calcium Iodobehenate		1319-91-1				
Calcium Iodostearate		1301-16-2				
Calcium Lactate		814-80-2				
Calcium Levulinate		591-64-0				
Calcium Mesoxalate		21085-60-9				
Calcium N-Carbamoylaspartate		16649-79-9				
calcium polycarbophil	Polycarbophil, calcium salt- [CAS]	126040-58-2 9003-97-8			GI inflammatory/bowel disorders	Irritable bowel syndrome
Calcium Propionate		4075-81-4				
Calcium Succinate		140-99-8				
caldaret	5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate	133804-44-1			Cardiostimulant	Heart failure
Calusterone		17021-26-0				
Camazepam		36104-80-0				
camostat	Benzeneacetic acid, 4-[[4-[(aminoiminomethyl)amino]benzoyl]oxy]-, 2-(dimethylamino)-2-oxoethyl ester, monomethanesulfonate [CAS]	59721-28-7 59721-29-8 71079-09-9	US	4021472	GI inflammatory/bowel disorders	Pancreatitis
Camphor		76-22-2				
Camphotamide		4876-45-3				
camptothecin	4-Ethyl-4-hydroxy-1H-pyrano-[l3'4':6,7]indolizinol[1,2-b;]quinoline-3,14(4H,12H)-dione				Formulation, optimized, microemulsion	Cancer, general
Candesartan		139481-59-7				
candesartan cilexetil	1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, (+/-)- [CAS]	145040-37-5	EP	520423	Antihypertensive, renin system	Hypertension, general
Candoxatril		123122-55-4				

NPC-UNIV-000004576

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 198 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
canertinib	N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3 morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide	289499-45-2			Anticancer, other	Cancer, lung, non-small cell
Canrenone		976-71-6				
Cantharidin		56-25-7				
cantuzumab mertansine	Maytansine, N2-deacetyl-N2-(3-mercapto-1-oxopropyl)-, conjugated humanized C242 monoclonal antibody	139504-50-0			Immunotoxin	Cancer, colorectal
capecitabine	Cytidine, 5-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]- [CAS]	154361-50-9	EP	602454	Anticancer, antimetabolite	Cancer, breast
Capobenic Acid		21434-91-3				
capravirine	1H-imidazole-2-methanol, 5-(3,5-dichlorophenyl)thio-4-(1-methylethyl)-1-(4-pyridinyl)methyl carbamate (ester) [CAS]	178979-85-6			Antiviral, anti-HIV	Infection, HIV/AIDS
Capromab		151763-64-3				
capsaicin cream	N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)- [CAS]	404-86-4			Formulation, dermal, topical	Pain, post-herpetic
Captodiamine		486-17-9				
captopril	L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)- [CAS]	62571-86-2	US	4105776	Antihypertensive, renin system	Hypertension, general
captopril + HCTZ	L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-, mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [CAS]	110075-07-5	US	4217347	Antihypertensive, renin system	
Capuride		5579-13-5				
carabersat	Benzamide, N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluoro, (3R-trans)- [CAS]	184653-84-7	WO	9811890	Antiepileptic	Epilepsy, general
Caramiphen		77-22-5				
carazolol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[(1-methylethyl)amino]- [CAS]	57775-29-8	DE	2240599	Antihypertensive, adrenergic	
Carbachol		51-83-2				
carbamazepine	5H-Dibenz[b,f]azepine-5-carboxamide [CAS]	298-46-4			Formulation, modified-release, other	Epilepsy, general

NPC-UNIV-000004577

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 199 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Carbamide Peroxide		124-43-6				
Carbarsone		121-59-5				
Carbaryl		63-25-2				
Carbazochrome		13051-01-9 51460-26-5				
carbendazim	Methyl-2-benzimidazolecarbamate				Anticancer, other	Cancer, general
Carbenicillin		4697-36-3				
Carbenoxolone		5697-56-3				
Carbetapentane		77-23-6				
Carbicarb	Carbonic acid disodium salt, mixt. with monosodium salt- [CAS]	72227-05-5			Alimentary/Metabolic, other	Acidosis
Carbidopa		28860-95-9				
carbidopa+levodopa-1	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate +3-hydroxy-L-tyrosine				Formulation, fixed-dose combinations	Parkinson's disease
Carbimazole		22232-54-8				
Carbinoxamine		486-16-8				
Carbocloral		541-79-7				
carbocysteine		151756-26-2 638-23-3	EP	546272	Cystic fibrosis treatment	Cystic fibrosis
Carbon Tetrachloride		56-23-5				
carboplatin	Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)- [CAS]	41575-94-4			Anticancer, alkylating	Cancer, ovarian
Carboprost		35700-23-3				
carboprost trometamol	Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9.alpha.,11Alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1) [CAS]	58551-69-2 74849-93-7	US	3728382	Prostaglandin	Abortion
Carboquone	2,5-Cyclohexadiene-1,4-dione, 2-[2-[(aminocarbonyl)oxy]-1-methoxyethyl]-3,6-bis(1-aziridinyl)-5-methyl- [CAS]	24279-91-2	DE	1905224	Anticancer, antibiotic	
Carbromal		77-65-6				

NPC-UNIV-000004578

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 200 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Carbubarb		960-05-4				
Carbutamide		339-43-5				
Carbuterol		34866-47-2				
Carfimate		3567-38-2				
carglumic acid	N-Carbamoyl-L-glutamic acid	1188-38-1			Metabolic and enzyme disorders	Hyperammonaemia
Cargutocin		33605-67-3				
Carindacillin		35531-88-5				
cariporide	Benzamide, N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)- [CAS]	159138-80-4 159138-81-5	EP	589336	Antianginal	Angina, general
Cariporide		159138-80-4				
Carisoprodol		78-44-4				
carmofur	1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- [CAS]	61422-45-5	US	4071519	Anticancer, antimetabolite	
Carmoxirole		98323-83-2				
carmustine	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8			Formulation, implant	Cancer, brain
Carnitine		461-06-3				
Caroverine		23465-76-1				
Caroxazone		18464-39-6				
Carphenazine		2622-30-2				
Carpipramine		5942-95-0				
carprofen	9H-Carbazole-2-acetic acid, 6-chloro-Alpha-methyl-, (+/-)- [CAS]	53716-49-7	US	3896145	Anti-inflammatory	
Carsalam		2037-95-8				
carteolol	2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride [CAS]	51781-06-7 51781-21-6	US	3910924	Antihypertensive, adrenergic	Glaucoma
Carticaine		23964-58-1				
Carubicin		50935-04-1				
Carumonam		87638-04-8				
Carvacrol		499-75-2				
carvedilol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-[CAS]	72956-09-3	EP	4920	Antihypertensive, adrenergic	Hypertension, general

NPC-UNIV-000004579

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 201 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Carvone		99-49-0				
Cascarillin		10118-56-6				
caspofungin	Pneumocandin B0, 1-((4R,5S)-5-((2-aminoethyl)amino)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-(threo-3-hydroxy-L-ornithine)-, diacetate (salt) [CAS]	162808-62-0 179463-17-3	WO	9421677	Antifungal	Infection, Aspergillus
Catechin		154-23-4				
cathepsin K inhibitors	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide		WO	9613523	Osteoporosis treatment	Osteoporosis
cathepsin S inhibitors	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide				Antiasthma	Asthma
CC-401			US	6342595	Immunosuppressant	Arthritis, rheumatoid
CCI-779	Rapamycin 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) [CAS]	162635-04-3			Anticancer, antibiotic	Cancer, renal
CCR5 antagonists			WO	9732019	Antiviral, anti-HIV	Infection, HIV/AIDS
CDC-394			US	634061	Anticancer, other	Cancer, myeloma
CDC-801			US	5605914	GI inflammatory/bowel disorders	Crohn's disease
CEE-03-310	1H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7-benzofuranyl)- 2,3,4,5,-tetrahydro-3-methyl-8-nitro, (5S)- [CAS]	128022-68-4	EP	347672	Dependence treatment	Addiction, alcohol
cefaclor	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	53994-73-3 70356-03-5	GB	1461323	Cephalosporin, oral	Infection, Haemophilus influenzae prophylaxis
cefadroxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	50370-12-2 66592-87-8	GB	1240687	Cephalosporin, oral	Infection, general
cefalexin	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [CAS]	105879-42-3 15686-71-2	US	4775751	Cephalosporin, oral	Infection, respiratory tract, upper

NPC-UNIV-000004580

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 202 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cefalexin pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7ß(R*)]]- [CAS]	27726-31-4			Cephalosporin, oral	Infection, general
cefamandole	7-D-mandelamido-3[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic acid	34444-01-4	US	3641021	Cephalosporin, injectable	Infection, general
cefatrizine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-, [6R-[6Alpha,7ß(R*)]]- [CAS]	51627-14-6	GB	1460914	Cephalosporin, oral	Infection, general
Cefazedone		56187-47-4				
Cefazolin		25953-19-9				
Cefbuperazone		76610-84-9				
cefcapene pivoxil	7ß-[(Z)-2-(2-amino-4-thiazolyl)-2-pentenoylamino]-3-carbamoyloxymethyl-3-cephem-4-carboxylic acid, pivaloyloxymethyl ester HCl- [CAS]	105889-45-0 105889-46-1	GB	2173194	Cephalosporin, oral	Infection, respiratory tract, general
Cefclidin		105239-91-6				
cefdinir	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	91832-40-5	EP	105459	Cephalosporin, oral	Infection, dermatological
cefditoren pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R-[3(Z),6Alpha,7ß(Z)]]- [CAS]	104145-95-1 104146-53-4 117467-28-4	JP	61178991	Cephalosporin, oral	Infection, general

NPC-UNIV-000004581

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 203 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cefepime	Pyrrolidinium, 1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, hydroxide, inner salt, [6R-[6Alpha,7ß(Z)]]- [CAS]	107648-80-6 123171-59-5 88040-23-7	EP	531981	Cephalosporin, injectable	Infection, respiratory tract, lower
Cefetamet		65052-63-3				
cefetamet pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7ß(Z)]]- [CAS]	111696-23-2	GB	1581854	Cephalosporin, oral	Infection, general
cefixime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	79350-37-1	EP	30630	Cephalosporin, oral	Infection, general
cefmenoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	65085-01-0 75738-58-8	GB	1536281	Cephalosporin, injectable	Infection, ocular
cefmetazole	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R-cis)- [CAS]	56796-20-4 56796-39-5	GB	1449420	Cephalosporin, injectable	Infection, general
cefminox	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7Alpha,7(S*)]]- [CAS]	84305-41-9	EP	24879	Cephalosporin, injectable	Infection, urinary tract

NPC-UNIV-000004582

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 204 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cefodizime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[5-(carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	69739-16-8 86329-79-5	US	4590267	Cephalosporin, injectable	Infection, respiratory tract, lower
cefonicid	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-[6Alpha,7ß(R*)]]- [CAS]	61270-78-8 61270-58-4	GB	1547473	Cephalosporin, injectable	Infection, general
cefoperazone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	62893-19-0	GB	1508071	Cephalosporin, injectable	Infection, general
cefoperazone + sulbactam		92739-15-6	US	4234579	Antibiotic, other	Infection, general
Ceforanide		60925-61-3				
cefoselis	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-, [6R-[6Alpha,7ß(Z)]]	122841-12-7 122841-10-5	EP	307804	Cephalosporin, injectable	Infection, general
cefotaxime	(6R,7R)-7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]cephalosporanic acidsodium salt	64485-93-4 63527-52-6	GB	1580621	Cephalosporin, injectable	Infection, general
Cefotetan		69712-56-7				
cefotiam	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R-trans)- [CAS]	61622-34-2 66309-69-1	US	4080498	Cephalosporin, injectable	Infection, general

NPC-UNIV-000004583

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 205 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cefotiam hexetil	1-(cyclohexyloxycarbonyloxy)ethyl 7ß-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate 2HCl [CAS]	95789-30-3	EP	128029	Cephalosporin, oral	Infection, respiratory tract, lower
cefoxitin	5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6R-cis)- [CAS]	33564-30-6 35607-66-0	GB	1348984	Cephalosporin, oral	Infection, general
cefozopran	Imidazo[1,2-b]pyridazinium, 1-[[7-[[(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7ß(Z)]]- [CAS]	113359-04-9	EP	203271	Cephalosporin, injectable	Infection, general
cefpimizole	Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, hydroxide, inner salt, [6R-[6Alpha,7ß(R*)]]- [CAS]	84880-03-5 85287-61-2	EP	60028	Cephalosporin, injectable	Infection, respiratory tract, general
cefpiramide	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	70797-11-4	US	4156724	Cephalosporin, injectable	Infection, general
cefpirome	5H-1-Pyrindinium, 1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-,hydroxide, inner salt, [6R-[6Alpha,7ß(Z)]]- [CAS]	84957-29-9 98753-19-6	EP	64740	Cephalosporin, injectable	Infection, respiratory tract, lower
Cefpodoxime Proxetil		87239-81-4				

NPC-UNIV-000004584

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 206 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cefprozil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7ß(R*)]]- [CAS]	92665-29-7 121123-17-9	GB	2173798	Cephalosporin, oral	Infection, dermatological
cefroxadine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)amino]-3-methoxy-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	51762-05-1	GB	1435111	Cephalosporin, oral	Infection, general
cefsulodin	Pyridinium, 4-(aminocarbonyl)-1-[[2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7ß(R*)]]- [CAS]	52152-93-9 62587-73-9	GB	1387656	Cephalosporin, injectable	Infection, pseudomonal
ceftazidime	Pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7ß(Z)]]- [CAS]	72558-82-8	GB	2025398	Cephalosporin, injectable	Infection, respiratory tract, upper
Cefteram		82547-58-8				
Ceftezole		26973-24-0				
ceftibuten	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	97519-39-6	EP	136721	Cephalosporin, oral	Infection, respiratory tract, lower
ceftizoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	68401-81-0 68401-82-1	GB	1600735	Cephalosporin, injectable	Infection, general

NPC-UNIV-000004585

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 207 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ceftizoxime alapivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[2-[(2-amino-1-oxopropyl)amino]-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7ß(Z(S*))]]- [CAS]	113812-94-5 135767-36-1	JP	62209112	Cephalosporin, oral	Infection, general
ceftriaxone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, [6R-[6Alpha,7ß(Z)]]- [CAS]	73384-59-5 74578-69-1	GB	2022090	Cephalosporin, injectable	Infection, respiratory tract, lower
cefuroxime axetil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester, [6R-[6Alpha,7ß(Z)]]- [CAS]	15686-71-2 64544-07-6	GB	1571683	Cephalosporin, oral	Infection, respiratory tract, upper
cefuroxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7ß(Z)]]- [CAS]	55268-75-2 56238-63-2	GB	1453049	Cephalosporin, injectable	Infection, general
Cefuzonam		82219-78-1				
celecoxib	Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)- [CAS]	169590-42-5	US	5760068	Antiarthritic, other	Arthritis, rheumatoid
celgosivir	Butanoic acid, octahydro-1,7,8-trihydroxy-6-indolizinyl ester, [1S-(1Alpha,6ß,7Alpha,8ß,8aß)]- [CAS]	121104-96-9	US	5017563	Antiviral, other	Infection, hepatitis virus, general
celiprolol	Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- [CAS]	56980-93-9 57470-78-7	GB	1441359	Antihypertensive, adrenergic	Angina, unstable
Cellulose Ethyl Hydroxyethyl Ether		9004-58-4				

NPC-UNIV-000004586

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 208 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Centchroman		31477-60-8				
CEP-1347	9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis((ethylthio)methyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-[CAS]	156177-65-0	WO	9731002	Antiparkinsonian	Parkinson's disease
CEP-701	9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-[CAS]	111358-88-4			Anticancer, antimetabolite	Cancer, prostate
Cephacetrile		23239-41-0				
Cephaeline		483-17-0				
Cephalexin		15686-71-2				
Cephaloglycin		3577-1-3				
Cephaloridine		50-59-9				
Cephalosporin C		61-24-5				
Cephalothin		153-61-7				
Cephapirin		24356-60-3				
Cephradine		38821-53-3				
Cerivastatin		145599-86-6				
Ceronapril		111223-26-8				
certoparin	Heparin [CAS]	9005-49-6			Anticoagulant	Thrombosis, venous
Ceruletide		17650-98-5				
Cerviprost	Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,-15S)-[CAS]	363-24-6			Formulation, dermal, topical	
Cetalkonium		122-18-9				
Cetamolol		34919-98-7				
Cethexonium		1794-74-7				

NPC-UNIV-000004587

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 209 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cethromycin	2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexapyranosyl)oxy)-,(3a S,4R,7R,9R,10R,11R,13R,15R,15aR)-[CAS]	205110-48-1	EP	929563	Macrolide antibiotic	Infection, respiratory tract, general
Cetiedil		14176-10-4				
Cetirizine		83881-51-0				
cetirizine	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, [CAS]	83881-51-0 83881-52-1	EP	58146	Antiallergic, non-asthma	Allergy, general
cetirizine+pseudoephedrine	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihyrochloride, Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*R*)]-	83881-52-1 90-82-4			Formulation, optimized, microencapsulate	Allergy, general
Cetotiamine		137-76-8				
Cetoxime		25394-78-9				
cetraxate	Benzenepropanoic acid, 4-[[[4-(aminomethyl)cyclohexyl]carbonyl]oxy]-, trans-[CAS]	27724-96-5 34675-84-8	JP	48075547	Antiulcer	
Cetrimonium		57-09-0				
Cetrorelix		120287-85-6				
C tyldimethylethylamm onium		124-03-8				
Cetylpyridinium		123-03-5				
cevimeline	Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, cis- [CAS]	107220-27-9 107233-08-9	EP	205247	Stomatological	Sjogren's syndrome
CG-1521	7-phenyl-2,4,6-heptatrienoylhydroxamic acid				Anticancer, other	Cancer, general
Chaulmoogric Acid		29106-32-9				
Chenodiol		474-25-9				

NPC-UNIV-000004588

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 210 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
CHF-3381			EP	951465	Analgesic, other	Pain, neuropathic
Chlophedianol		791-35-5				
Chloracizine		800-22-6				
chloral	1,1-Ethanediol, 2,2,2-trichloro- [CAS]	302-17-0 2218-68-0 515-82-2			Formulation, transmucosal, systemic	Insomnia
Chlorambucil		305-03-3				
Chloramine-B		127-52-6				
Chloramine-T		127-65-1				
Chloraminophenamide		121-30-2				
Chloramphenicol		56-75-7				
Chlorazanil		500-42-5				
Chlorbenzoxamine		522-18-9				
Chlorbetamide		97-27-8				
Chlorcyclizine		82-93-9				
Chlordantoin		5588-20-5				
Chlordiazepoxide		58-25-3				
Chlorguanide		500-92-5				
Chlorhexadol		3563-58-4				
chlorhexidine	2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino- [CAS]	55-56-1			Formulation, other	Xerostomia, Periodontitis
Chlorisondamine		69-27-2				
Chlormadinone		302-22-7				
Chlormerodrin		62-37-3				
Chlormezanone		80-77-3				
Chlormidazole		3689-76-7				
Chlornaphazine		494-03-1				
Chloroazodin		502-98-7				
Chlorophyll		1406-65-1				
Chloroprednisone		52080-57-6				
Chloroprocaine		3858-89-7				
Chloropyramine		59-32-5				

NPC-UNIV-000004589

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 211 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Chloroquine		54-05-7				
Chlorothen		148-65-2				
Chlorothiazide		58-94-6				
Chlorotrianisene		569-57-3				
Chloroxine		773-76-2				
Chloroxylenol		88-04-0				
Chlorozotocin		54749-90-5				
chlorphenamine	2-Pyridinepropanamine, Gamma-(4-chlorophenyl)-N,N-dimethyl- [CAS]	132-22-9			Formulation, modified-release, other	Allergy, general
Chlorphenesin		104-29-0 886-74-8				
Chlorpheniramine		132-22-9				
Chlorphenoxamide		3576-64-5				
Chlorphenoxamine		77-38-3				
Chlorphentermine		461-78-9				
Chlorproethazine		84-01-5				
Chlorproguanil		537-21-3				
chlorproguanil + dapsone	4,4'-Sulfonyldianiline + 1-(3,4-Dichlorophenyl)5-isopropylbiguanide	537-21-3 80-08-0			Antimalarial	Infection, malaria
Chlorpromazine		50-53-3				
Chlorpropamide		94-20-2				
Chlorprothixene		113-59-7				
Chlorquinaldol		72-80-0				
Chlortetracycline		57-62-5				
Chlorthalidone		77-36-1				
Chlorthenoxazin(e)		132-89-8				
Chlorzoxazone		95-25-0				
Cholic Acid		81-25-4				
Choline		67-48-1 2016-36-6 28319-77-9				

NPC-UNIV-000004590

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 212 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
choline theophyllinate	Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1) [CAS]	4499-40-5			Formulation, modified-release, other	
choline-L-alfoscerate	Ethanaminium, 2-[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, hydroxide, inner salt, (R)-[CAS]	28319-77-9	JP	55028955	Cognition enhancer	Amnesia
Chromocarb		4940-39-0				
Chromonar		804-10-4				
Chrysoidine		532-82-1				
CHS-828	Guanidine, N-[6-(4-chlorophenoxy)hexyl]-N'-cyano-N''-4-pyridinyl- [CAS]	200484-11-3	US	5696140	Anticancer, other	Cancer, general
CI-1031	Glycine, N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl- [CAS]	183305-24-0	WO	9638421	Antianginal	Angina, unstable
CI-1040	Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- [CAS]	212631-79-3	WO	9837881	Anticancer, other	Cancer, general
cibenzoline	1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro- [CAS]	53267-01-9	GB	1417174	Antiarrhythmic	Arrhythmia, general
ciclesonide	Pregna-1,4-diene-3,20-dione 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-(11ß,16Alpha) [CAS]	126544-47-6	DE	4129535	Antiasthma	Asthma
cicletanine	Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (+/-)- [CAS]	82747-56-6 89943-82-8	US	4383998	Antihypertensive, other	
ciclonicate	3-Pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- [CAS]	53449-58-4	DE	1910481	Vasodilator, peripheral	Cancer, lung, small cell
ciclopirox	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, [CAS]	41621-49-2 29342-05-0	US	3883545	Antifungal	Infection, fungal, general
Ciclosidomine		66564-16-7				

NPC-UNIV-000004591

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 213 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ciclosporin A	Cyclosporin A- [CAS]	59865-13-3			Formulation, optimized, microemulsion	Transplant rejection, general
cidofovir	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)- [CAS]	113852-37-2	EP	253412	Antiviral, other	Infection, cytomegalovirus
Cifenline		53267-01-9				
cilansetron	4H-Pyrido[3,2,1-jk]carbazol-11(8H)-one, 5,6,9,10-tetrahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-, (R)- [CAS]	120635-74-7	EP	297651	GI inflammatory/bowel disorders	Irritable bowel syndrome
Cilastatin		82009-34-5				
cilazapril	6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [1S-[1Alpha,9Alpha(R*)]]- [CAS]	88768-40-5 90139-06-3	GB	2128984	Antihypertensive, renin system	Hypertension, general
cilengitide	Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl) [CAS]	188968-51-6	EP	770622	Anticancer, other	Cancer, lung, non-small cell
cilnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester- [CAS]	102106-21-8 132203-70-4	EP	161877	Antihypertensive, other	Hypertension, general
cilomilast	Cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid	153259-65-5	US	5602157	COPD treatment	Chronic obstructive pulmonary disease
cilostazol	2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-[CAS]	73963-72-1	GB	2033893	Antithrombotic	Peripheral vascular disease
Cimetidine		51481-61-9				
cimetropium	3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, [7(S)-(1Alpha,2ß,4ß,5Alpha,7ß)]-[CAS]	51598-60-8	US	3853886	Antispasmodic	Muscle spasm, general
cinacalcet	1-napthalenemethanamine,Alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-, (AlphaR)-,	364782-34-3			Hormone	Hyperparathyroidism

NPC-UNIV-000004592

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 214 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Cinchonidine		485-71-2				
Cinchonine		118-10-5				
Cinchophen		132-60-5				
Cinepazet		23887-41-4				
Cinepazide		23887-46-9				
cinepazide	Piperazine, 1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-, (Z)-2-butenedioate (1:1) [CAS]	26328-04-1	GB	1218591	Vasodilator, peripheral	Peripheral vascular disease
Cinitapride		66564-14-5				
Cinmetacin		20168-99-4				
Cinnamedrine		90-86-8				
Cinnarizine		298-57-7				
cinolazepam	1H-1,4-Benzodiazepine-1-propanenitrile, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo- [CAS]	75696-02-5	DE	2950235	Hypnotic/Sedative	Insomnia
cinoxacin	[1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-[CAS]	28657-80-9	GB	1296753	Quinolone antibacterial	Infection, urinary tract
Cinoxate		104-28-9				
Cinromide		58473-74-8				
Cioteronel		89672-11-7				
cipamfylline	1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- [CAS]	132210-43-6	EP	389282	Antipruritic/inflamm, allergic	Eczema, atopic
cipralisant	1H-Imidazole, 4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]- [CAS]	213027-19-1	US	6008240	Psychostimulant	Attention deficit disorder
ciprofibrate	Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl- [CAS]	52214-84-3	GB	1385828	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
ciprofloxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	85721-33-1	US	4670444	Quinolone antibacterial	Infection, general

NPC-UNIV-000004593

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 215 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ciprofloxacin+fluocinolone,SAL	3-Quinolinecarboxylic acid, 1-cyclopropyl-6 fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- + (6Alpha, 11ß, 16Alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione				Formulation, fixed-dose combinations	Otitis
Ciramadol		63269-31-8				
cisapride	Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- [CAS]	81098-60-4	EP	76530	Gastroprokinetic	
cisatracurium	Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, [1R-[1Alpha,2Alpha(1'R*,2'R*)]]-, [CAS]	96946-42-8	US	5453510	Muscle relaxant	Surgery adjunct
cisplatin	Platinum, diamminedichloro-, (SP-4-2)- [CAS]	15663-27-1	US	4177263	Anticancer, alkylating	
citalopram	5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro- [CAS]	59729-32-7 59729-33-8	GB	1526331	Antidepressant	Depression, general
citicoline	Cytidine 5'-(trihydrogen diphosphate), P'-[2 (trimethylammonio)ethyl]ester, hydroxide, inner salt [CAS]	987-78-0	JP	39006541	Cognition enhancer	Infarction, cerebral
Citiolone		1195-16-0				
Citric Acid		77-92-9				
Citrulline		372-75-8				
cizolirtine	Ethanamine, N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate [CAS]	142155-44-0			Urological	Incontinence
CJ-13610	4-(3-[4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl]-phenyl)-tetrahydro-pyran-4-carboxylic acid amide				COPD treatment	Chronic obstructive pulmonary disease

NPC-UNIV-000004594

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 216 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
CKD-602	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-, monohydrochloride, (4S)- [CAS]	213819-48-8	WO	9902530	Anticancer, other	Cancer, ovarian
cladribine	Adenosine, 2-chloro-2'-deoxy- [CAS]	4291-63-8	EP	173059	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
Clanobutin		30544-61-7				
clarithromycin	Erythromycin, 6-O-methyl- [CAS]	81103-11-9	EP	41355	Macrolide antibiotic	Infection, respiratory tract, lower
Clavulanate, Disodium						
Clavulanic Acid		58001-44-8				
Clebopride		55905-53-8				
Clemastine		15686-51-8				
Cl mizol		442-52-4				
Clenbuterol		37148-27-9				
Clentiazem		96125-53-0				
clevidipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester (±) [CAS]	167221-71-8	WO	9512578	Antihypertensive, other	Hypertension, general
clevudine	2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2-fluoro-ß-L-arabinofuranosyl)-5-methyl- [CAS]	163252-36-6			Antiviral, other	Infection, hepatitis-B virus
Clidanac		28968-07-2				
Clidinium		3485-62-9				
Clinafloxacin		105956-97-6				
Clindamycin		18323-44-9				
clindamycin + tretinoin	L-threo-Alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, (2S-trans)- + retinoic acid				Formulation, fixed-dose combinations	Acne

NPC-UNIV-000004595

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 217 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
clindamycin	L-Threo-Alpha-D-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-	18323-44-9 24729-96-2			Formulation, parenteral, other	Infection, gynaecological
Clinofibrate		30299-08-2				
Clinprost		88931-51-5				
clobazam	1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- [CAS]	22316-47-8	GB	1214662	Anxiolytic	
Clobenfurol		3611-72-1				
Clobenoside		29899-95-4				
Clobenzepam		1159-93-9				
Clobenzorex		13364-32-4				
Clobenztropine		5627-46-3				
clobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11ß,16ß)- [CAS]	25122-41-2			Formulation, dermal, topical	Psoriasis
clobetasone	Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16ß)- [CAS]	25122-57-0 54063-32-0	GB	1253831	Antipruritic/inflamm, allergic	
Clobutinol		14860-49-2				
Clocapramine		47739-98-0				
Clocinizine		298-55-5				
Cloconazole		77175-51-0				
Clocortolone		4828-27-7				
clodronate	Phosphonic acid, (dichloromethylene)bis- [CAS]	22560-50-5			Osteoporosis treatment, Anticancer, hormonal	Pain, cancer, Hypercalcaemia of malignancy
Clodronic Acid		10596-23-3				
clofarabine	2-chloro-9-(2-deoxy-2-fluoro-ß-D-arabinofurasonyl)adenine				Anticancer, antimetabolite	Cancer, leukaemia, chronic lymphocytic

NPC-UNIV-000004596

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 218 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
clofazimine	3-(p-chloroanilo)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine	2030-63-9			Formulation, optimized, microencapsulate	Infection, tuberculosis
Clofenamide		671-95-4				
Clofibrat		637-07-0				
Clofibric Acid		882-09-7				
Cloflucarban		369-77-7				
Clofoctol		37693-01-9				
Cloforex		14261-75-7				
Clomacran		5310-55-4				
Clomestrone		4091-75-2				
Clometacin		25803-14-9				
Clomethiazole		533-45-9				
Clometocillin		1926-49-4				
Clomiphene		911-45-5				
Clomipramine		303-49-1				
Clomocycline		1181-54-0				
clonazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- [CAS]	1622-61-3	US	4316897	Antiepileptic	Epilepsy, general
clonidine	1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS]	4205-90-7	US	4060084	Formulation, transdermal, patch	Hypertension, general
Clonitazene		3861-76-5				
Clonitrate		2612-33-1				
Clonixin		17737-65-4				
Clopamid		636-54-4				
Clopenthixol		982-24-1				
Cloperastine		3703-76-2				
clopidogrel	Thieno[3,2-c]pyridine-5(4H)-acetic acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)- [CAS]	120202-48-4 90055-48-4 113665-84-2	EP	99802	Antithrombotic	Infarction, myocardial
Clopirac		42779-82-8				
Cloprednol		5251-34-3				
cloranolol	2-Propanol, 1-(2,5-dichlorophenoxy)-3-[(1,1-dimethylethyl)amino]- [CAS]	39563-28-5 54247-25-5	US	4310549	Antihypertensive, adrenergic	

NPC-UNIV-000004597

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 219 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Clorazepic Acid		23887-31-2				
Clorexolone		2127-1-7				
cloricromene	Acetic acid, [[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]-, ethyl ester [CAS]	68206-94-0	US	4349566	Vasodilator, coronary	Peripheral vascular disease
Clorindione		1146-99-2				
Clorprenaline		3811-25-4				
Clort rmine		10389-73-8				
Clospirazine		24527-27-3				
Clostebol		1093-58-9				
Clothiapine		2058-52-8				
clotiazepam	2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl- [CAS]	33671-46-4	US	3849405	Anxiolytic	Anxiety, general
clotrimazole	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole	23593-75-1	US	3705172	Antifungal	
clotrimazole + betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11ß,16ß)-, mixt. with 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole [CAS]	92522-91-3			Formulation, fixed-dose combinations	Infection, fungal, general
Cloxacillin		61-72-3				
cloxazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro- [CAS]	24166-13-0	US	3772371	Anxiolytic	
Cloxotestosterone		53608-96-1				
Cloxyquin		130-16-5				
clozapine	5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)- [CAS]	5786-21-0	US	3539573	Neuroleptic	Schizophrenia
CMI-392	Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	193739-23-0	US	5648486	Antipsoriasis	Psoriasis

NPC-UNIV-000004598

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 220 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
CMT-3	2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- [CAS]	15866-90-7	US	5837696	Anticancer, other	Cancer, sarcoma, Kaposi's
CNI-1493	Decanediamide, N,N'-bis[3,5-bis[1-[(aminoiminomethyl)hydrazono]ethyl]phenyl]-, tetrahydrochloride [CAS]	164301-51-3	US	5750573	Anti-inflammatory	Psoriasis
CNS-5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]	160754-76-7	WO	9427591	Analgesic, other	Pain, neuropathic
Cobamamide		13870-90-1				
Cocaethylene		529-38-4				
Cocaine		50-36-2				
Codeine		76-57-3 52-28-8				
CoFactor	5,10 methylene - tetrahydrofolate				Anticancer, antimetabolite	Cancer, colorectal
Colchicine		64-86-8				
colesevelam	1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	182815-44-7	US	5607669	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
colestilan	1H-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS]	95522-45-5	JP	59155421	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
Colestipol		26658-42-4				
colforsin daropate	6-(3-dimethylaminopropionyl)forskolin- [CAS]	138605-00-2	EP	222413	Cardiostimulant	Heart failure
colfosceril	3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, inner salt, 4-oxide, (R)- [CAS]	63-89-8 99732-49-7	US	4826821	Lung Surfactant	Respiratory distress syndrome, infant
Collagraft		138331-02-9			Formulation, implant	Regeneration, bone
Colocynthin		1398-78-3				
Colpormon		1247-71-8				

NPC-UNIV-000004599

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 221 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
coluracetam	1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- [CAS]	135463-81-9	EP	427636	Cognition enhancer	Alzheimer's disease
combretastatin A-4 prodrug	disodium combretastatin-A-4-3-O-phosphate				Anticancer, other	Cancer, thyroid
compound B, Pharmacor			US	6362165	Antiviral, anti-HIV	Infection, HIV/AIDS
conivaptin	[1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1-benzazepin-6(1H)-yl)carbonyl]phenyl]-, [CAS]	168626-94-6	WO	9503305	GI inflammatory/bowel disorders	Hyponatraemia
Connettivina	Hyaluronic acid [CAS]	9004-61-9			Vulnerary	
Convallatoxin		508-75-8				
Coparaffinate		8001-60-3				
Corticorelin Ovine Triflutate						
Corticosterone		50-22-6				
Cortisone		53-06-5				
Cortivazol		1110-40-3				
Cosyntropin		16960-16-0				
Cotarnine		82-54-2				
Cotinine		486-56-6				
co-trimazine	Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	39474-58-3			Trimethoprim and analogues	Infection, urinary tract
Coumetarol		4366-18-1				
CP-248	1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene]-, (1Z)- [CAS]	200803-37-8	WO	9747303	Anticancer, other	Barrett's oesophagus
CP-461			US	5948779	Anticancer, other	Cancer, prostate
CPC-211	Acetic acid, dichloro-, sodium salt [CAS]	2156-56-1			Neuroprotective	Acidosis, lactic
CPI-1189	CPI 1189 [CAS]	210475-67-5	WO	9631462	Cognition enhancer	Dementia, AIDS-related
CRA-0450			WO	0202549	Anxiolytic	Unspecified

NPC-UNIV-000004600

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 222 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
creatinol-O-phosphate	Guanidine, N-methyl-N-[2-(phosphonooxy)ethyl]- [CAS]	6903-79-3			Antianginal	
CRL-5861	Oxirane, methyl-, polymer with oxirane, block [CAS]	106392-12-5	US	4837014	Antisickling	Anaemia, sickle cell
crobenetine	(2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6,-hexahydro-2,6-methano-3-benzazocin-10-ol		WO	9914199	Neuroprotective	Ischaemia, cerebral
croconazole	1H-Imidazole, 1-[1-[2-[(3-chlorophenyl)methoxy]phenyl]ethenyl]- [CAS]	77175-51-0	DE	3021467	Antifungal	Infection, fungal, general
cromoglicic acid	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bs4-oxo- [CAS]	53736-52-0			Formulation, mucosal, topical	Conjunctivitis
cromolyn	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-, [CAS]	15826-37-6 16110-51-3			Formulation, inhalable, solution	Asthma
Cropropamide		633-47-6				
Crotamiton		483-63-6				
Crotethamide		6168-76-9				
Crystacide			US	4557935	Formulation, dermal, topical	Infection, dermatological
CS-502	□		EP	799823	Analgesic, other	Pain, general
CS-758	4-[(1E,3E)-4-[trans-5-[[1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-1,3-butadienyl]-3-fluorobenzonitrile				Antifungal	Infection, fungal, general
CS-834	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5-oxo-3-pyrrolidinyl]thio]-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- [CAS]	157542-49-9	EP	599512	Beta-lactam antibiotic	Infection, general

NPC-UNIV-000004601

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 223 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
CT-052923	[(2H-benzo[d]1,3-dioxalan-5-methyl)amino][4-(6,7-dimethoxyquinazolin-4-yl)piperazinyl]methane-1-thione				Cardiovascular	Restenosis
CT-32228	N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-[1,3,5]triazine-2,4-diamine				Anticancer, other	Cancer, general
Cupric Citrate		866-82-0				
Cuproxoline		13007-93-7				
CVT-2584	Ethanol, 2,2'-[[6-[[(4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bis- [CAS]	199986-75-9	WO	9805335	Cardiovascular	Restenosis
CX-659S	((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-phenyl-2,4-(1H,3H)-pyrmidinedione				Dermatological	Eczema, general
Cyacetacide		140-87-4				
Cyamemazine		3546-03-0				
Cyanidin		528-58-5				
CYC400			WO	00172745	Anticancer, other	Cancer, general
Cyclacillin		3485-14-1				
Cyclandelate		456-59-7				
Cyclazocine		3572-80-3				
Cyclexanone		15301-52-7				
Cyclexedrine		532-52-5				
cyclidrol	3-Cyclohexene-1-methanol, 5-hydroxy-Alpha,Alpha,4-trimethyl- [CAS]	498-71-5			COPD treatment, Respiratory	Bronchitis, chronic
cyclin D1 inhibitors			US	6033843	Anticancer, hormonal	Cancer, breast
Cyclizine		82-92-8				
Cyclobarbital		52-31-3				
Cyclobendazole		31431-43-3				

NPC-UNIV-000004602

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 224 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
cyclobenzaprine	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7			Formulation, modified-release, other	Muscle spasm, general
Cyclobutyrol		512-16-3				
Cyclocumarol		518-20-7				
Cyclodrine		52109-93-0				
Cyclofenil		2624-43-3				
Cycloguanil		516-21-2				
Cyclomethycaine		139-62-8				
Cyclonium Iodide		6577-41-9				
Cyclopentamine		102-45-4				
Cyclopenthiazide		742-20-1				
Cyclopentobarbital		76-68-6				
Cyclopentolate		512-15-2				
cyclophosphamide	N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate	50-18-0 6055-19-2			Formulation, parenteral, targeted	Cancer, general
cyclopiroxalamine	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, cmpd with 2-aminoethanol(1:1) [CAS]	41621-49-2			Formulation, transdermal, other	Vaginitis
Cycloserine		68-41-7				
Cyclothiazide		2259-96-3				
Cyclovalone		579-23-7				
Cymarin		508-77-0				
cymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-39-8	WO	9902154	Cognition enhancer	Alzheimer's disease
Cynarin(e)		30964-13-7				
CYP26 inhibitors			US	6063606	Dermatological	Unspecified
Cyproheptadine		129-03-3				
cyproterone	(1ß,2ß)-6-Chloro-1,2-dihydro-17-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]	2098-66-0			Radio/chemoprotective	Chemotherapy-induced injury, general

NPC-UNIV-000004603

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 225 of 1101

Table IV

API G n ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Cysteamine		60-23-1				
cystic fibrosis ther	[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-, ethyl ester				Cystic fibrosis treatment	Cystic fibrosis
cytarabine	2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-ß-D-arabinofuranosyl]-, [CAS]	65093-40-5 147-94-4	EP	239015	Anticancer, antimetabolite	Myelodysplastic syndrome
D-24851	N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)-indol-3-yl)-glyoxyl-amide)				Anticancer, other	Cancer, general
D-4418	8-Methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide				Antiasthma	Asthma
DA-5018	Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride [CAS]	174661-97-3	US	5242944	Analgesic, other	Pain, musculoskeletal
DA-6034			US	6025387	GI inflammatory/bowel disorders	Crohn's disease
DA-7867			KR	9957803	Antibacterial, other	Infection, general
DA-7911			KR	56034	Antiarthritic, other	Arthritis, rheumatoid
DA-8159	3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo-[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide		KR	353014	Male sexual dysfunction	Sexual dysfunction, male, general
Dacarbazine		4342-3-4				
Daclizumab		152923-56-3				
Dactinomycin		50-76-0				
dalbavancin	5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-(10-methylundecanamido)-ß-D-glucopyranurosyl]-38-[N-[3-(dimethylamino)propyl]carbamoyl]-42-O-Alpha-D-mannopyranosyl-N15-methylristomycin A aglycone	171500-79-1			Peptide antibiotic	Infection, dermatological
Dalfopristin		112362-50-2				

NPC-UNIV-000004604

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 226 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dalfopristin + quinupristin	Virginiamycin M1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26R,27S)-, mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin S1- [CAS]	126602-89-9	EP	248703	Antibiotic, other	Infection, respiratory tract, general
dalteparin	Heparin-, [CAS]	9041-08-1	US	4303651	Anticoagulant	Thromboprophylaxis
Daltroban		79094-20-5				
δ-Aminolevulinic Acid		106-60-5				
danaparoid			EP	66908	Anticoagulant	Thrombosis, venous
danazol	Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17Alpha)- [CAS]	17230-88-5	GB	905844	Menstruation disorders	
Danthron		117-10-2				
Dantrolene		7261-97-4				
dapiprazole	1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- [CAS]	72822-12-9 72822-13-0	US	4252721	Ophthalmological	Glaucoma
dapivirine	4-[[4-(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl]amino]benzonitrile	244767-67-7			Antiviral, anti-HIV	Infection, HIV/AIDS
dapoxetine	(+)-(S)-N,N-dimethyl-Alpha-[2-(1-naphthyl-oxy)ethyl]benzylamine HCl	119356-77-3	EP	288188	Male sexual dysfunction	Premature ejaculation
dapsone	4,4'-Sulfonyldianiline	80-08-0			Formulation, dermal, topical	Acne
daptomycin	Daptomycin [CAS]	103060-53-3	EP	178152	Peptide antibiotic	Infection, dermatological
Darbepoetin Alfa						
darifenacin	3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-Alpha,Alpha-diphenyl-, (S)- [CAS]	133099-04-4	EP	388054	Urological	Overactive bladder
daunorubicin	5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- [CAS]	20830-81-3	US	5441745	Formulation, optimized, liposomes	Cancer, sarcoma, Kaposi's

NPC-UNIV-000004605

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 227 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
DAX, SciClone	3-diallyl-8-cyclohexylxanthine				Cystic fibrosis treatment	Cystic fibrosis
DB-67	7-tert-Butyldimethylsilyl-10-hydroxycamptothecin				Anticancer, other	Cancer, general
d-Camphocarboxylic Acid		18530-30-8				
DCF-987	Dextran		US	5514665	Formulation, other	Cystic fibrosis
DDT		50-29-3				
Deaminooxytocin		113-78-0				
Deanol		108-01-0				
Debrisoquin		1131-64-2				
Decamethonium		541-22-0				
Decimemide		14817-09-5				
decitabine	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-ß-D-erythro-pentofuranosyl)-[CAS]	23339-46-0 2353-33-5			Anticancer, antimetabolite	Myelodysplastic syndrome
declopramide	Benzamide, 4-amino-3-chloro-N-(2-(diethylamino)ethyl)- [CAS]	891-60-1	WO	9732582	Anticancer, other	Cancer, colorectal
Deferiprone		30652-11-0				
D feroxamine		70-51-9				
deflazacort	5'H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11ß,16ß)- [CAS]	14484-47-0 74712-90-6	GB	1077393	Hormone	Asthma
Defosfamide		3733-81-1				
degarelix	N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-[[[(4S)-2,6-dioxohexahydropyrimidin-4-yl]carbonyl]amino]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	214766-78-6			Anticancer, hormonal	Cancer, prostate
dehydroascorbic acid	L-threo-2,3-Hexodiulosonic acid gamma-lactone	490-83-5			Cognition enhancer	Alzheimer's disease
Dehydrocholic Acid		81-23-2				

NPC-UNIV-000004606

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 228 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Dehydroemetine		4914-30-1				
delapril	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)- [CAS]	83435-66-9 83435-67-0	EP	51391	Antihypertensive, renin system	Hypertension, general
delapril+manidipine	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]		FR	2733911	Formulation, fixed-dose combinations	Hypertension, general
delavirdine	Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- [CAS]	136817-59-9	WO	9109849	Antiviral, anti-HIV	Infection, HIV/AIDS
Delmadinone		13698-49-2				
Delmopinol		79874-76-3				
delorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro- [CAS]	2894-67-9	CH	408029	Anxiolytic	
delucemine	3,3-Bis-(m-fluorophenyl)-N-methylpropylamine [CAS]	186495-99-8			Neuroprotective	Ischaemia, cerebral
Demanyl		6909-62-2				
D m carium		56-94-0				
demeclocycline	2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6ß,12aAlpha)]- [CAS]	127-33-3			Formulation, modified-release, <=24hr	Infection, general
Demecolcine		477-30-5				
Demegestone		10116-22-0				
Demexiptiline		24701-51-7				
denaverine	Benzeneacetic acid, Alpha-(2-ethylbutoxy)-Alpha-phenyl-, 2-(dimethylamino)ethyl ester, [CAS]	3321-06-0	DE	4133785	Analgesic, NSAID	Pain, musculoskeletal
Denil ukin Diftitox		173146-27-5				
D nopamine		71771-90-9				

NPC-UNIV-000004607

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 229 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Denopterin		22006-84-4				
Deoxycholic Acid		83-44-3				
Deoxycorticosterone		64-85-7 56-47-3				
Deoxydihydrostreptomycin		26086-49-7				
Deoxyepinephrine		501-15-5				
D pr otide		161982-62-3				
depsipeptide	L-Valine, N-[(3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-, (4-1)-lactone, cyclic (1-2)-disulfide [CAS]	128517-07-7	EP	352646	Anticancer, antibiotic	Cancer, general
Deptropine		604-51-3				
Dequalinium		522-51-0				
dersalazine	Benzoic acid, 2-hydroxy-5-[[4-[3-[4-(2-methyl-1H-imidazol[4,5-c]pyridin-1-yl]methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo] (Z) [CAS]	188913-57-7 188913-58-8	US	5747477	Anti-inflammatory	Colitis, ulcerative
Deserpidine		131-01-1				
desferrioxamine	Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy- [CAS]	70-51-9			Antidote	Poisoning, metal
Desflurane		57041-67-5				
Desipramine		50-47-5				
Deslanoside		17598-65-1				
desloratadine	5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- [CAS]	100643-71-8	US	5595997	Antiallergic, non-asthma	Rhinitis, allergic, perennial
deslorelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57773-65-6	US	4034082	Releasing hormones	Cancer, prostate
desmopressin	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]	16679-58-6	DE	2948345	Hormone	Enuresis
Desogestrel		54024-22-5				

NPC-UNIV-000004608

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 230 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
desogestrel + estradiol	Estra-1,3,5(10)-triene-3,17-diol (17ß)-, mixt. with (17Alpha)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol [CAS]	122364-17-4			Menopausal disorders	Hormone replacement therapy
desogestrel, Akzo Nobel	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17Alpha)- [CAS]	54024-55-5			Formulation, oral, other	Contraceptive, female
desogestrel+ethinylestrad (1)	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17Alpha)- [CAS]	54024-22-5 71138-35-7	US	3927046	Formulation, oral, other	Contraceptive, female
Desomorphine		427-00-9				
Desonide		638-94-8				
Desoximetasone		382-67-2				
Detaxtran		9015-73-0				
Devacade			WO	9308176	Analgesic, other	Pain, general
dexamethasone	Pregna-1,4-diene-3,20-dione,9-fluoro-11,17,21-trihydroxy-16-methyl-, (11ß,16Alpha)- [CAS]	50-02-2 2392-39-4 312-93-6			Formulation, other	Inflammation, ocular
dexanabinol	6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)- [CAS]	112924-45-5	EP	427518	Neuroprotective	Head trauma
dexecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (R)- [CAS]	112573-72-5	EP	318377	Alimentary/Metabolic, other	Unspecified
dexefaroxan	1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro- [CAS]	89197-00-2 89197-32-0	EP	71368	Cognition enhancer	Alzheimer's disease
Dexetimide		21888-98-2				
dexibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, (AlphaS)- [CAS]	51146-56-6			Analgesic, NSAID	Pain, general
dexketoprofen	Benzeneacetic acid, 3-benzoyl-Alpha-methyl-, (S)- [CAS]	22161-81-5			Anti-inflammatory	Inflammation, general
dexloxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (R)- [CAS]	119817-90-2	EP	0344184	GI inflammatory/bowel disorders	Irritable bowel syndrome
dexmedetomidine	1H-Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, (R)- [CAS]	113775-47-6 86347-15-1	EP	187471	Hypnotic/Sedative	Anaesthesia

NPC-UNIV-000004609

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 231 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dexmethylphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, (AlphaR,2R)-	19262-68-1			Psychostimulant	Attention deficit disorder
Dexpanthenol		81-13-0				
dexrazoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)- [CAS]	24584-09-6	DE	1910283	Radio/chemoprotective	Chemotherapy-induced injury, general
Dextran-1	Dextran [CAS]	9004-54-0			Plasma substitute	
Dextranomer		56087-11-7				
Dextroamphetamine		51-64-9				
dextromethorphan	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)-,	6700-34-1 125-71-3	US	4221788	Formulation, oral, other	Cough, Emotional lability
Dextromoramide		357-56-2				
dextropropoxyphene	Benzeneethanol, Alpha-[2-(dimethylamino) 1-methylethyl]-Alpha-phenyl-, propanoate (ester), [S-(R*,S*)]- [CAS]	469-62-5			Formulation, modified-release, other	Pain, general
Dezocine		53648-55-8				
DF-1012	N-Tropyl 7-azaindol-3-ylcarboxamide	163220-65-3	WO	9504742	Respiratory	Respiratory disease, general
DFA-IV	di-D-fructofuranose 2,6':6,2' dianhydride		US	5700832	Antianaemic	Anaemia, aplastic
d-Fenchone		4695-62-9				
D-Glucuronolactone		32449-92-6				
Diab II	Diab II	309956-85-2	US	6153632	Antidiabetic	Diabetes, Type II
diacerein	2-Anthracenecarboxylic acid, 4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo- [CAS]	13739-02-1	US	4244968	Antiarthritic, other	Arthritis, rheumatoid
Diampromide		552-25-0				
Diamthazole		136-96-9				
Diathymosulfone		5964-62-5				
Diatrizoate		737-31-5				
diazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5			Formulation, transmucosal, systemic	Anxiety, epilepsy, general
Diaziquone		57998-68-2				
Diazoxide		364-98-7				

NPC-UNIV-000004610

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 232 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dibekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]	34493-98-6 58580-55-5	GB	1349302	Aminoglycoside antibiotic	Infection, general
Dibenzepin		4498-32-2				
Dibromopropamidine		496-00-4				
Dibucaine		61-12-1				
Dichloralphenazone		480-30-8				
Dichloramine T		473-34-7				
Dichlorisone		7008-26-6				
Dichlorobenzyl Alcohol		1777-82-8				
Dichlorophen		97-23-4				
Dichlorophenarsine		536-29-8				
Dichlorphenamide		120-97-8				
diclofenac + HA	Hyaluronic acid + benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- [CAS]				Formulation, transdermal, systemic	Keratosis
diclofenac	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, [CAS]	15307-79-6 15307-86-5 15307-81-0			Formulation, modified-release, <=24hr	Pain, general
Dicloxacillin		3116-76-5				
Dicumarol		66-76-2				
Dicyclomine		77-19-0				
didanosine	Inosine, 2',3'-dideoxy- [CAS]	69655-05-6	US	4861759	Antiviral, anti-HIV	Infection, HIV/AIDS
Dideoxyadenosine		4097-22-7				
didox	Benzamide, N,3,4-trihydroxy- [CAS]	69839-83-4	US	4263322	Anticancer, antimetabolite	Cancer, general
Dienestrol		84-17-3				
dienogest	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17Alpha)- [CAS]	65928-58-7	GB	1524917	Menstruation disorders	Endometriosis
dienogest+estradiol	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-,(17Alpha) + Estra-1,3,5(10)-triene-3,17-diol(17ß)				Formulation, fixed-dose combinations	Contraceptive, female
Diethadione		702-54-5				
Diethazine		60-91-3				

NPC-UNIV-000004611

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 233 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Diethylbromoacetamide		511-70-6				
Diethylcarbamazine		90-89-1				
diethylpropion	1-Propanone, 2-(diethylamino)-1-phenyl- [CAS]	90-84-6			Formulation, modified-release, <=24hr	Obesity
Diethylstilbestrol		56-53-1				
Difemerine		80387-96-8				
Difenamizole		20170-20-1				
Dif noxin		28782-42-5				
Difenpiramide		51484-40-3				
diflomotecan	(5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino[3',4':6,indolizino[1,2-b]quinoline-3,15-dione	220997-97-7			Anticancer, other	Cancer, general
diflorasone	Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6Alpha,11ß,16ß)- [CAS]	33564-31-7 2557-49-5	US	3980778	Antipsoriasis	
Difloxacin		98106-17-3				
Diflucortolone		2607-6-9				
diflunisal	2',4'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid	23674-86-4 22494-42-4	GB	1175212	Analgesic, NSAID	Pain, post-operative
Difluprednate		23674-86-4				
Digitalin		752-61-4				
Digitoxin		71-63-6				
digoxin	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-ß-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-ß-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-ß-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3ß,5ß,12ß)- [CAS]	20830-75-5	US	4088750	Formulation, oral, enteric-coated	Heart failure
Dihexyverine		561-77-3				
Dihydralazine		484-23-1				
Dihydrocodeine		125-28-0				
Dihydrocodeinone Enol		466-90-0				

NPC-UNIV-000004612

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 234 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dihydroergocryptine	Ergocryptine, dihydro- [CAS]	25447-66-9			Formulation, other	Depression, general
dihydroergotamine	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)- [CAS]	511-12-6		6495535	Formulation, modified-release, other	Migraine
Dihydromorphine		509-60-4				
Dihydrostreptomycin		128-46-1				
Dihydrotachysterol		67-96-9				
Dihydroxyaluminum		13682-92-3 539-68-4				
Diisopromine		5966-41-6				
Diisopropyl Paraoxon		3254-66-8				
Diisopropylamine		660-27-5				
dilazep	Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester [CAS]	35898-87-4	JP	51095086	Vasodilator, coronary	
Dilevalol		75659-07-3				
diloxanide	2-Furancarboxylic acid, 4-[(dichloroacetyl)methylamino]phenyl ester [CAS]	3736-81-0 579-38-4			Amoebicide	
diltiazem	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US US EP	4721619 5529791 322277	Antianginal	Angina, hypertension, general
Dimecrotic Acid		7706-67-4				
Dimefline		1165-48-6				
Dimemorfan		36309-01-0				
Dimenhydrinate		523-87-5				
Dimenoxadol		509-78-4				
Dim pheptanol		545-90-4				
Dimercaprol		59-52-9				
Dimetacrine		4757-55-5				
Dimethadione		695-53-4				
Dimethazan		519-30-2				
Dimethindene		5636-83-9				
Dimethisoquin		86-80-6				

NPC-UNIV-000004613

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 235 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Dimethisterone		79-64-1				
Dimethocaine		94-15-5				
Dimethoxanate		477-93-0				
Dimethyl Sulfoxide		67-68-5				
Dimethylthiambutene		524-84-5				
Dimetofrine		22950-29-4				
Dimorpholamine		119-48-2				
dinoprostone	Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,15S)- [CAS]	363-24-6			Formulation, modified-release, <=24hr	Labour, induction
diosmectite	Smecta- [CAS]	110070-78-5	FR	2770778	Antidiarrhoeal	Diarrhoea, general
diosmin	4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-Alpha-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)- [CAS]	520-27-4	DE	2602314	Vasoprotective, systemic	
Dioxadrol		6495-46-1				
Dioxaphetyl		467-86-7				
Dioxethedrine		497-75-6				
Dioxybenzone		131-53-3				
Diphemanil		62-97-5				
Diphenadione		82-66-6				
Diphencyprone		886-38-4				
Diphenhydramine		58-73-1				
Diphenidol		972-02-1				
Diphenoxylate		915-30-0				
Diphenylpyraline		147-20-6				
Diphetarsone		515-76-4				
Diphtheria & Tetanus Toxoids And Acellular Pertussis Vaccine Adsorbed						
Dipipanone		467-83-4				

NPC-UNIV-000004614

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 236 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dipivefrin	Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester, (+/-)- [CAS]	52365-63-6	US	3809714	Antiglaucoma	Glaucoma
Dipyridamole		58-32-2				
Dipyroc tyl		486-79-3				
Dipyrone		5907-38-0				
diquafosol	Uridine 5'-(pentahydrogen tetraphosphate)-5'-ester with uridine, [CAS]	211427-08-6			Ophthalmological	Dry eye syndrome
dirithromycin	Erythromycin, 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]oxy]-, [9S(R)]- [CAS]	62013-04-1	DE	2515075	Macrolide antibiotic	Tonsillitis
disodium pamidronate	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	EP	177443	Osteoporosis treatment	Hypercalcaemia of malignancy
Disofenin		65717-97-7				
disopyramide	2-Pyridineacetamide, Alpha-[2-[bis(1-methylethyl)amino]ethyl]-Alpha-phenyl- [CAS]	3737-09-5			Formulation, modified-release, <=24hr	Arrhythmia, general
Distigmine		15876-67-2				
Disulfamide		671-88-5				
Disulfiram		97-77-8				
Ditazol		18471-20-0				
Dithiazanine		514-73-8				
dithranol	9(10H)-Anthracenone, 1,8-dihydroxy- [CAS]	1143-38-0			Formulation, dermal, topical	Psoriasis
Ditiocarb		148-18-5				
Dixanthogen		502-55-6				
Dixyrazine		2470-73-7				
DJ-927			WO	01027115	Anticancer, other	Cancer, general

NPC-UNIV-000004615

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 237 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
DK-507k	(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate				Quinolone antibacterial	Infection, general
DL-Lactic Acid		598-82-3				
DMDC	Cytidine, 2'-deoxy-2'-methylene-, monohydrochloride [CAS]	113648-25-2	WO	8807049	Anticancer, antimetabolite	Cancer, general
DMXAA	5,6-dimethylxanthenone-4-acetic acid				Anticancer, other	Cancer, lung, general
DNA Stealth Nucleosides			US	6132776	Antiviral, anti-HIV	Infection, HIV/AIDS
Dobesilate		20123-80-2				
dobutamine	1,2-Benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, (+/-)- [CAS]	34368-04-2 49745-95-1	US	3987200	Cardiostimulant	
Docarpamine		74639-40-0				
docetaxel	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5ß,20-epoxy-1,2Alpha,4,7ß,10ß,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate- [CAS]	114977-28-5 148408-66-6	EP	253738	Anticancer, other	Cancer, breast
docosahexaenoic acid			EP	707487	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
docosanol	1-Docosanol [CAS]	661-19-8	EP	469064	Antiviral, other	Infection, herpes simplex virus
docusate		128-49-4 577-11-7	US	4752617	Formulation, dermal, topical	Infection, herpes simplex virus prophylaxis
dofetilide	Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]- [CAS]	115256-11-6	EP	245997	Antiarrhythmic	Fibrillation, atrial
dolasetron mesilate	1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2Alpha,6Alpha,8Alpha,9Alphaß)-, monomethanesulfonate- [CAS]	115956-13-3 115956-12-2	EP	266730	Antiemetic	Chemotherapy-induced nausea and vomiting
Domiodol		61869-07-6				
Domiphen		538-71-6				

NPC-UNIV-000004616

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 238 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Domitroban		112966-96-8				
domperidone	2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- [CAS]	57808-66-9	US	4066772	Antiemetic	
donepezil	1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, [CAS]	120011-70-3 120014-06-4	EP	296560	Cognition enhancer	Alzheimer's disease
donitriptan	Piperazine, 1-(((3-(2-aminoethyl)-1H-indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)- [CAS]	170912-52-4			Antimigraine	Migraine
Dopamine		51-61-6				
Dopexamine		86197-47-9				
doramapimod	urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-napthalenyl]-	285983-48-4			Antiarthritic, immunological	Arthritis, rheumatoid
doranidazole	(±)-1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)- [CAS]	137339-64-1	WO	9414778	Radio/chemosensitizer	Surgery adjunct
doripenem	(1R,5S,6S)-2-[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid	148016-81-3	EP	528678	Beta-lactam antibiotic	Infection, urinary tract
dorzolamide	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-,7,7-dioxide (4S-trans)- [CAS]	120279-96-1	EP	296879	Antiglaucoma	Glaucoma
dorzolamide + timolol	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]	120279-96-1 26839-75-8 26921-17-5			Formulation, fixed-dose combinations	Glaucoma

NPC-UNIV-000004617

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 239 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dosmalfate	Aluminium, (μ7-(7-((6-O-(6-deoxy-2,3,4-tri-O-sulfo-Alpha-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo-ß-D-glucopyranosyl)oxy)-5-hydroxy-2-(4-methoxy-3-(sulfooxy)phenyl-4H-1-benzopyran-4-onato(7-)))tetradeca-μ-hydroxyheneicosahydroxytetradeca- [CAS]	122312-55-4			Antiulcer	Ulcer, gastric
dosulepine	1-Propanamine, 3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethyl- [CAS]	113-53-1			Antidepressant	
Dotarizine		84625-59-2				
Dothiepin		113-53-1				
Doxacurium		106819-53-8				
Doxapram		309-29-5				
doxazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8	GB	2007656	Antihypertensive, adrenergic	Hypertension, general
Doxefazepam		40762-15-0				
Doxenitoin		3254-93-1				
doxepin	1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-	1668-19-5			Formulation, dermal, topical	Pruritus
doxercalciferol	9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol (1Alpha, 3ß, 5Z, 7E, 22E) [CAS]	54573-75-0	US	5104854	Hormone	Hyperparathyroidism
doxifluridine	Uridine, 5'-deoxy-5-fluoro- [CAS]	3094-09-5	US	4071680	Anticancer, antimetabolite	Cancer, colorectal
doxofylline	1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-[CAS]	69975-86-6	US	4187308	Antiasthma	Asthma
doxorubicin	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8	EP	191824	Formulation, optimized, liposomes	Cancer, general

NPC-UNIV-000004618

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 240 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
doxycycline	2-Naphthacenecarboxamine, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-[4S-(4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,12aAlpha)]- [CAS]	564-25-0 17086-28-1			Formulation, modified-release, immediate	Periodontitis
doxylamine	N,N-Dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine	469-21-6			Formulation, transmucosal, systemic	Rhinitis, allergic, general
DPC-817	ß-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine				Antiviral, anti-HIV	Infection, HIV/AIDS
DPI-3290			US	5681830	Analgesic, other	Pain, general
DQ-113	5-Amino-7-[(3S,4R)-(1-aminocyclopropyl)-3-fluoropyrrolidin-1-yl]-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid				Quinolone antibacterial	Infection, general
Drofenine		1679-76-1				
Droloxifene		82413-20-5				
Drometrizole		2440-22-4				
Dromostanolone		58-19-5				
dronabinol	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)- [CAS]	1972-08-3			Antiemetic	Chemotherapy-induced nausea and vomiting
dronedarone	2-n-Butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]5-methylsulfonamidobenzofuran				Antiarrhythmic	Arrhythmia, general
Droperidol		548-73-2				
Droprenilamine		57653-27-7				
Dropropizine		17692-31-8				
Drospirenone		67392-87-4				
Drotaverine		14009-24-6				
Drotebanol		03/02/3176				

NPC-UNIV-000004619

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 241 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
droxicam	2H,5H-1,3-Oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl)-, 6,6-dioxide [CAS]	90101-16-9	EP	99770	Anti-inflammatory	Inflammation, general
droxidopa	L-Tyrosine, ß,3-dihydroxy-, threo- [CAS]	23651-95-8	EP	128684	Antiparkinsonian	Parkinson's disease
Droxidopa		23651-95-8				
DU-125530	1,2-Benzisothiazol-3(2H)-one, 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]butyl]-, 1,1-dioxide [CAS]	161611-99-0	EP	633260	Anxiolytic	Anxiety, general
duloxetine	2-Thiophenepropanamine, N-methyl-Gamma-(1-naphthalenyloxy)-, hydrochloride, (S)- [CAS]	136434-34-9 116539-59-4	US	5362886	Antidepressant	Depression, general
duramycin			WO	9428726	Formulation, inhalable, solution	Cystic fibrosis
Durapatite		1306-06-5				
dutasteride	4-Azaandrost-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5Alpha,17ß)- [CAS]	164656-23-9	US	5565467	Prostate disorders	Benign prostatic hyperplasia
DW-1141	N,N-diisopropyl-4-[4-(3-aminobenzo[d]isoxazol-6-yloxy)butoxy]-3-methoxybenzamide				Osteoporosis treatment	Osteoporosis
DW-286a	(R)-(-)-7-((4-aminomethyl-4-methyl-3-(Z)-methyloxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid				Quinolone antibacterial	Infection, general
DW-471			US	5922871	Antiviral, other	Infection, hepatitis-B virus
DX-9065a	2-Naphthalenepropanoic acid, 7-(aminoiminomethyl)-Alpha-[4-[[1-(1-iminoethyl)-3-pyrrolidinyl]oxy]phenyl]-, monohydrochloride, pentahydrate, [S-(R*,R*)]- [CAS]	155204-81-2			Antithrombotic	Thrombosis, general

NPC-UNIV-000004620

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 242 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
DY-9760e	1H-Indazole, 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy- [CAS]	160522-00-9	US	5681954	Neuroprotective	Ischaemia, cerebral
Dyclonine		586-60-7				
Dydrogesterone		152-62-5				
Dymanthine		124-28-7				
Dyphyllin		479-18-5				
E-1010	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]	186319-97-1			Beta-lactam antibiotic	Infection, general
E-2101	N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide				Muscle relaxant	Muscle spasm, general
E2F antagonists			WO	9606943	Anticancer, other	Cancer, general
E-3620	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2-butynyl)oxy]-, monohydrochloride, [3(S)-endo]- [CAS]	151213-86-4	EP	554794	Antacid/Antiflatulent	Dyspepsia
E-5564	Alpha-D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-(2-deoxy-3-O-((3R)-3-methoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-11-octadecenyl)amino)-4-O-phosphono-ß-D-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)- 1-(dihydrogen phosphate), tetrasodium salt [CAS]	185954-98-7	EP	536969	Septic shock treatment	Sepsis
E-5842	Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	220120-14-9			Neuroleptic	Schizophrenia

NPC-UNIV-000004621

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 243 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
E-6259	1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1-H-pyrazole				Antiarthritic, other	Unspecified
EAA-90	[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid				Analgesic, other	Pain, neuropathic
ε-Acetamidocaproic Acid		57-08-9				
ε-Aminocaproic Acid		60-32-2				
ebastine	1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- [CAS]	90729-43-4	EP	134124	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
eberconazole	1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)- [CAS]	128326-82-9 130104-32-4	ES	2012297	Antifungal	Infection, dermatological
ebrotidine	Benzenesulfonamide, N-[[[2-[[[2-[(aminoiminomethyl)amino]-4-thiazoly]methyl]thio]ethyl]amino]methylene]-4-bromo- [CAS]	100981-43-9	EP	159012	Antiulcer	Ulcer, duodenal
ebselen	1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- [CAS]	60940-34-3	EP	44971	Neuroprotective	Haemorrhage, subarachnoid
Eburnamonine		474-00-0				
Ecabapide		104775-36-2				
ecabet	1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, [1R-(1Alpha,4aß,10aAlpha)]- [CAS]	33159-27-2 86408-72-2	DE	3239172	Antiulcer	Ulcer, gastric
ecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-,phenylmethyl ester, (S)- [CAS]	112573-73-6	EP	318377	Antihypertensive, other	Hypertension, general
Ecgonidine		484-93-5				
Ecgonine		481-37-8				
Echothiophate		513-10-0				
Econazole		27220-47-9				

NPC-UNIV-000004622

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 244 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ecopipam	5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS-trans)- [CAS]	112108-01-7	EP	230270	Anorectic/Antiobesity	Obesity
ecraprost	Prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11Alpha,13E,15S)- [CAS]	136892-64-3	EP	423697	Vasodilator, peripheral	Peripheral vascular disease
Ectylurea		95-04-5				
ED-71	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1Alpha,2ß,3ß,5Z,7E)- [CAS]	104121-92-8	EP	184206	Osteoporosis treatment	Osteoporosis
edaravone	3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- [CAS]	89-25-8	JP	62108814	Neuroprotective	Infarction, cerebral
Edatrexate		80576-83-6				
Edetate Calcium Disodium		62-33-9				
Edetate Disodium		139-33-3				
Edetate Sodium		64-02-8				
Edetate Trisodium		150-38-9				
edonentan	Butanamide,N-[[2'-[[4,5-dimethyl-3-isoxazoyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl-, monohydrate	210891-04-6			Cardiostimulant	Heart failure
edotreotide	[N-[2-[4,7-Bis[(carboxy-kappaO)methyl]-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfidato(3-)]yttrium	204318-14-9	US	6183721	Anticancer, hormonal	Cancer, lung, small cell
edoxudine	Uridine, 2'-deoxy-5-ethyl- [CAS]	15176-29-1	GB	1170565	Antiviral, other	Infection, herpes virus, general
Edrecolomab		156586-89-9				
Edrophonium		116-38-1				
Efalith	Butanedioic acid, lithium salt [CAS]	16090-09-8			Antipruritic/inflamm, allergic	Eczema, seborrhoeic

NPC-UNIV-000004623

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 245 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
efaproxiral	Propanoic acid, 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl- [CAS]	131179-95-8	US	5705521	Radio/chemosensitizer	Cancer, brain
efavirenz	2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)- [CAS]	154598-52-4	WO	9403440	Antiviral, anti-HIV	Infection, HIV/AIDS
efletirizine	[2-[4-[Bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid	150756-35-7	GB	2311940	Antiallergic, non-asthma	Allergy, general
eflornithine	DL-Ornithine, 2-(difluoromethyl)- [CAS]	70052-12-9 67037-37-0	US	4413141	Protozoacide, dermal, topical	Infection, trypanosomiasis, African, Hirsutism
Efloxate		119-41-5				
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2			Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
efonidipine	3-pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide [CAS]	111011-53-1 111011-63-3 111011-76-8	EP	230944	Antihypertensive, other	Hypertension, general
EGIS-7229	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propylamino]- 3(2H)-pyridazinone fumarate [CAS]	150800-12-7 190333-92-7	DE	4243381	Antiarrhythmic	Arrhythmia, general
eglumegad	Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- [CAS]	176199-48-7 209216-09-1			Anxiolytic	Anxiety, general
egualen	1-Azulenesulfonic acid, 3-ethyl-7-(1-methylethyl)-,	97683-31-3 99287-30-6	EP	147915	Antiulcer	Ulcer, gastric
Eicosapentaenoic Acid		10417-94-4				
elarofiban	3-Pyridinepropanoic acid, ß-[((3R)-1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-, (ßS)- [CAS]	198958-88-2	WO	9741102	Antithrombotic	Thrombosis, general
Elcatonin		60731-46-6				
Eledoisin		69-25-0				
eletriptan	1H-Indole, 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)- (R)- [CAS]	143322-58-1	US	5607951	Antimigraine	Migraine

NPC-UNIV-000004624

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 246 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Elgodipine		119413-55-7				
Ellagic Acid		476-66-4				
Elliptinium		58337-35-2				
Eltoprazine		98224-03-4				
elvucitabine	ß-L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine	181785-84-2			Antiviral, other	Infection, hepatitis-B virus
elzasonan	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one monohydrochloride- [CAS]	220322-05-4 361343-20-6			Antidepressant	Depression, general
Embelin		550-24-3				
Embramine		3565-72-8				
emedastine	1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, (E)-2-butenedioate (1:2) [CAS]	87233-61-2 87233-62-3	EP	79545	Antiallergic, non-asthma	Rhinitis, allergic, general
Emepronium		3614-30-0				
Emetine		483-18-1				
Emitefur		110690-43-2				
EMM-210525	17Alpha-Acetoxy-6Alpha-methyl-19-nor-1ß,2ß-dihydrocyclopropa[1,2']pregn-4-ene-3,20-dione+Estra-1,3,5(10)-triene-3,17-diol(17ß)				Formulation, fixed-dose combinations	Hormone replacement therapy
Emodin		518-82-1				
emorfazone	3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-(4-morpholinyl)- [CAS]	38957-41-4	JP	7224030	Anti-inflammatory	
EMR-62203			WO	9806722	Male sexual dysfunction	Impotence
emtricitabine	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)- [CAS]	143491-57-0	WO	9214743	Antiviral, anti-HIV	Infection, HIV/AIDS
Emylcamate		78-28-4				
enalapril	L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-, (Z)-2-butenedioate [CAS]	76095-16-4	US	4374829	Antihypertensive, renin system	
Enalaprilat		76420-72-9				
Enallylpropymal		1861-21-8				

NPC-UNIV-000004625

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 247 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Encainide		66778-36-7				
Enciprazine		68576-86-3				
Endralazine		39715-02-1				
enfenamic acid	Benzoic acid, 2-[(2-phenylethyl)amino]- [CAS]	23049-93-6	IN	103066	Anti-inflammatory	
enflurane	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro- [CAS]	13838-16-9	US	3469011	Anaesthetic, inhalation	Anaesthesia
Enilconazole		35554-44-0				
Eniluracil		59989-18-3				
ENMD-0995	S-3-amino-phthalidoglutarimide		US	5712291	Anticancer, other	Cancer, myeloma
Enocitabine		55726-47-1				
Enol-3-IPA	1H-Indole-3-propanoic acid, Alpha-oxo- [CAS]	392-12-1	EP	106813	Hypnotic/Sedative	Insomnia
enoxacin	1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	74011-58-8	US	4359578	Quinolone antibacterial	Infection, general
enoxaparin	Heparin, [CAS]	9005-49-6 9041-08-1	EP	40144	Antithrombotic	Thrombosis, venous
enoximone	2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]- [CAS]	77671-31-9	EP	59948	Cardiostimulant	Heart failure
Enoxolone		471-53-4				
enprostil	4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, methyl ester, [1Alpha,2ß(1E,3R*),3Alpha]- [CAS]	73121-56-9	GB	2025431	Prostaglandin	Ulcer, duodenal
enrasentan	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1Alpha,2ß,3Alpha))- [CAS]	167256-08-8	US	5817693	Antihypertensive, other	Hypertension, pulmonary
entacapone	2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-diethyl- [CAS]	130929-57-6	EP	426468	Antiparkinsonian	Parkinson's disease
entecavir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]- [CAS]	142217-69-4	EP	481754	Antiviral, other	Infection, hepatitis-B virus

NPC-UNIV-000004626

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 248 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Enviomycin		33103-22-9				
epalrestat	3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS]	82159-09-9	EP	47109	Symptomatic antidiabetic	Neuropathy, diabetic
Epavir	L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate				Antiviral, other	Infection, herpes simplex virus
EPC-K1	L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate]potassium- [CAS]	127061-56-7	EP	127471	Neuroprotective	Infarction, cerebral
eperisone	1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS]	64840-90-0	US	3995047	Muscle relaxant	Spastic paralysis
epervudine	Uridine, 2'-deoxy-5-(1-methylethyl)- [CAS]	60136-25-6	DE	2918260	Antiviral, other	Infection, herpes simplex virus
Ephedrine		299-42-3				
Epicillin		26774-90-3				
Epimestrol		7004-98-0				
epinastine	1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- [CAS]	80012-43-7	DE	3008944	Antiasthma	Asthma
epinephrine	(R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol	51-43-4			Formulation, inhalable, dry powder	Anaphylaxis
Epirizole		18694-40-1				
epirubicin	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	56390-09-1 56420-45-2	GB	1457632	Anticancer, antibiotic	
Epitiostanol		2363-58-8				
eplerenone	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,Gamma-lactone, methyl ester (7Alpha,11Alpha,17Alpha)- [CAS]	107724-20-9	EP	122232	Antihypertensive, diuretic	Hypertension, general

NPC-UNIV-000004627

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 249 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
eplivanserin	1-Propanone, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z)-, (E)-2-butenedioate (2:1) (salt) [CAS]	130580-02-8	EP	373998	Anxiolytic	Schizophrenia
epoprostenol	Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9Alpha,11Alpha,13E,15S)-[CAS]	35121-78-9 61849-14-7	DE	2720999	Prostaglandin	Hypertension, pulmonary
Epostane		80471-63-2				
Eprazinone		10402-90-1				
Epristeride		119169-78-7				
eprosartan	3-[2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-5-yl]-2-(2-thienylmethyl)-2-(E)-propenoic acid	133040-01-4	EP	403159	Antihypertensive, renin system	Hypertension, general
Eprozinol		32665-36-4				
eptapirone	4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione	179756-85-5			Antidepressant	Depression, general
eptaplatin	Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]	146665-77-2	WO	9216539	Anticancer, alkylating	Cancer, lung, small cell
Eptastigmine		101246-68-8				
eptazocine	1,6-Methano-1H-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)-[CAS]	72522-13-5	US	4082744	Analgesic, other	
Eptifibatide		188627-80-7				
Equilenin		517-09-9				
Equilin		474-86-2				
ERA-923	ERA 923 [CAS]	352233-89-7	EP	802183	Female contraceptive	Contraceptive, female
erdosteine	Acetic acid, [[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]- [CAS]	84611-23-4	EP	61386	Respiratory	Respiratory disease, general
Ergocornine		564-36-3				
Ergocorninine		564-37-4				
Ergoloid Mesylates		8067-24-1				
Ergonovine		60-79-7				
Ergosterol		57-87-4				

NPC-UNIV-000004628

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 250 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ergotamine	(5'Alpha)-12'-Hydroxy-2'methyl-(phenylmethyl)ergotaman-3',6', 18-trione	113-15-5			Formulation, inhalable, systemic	Migraine
Eritadenine		23918-98-1				
erlotinib	4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride [CAS]	183319-69-9	WO	9630347	Anticancer, other	Cancer, lung, non-small cell
ertapenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, [CAS]	153773-82-1 153832-46-3	WO	9315078	Beta-lactam antibiotic	Infection, GI tract
Erythrityl Tetranitrate		7297-25-8				
Erythrocentaurin		50276-98-7				
erythromycin acistrate	Erythromycin, 2'-acetate, octadecanoate (salt) [CAS]	96128-89-1	US	4599326	Macrolide antibiotic	Infection, general
Erythromycin Estolate		3521-62-8				
Erythromycin Glucoheptonate		23067-13-2				
Erythromycin Lactobionate		3847-29-8				
Erythromycin Propionate		134-36-1				
Erythromycin Stearate		643-22-1				
erythromycin stinoprate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	84252-03-9	EP	57489	Macrolide antibiotic	Infection, respiratory tract, lower
erythromycin	Erythromycin [CAS]	114-07-8			Formulation, dermal, topical	Acne
Erythrophleine		36150-73-9				
Esaprazole		64204-55-3				
escitalopram	5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)- [CAS]	128196-01-0	EP	347066	Antidepressant	Depression, general
Esculin		531-75-9				
Eseridine		25573-43-7				

NPC-UNIV-000004629

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 251 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
esmolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[(1 methylethyl)amino]propoxy]-, methyl ester, (+/-)- [CAS]	81147-92-4	US	4387103	Antihypertensive, adrenergic	Tachycardia, supraventricular
esomeprazole	bis (5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazolato)	161973-10-0	US	5877192	Antispasmodic	Gastro-oesophageal reflux
estazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl- [CAS]	29975-16-4	US	3987052	Hypnotic/Sedative	
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17ß)- [CAS]	58-22-0	US	5460820	Formulation, transdermal, patch	Sexual dysfunction, female
estradiol	Estra-1,3,5(10)-triene-3,17-diol (17ß)- [CAS]	50-28-2	EP	430491	Formulation, transdermal, systemic	Menopausal symptoms, general
estramustine	Estra-1,3,5(10)-triene-3,17-diol (17ß)-, 3-[bis(2-chloroethyl)carbamate] 17- [CAS]	2998-57-4 4891-15-0 52205-73-9			Anticancer, alkylating	Cancer, prostate
Estriol		50-27-1				
estrogen			WO	9924041	Menopausal disorders	Menopausal symptoms, general
Estrone		53-16-7				
eszopiclone	1-Piperazinecarboxylic acid, 4-methyl- 6-(5 chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester (S)- [CAS]	138729-47-2	US	5786357	Hypnotic/Sedative	Insomnia
Etafedrine		7681-79-0				
Etafenone		90-54-0				
Etamiphyllin		314-35-2				
Etanercept		185243-69-0				
Etanidazole		22668-01-5				
Etaqualone		7432-25-9				
Eterobarb		27511-99-5				
Ethacridine		442-16-0				
Ethacrynic Acid		58-54-8				
Ethadion		520-77-4				
Ethambutol		74-55-5				
Ethamivan		304-84-7				

NPC-UNIV-000004630

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 252 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Ethamsylate		2624-44-4				
Ethanolamine		141-43-5				
Ethaverine		486-47-5				
Ethchlorvynol		113-18-8				
Ethenzamide		938-73-8				
Ethiazide		1824-58-4				
Ethinamate		126-52-3				
Ethinyl Estradiol		57-63-6				
ethinyl estradiol	19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17Alpha)- [CAS]	28913-23-7	DE	1949095	Formulation, modified-release, >24hr	Cancer, prostate
Ethionamide		536-33-4				
Ethisterone		434-03-7				
Ethoheptazine		77-15-6				
Ethopropazine		522-00-9				
Ethosuximide		77-67-8				
Ethotoin		86-35-1				
Ethoxzolamide		452-35-7				
Ethybenztropine		524-83-4				
Ethyl Alcohol		64-17-5				
Ethyl Biscoumacetate		548-00-5				
Ethyl Chloride		75-00-3				
Ethyl Dibunate		5560-69-0				
Ethyl Ether		60-29-7				
ethyl icosapentate	5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- [CAS]	86227-47-6	JP	61043143	Antithrombotic	Peripheral vascular disease
ethyl loflazepate	1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester [CAS]	29177-84-2	US	3657223	Anxiolytic	Anxiety, general
Ethyl Loflazepate		29177-84-2				
Ethylamine		75-04-7				
Ethylene		74-85-1				
Ethylestrenol		965-90-2				
Ethylidene Dicoumarol		1821-16-5				

NPC-UNIV-000004631

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 253 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Ethylmethylthiambutene		441-61-2				
Ethylmorphine		76-58-4				
Ethylnorepinephrine		536-24-3				
Ethynodiol		1231-93-2				
ethynylcytidine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	WO	9618636	Anticancer, antimetabolite	Cancer, general
Etidocaine		36637-18-0				
etidronate	Phosphonic acid, (1-hydroxyethylidene)bis-, [CAS]	2809-21-4 7414-83-7	US	4137309	Osteoporosis treatment	Osteoporosis
Etidronic Acid		2809-21-4				
Etifelmin		341-00-4				
etifoxine	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-ethyl-4-methyl-4-phenyl- [CAS]	21715-46-8	US	3725404	Anxiolytic	
Etilefrin		709-55-7				
etilevodopa	L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]	37178-37-3	US	5354885	Antiparkinsonian	Parkinson's disease
etiprednol	androsta-1,4-diene-17-carboxylic acid, 17-[(dichloroacetyl)oxy]-11-hydroxy-3-oxo-, ethyl ester, (11ß,17Alpha)-	199331-40-3			GI inflammatory/bowel disorders	Crohn's disease
Etiroxate		17365-01-4				
Etizolam		40054-69-1				
etodolac	Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- [CAS]	41340-25-4	US	3939178	Antiarthritic, other	Arthritis, osteo
Etodroxizine		17692-34-1				
etofenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 2-(2-hydroxyethoxy)ethyl ester [CAS]	30544-47-9	GB	1285400	Anti-inflammatory, topical	Inflammation, general
etofibrate	3-Pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester [CAS]	31637-97-5	US	3723446	Hypolipaemic/Antiatherosclerosis	
Etofylline		519-37-9				
etofylline clofibrate	Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)ethyl ester [CAS]	54504-70-0	DE	2308826	Hypolipaemic/Antiatherosclerosis	
Etofylline Nicotinate		13425-39-3				

NPC-UNIV-000004632

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 254 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Etoglucid		1954-28-5				
Etomidate		33125-97-2				
Etomidoline		21590-92-1				
Etonitazene		911-65-9				
etonogestrel	18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene, (17Alpha)- [CAS]	54048-10-1			Formulation, implant	Contraceptive, female
Etoperidone		52942-31-1				
etoposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[(4,6-O-ethylidene-ß-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5Alpha,5aß,8aAlpha,9ß(R*)]]- [CAS]	33419-42-0	GB	1205966	Anticancer, other	Cancer, testicular
etoposide phosphate	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[(4,6-0-ethylidene-ß-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-, [5R-[5Alpha,5aß,8aAlpha,9ß(R*)]]- [CAS]	117091-64-2	EP	302473	Anticancer, other	Cancer, testicular
etoricoxib	2,3-Bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl) [CAS]	202409-33-4	WO	9803484	Antiarthritic, other	Arthritis, osteo
Etoxadrol		28189-85-7				
Etozolin		73-09-6				
etretinate	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- [CAS]	54350-48-0	US	4215215	Antipsoriasis	
Etryptamine		2235-90-7				
Etymemazine		523-54-6				
Eucatropine		100-91-4				
Eugenol		97-53-0				
EUK-134	Manganese, chloro[[2,2'-[1,2-ethanediylbis[(nitrilo-kappaN)methylidyne]]bis(6-methoxyphenolato-kappaO)]]-, (SP-5-13)- [CAS]	81065-76-1	US	6046188	Cardiovascular	Unspecified

NPC-UNIV-000004633

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 255 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
EUK-189			US	6046188	Radio/chemoprotective	Chemotherapy-induced injury, general
Evan's Blue		314-13-6				
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)- [CAS]	159351-69-6	WO	9409010	Immunosuppressant	Transplant rejection, general
exalamide	Benzamide, 2-(hexyloxy)- [CAS]	53370-90-4	GB	726786	Antifungal	Infection, fungal, general
Exametazime		105613-48-7				
exatecan	10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]	171335-80-1			Anticancer, other	Cancer, pancreatic
exemestane	Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]	107868-30-4	DE	3622841	Anticancer, hormonal	Cancer, breast
Exifone		52479-85-3				
exisulind	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (Z)- [CAS]	59973-80-7			Anticancer, other	Polyp
Exosurf®		99732-49-7				
ezetimibe	2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]	163222-33-1	US	5846966	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
Factor IX		9001-28-9				
Factor VIII		9001-27-8				
Factor XIII		9013-56-3				
fadolmidine	1H-Inden-5-ol, 2,3-dihydro-3-(1H-imidazol-4-ylmethyl)-, monohydrochloride [CAS]	189353-32-0	WO	9712874	Analgesic, other	Pain, general
Fadrozole		102676-47-1				
falecalcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,26,27,27,27-hexafluoro-, (1Alpha,3ß,5Z,7E)- [CAS]	83805-11-2	JP	03099022	Osteoporosis treatment	Hyperparathyroidism
famciclovir	1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)- [CAS]	104227-87-4	JP	61085388	Antiviral, other	Infection, gynaecological

NPC-UNIV-000004634

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 256 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
famotidine	Propanimidamide, 3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)- [CAS]	76824-35-6	US	4283408	Antiulcer	Ulcer, duodenal
fampridine	4-pyridinamine	504-24-5			Neuroprotective	Spinal cord injury
fandofloxacin	3-Quinolinecarboxylic acid, 6-fluoro-1-(5-fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo, [CAS]	164150-85-0 164150-99-6	US	5496947	Quinolone antibacterial	Infection, urinary tract
Fantofarone		114432-13-2				
faropenem daloxate	(5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-tetrahydrofuryl]-2-penem-3-carboxylic acid-5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester				Beta-lactam antibiotic	Infection, general
faropenem	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, [5R-[3(R*),5Alpha,6Alpha(R*)]]-[CAS]	122547-49-3	EP	410727	Beta-lactam antibiotic	Infection, ocular
fasidotril	L-Alanine, N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]-, phenylmethyl ester [CAS]	135038-57-2	EP	419327	Antihypertensive, renin system	Hypertension, general
fasudil	1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)- [CAS]	103745-39-7 105628-07-7	EP	187371	Neuroprotective	Vasospasm, general
Fazadinium Bromide		49564-56-9				
febarbamate	2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-[2-[(aminocarbonyl)oxy]-3-butoxypropyl]-5-ethyl-5-phenyl- [CAS]	13246-02-1	US	3075983	Psychostimulant	
Febuprol		3102-00-9				
febuxostat	5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl- [CAS]	144060-53-7	WO	9209279	Antigout	Hyperuricaemia
Fedotozine		123618-00-8				
felbamate	1,3-Propanediol, 2-phenyl-, dicarbamate [CAS]	25451-15-4	US	4868327	Antiepileptic	Epilepsy, general
felbinac	[1,1'-Biphenyl]-4-acetic acid [CAS]	5728-52-9	EP	127840	Anti-inflammatory, topical	
felodipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester [CAS]	72509-76-3	US	4264611	Antihypertensive, other	Hypertension, general
Felypressin		56-59-7				

NPC-UNIV-000004635

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 257 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Femoxetine		59859-58-4				
Fenbenicillin		1926-48-3				
fenbufen	[1,1'-Biphenyl]-4-butanoic acid, Gamma-oxo- [CAS]	36330-85-5	US	3784701	Anti-inflammatory	
Fenbutrazate		4378-36-3				
Fencamfamine		1209-98-9				
Fencamine		28947-50-4				
Fenclozic Acid		17969-20-9				
Fendiline		13042-18-7				
Fendosal		53597-27-6				
Fenethylline		3736081				
Fenfluramine		458-24-2				
Fenipentol		583-03-9				
fenofibrate	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS]	26129-32-8 49562-28-9			Formulation, modified-release, <=24hr	Hyperlipidaemia, general
fenoldopam	1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS]	67227-56-9 67227-57-0	EP	22330	Antihypertensive, other	Hypertension, general
Fenoprofen		31879-05-7				
Fenoterol		13392-18-2				
fenoverine	10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl]-[CAS]	37561-27-6	FR	2092639	Antispasmodic	
Fenoxazoline		4846-91-7				
Fenoxedil		54063-40-0				
Fenozolone		15302-16-6				
Fenpentadiol		15687-18-0				
Fenpiprane		3540-95-2				
Fenpiverinium Bromide		125-60-0				
Fenproporex		15686-61-0				
Fenquizone		20287-37-0				
fenretinide	Retinamide, N-(4-hydroxyphenyl)- [CAS]	65646-68-6	BE	847942	Anticancer, other	Cancer, breast
Fenspiride		5053066				

NPC-UNIV-000004636

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 258 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
fentanyl	Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- [CAS]	437-38-7			Formulation, transmucosal, systemic	Anaesthesia, adjunct
Fentiazac		18046-21-4				
Fenticlor		97-24-5				
fenticonazole	1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]- [CAS]	72479-26-6 73151-29-8	US	4221803	Antifungal	Infection, gynaecological
Fentonium Bromide		5868064				
fepradinol	Benzenemethanol, Alpha-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]-, (+/-)- [CAS]	36981-91-6 67704-50-1 63075-47-8			Anti-inflammatory, topical	
Feprazone		30748-29-9				
Ferric Sodium Edetate		15708-41-5				
ferrioxamine B			WO	9426263	Septic shock treatment	Respiratory distress syndrome, adult
Ferrocholinate		1336-80-7				
Ferrous Gluconate		299-29-6				
ferumoxytol	Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite				Imaging agent	Diagnosis, cancer
fesoterodine	2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt) - [CAS]	286930-03-8			Urological	Incontinence
fexofenadine	Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]	153439-40-8 83799-24-0 138452-21-8	US	5375693	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Fibrostat			CA	2132416	Vulnerary	Wound healing
fidarestat	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]	136087-85-9	EP	418834	Symptomatic antidiabetic	Neuropathy, diabetic

NPC-UNIV-000004637

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 259 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
fiduxosin	8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione	208993-54-8			Prostate disorders	Benign prostatic hyperplasia
finasteride	4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5Alpha,17ß)-[CAS]	98319-26-7	EP	155096	Prostate disorders	Benign prostatic hyperplasia
finrozole	Benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)-propyl)-[CAS]	160146-16-7	EP	476944	Urological	Urinary retention
Fipexide		34161-24-5				
FK-960	N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide monohydrate- [CAS]	133920-70-4	WO	9101979	Cognition enhancer	Alzheimer's disease
Flavopiridol		146426-40-6				
flavoxate	4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester [CAS]	15301-69-6 3717-88-2	US	2921070	Urological	
flecainide	Benzamide,N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-,[CAS]	54143-55-4 54143-56-5			Formulation, modified-release, <=24hr	Fibrillation, atrial
fleroxacin	3-Quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	79660-53-0 79660-72-3	US	4398029	Quinolone antibacterial	Infection, general
Flesinoxan		98206-10-1				
flibanserin	2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- [CAS]	167933-07-5			Reproductive/gonadal, general	Sexual dysfunction, female
floctafenine	Benzoic acid, 2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydroxypropyl ester [CAS]	23779-99-9	US	3644368	Analgesic, NSAID	
flomoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (6R-cis)-[CAS]	92823-03-5 99665-00-6	EP	128536	Cephalosporin, injectable	Infection, general

NPC-UNIV-000004638

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 260 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Flopropione		2295-58-1				
Florantyrone		519-95-9				
Flosequinan		76568-02-0				
Floxacillin		5250-39-5				
Floxuridine		50-91-9				
Fluacizine		30223-48-4				
Fluanisone		1480-19-9				
fluasterone	Androst-5-en-17-one, 16-fluoro-, (16Alpha)- [CAS]	112859-71-9	EP	246650	Cardiovascular	Keratosis
fluazacort	5'H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-2'-methyl-, (11ß,16ß)- [CAS]	19888-56-3	US	3461119	Antipruritic/inflamm, non-allergic	
Flucloronide		3693-39-8				
flucloxacillin		1847-24-1 34214-51-2			Formulation, other	Infection, general
fluconazole	1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difluorophenyl)-Alpha-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	86386-73-4	EP	96569	Antifungal	Infection, dermatological
Flucytosine		2022-85-7				
fludarabine	9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-ß-D-arabinofuranosyl)- [CAS]	75607-67-9 21679-14-1	US	4357324	Anticancer, antimetabolite	Cancer, leukaemia, chronic lymphocytic
Fludeoxyglucose F_{18}		105851-17-0				
Fludiazepam		3900-31-0				
Fludrocortisone		127-31-1				
Flufenamic Acid		530-78-9				
Fluindione		957-56-2				
flumazenil	4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester [CAS]	78755-81-4	EP	27214	Neurological	
Flumecinol		56430-99-0				
Flumequine		42835-25-6				
Flumethasone		2135-17-3				
Flumethiazide		148-56-1				

NPC-UNIV-000004639

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 261 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-,(E)- [CAS]	30484-77-6 52468-60-7 27848-84-6	GB	1268710	Antimigraine	
flunisolide	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6Alpha,11ß,16Alpha)- [CAS]	3385-03-3	US	3124571	Antiasthma	Rhinitis, allergic, general
flunitrazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro- [CAS]	1622-62-4	US	3116203	Hypnotic/Sedative	
Flunoxaprofen		66934-18-7				
Fluocinolone Acetonide		67-73-2				
Fluocinonide		356-12-7				
Fluocortin Butyl		41767-29-7				
Fluocortolone		152-97-6				
Fluorescein		2321-07-5				
Fluoresone		2924-67-6				
Fluorometholone		426-13-1				
Fluorosalan		4776061				
fluorouracil	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8			Formulation, transdermal, enhanced	Keratosis
fluoxetine	Benzenepropanamine, N-methyl-Gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)- [CAS]	54910-89-3 56296-78-7	US	4314081	Antidepressant	Depression, general
Fluoxymesterone		76-43-7				
Flupentixol		2709-56-0				
Fluperolone		2119-75-7				
Fluphenazine		69-23-8				
flupirtine	Carbamic acid, [2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester [CAS]	33400-45-2 56995-20-1 75507-68-5	US	4481205	Analgesic, other	Pain, post-operative
Fluprednidene Acetate		1255-35-2				
Fluprednisolone		53-34-9				
Fluproquazone		40507-23-1				

NPC-UNIV-000004640

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 262 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Flurandrenolide		1524-88-5				
Flurazepam		17617-23-1				
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4	US	3793457	Anti-inflammatory	
flurithromycin	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP	56291	Macrolide antibiotic	Infection, respiratory tract, lower
Flurogestone		2529-45-5				
Flurothyl		333-36-8				
Flurox n		406-90-6				
Fluspirilene		1841-19-6				
flutamide	Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- [CAS]	13311-84-7	US	4329364	Anticancer, hormonal	
flutazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27060-91-9	US	3905956	Anxiolytic	
fluticasone	Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6Alpha,11ß,16Alpha,17Alpha)- [CAS]	80474-14-2 90566-53-3			Formulation, inhalable, solution	Asthma
flutoprazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro- [CAS]	25967-29-7	GB	1253368	Anxiolytic	Psychosis, general
flutrimazole	1H-Imidazole, 1-[(2-fluorophenyl)(4-fluorophenyl)phenylmethyl]- [CAS]	119006-77-8	EP	352352	Antifungal	Infection, dermatological
Flutropium Bromide		63516-07-4				
fluvastatin	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, [R*,S*-(E)]-(±)- [CAS]	93957-55-2 93957-54-1	EP	114027	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
fluvoxamine	1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-O-(2-aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB	1535226	Antidepressant	Depression, general, Obsessive-compulsive disorder
Folic Acid		59-30-3				
Folinic Acid		58-05-9				
Fomepizole		7554-65-6				

NPC-UNIV-000004641

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 263 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
fominoben	Benzamide, N-[3-chloro-2-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]methyl]phenyl]- [CAS]	18053-31-1 24600-36-0	US	3661903	Respiratory stimulant	Eczema, general
Fomivirsen		144245-52-3				
Fomocaine		17692-39-6				
Fonazine		7456-24-8				
fondaparinux	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-ß-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-,6-(hydrogen sulfate) [CAS]	104993-28-4 114870-03-0			Anticoagulant	Thrombosis, venous
Formebolone		2454117				
formestane	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3	EP	346953	Anticancer, hormonal	Cancer, breast
Formocortal		2825-60-7				
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(+/-)- [CAS]	43229-80-7 73573-87-2	GB	1415256	Antiasthma	Asthma
fosamprenavir	Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)- C-((3S)-tetrahydro-3-furanyl ester, [CAS]	226700-81-8			Antiviral, anti-HIV	Infection, HIV/AIDS
foscarnet	Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	34156-56-4 4428-95-9 63585-09-1	US	4839445	Antiviral, other	Infection, cytomegalovirus
Fosfestrol		522-40-7				
fosfluconazole	2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194798-83-9			Antifungal	Infection, fungal, general
fosfomycin	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)- [CAS]	23155-02-4 26016-98-8	GB	1223923	Antibiotic, other	Infection, general

NPC-UNIV-000004642

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 264 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
fosfomycin trometamol	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)- [CAS]	78964-85-9	EP	27597	Antibiotic, other	Infection, urinary tract
Fosfosal		6064-83-1				
fosinopril	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-, (2Alpha,4ß)- [CAS]	88889-14-9 98048-97-6	EP	63896	Antihypertensive, renin system	Hypertension, general
fosphenytoin	2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]- [CAS]	92134-98-0 93390-81-9	US	4260769	Antiepileptic	Epilepsy, generalized, tonic-clonic
fotemustine	Phosphonic acid, [1-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester [CAS]	92118-27-9	EP	117959	Anticancer, alkylating	Cancer, melanoma
Fropenem		106560-14-9				
frovatriptan	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)- [CAS]	158747-02-5	WO	9922730	Antimigraine	Migraine
Fructose		57-48-7				
Fructose-1,6-diphosphate		488-69-7				
FTC	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- (4R)				Antiviral, anti-HIV	Infection, HIV/AIDS
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-,hydrochloride [CAS]	162359-56-0	WO	9408943	Immunosuppressant	Transplant rejection, general
fudosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US	5047428	Antitussive	Cough
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7Alpha,17ß)- [CAS]	129453-61-8	EP	346014	Anticancer, hormonal	Cancer, breast
fumagiline	2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-[3Alpha,4Alpha(2R*,3R*),5ß,6ß(all-E)]]- [CAS]	23110-15-8			Protozoacide	Infection, GI tract

NPC-UNIV-000004643

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 265 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Fumagillin		23110-15-8				
Furaltadone		139-91-3				
Furazabol		1239-29-8				
Furazolidone		67-45-8				
Furazolium Chloride		5118-17-2				
Furonazide		3460-67-1				
furosemide	Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- [CAS]	54-31-9			Formulation, modified-release, other	Hypertension, general
Fursultiamine		804-30-8				
Furtrethonium		7618-86-2				
Fusidic Acid		06/03/6990				
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene				Antifungal	Infection, gynaecological
G25			WO	9804252	Antimalarial	Infection, malaria
GABA-A Alpha5 inverse agonist,Mer			WO	0206285	Cognition enhancer	Alzheimer's disease
gabapentin	Cyclohexaneacetic acid, 1-(aminomethyl)- [CAS]	60142-96-3	US	4152326	Antiepileptic	Epilepsy, general
gabexate	Benzoic acid, 4-[[6-[(aminoiminomethyl)amino]-1-oxohexyl]oxy]-, ethyl ester, monomethanesulfonate [CAS]	39492-01-8 56974-61-9	US	3751447	GI inflammatory/bowel disorders	Pancreatitis
gaboxadol	Isoxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro- [CAS]	64603-91-4	CA	1125288	Hypnotic/Sedative	Sleep disorder, general
Gadobenat Dimeglumine		127000-20-8				
Gadobutrol		138071-82-6				
Gadodiamide		131410-48-5				
Gadopentetic Acid		80529-93-7				
Gadoteridol		120066-54-8				
Gadoversetamide		131069-91-5				
Gadoxetic Acid		135326-11-3				

NPC-UNIV-000004644

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 266 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
galantamine	(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-benzofuro[3a,3,2-e,f][2]benzazepine				Formulation, modified-release, other	Alzheimer's disease
Galanthamine		357-70-0				
galarubicin	ß-Alanine, 2-[4-[(2,6-dideoxy-2-fluoro-Alpha-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester, [CAS]	140637-82-7 140637-86-1	EP	424899	Anticancer, antibiotic	Cancer, breast
Gallamine Triethiodide		65-29-2				
Gallic Acid		149-91-7				
gallium maltolate	4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex				Anticancer, other	Cancer, myeloma
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US	4529593	Osteoporosis treatment	Hypercalcaemia of malignancy
gallopamil	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4,5-trimethoxy-Alpha-(1-methylethyl)-[CAS]	16662-47-8	GB	1367677	Antianginal	Angina, general
γ-Aminobutyric Acid		56-12-2				
Ganaxolone		38398-32-2				
ganciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-[CAS]	107910-75-8 82410-32-0	EP	49072	Antiviral, other	Infection, cytomegalovirus
ganirelix	[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala]GnRH- [CAS]	124904-93-4	EP	312052	Releasing hormones	Infertility, female
ganstigmine	Carbamic acid, (2-ethylphenyl)-, (3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester,	223585-99-7	EP	1023297	Cognition enhancer	Alzheimer's disease

NPC-UNIV-000004645

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 267 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
gantofiban	1-Piperazineacetic acid, 4-[[(5R)-3-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethylester [CAS]	183547-57-1	EP	741133	Antithrombotic	Thrombosis, general
garenoxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl)-1,4-dihydro-4-oxo-, monomethanesulfonate [CAS]	223652-82-2			Quinolone antibacterial	Infection, respiratory tract, lower
garnocestim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1			Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, neutropenia
gatifloxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)- [CAS]	112811-59-3	EP	230295	Quinolone antibacterial	Infection, respiratory tract, general
Gefarnate		51-77-4				
gefitinib	4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy) [CAS]	184475-35-2	WO	9633980	Anticancer, other	Cancer, lung, non-small cell
gemcabene	6,6'-oxybis(2,2-dimethylhexanoate)	209789-08-2			Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
gemcitabine	Cytidine, 2'-deoxy-2', 2'-difluoro-, [CAS]	122111-03-9 95058-81-4	GB	2136425	Anticancer, antimetabolite	Cancer, pancreatic
gemeprost	Prosta-2,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-,methyl ester, (2E,11Alpha,13E,15R)- [CAS]	64318-79-2	GB	1540427	Prostaglandin	
gemfibrozil	Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- [CAS]	25812-30-0	US	3674836	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
gemifloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- [CAS]	175463-14-6	US	5869670	Quinolone antibacterial	Infection, respiratory tract, general
gentamicin	Gentamicin [CAS]	1403-66-3			Formulation, implant	Infection, general
Gentian Violet		548-62-9				
Gentiopicrin		20831-76-9				

NPC-UNIV-000004646

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 268 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Gentisic Acid		490-79-9				
Gepefrine		18840-47-6				
gepirone	2,6-Piperidinedione, 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- [CAS]				Formulation, modified-release, other	Depression, general
gestodene	18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	109852-02-0 60282-87-3	GB	1569135	Formulation, fixed-dose combinations	Contraceptive, female
gestodene + ethinylest	18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha) mixt with 19-Norpregna-1,3,5(10)-trien-20-yne-13,17-diol (17Alpha)				Formulation, modified-release, >24hr	Contraceptive, female
Gestonorone Caproate		1253-28-7				
Gestrinone		16320-04-0				
γ-Hydroxybutyrate		591-81-1				
gimatecan	(4S)-11-[(E)-[(1,1-dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione	292618-32-7			Anticancer, other	Cancer, brain
Giractide		24870-04-0				
Gitoxin		4562-36-1				
GL-406349	N,N'-Bis[2-[N-[2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbamoyl]1H-indol-6-yl]-1H-indole-2,5-dicarboxamide				Antifungal	Infection, fungal, general
Glafenine		3820-67-5				
glatiramer	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, [CAS]	147245-92-9 28704-27-0	WO	5800808	Multiple sclerosis treatment	Multiple sclerosis, relapsing-remitting
Glibornuride		26944-48-9				
gliclazide	Benzenesulfonamide, N-[[(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB	1153982	Antidiabetic	Diabetes, Type II

NPC-UNIV-000004647

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 269 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
glimepiride	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- [CAS]	93479-97-1	WO	9303724	Antidiabetic	Diabetes, Type II
γ-Linolenic Acid		506-26-3				
glipizide	Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	29094-61-9	US	3669966	Antidiabetic	
gliquidone	Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolinyl)ethyl]- [CAS]	33342-05-1	GB	1277847	Antidiabetic	Diabetes, general
glisolamide	3-Isoxazolecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	24477-37-0			Antidiabetic	Diabetes, general
Glisoxepid		25046-79-1				
Glucametacin		52443-21-7				
Glucoheptonic Acid		87-74-1				
Gluconic Acid		526-95-4				
glucosamine	D-Glucose, 2-amino-2-deoxy-, [CAS]	29031-19-4 3416-24-8	DE	1953689	Antiarthritic, other	Arthritis, osteo
Glucosulfone		554-18-7				
glufosfamide	ß-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate)- [CAS]	132682-98-5	DE	3835772	Anticancer, alkylating	Cancer, general
Glutamic Acid		56-86-0				
Glutaraldehyde		111-30-8				
Glutethimide		77-21-4				
Glyburide		10238-21-8				
Glybuthiazol(e)		535-65-9				
Glybuzole		1492-02-0				
Glycerol		56-81-5				
Glycocyamine		352-97-6				
Glycol Salicylate		87-28-5				
Glyconiazide		3691-74-5				

NPC-UNIV-000004648

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 270 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Glycopyrrolate		596-51-0				
Glyhexamide		451-71-8				
Glymidine		339-44-6				
Glypinamide		1228-19-9				
GMDP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide				Anti-infective, other	Infection, general
Gold Sodium Thi malat		12244-57-4				
Gold Sodium Thiosulfate		10233-88-2				
goserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide-, 2-(aminocarbonyl)hydrazide [CAS]	65807-02-5	US	4100274	Releasing hormones	Cancer, prostate
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester [CAS]	186452-09-5			Antiparkinsonian	Parkinson's disease
GPI-5693	2-(Phosphonomethyl)pentanedioic acid		US	5672592	Analgesic, other	Pain, neuropathic
Graftskin						
granisetron	1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo- [CAS]	107007-99-8 109889-09-0	EP	200444	Antiemetic	Chemotherapy-induced nausea and vomiting
Grepafloxacin		119914-60-2				
griseofulvin	Spiro[benzofuran-2(3H),1'-[2]cyclohexane]-3,4'-dione, 7-chloro-2',4,6-trimeth-oxy-6'methyl-, (1'S-trans)- [CAS]	126-07-8			Formulation, dermal, topical	Infection, dermatological
Guaiacol		90-05-1				
Guaiapate		852-42-6				
Guaiazul ne		489-84-9				
Guaifenesin		93-14-1				
guaimesal	4H-1,3-Benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB	2098201	Anti-inflammatory	
Guamecycline		16545-11-2				

NPC-UNIV-000004649

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 271 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Guanabenz		5051-62-7				
Guanadrel		40580-59-4				
Guanethidine		55-65-2				
Guanfacine		29110-47-2				
Guanoxabenz		24047-25-4				
Guanoxan		2165-19-7				
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP	447706	Hypolipaemic/Antiatherosclerosis	
Gusperimus		104317-84-2				
GW-280430A	(Z)-2-Chlorofumaric acid 1-[3-[-[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl]				Muscle relaxant	Anaesthesia, adjunct
GW-320659	[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol				Anorectic/Antiobesity	Obesity
GYKI-16084	(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyridazinone hydrochloride		US	6194411	Prostate disorders	Benign prostatic hyperplasia
Hachimycin		1394-02-1				
Halazepam		23092-17-3				
Halcinonide		3093-35-4				
halobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11ß,16ß)- [CAS]	66852-54-8	US	4619921	Antipsoriasis	Psoriasis
halofantrine	9-Phenanthrenemethanol, 1,3-dichloro-Alpha-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP	138374	Antimalarial	Infection, malaria
halometasone	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11ß,16Alpha)- [CAS]	50629-82-8	US	4076737	Antipruritic/inflamm, allergic	
Haloperidol		52-86-8				
Halopredone		57781-14-3				

NPC-UNIV-000004650

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 272 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Haloprogin		777-11-7				
Halopropane		679-84-5				
Halothane		151-67-7				
Haloxazolam		59128-97-1				
harkoseride	2(R)-Acetamido-N-benzyl-3-methoxypropionamide		WO	9733861	Antiepileptic	Epilepsy, general
HE-2000	16Alpha-Bromo-3ß-hydroxy-5Alpha-androstane-17-one				Antiviral, anti-HIV	Infection, HIV/AIDS
Healos			WO	9714376	Musculoskeletal	Regeneration, bone
H matoporphyrin		14459-29-1				
Hepronicate		7237-81-2				
Heptabarbital		509-86-4				
Heptaminol		372-66-7				
Hetacillin		3511-16-8				
Hetastarch		9004-62-0				
Hexachlorophene		70-30-4				
Hexadimethrine Bromide		28728-55-4				
Hexafluorenium Bromide		317-52-2				
Hexamethonium		60-26-4				
Hexamidine		3811-75-4				
Hexapropymate		358-52-1				
Hexedine		5980-31-4				
Hexestrol		84-16-2				
Hexestrol Bis(β-di thylaminoethyl ether)		2691-45-4				
Hexethal		144-00-3				
Hexetidine		141-94-6				
Hexobarbital		56-29-1				

NPC-UNIV-000004651

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 273 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Hexobendine		54-03-5				
H xocyclium Methyl Sulfate		115-63-9				
Hexoprenaline		3215-70-1				
Hextend	Hextend [CAS]	235746-51-7	US	5407428	Plasma substitute	Surgery adjunct
Hexylcaine		532-76-3				
HF-0299	11b-hydroxy androstenedione				Osteoporosis treatment	Osteoporosis
HGP-2	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.13,7]dec-1-ylethyl ester, (2Z)-2-butenedioate (1:1) (salt) [CAS]	121009-31-2			Antiglaucoma	Glaucoma
HGP-6^	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5			Antiepileptic	Epilepsy, general
hidrosmin	Hydrosmin- [CAS]	120250-44-4			Vasoprotective, systemic	
histamine	histamine	51-45-6	EP	0493468	Anticancer, immunological	Cancer, melanoma
Histapyrrodine		493-80-1				
histrelin	Luteinizing hormone-releasing factor (pig), 6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	76712-82-8	EP	217659	Releasing hormones	Precocious puberty
HM-101	HM 101 [CAS]	217311-70-1			Osteoporosis treatment	Osteoporosis
HMN-214	(E)-4-[2-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenyl]pyridine-1-oxide				Anticancer, other	Cancer, general
Homatropine		87-00-3				
Homocamfin		535-86-4				
Homochlorcyclizine		848-53-3				
Hopantenic Acid		18679-90-8				
HP-228	Glycinamide, N-acetyl-L-norleucyl-L-glutaminyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl- [CAS]	172617-89-9	EP	759770	Analgesic, other	Pain, post-operative

NPC-UNIV-000004652

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 274 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Huperzine A		102518-79-6				
hyaluronan	Hyaluronic acid [CAS]	9004-61-9			Formulation, other	Restenosis
Hycanthone		3105-97-3				
Hydnocarpic Acid		459-67-6				
Hydralazine		86-54-4				
Hydrastine		118-08-1				
Hydrastinine		6592-85-4				
Hydrochlorothiazide		58-93-5				
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-,(5Alpha)- [CAS]	466-99-9 125-29-1			Formulation, modified-release, other	Pain, general
Hydrocortamate		76-47-1				
hydrocortisone	Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11ß)-[CAS]	74050-20-7 50-23-7	DE	2826257	Dermatological	Unspecified
hydrocortisone butyrate propio	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11ß)-[CAS]	72590-77-3	DE	2910899	Antipruritic/inflamm, allergic	
Hydroflumethiazide		135-09-1				
hydromorphone	Morphinan-6-one,4,5-epoxy-3-hydroxy-17-methyl-,(5Alpha)-, mixt with acetamide, N-(4-hydroxyphenyl)-, mixt with morphinan-6-one,17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-	103-90-2 16590-41-3 466-99-9			Formulation, fixed-dose combinations	Pain, general
Hydroquinidine		1435-55-8				
Hydroquinine		522-66-7				
Hydroquinone		123-31-9				
Hydroxocobalamin		13422-51-0				
Hydroxyamphetamine		1518-86-1				
Hydroxychloroquine		118-42-3				
Hydroxydione		53-10-1				
Hydroxypethidine		468-56-4				
Hydroxyphenamate		50-19-1				

NPC-UNIV-000004653

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 275 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Hydroxypropyl Cellulose		9004-64-2				
Hydroxystilbamidine		495-99-8				
Hydroxytetracaine		490-98-2				
Hydroxyzine		68-88-2				
Hylan G-F 20						
Hymecromone		90-33-5				
hyoscyamine	benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo],	101-31-5			Formulation, oral, orally-disintegrating	Ulcer, GI, general
hypericin	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9			Anticancer, other	Cancer, brain
IACFT		180468-34-2				
ibandronic acid	Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene] bis- [CAS]	114084-78-5	EP	252504	Osteoporosis treatment	Hypercalcaemia of malignancy
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB	1551661	Cardiostimulant	Heart failure
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1			Formulation, mucosal, topical	Surgery adjunct
Ibritumomab Tiuxetan		206181-63-7				
ibrolipim	Phosphonic acid, [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl].-, diethyl ester [CAS]	133208-93-2	EP	402033	Hypolipaemic/Antiatherosclerosis	Hypertriglyceridaemia
ibudilast	1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]- [CAS]	50847-11-5	EP	215438	Antiasthma	Asthma
Ibufenac		1553-60-2				
ibuprofen piconol	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester [CAS]	64622-45-3	DE	2658610	Antipruritic/inflamm, non-allergic	Eczema, contact

NPC-UNIV-000004654

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 276 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15687-27-1			Formulation, modified-release, other	Inflammation, general
Ibuproxam		53648-05-8				
ibutilide	Methanesulfonamide, N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (+/-)-, [CAS]	122647-31-8 122647-32-9	JP	60239458	Antiarrhythmic	Fibrillation, atrial
ICA-17043			US	6288122	Antisickling	Anaemia, sickle cell
icodextrin	Dextrin- [CAS]	9004-53-9			Urological	Renal failure
idarubicin	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4	US	4471052	Anticancer, antibiotic	Cancer, leukaemia, acute lymphocytic
Idazoxan		79944-58-4				
IdB-1016	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134499-06-2	EP	209038	Anticancer, hormonal	Cancer, ovarian
idebenone	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- [CAS]	58186-27-9	EP	58057	Neuroprotective	Ischaemia, cerebral
IDN-5109	4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methano-13aH-oxeto [2",3",5',6'] benzo[1,2:4,5] cyclodeca [1,2-d] dioxyl-4-yl ester, 2R,3S) [CAS}	186348-05-0	US	5264591	Anticancer, other	Cancer, colorectal
Idoxifen		116057-75-1				

NPC-UNIV-000004655

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 277 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
idraparinux	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-ß-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl-(1-4)-, tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU	698456	Antithrombotic	Thrombosis, venous
idrocilamide	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US	3659014	Anti-inflammatory, topical	
ifenprodil	(7)-2-(4-benzyl piperidino)-1-p-hydroxyphenylpropanol tartrate	23210-58-4 23210-56-2	US	3509164	Neuroprotective	
ifosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-,2-oxide [CAS]	3778-73-2	US	3732340	Anticancer, alkylating	Cancer, lung, general
iguratimod	N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE	3834204	Antiarthritic, other	Arthritis, rheumatoid
ilaprazole	1H-Benzimidazole, 2-(((4-methoxy-3-methyl-2-pyridinyl) methyl)sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US	5703097	Antiulcer	Ulcer, GI, general
ilomastat	Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))- [CAS]	142880-36-2	US	5892112	COPD treatment	Emphysema, smoking-related
iloperidone	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- [CAS]	133454-47-4	US	5776963	Neuroleptic	Schizophrenia
iloprost trometamol	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]- [CAS]	78919-13-8	DE	3417638	Prostaglandin	Peripheral vascular disease
ILX23-7553	1Alpha,25-Hydroxy-16-yne vitamin D3				Anticancer, other	Cancer, general

NPC-UNIV-000004656

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 278 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
imatinib	4-((Methyl-1-piperazinyl)methyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate	152459-95-5	US	5521184	Anticancer, other	Cancer, leukaemia, chronic myelogenous
imidapril	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3[R*(R*)],4R*]]- [CAS]	89371-37-9 89396-94-1	EP	95163	Antihypertensive, renin system, Musculoskeletal	Hypertension, general, Cachexia
imidazole salicylate	Benzoic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36364-49-5	US	4329340	Anti-inflammatory	Pain, general
imipenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, [5R-[5Alpha,6Alpha(R*)]]- [CAS]	64221-86-9 74431-23-5 81129-83-1	GB	1570990	Beta-lactam antibiotic	Infection, general
Imipramine		50-49-7				
Imipramine N-Oxide		6829-98-7				
imiquimod	1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6	EP	145340	Antiviral, other	Infection, human papilloma virus
Imolamine		318-23-0				
implitapide	Benzeneacetamide, Alpha-cyclopentyl-4-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-yl)methyl)-N-((1R)-2-hydroxy-1-phenylethyl)- (AlphaS)- [CAS]	177469-96-4	EP	705831	Hypolipaemic/Antiatherosclerosis	Atherosclerosis
Improsulfan		13425-98-4				
Inaperisone		99323-21-4				
incadronate	Phosphonic acid, [(cycloheptylamino)methylene]bis-, [CAS]	138330-18-4			Musculoskeletal	Hypercalcaemia of malignancy
Incadronic Acid		124351-85-5				
Indalpine		63758-79-2				
Indanazoline		40507-78-6				
indapamide	4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB	1203691	Antihypertensive, diuretic	Hypertension, general
Indecainid		74517-78-5				

NPC-UNIV-000004657

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 279 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
indeloxazine	Morpholine, 2-[(1H-inden-7-yloxy)methyl]- [CAS]	60929-23-9 65043-22-3	JP	52083773	Cognition enhancer	Alzheimer's disease
Indeloxazine		65043-22-3				
indenolol	2-Propanol, 1-[1H-inden-4(or 7)-yloxy]-3-[(1-methylethyl)amino]- [CAS]	30190-87-5 60607-68-3 68906-88-7	GB	1290343	Antihypertensive, adrenergic	
indinavir	D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R*),2Alpha]]-, [CAS]	150378-17-9 157810-81-6	EP	0541168	Antiviral, anti-HIV	Infection, HIV/AIDS
indiplon	Acetamide, N-methyl-N-(3-(3-(2-thienylcarbonyl)pyrazolo(1,5-a) pyrimidin-7-yl)phenyl)- [CAS]	325715-02-4	US	6399621	Hypnotic/Sedative	Insomnia
indisetron	1H-Indazole-3-carboxamide, N-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, diendo- [CAS]	160472-97-9			Antiemetic	Nausea and vomiting, general
indisulam	1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]	165668-41-7			Anticancer, other	Cancer, lung, non-small cell
Indobufen		63610-08-2				
Indocyanine Green		3599-32-4				
indometacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-86-1			Formulation, modified-release, other	Inflammation, general
Indoprofen		31842-01-0				
indoramin	Benzamide, N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]- [CAS]	26844-12-2 38821-52-2	GB	1218570	Antihypertensive, adrenergic	
Inducterm			US	5993810	Labour inducer	Labour, induction
Infliximab		170277-31-3				
Inosine Pranobex		36703-88-5				
Inositol		87-89-8				
Inositol Niacinate		6556112				
Iobenguane		80663-95-2				
Iobenzamic Acid		3115057				

NPC-UNIV-000004658

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 280 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Iobitridol		136949-58-1			
Iocarmic Acid		10397-75-8			
Iocetamic Acid		16034-77-8			
Iodamide		440-58-4			
Iodine	Iodine [CAS]	7553-56-2		Formulation, oral, other	Fibrocystic breast disorder
Iodipamide		606-17-7			
Iodixanol		92339-11-2			
Iodoalphionic Acid		577-91-3			
Iodochlorhydroxyquin	5-Chloro-7-iodo-8-quinolinol	130-26-7		Cognition enhancer	Alzheimer's disease
Iodoform		75-47-8			
Iodopyracet		300-37-8			
Iodopyrrole		87-58-1			
Iodoquinol		83-73-8			
Iofetamine ^{123}I		75917-92-9			
Ioglycamic Acid		2618-25-9			
Iohexol		66108-95-0			
Iomeglamic Acid		25827-76-3			
Iomeprol		78649-41-9			
Iopamidol		60166-93-0			
Iopanoic Acid		96-83-3			
Iopentol		89797-00-2			
Iophendylate		99-79-6			
Iophenoxic Acid		96-84-4			
Iopromide		73334-07-3			
Iopronic Acid		41473-08-9			
Iopydol		5579-92-0			
Iopydone		5579-93-1			
Iothalamic Acid		2276-90-6			
Iotrolan		79770-24-4			
Ioversol		87771-40-2			
Ioxaglic Acid		59017-64-0			

NPC-UNIV-000004659

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 281 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
loxilan		107793-72-6				
IP-751	(3R,4R)-(delta6)-THC-DMH-11-oic acid		WO	9401429	Analgesic, other	Pain, neuropathic
lpidacrine		62732-44-9				
IPL-576092	Stigmastan-15-one, 22,29-epoxy-3,4,6,7,29-pentahydroxy-, (3Alpha,4ß,5Alpha,6Alpha,7ß,14ß,22S)- [CAS]	137571-30-3	US	6046185	Antiasthma	Asthma
lpodate		5587-89-3				
ipratropium bromide		66985-17-9 22254-24-6			Formulation, inhalable, solution	Chronic obstructive pulmonary disease
ipratropium	(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane				Formulation, inhalable, topical	Asthma
iprazochrome	Hydrazinecarboxamide, 2-[1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene]- [CAS]	7248-21-7			Haemostatic	
ipriflavone	4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP	214647	Osteoporosis treatment	Osteoporosis
lprindole		5560-72-5				
lproclozid		3544-35-2				
lproniazid		54-92-2				
lpsapiron		95847-70-4				
irbesartan	2-n-butyl-4-spirocyclopentane-1-[((2'-tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one	138402-11-6	WO	9114679	Antihypertensive, renin system	Hypertension, general
IRFI-042	Butanedioic acid, mono[2-[2-(acetylthio)ethyl]-2,3-dihydro-4,6,7-trimethyl-5-benzofuranyl] ester, (+/-)- [CAS]	134867-62-2	US	5114966	Cardiovascular	Atherosclerosis
IRFI-165	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine	191349-26-5	EP	865442	Antidepressant	Depression, general
Iridomyrmecin		485-43-8				

NPC-UNIV-000004660

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 282 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
irindalone	-Imidazolidinone, 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazinyl]ethyl]-, (1R-trans)- [CAS]	104113-57-7 96478-43-2	EP	183349	Antidepressant	Depression, general
Irinotecan		97682-44-5				
irofulven	Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	125392-76-9	US	5563176	Anticancer, other	Cancer, prostate
Iron Sorbitex		1338-16-5				
irsogladine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- [CAS]	57381-26-7 57381-28-9 57381-33-6	US	4657907	Antihypertensive, diuretic	Hypertension, general
IS-741	Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]- [CAS]	141283-87-6	EP	465913	GI inflammatory/bowel disorders	Pancreatitis
isaglitazone	2,4-Thiazolidinedione, 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-[CAS]	161600-01-7	US	5594016	Antidiabetic	Diabetes, Type II
ISAtx-247			NZ	502362	Immunosuppressant	Transplant rejection, general
Isbogrel		89667-40-3				
isepamicin	D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-ß-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7	US	4029882	Aminoglycoside antibiotic	Infection, dermatological
Isoaminile		77-51-0				
Isobutyl p-Aminobenzoate		94-14-4				
Isocarboxazid		59-63-2				
isoconazole	1-[2-(2-6-dichlorobenzyloxy)-2-(2-,4-dichlorophenyl)ethyl]	24168-96-5 27523-40-6	GB	1244530	Antifungal	Infection, fungal, general
Isoetharine		530-08-5				

NPC-UNIV-000004661

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 283 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
isofloxythepin	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methylethyl)dibenzo[b,f]thiepin-10-yl]- [CAS]	106819-39-0 106819-41-4 70931-18-9	GB	2010843	Neuroleptic	
isoflurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US	3535388	Anaesthetic, inhalation	Anaesthesia
Isoflurophate		55-91-4				
Isoladol		530-34-7				
Isomethadone		466-40-0				
Isometheptene		503-01-5				
Isoniazid		54-85-3				
Isonixin		57021-61-1				
Isopromethazine		303-14-0				
Isopropamide Iodide		71-81-8				
Isopropyl Alcohol		67-63-0				
isopropyl unoprostone	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-, 1-methylethylester, (1R-(1Alpha(Z), 2ß,3Alpha,5Alpha))- [CAS]	120373-24-2	EP	289349	Prostaglandin	Glaucoma
Isoproterenol		7683-59-2				
Isosorbide		652-67-5				
isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2			Formulation, modified-release, other	Angina, general
isosorbide mononitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	16051-77-7			Formulation, modified-release, other	Angina, general
Isothipendyl		482-15-5				
isotretinoin	Retinoic acid, 13-cis- [CAS]	4759-48-2	US	4843096	Antiacne	Acne
Isovaleryl Diethylamide		533-32-4				
Isoxepac		55453-87-7				
Isoxicam		34552-84-6				
Isoxsuprine		395-28-8				

NPC-UNIV-000004662

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 284 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
isradipine	3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester [CAS]	75695-93-1	GB	2037766	Antihypertensive, other	Hypertension, general
israpafant	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]	117279-73-9	EP	268242	Antiasthma	Asthma
ISV-403			US	5447926	Formulation, mucosal, topical	Conjunctivitis
Itasetron		123258-84-4				
ITF-282	ITF 282 [CAS]	93615-44-2	GB	2115821	Antianaemic	Anaemia, general
itopride	Benzamide, N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-, monohydrochloride [CAS]	122892-31-3	EP	306827	Gastroprokinetic	Gastritis
itraconazole	3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	EP	6711	Antifungal	Infection, fungal, general
Itramin		13445-63-1				
itriglumide	1-Naphthalenepropanoic acid, ß-[2-[[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenyl]amino]-2-oxoethyl]-, (ßR)-[CAS]	201605-51-8	WO	9800404	Anxiolytic	Anxiety, general
iturelix	D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	WO	8901944	Fertility enhancer	Infertility, female
ivabradine	7,8-dimethoxy-3-(3-[[(1S)(4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one				Antianginal	Angina, general

NPC-UNIV-000004663

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 285 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ixabepilone	17-Oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl, (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1			Anticancer, other	Cancer, breast
J-104132	5H-Cyclopenta[b]pyridine-6-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	WO	9737665	Antihypertensive, other	Heart failure
J-107088	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12-ß-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino- [CAS]	174402-32-5			Anticancer, other	Cancer, bladder
J-113397	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one				Analgesic, other	Pain, general
Janex-1	Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-[CAS]	202475-60-3			Anticancer, other	Cancer, leukaemia, general
josamycin	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP	41021759	Macrolide antibiotic	Infection, general
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6	WO	9212148	Cardiovascular	Infarction, myocardial
K-777			US	6287840	Protozoacide	Infection, trypanosomiasis, American
Kainic Acid		487-79-6				
Kalimate	Kalimate- [CAS]	92354-70-6			Urological	
Kallidin		342-10-9				
KB-130015	Acetic acid (2,6-diiodo-4-((2-methyl-3-benzofuranyl)methyl)phenoxy)- [CAS]	147030-48-6			Antiarrhythmic	Arrhythmia, general

NPC-UNIV-000004664

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 286 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
KCB-328	Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]	177596-55-3	WO	9604231	Antiarrhythmic	Arrhythmia, general
Kebuzone		853-34-9				
ketamine	2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride	6740-88-1			Formulation, transmucosal, nasal	Pain, post-operative
ketanserin	2,4(1H,3H)-Quinazolinedione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-[CAS]	74050-98-9 83846-83-7	EP	13612	Antihypertensive, other	Hypertension, general
ketazolam	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4	GB	1222294	Anxiolytic	
Kethoxal		27762-78-3				
Ketobemidone		469-79-4				
ketoconazole	Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- [CAS]	65277-42-1	US	4335125	Antifungal	Infection, fungal, general
ketoprofen	mono(3-benzoyl-Alpha-methylbenzeneacetate) [CAS]	173011-11-5	EP	502502	Formulation, transdermal, systemic	Pain, general
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+/-)- [CAS]	74103-06-3 74103-07-4	EP	53021	Analgesic, NSAID	
Ketorolac Tromethamine						
ketotifen	10-H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1) [CAS]	34580-13-7 34580-14-8	GB	1355539	Antiasthma	Asthma
Khellin		82-02-0				
kinetin		9001-29-0			Dermatological	Photodamage

NPC-UNIV-000004665

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 287 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
KNI-272	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, [4R-[3[2S*,3S*(R*)],4R*]]- [CAS]	147318-81-8	US	5644028	Antiviral, anti-HIV	Infection, HIV/AIDS
KP-103	(R,R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol				Antifungal	Infection, general
KP-157			US	6110961	Antidepressant	Depression, general
KP-544			WO	9919305	Cognition enhancer	Unspecified
KRN-5500	L-glycero-ß-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H-purin-6-yl- [CAS]	151276-95-8	WO	9015811	Anticancer, antibiotic	Cancer, colorectal
KT-136	Alpha-D-Glucopyranoside, ß-D-fructofuranosyl, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer compd. with iodine [CAS]	121602-88-8			Formulation, dermal, topical	Ulcer, decubitus
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[[(2R)-2-hydroxy-2-(4-hydroxphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate				Urological	Urinary calculus
KW-2170	6H-Pyrazolo[4,5,1-de]acridin-6-one,5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, dihydrochloride [CAS]	207862-44-0			Anticancer, alkylating	Cancer, lung, non-small cell
KW-6002	1H-Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl- (E)- [CAS]	155270-99-8			Antiparkinsonian	Parkinson's disease
KW-7158	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrothieno[3,2-C][1] benzothiepin-9-yl)propanamide 5,5 dioxide				Urological	Incontinence

NPC-UNIV-000004666

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 288 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
L-365260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)- [CAS]	118101-09-0	EP	284256	Anticancer, other	Cancer, general
L-5-hydroxytryptophan	L-Tryptophan, 5-hydroxy- [CAS]	4350-09-8			Metabolic and enzyme disorders	Unspecified
L-745337	Methanesulfonamide, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]- [CAS]	158205-05-1	WO	9413635	Analgesic, NSAID	Pain, general
L-758298	Phosphonic acid, [3-[[(2R,3S)-2-.(.(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- [CAS]	172673-20-0	WO	9523798	Antiemetic	Chemotherapy-induced nausea and vomiting
L-826141			WO	9722585	Antiasthma	Unspecified
labetalol	5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide HCl	32780-64-6 36894-69-6	US	4012444	Antihypertensive, adrenergic	
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E) [CAS]	103890-78-4	GB	2164336	Antihypertensive, other	Hypertension, general
Lactic Acid						
lactitol	D-Glucitol, 4-O-ß-D-galactopyranosyl- [CAS]	585-86-4			Hepatoprotective	Infection, neurological
Lactulose		4618-18-2				
lafutidine	Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-butenyl]-, (Z)- [CAS]	118288-08-7 169899-19-8	EP	282077	Antiulcer	Ulcer, gastric
Lamifiban		144412-49-7				
lamivudine	2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R-cis)- [CAS]	134678-17-4	EP	513917	Antiviral, anti-HIV	Infection, HIV/AIDS
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- [CAS]	84057-84-1	EP	21121	Antiepileptic	Epilepsy, partial (focal, local)

NPC-UNIV-000004667

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 289 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
landiolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, [S-(R*,R*)]- HCL	133242-30-5	EP	397031	Antiarrhythmic	Tachycardia, general
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	153322-05-5			Neurological	Unspecified
laniquidar	Methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate	197509-46-9	WO	9734897	Radio/chemosensitizer	Cancer, general
lanoconazole	1H-Imidazole-1-acetonitrile, Alpha-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)-(±)- [CAS]	101530-10-3	US	4738976	Antifungal	Infection, fungal, general
Lanoteplase		171870-23-8				
Lanreotide		108736-35-2				
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-[CAS]	103577-45-3	EP	174726	Antiulcer	Ulcer, duodenal
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2)[CAS]	587-26-8	US	5968976	Urological	Hyperphosphataemia
lapatinib	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl]-6-[5-[[[2-[methylsulfonyl]ethyl]amino]methyl]furan-2-yl]	388082-78-8			Anticancer, other	Cancer, breast
laquinimod		248281-84-7			Multiple sclerosis treatment	Multiple sclerosis, general
lasofoxifene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl-(5R-cis)-, (S-(R*, R*))-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO	9716434	Menopausal disorders	Hormone replacement therapy

NPC-UNIV-000004668

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 290 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB	1547351	Beta-lactam antibiotic	Infection, general
latanoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1Alpha(Z),2ß(R*),3Alpha,5Alpha))- [CAS]	130209-82-4	WO	9002553	Prostaglandin	Glaucoma
Lauroguadine		135-43-3				
Laurolinium Acetate		146-37-2				
Lawsone		83-72-7				
LAX-111	1-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenoyloxy)-propane				Neuroleptic	Schizophrenia
Lazabemide		103878-84-8				
LB-30057	Benzenecarboximidic acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide [CAS]		WO	9749673	Antithrombotic	Thrombosis, venous
L-Cystine						
Lefetamine		7262-75-1				
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP	13376	Antiarthritic, immunological	Arthritis, rheumatoid
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	104981-93-3 75706-12-6	US	5610173	Anticancer, other	Cancer, ovarian
Leiopyrrole		5633-16-9				
lenampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S-[2Alpha,5Alpha,6ß(S*)]]- [CAS]	80734-02-7 86273-18-9	EP	61206	Penicillin, oral	Infection, general
lentinan	Lentinan [CAS]	37339-90-5			Anticancer, immunological	Cancer, stomach

NPC-UNIV-000004669

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 291 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Lepirudin						
lercanidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester-, hydrochloride [CAS]	100427-26-7 132866-11-6	US	4705797	Antihypertensive, other	Hypertension, general
lerisetron	1H-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	143257-98-1	US	5256665	Antiemetic	Nausea and vomiting, general
Lesopitron		132449-46-8				
leteprinim	Benzoic acid, 4-((3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)-, monopotassium salt [CAS]	138117-50-7	US	6338963	Antiparkinsonian	Parkinson's disease
letosteine	4-Thiazolidinecarboxylic acid, 2-[2-[(2-ethoxy-2-oxoethyl)thio]ethyl]- [CAS]	53943-88-7	US	4032534	COPD treatment	Bronchitis, chronic
letrozole	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- [CAS]	112809-51-5	EP	236940	Anticancer, hormonal	Cancer, breast
Leucocyanidin		480-17-1				
Leuprolide		53714-56-0				
leuprolide acetate	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, monoacetate (salt) [CAS]	53714-56-0 74381-53-6			Formulation, implant	Cancer, prostate
leuprorelin	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	53714-56-0			Formulation, implant	Cancer, prostate
Levallorphan		152-02-3				
levamisole	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	14769-73-4 16595-80-5	US	4584305	Anthelmintic	Infection, helminth, general
Levcromakalim		94535-50-9				
levetiracetam	1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]	102767-28-2	EP	162036	Antiepileptic	Epilepsy, general
levobetaxolol	2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino) hydrochloride [CAS]	116209-55-3			Formulation, mucosal, topical	Glaucoma

NPC-UNIV-000004670

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 292 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
levobunolol	1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, (S)- [CAS]	27912-14-7 47141-42-4	US	3641152	Formulation, mucosal, topical	Glaucoma
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	WO	9510276	Anaesthetic, injectable	Anaesthesia
levocabastine	4-Piperidinecarboxylic acid, 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, [3S-[1(cis),3Alpha,4ß]]- [CAS]	79449-98-2 79516-68-0 79547-78-7	US	4369184	Antiallergic, non-asthma	Rhinitis, allergic, general
levocetirizine	Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (R)- [CAS]	130018-77-8	WO	9406429	Antiallergic, non-asthma	Allergy, general
Levodopa		59-92-7				
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	99291-25-5	EP	147847	Antitussive	Cough
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	100986-85-4 138199-71-0	EP	206283	Quinolone antibacterial	Infection, respiratory tract, lower
Levomethadyl Acetate		1477-40-3				
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	27058-84-0 5741-22-0 77164-20-6	EP	15418	Antihypertensive, adrenergic	
levonorgestrel	18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	797-63-7			Formulation, implant	Contraceptive, female
Levophacetoperane		24558-01-8				
Levopropoxyphene		2338-37-6				
Levorphanol		77-07-6				
levosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP	383449	Cardiostimulant	Heart failure
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB	2014990	Antiemetic	Dyspepsia

NPC-UNIV-000004671

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 293 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Levothyroxine						
levovirin	1-ß-L-ribofuranosyl-1,2,4-triazole-3-carboxamide				Antiviral, other	Infection, hepatitis-C virus
lexipafant	L-Leucine, N-methyl-N-[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester- [CAS]	139133-26-9	WO	9203423	Neurological	Dementia, AIDS-related
LF-15-0195			WO	9624579	Immunosuppressant	Lupus erythematosus, general
LF-16-0687	2-Pyrrolidinecarboxamide, N-[3-[[4-(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]-, (2S)- [CAS]	209733-45-9	FR	2756562	Neuroprotective	Head trauma
LGD-1550	2,4,6-Octatrienoic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl-, (2E,4E,6E)- [CAS]	178600-20-9			Anticancer, other	Cancer, cervical
LH		9002-67-9				
LH-RH		9034-40-6				
liarozole	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6			Formulation, other	Psoriasis
licofelone	1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl- [CAS]	156897-06-2			Antiarthritic, other	Arthritis, osteo
Licostinel		153504-81-5				
lidadronate	Phosphonic acid, [1-amino-3-(dimethylamino)propylidene]bis- [CAS]	63132-38-7	WO	9702827	Urological	Unspecified
Lidamidine		66871-56-5				
lidocaine	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	137-58-6			Formulation, transdermal, patch	Pain, post-herpetic
Lidofenin		59160-29-1				
Lidoflazine		3416-26-0				
limaprost	Prosta-2,13-dien-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-,(2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	GB	2041368	Prostaglandin	Buerger's syndrome

NPC-UNIV-000004672

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 294 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Lincomycin		154-21-2				
Lindan		58-89-9				
linezolid	Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)- [CAS]	165800-03-3	WO	9507271	Antibiotic, other	Infection, dermatological
Linoleic Acid		60-33-3				
Linolenic Acid		463-40-1				
Liothyronine		6893023				
Lipase		9001-62-1				
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyl)oxy]-, (11ß,16Alpha)- [CAS]	14899-36-6			Formulation, optimized, microemulsion	Arthritis, rheumatoid
lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-, 1-(acetyloxy)ethyl ester [CAS]	91503-79-6	JP	60208910	Formulation, optimized, microemulsion	Pain, cancer
Lipogel HA			EP	525655	Formulation, optimized, liposomes	Unspecified
LiquiVent	perfluorooctylbromide	423-55-2	US	5437272	Lung Surfactant	Respiratory distress syndrome, adult
liranaftate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB	2124617	Antifungal	Infection, dermatological
lisinopril	L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)- [CAS]	76547-98-3 83915-83-7	EP	12401	Antihypertensive, renin system	Hypertension, general
Lisofyllin		100324-81-0				
lisuride	Urea, N'-[(8Alpha)-9,10-didehydro-6-methylergolin-8-yl]-N,N-diethyl-, [CAS]	19875-60-6 305-13-5 18016-80-3			Antiprolactin	Acromegaly
Lithium Citrate		919-16-4				
lithium	Carbonic acid, dilithium salt [CAS]	554-13-2			Formulation, modified-release, <=24hr	Depression, bipolar
lixivaptan	Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS]	168079-32-1	US	5736540	Cardiovascular	Heart failure
LJP-1082			US	6207160	Immunosuppressant	Thrombosis, venous

NPC-UNIV-000004673

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 295 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
LLUAlpha	S-2,7,8-Trimethyl-6-(ß-carboxyethyl)-6-hydroxychroman				Antihypertensive, other	Hypertension, general
LMP-160			US	5643893	Antiasthma	Asthma
LMP-420			US	5643893	Antiarthritic, other	Arthritis, rheumatoid
lobaplatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')[2-hydroxypropanoato(2-)-O1,O2]-, [SP-4-3-(S),(trans)]- [CAS]	135558-11-1	DE	4115559	Anticancer, alkylating	Cancer, lung, small cell
Lobeline		90-69-7				
Lobenzarit		63329-53-3				
lodoxamide	2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxoacetate):2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)	63610-09-3 53882-12-5	US	4439445	Antiasthma	Asthma
Lofentanil		61380-40-3				
lofepramine	Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]- [CAS]	23047-25-8 26786-32-3	GB	1177525	Antidepressant	
lofexidine	1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-80-3	GB	1181356	Antihypertensive, adrenergic	Hypertension, general
Loflucarban		790-69-2				
lomefloxacin	3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-51-7 98079-52-8	EP	140116	Quinolone antibacterial	Infection, respiratory tract, lower
lomerizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, [CAS]	101477-54-7 101477-55-8	EP	159566	Antimigraine	Migraine
lomifylline	7-(5-oxohexyl)theophylline	10226-54-7	DE	2207860	Neurological	
lomustine	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- [CAS]	13010-47-4	JP	48075526	Anticancer, alkylating	
lonafarnib	1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- [CAS]	193275-84-2	US	5874442	Anticancer, other	Cancer, lung, non-small cell

NPC-UNIV-000004674

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 296 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Lonapalene		91431-42-4				
Lonazolac		53808-88-1				
lonidamine	1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- [CAS]	50264-69-2	DE	2310031	Radio/chemosensitizer	Cancer, breast
loperamide	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US	3714159	Antidiarrhoeal	Diarrhoea, general
loperamide oxide	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans- [CAS]	106900-12-3	EP	219898	Antidiarrhoeal	Diarrhoea, general
loprazolam	1H-Imidazo[1,2-a][1,4]benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methylene]-8-nitro- [CAS]	61197-73-7 61197-93-1 70111-54-5	GB	1496426	Hypnotic/Sedative	
Loprinone		106730-54-5				
loracarbef	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7ß(R*)]]- [CAS]	76470-66-1 121961-22-6	EP	14475	Cephalosporin, oral	Infection, respiratory tract, lower
Lorajmine		47562-08-3				
loratadine	1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester- [CAS]	79794-75-5	EP	42544	Antiallergic, non-asthma	Rhinitis, allergic, general
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-	846-49-1			Formulation, oral, orally-disintegrating	Epilepsy, general
lorcainide	Benzeneacetamide, N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-[CAS]	58934-46-6 59729-31-6	DE	2642856	Antiarrhythmic	
lormetazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl- [CAS]	848-75-9	US	3296249	Hypnotic/Sedative	Insomnia

NPC-UNIV-000004675

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 297 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
lornoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS]	70374-39-9	EP	313935	Analgesic, NSAID	Pain, post-operative
losartan	1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, [CAS]	124750-99-8 114798-26-4	EP	253310	Antihypertensive, renin system	Hypertension, general
loteprednol	Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11ß,17Alpha)- [CAS]	82034-46-6	GB	2079755	Anti-inflammatory, topical	Uveitis
Lotrafiban		171049-14-2				
Lovastatin		75330-75-5				
Loxapine		10/02/1977				
loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS]	107097-80-3	WO	8703869	GI inflammatory/bowel disorders	Pancreatitis
loxoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]- [CAS]	68767-14-6 80382-23-6 87828-36-2	EP	55588	Antiarthritic, other	Arthritis, rheumatoid
Lu-35-138	1-[3[[2-[5-chloro-1-(4-fluorophenyl)-3-1H-indolyl]ethyl]methylamino]propyl]-2-imidazolidinone hydrochloride		WO	9516684	Neuroleptic	Psychosis, general
Lubeluzole		144665-07-6				
lubiprostone	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid	136790-76-6			Laxative	Constipation
lucanthone	Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino-4-methyl- [CAS]	479-50-5			Radio/chemosensitizer	Cancer, brain
Lucanthone		548-57-2				
Lumefantrine		82186-77-4				
lumiracoxib	Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- [CAS]	220991-20-8			Analgesic, NSAID	Pain, general

NPC-UNIV-000004676

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 298 of 1101

Table IV

API G n ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
lurtotecan	11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperazinyl]methyl]-, [CAS]	155773-58-3			Formulation, optimized, liposomes	Cancer, ovarian
lutetium texaphyrin	Lutetium, bis(acetato-O)[9,10-diethyl-20,21-bis-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24,N25]-, (PB 7-11-233'2'4)- [CAS]	156436-90-7	WO	9906411	Radio/chemosensitizer	Atherosclerosis
LV-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate				Anti-inflammatory	Arthritis, rheumatoid
LX-104	Hexadecanamide, N-[4-[[2-[2-[2-[[O-(N-acetyl-Alpha-neuraminosyl)-(2-3)-O-ß-D-galactopyranosyl-(1-4)-O-[6-deoxy-Alpha-L-galactopyranosyl-(1-3)]-ß-D-glucopyranosyl]oxy]ethoxy]ethoxy]ethoxy] methyl]phenyl]-2-tetradecyl- [CAS]	158792-45-1			Cognition enhancer	Dementia, senile, general
LY-156735	ß-methyl-6-chloromelatonin		EP	655243	Hypnotic/Sedative	Sleep disorder, general
LY-293111	Benzoic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]- [CAS]	161172-51-6			Anticancer, other	Cancer, melanoma
LY-293558	3-Isoquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3Alpha.,4aAlpha ,6ß ,8aAlpha.)]- [CAS]	154652-83-2			Analgesic, other	Pain, neuropathic
LY-355703	1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2S,3R)-3-phenyloxiranyl]ethyl]-, (3S,10R,13E,16S)- [CAS]	18256-67-7	WO	9707798	Anticancer, other	Cancer, lung, non-small cell
Lyapolate		25053-27-4				
Lymecycline		992-21-2				

NPC-UNIV-000004677

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 299 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Lynestrenol		52-76-6				
Lypressin		50-57-7				
Lysine Acetylsalicylate		62952-06-1				
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO	9624331	Analgesic, NSAID	
lysophospholipids			WO	9843093	Diagnostic	Diagnosis, cancer
M-40403	Dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-1,7-nitrilo-7H-dibenzo[b,h] [1,4,7,10]tetraazacyclo-heptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22]manganese		US	6180620	Anticancer, other	Unspecified
mabuprofen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+/-)- [CAS]	82821-47-4	DE	3121595	Anti-inflammatory	
Mabuterol		56341-08-3				
Macrophage Colony-Stimulating Factor		81627-83-0				
MADU		840-50-6				
mafenide	Benzenesulfonamide, 4-(aminomethyl)-monoacetate [CAS]	13009-99-9 138-39-6			Vulnerary	Burns
mafosfamide	Ethanesulfonic acid, 2-[[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]-, P-oxide, cis-(±)- [CAS]	88859-04-5 98845-64-8	EP	393575	Anticancer, alkylating	Cancer, renal
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2), hydrate [CAS]	74978-16-8	US	2923660	Antacid/Antiflatulent	
Magenta I		632-99-5				
Magnesium Acetylsalicylate		132-49-0				
Magnesium Carbonate Hydroxid		39409-82-0				
magnesium chloride	Magnesium chloride (MgCl2) [CAS]	7786-30-3			Formulation, oral, enteric-coated	Nutrition

NPC-UNIV-000004678

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 300 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Magnesium Citrate		3344-18-1				
magnesium gluconate	D-Gluconic acid, magnesium salt (2:1) [CAS]	3632-91-5			Formulation, other	Hypertension, general
Magnesium Lactate		18917-93-6				
Magnesium Salicylate		18917-89-0				
Malathion		121-75-5				
Malotilate		59937-28-9				
Mandelic Acid		90-64-2				
Mandelic Acid Isoamyl Ester		5421045				
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen)				
manidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]	89226-50-6 89226-75-5	EP	94159	Antihypertensive, other	Hypertension, general
Mannomustine		551-74-6				
mannose-6-phosphate	mannose-6-phosphate				Vulnerary	Wound healing
Maprotiline		10262-69-8				
maribavir	1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-ß-L-ribofuranosyl- [CAS]	176161-24-3			Antiviral, other	Infection, cytomegalovirus
marimastat	N-[2,2-Dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide	154039-60-8	WO	9402447	Anticancer, other	Cancer, pancreatic
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-(octahydro-1-(1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1S-(1Alpha(R*),3aß,4E(1S*,3R*,5Z),7aAlpha))- [CAS]	103909-75-7	US	4891364	Hormone	Hyperparathyroidism

NPC-UNIV-000004679

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 301 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
mazindol	3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US	3763178	Anorectic/Antiobesity	Obesity
Mazipredone		13085-08-0				
MC-5723			US	6043259	Cardiovascular	Unspecified
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)				Antiviral, other	Infection, hepatitis-B virus
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP	145019	Cardiostimulant	Heart failure
m-Cresyl Acetate		122-46-3				
MDAM	Gamma-Methylene-10-deazaaminopterin				Anticancer, antimetabolite	Cancer, general
MDI-101			US	4885311	Antiacne	Acne
MDI-403		403849-94-5	US	4677120	Antiacne	Acne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6			Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB	1307306	Anthelmintic	
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester [CAS]	3625-06-7			Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2				
Mebrofenin		78266-06-5				
Mebutamate		64-55-1				
mecamylamine	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2			Neurological	Unspecified
Mechlorethamine		51-75-2				
Mechlorethamine Oxide		302-70-5				

NPC-UNIV-000004680

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 302 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
mecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6.beta.)]- [CAS]	32887-01-7 32887-03-9	GB	1293590	Penicillin, injectable	Infection, general
Meclizine		569-65-3				
Meclocycline		2013-58-3				
meclofenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	6385-02-0 644-62-2			Antiarthritic, other	Arthritis, osteo
Meclofenamic Acid		644-62-2				
Meclofenoxate		51-68-3				
Mecloqualone		340-57-8				
Mecysteine		18598-63-5				
Medazepam		12/06/2898				
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR	M5498	Antidepressant	
Medrogestone		977-79-7				
Medronic Acid		1984-15-2				
medroxyprogesterone	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-,(6Alpha)	71-58-9 520-85-4			Formulation, fixed-dose combinations	Contraceptive, female
Medrysone		2668-66-8				
Mefenamic Acid		61-68-7				
Mefenorex		17243-57-1				
Mefexamide		1227-61-8				
mefloquine	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB	1594282	Antimalarial	
Mefruside		7195-27-9				
Megestrol		595-33-5				
Meglumin		22154-43-4 131-49-7				
meglutol	2-hydroxy-2-methyl-1,3-propandicarboxylic acid	503-49-1	US	3629449	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general

NPC-UNIV-000004681

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 303 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- [CAS]	159776-70-2	WO	9616671	Antithrombotic	Thrombosis, general
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine(1)				Anorectic/Antiobesity	Obesity
Melarsoprol		494-79-1				
Melengestrol		5633-18-1				
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methylester [CAS]	7101-51-1	EP	252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0				
Melitracen		5118-29-6				
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US	4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE	651144	Neuroleptic	
Melphalan		148-82-3				
meluadrine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	134865-37-5	EP	420120	Labour inhibitor	Labour, preterm
memantine	Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl [CAS]	41100-52-1 19982-08-2	EP	392059	Cognition enhancer	Dementia, AIDS-related
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO	9406803	Beta-lactam antibiotic	Infection, general

NPC-UNIV-000004682

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 304 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO	9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6				
Menadione		58-27-5				
Menadoxime		573-01-3				
Menbutone		3562-99-0				
Menogaril		71628-96-1				
MENT	7Alpha-Methyl-19-nortestosterone				Formulation, transdermal, systemic	Contraceptive, male
menthol	Cyclohexanol, 5-methyl-2-(1-methlethyl)- [CAS]	1490-04-6 89-78-1			Formulation, dermal, topical	Pruritus
Menthyl Valerate		89-47-4				
Meobentine		46464-11-3				
Meparfynol		77-75-8				
mepartricin	Partricin, methyl ester [CAS]	11121-32-7	US	3780173	Antifungal	Infection, Candida, general
Mepazine		60-89-9				
Mepenzolate Bromide		76-90-4				
Meperidine		57-42-1				
Mephenesin		59-47-2				
Mephenoxalone		70-07-5				
Mephentermine		100-92-5				
Mephenytoin		50-12-4				
Mephobarbital		115-38-8				
Mepindolol		23694-81-7				
Mepitiostane		21362-69-6				
mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8			Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0				

NPC-UNIV-000004683

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 305 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Meprednisone		1247-42-3				
Meprobamate		57-53-4				
meproscillarin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyl)oxy]-14-hydroxy-, (3ß)- [CAS]	33396-37-1	DE	1910207	Cardiostimulant	Heart failure
meptazinol	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	54340-58-8 59263-76-2	GB	1285025	Analgesic, other	Pain, general
mequitazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	29216-28-2	GB	1250534	Antiallergic, non-asthma	
Meralein		4386-35-0				
Meralluride		8069-64-5				
Merbromin		129-16-8				
Mercaptomerin		21259-76-7				
Mercumallylic Acid		86-36-2				
Mercuric Chloride, Ammoniated		10124-48-8				
Mercuric Oleate		1191-80-6				
Mercuric Oxycyanide		1335-31-5				
merimepodib	Carbamic acid, ((3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)- (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-6	US	5807876	Antiviral, other	Infection, hepatitis-C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4Alpha,5ß,6ß(R*)]]- [CAS]	96036-03-2	EP	126587	Beta-lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2				
Mesalamine		89-57-6				
mesalazine	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO	5541170	Formulation, oral, other	Colitis, ulcerative
Mesna		19767-45-4				
Mesoridazine		5588-33-0				

NPC-UNIV-000004684

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 306 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9				
Mesterolone		1424-00-6				
Mestranol		72-33-3				
Mesulfen		135-58-0				
Metaclazepam		84031-17-4				
Metampicillin		6489-97-0				
Metapramine		21730-16-5				
Metaproterenol		586-06-1				
Metaraminol		54-49-9				
Metazocine		3734-52-9				
metergoline	Carbamic acid, [[(8ß)-1,6-dimethylergolin-8-yl]methyl]-, phenylmethyl ester [CAS]	17692-51-2 21631-37-8 2706-42-5	GB	1401935	Antiprolactin	Amenorrhoea
metformin	Imidodicarbonimidic diamide, N,N-dimethyl [CAS]	657-24-9			Formulation, modified-release, <=24hr	Diabetes, Type II
Methacholine		62-51-1				
Methacycline		914-00-1				
Methadone		76-99-3				
Methafuryl ne		531-06-6				
Methamphetamine		537-46-2				
Methandriol		521-10-8				
Methandrostenolone		72-63-9				
Methantheline		53-46-3				
Methapyrilene		91-80-5				
Methaqualone		72-44-6				
Metharbital		50-11-3				
Methazolamide		554-57-4				
Methdilazine		1982-37-2				
Methenamine		100-97-0				
Methenolone		153-00-4				
Methestrol		130-73-4				
Methetoin		5696-06-0				
Methicillin		132-92-3				

NPC-UNIV-000004685

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 307 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0				
Methiodal		126-31-8				
Methionic Acid		503-40-2				
Methionine		63-68-3				
Methisazone		1910-68-5				
Methitural		467-43-6				
Methixene		02/02/4969				
Methocarbamol		532-03-6				
Methohexital		22151-68-4				
methotrexate	L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-[CAS]	59-05-2	US	2512572	Anticancer, antimetabolite	Cancer, general
Methotrimeprazine		60-99-1				
Methoxamine		390-28-3				
Methoxsalen		298-81-7				
Methoxyflurane		76-38-0				
Methoxyphenamine		93-30-1				
Methoxypromazine		61-01-8				
Methscopolamine		155-41-9				
Methsuximide		77-41-8				
Methyclothiazide		135-07-9				
Methyl Blue		28983-56-4				
Methyl Nicotinate		93-60-7				
Methyl Propyl Ether		557-17-5				
Methyl Salicylate		119-36-8				
Methyl tert-Butyl Ether		1634-04-4				
Methylbenzethonium Chloride		25155-18-4				
Methylcobalamin		13422-55-4				
methyldopa	L-Tyrosine, 3-hydroxy-Alpha-methyl-[CAS]	555-30-6			Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4				
Methylergonovine		113-42-8				

NPC-UNIV-000004686

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 308 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Methylhexaneamine		105-41-9				
methylphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-45-1 298-59-9			Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone		83-43-2				
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha,11ß)- [CAS]	86401-95-8	EP	72547	Antipruritic/inflamm, allergic	Pruritus
methylprednisolone suleptanate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]-, monosodium salt, (6Alpha,11ß)- [CAS]	90350-40-6	JP	59137500	Antiasthma	Asthma
Methylthiouracil		56-04-2				
Methyltrienolone		965-93-5				
Methyprylon		125-64-4				
Methysergide		361-37-5				
Metiazinic Acid		13993-65-2				
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate [CAS]	22664-55-7	GB	1206148	Antihypertensive, adrenergic	
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5			Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
Metocurine Iodide		7601-55-0				
Metofenazate		388-51-2				
metolazone	6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US	4517179	Antihypertensive, diuretic	
Metopimazine		14008-44-7				
Metopon		143-52-2				
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (+/-)- [CAS]	51384-51-1 56392-17-7 37350-58-6			Formulation, modified-release, other	Hypertension, general
Metralindole		54188-38-4				
Metrizamide		31112-62-6				
Metrizoic Acid		1949-45-7				
Metron S		13946-02-6				

NPC-UNIV-000004687

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 309 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Metyrapone		54-36-4				
Metyrosine		672-87-7				
Mexazolam		31868-18-5				
Mexenone		1641-17-4				
Mexiletine		31828-71-4				
mezlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2Alpha,5Alpha,6ß(S*)]]- [CAS]	42057-22-7 51481-65-3 72539-76-5	GB	1301961	Penicillin, injectable	Infection, general
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US	4623659	Cardiovascular	Reperfusion injury
mianserin	Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- [CAS]	21535-47-7 24219-97-4	GB	1173783	Antidepressant	Depression, general
Mibefradil		116644-53-2				
Miboplatin		103775-75-3				
Micafungin		235114-32-6				
miconazole	1H-Imidazole,1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl)methoxy]ethyl]	22916-47-8			Formulation, modified-release, other	Infection, Candida, general
Micronomicin		52093-21-7				
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	US	5378844	Cardiovascular	Unspecified
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-[CAS]	59467-70-8 59467-94-6	US	4280957	Anaesthetic, injectable	
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US	3761588	Macrolide antibiotic	Infection, general
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP	49124087	Macrolide antibiotic	Infection, general
midesteine	2-Thiophenecarbothioic acid, S-[1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP	120534	COPD treatment	Emphysema, general

NPC-UNIV-000004688

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 310 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP	164571	Urological	Incontinence
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, (9Alpha,10ß,11ß,13Alpha)- [CAS]	120685-11-2	EP	296110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11ß,17ß)- [CAS]	84371-65-3	EP	57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3ß,4Alpha,5ß)]- [CAS]	72432-03-2	EP	55431	Antidiabetic	Diabetes, Type I
miglustat	3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-(2R-(2Alpha, 3ß, 4Alpha, 5ß)) [CAS]	72599-27-0	DE	2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt- [CAS]	76144-81-5	WO	8001068	Cardiostimulant	Heart failure
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(±)-[CAS]	101152-94-7 92623-85-3	US	4478836	Antidepressant	Depression, general
Miloxacin		37065-29-5				
milrinone	[3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US	4313951	Cardiostimulant	Heart failure
miltefosine	Ethanaminium, 2-[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP	225608	Anticancer, other	Cancer, skin, general
minaprine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB	1345880	Antidepressant	Depression, general

NPC-UNIV-000004689

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 311 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
minocycline	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5a.alpha.,12aAlpha)]-[CAS]	10118-90-8			Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	EP	354806	Anticancer, other	Cancer, myeloma
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US	4139619	Vasodilator, peripheral	Hypertension, general
Miokamycin		55881-07-7				
mirtazapine	Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8 61337-67-5	GB	1543171	Antidepressant	Depression, general
misoprostol	Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11Alpha,13E)-(±)- [CAS]	59122-46-2 59122-48-4	US	4301146	Prostaglandin	Ulcer, gastric
mitemcinal	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO	9324509	Gastroprokinetic	Gastro-oesophageal reflux
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate, dihydrate-[CAS]	145525-41-3	EP	507534	Antidiabetic	Diabetes, Type II
Mitobronitol		488-41-5				
Mitoguazone		459-86-9				
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US	3993781	Anticancer, alkylating	Cancer, cervical

NPC-UNIV-000004690

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 312 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
mitomycin	Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8ß,8aAlpha,8bAlpha)]- [CAS]	50-07-7			Formulation, parenteral, other	Cancer, stomach
Mitotane		53-19-0				
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US	4197249	Anticancer, other	Cancer, breast
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9			Formulation, optimized, liposomes	Cancer, general
MIV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)				Antiviral, other	Infection, hepatitis-B virus
mivacurium	Isoquinolinium, 2,2'-[(1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R-[R*,R*-(E)]]]- [CAS]	106861-44-3	EP	181055	Muscle relaxant	Anaesthesia, adjunct
Mivazerol		125472-02-8				
mizolastine	4(1H)-Pyrimidinone, 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	EP	217700	Antiallergic, non-asthma	Rhinitis, allergic, general
Mizoribine		50924-49-7				
MKC-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP	09216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO	9915183	Neuroprotective	Ischaemia, cerebral
MLN-576	4-Methoxy-benzo[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methylethyl)-amide				Anticancer, other	Cancer, general

NPC-UNIV-000004691

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 313 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP	326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68693-11-8	DE	2809625	Psychostimulant	Narcolepsy
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R*(R*)),3R*))- [CAS]	103775-10-6 103775-14-0	US	4344949	Antihypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2				
Mofebutazone		2210-63-1				
Mofegiline		119386-96-8				
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP	26928	Analgesic, NSAID	Pain, post-operative
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-[2-(4-aminophenyl)-acetamido]butyryl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]-pyridazine-5(R)-carboxamide				Antiasthma	Asthma
Molindone		7416-34-4				
molsidomine	Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US	3769283	Vasodilator, coronary	
mometasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11ß,16Alpha)- [CAS]	105102-22-5 83919-23-7	EP	57401	Antipruritic/inflamm, allergic	Psoriasis
Monatepil		103377-41-9				
Monobenzone		103-16-2				
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US	4885282	Dermatological	Ichthyosis
montelukast	Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [CAS]	151767-02-1 158966-92-8			Antiasthma	Asthma
Monteplase		122007-85-6				

NPC-UNIV-000004692

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 314 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Moperone		1050-79-9				
Mopidamol		13665-88-8				
Moprolol		5741-22-0				
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US	3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1				
Moricizine		31883-05-3				
Moroxydine		3731-59-7				
Morphazinamide		952-54-5				
morphine	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5Alpha,6Alpha)-, [CAS]	57-27-2 6055-06-7 64-31-3			Formulation, parenteral, other	Pain, cancer
morphine-6-glucuronide	morphine-6-glucuronide				Formulation, inhalable, systemic	Pain, general
mosapramine	Spiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+/-)- [CAS]	89419-40-9 98043-60-8	US	4337260	Neuroleptic	
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP	243959	GI inflammatory/bowel disorders	Gastritis
motexafin gadolinium	Gadolinium, bis(acetetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanalato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233'2'4) [CAS]	246252-06-2			Radio/chemosensitizer	Cancer, brain
Motretinide		56281-36-8				
Moveltipril		85856-54-8				
Moxalactam		64952-97-2				
Moxastine		3572-74-5				
Moxaverine		10539-19-2				
Mox strol		34816-55-2				

NPC-UNIV-000004693

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 315 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-6 fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	186826-86-8 151096-09-2	DE	19546249	Quinolone antibacterial	Infection, respiratory tract, general
moxisylyte	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), [CAS]	964-52-3 54-32-0			Male sexual dysfunction	Impotence
moxonidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE	2849537	Antihypertensive, other	Hypertension, general
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)pentanedioic acid		US	5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US	6224883	Formulation, parenteral, other	Cancer, head and neck
MPI-5020	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8	US	5750146	Formulation, parenteral, other	Cancer, breast
MPL		198076-81-2			Immunostimulant, other	Vaccine adjunct
MRS-1754			US	6060481	Antiasthma	Asthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[(5-quinolinyloxy)methyl]-, (2E)-2-butenedioate(2:3) (salt) [CAS]	158681-49-3			Radio/chemosensitizer	Cancer, breast
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide				Anticancer, antimetabolite	Cancer, lung, general
MS-325		201688-00-8				
MS-377			EP	839805	Neuroleptic	Schizophrenia
Mupirocin		12650-69-0				
Muscarin		300-54-9				
Muzolimine		55294-15-0				
MX-1013			US	6153591	Hepatoprotective	Unspecified

NPC-UNIV-000004694

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 316 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)- [CAS]	116680-01-4 128794-94-5	WO	9119498	Immunosuppressant	Transplant rejection, general
mycophenolic acid	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-,	37415-62-6 24280-93-1			Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine		467-18-5				
N-(Hydroxymethyl)nicotinamide		3569-99-1				
N,N,N',N'-Tetraethylphthalamide		83-81-8				
N_2-Formylsulfisomidine		795-13-1				
N_4-β-D-Glucosylsulfanilamide		53274-53-6				
N_4-Sulfanilylsulfanilamide		547-52-4				
Nabilone		51022-71-0				
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)- [CAS]	42924-53-8	GB	1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1			Anticancer, other	Cancer, general
N-Acetylmethionine		65-82-7				
nadifloxacin	1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	US	4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US	4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3				

NPC-UNIV-000004695

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 317 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
nafamostat	Benzoic acid, 4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester-[CAS]	80251-32-7 81525-10-2 82956-11-4	EP	450232	GI inflammatory/bowel disorders	Pancreatitis
nafarelin	Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP	21234	Releasing hormones	Endometriosis
Nafcillin		147-52-4				
Nafronyl		31329-57-4				
naftidrofuryl	2-Furanpropanoic acid, tetrahydro-Alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4			Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US	4282251	Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)-Alpha-[(1-naphthalenyloxy)methyl]- [CAS]	57149-07-2	US	3997666	Antihypertensive, adrenergic	Hypertension, general
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5Alpha,6Alpha)- [CAS]	20594-83-6 23277-43-2	US	3393197	Analgesic, other	Pain, general
Nalidixic Acid		389-08-2				
nalmefene	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-,(5Alpha)-[CAS]	55096-26-9	JP	56167687	Dependence treatment	Poisoning, drug
Nalorphine		62-67-9				
naloxone	Morphinan-6-one, 17-allyl-4,5Alpha-epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-65-6			Septic shock treatment	
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-[CAS]	16590-41-3 16676-29-2	US	3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachlororuthenate (III)				Anticancer, other	Cancer, general

NPC-UNIV-000004696

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 318 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
naminidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N"-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220641-11-2			Dermatological	Alopecia, general
Nandrolone		434-22-0				
Naphazoline		835-31-4				
Naphthalene		91-20-3				
naproxen betainate	Methanaminium, 1-carboxy-N, N, N-trimethyl- salt with (R)-6-methoxy- Alpha-methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US	4672077	Antiarthritic, other	Arthritis, rheumatoid
naproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl-, [CAS]	26159-34-2 22204-53-1	GB	1211134	Analgesic, NSAID	Pain, general
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	EP	303507	Antimigraine	Migraine
Narceine		131-28-2				
Narcobarbital		125-55-3				
Natamycin		7681-93-8				
nateglinide	D-phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-[CAS]	105816-04-4	EP	196222	Antidiabetic	Diabetes, Type II
N-Butyldeoxynojirimycin		72599-27-0				
N-Butylscopolammonium Bromide		149-64-4				
NC-503			US	5643562	Anti-inflammatory	Amyloidosis
NC-531			US	5643562	Cognition enhancer	Alzheimer's disease
NCX-1000			WO	0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	175033-36-0	WO	9716405	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0			GI inflammatory/bowel disorders	Inflammatory bowel disease

NPC-UNIV-000004697

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 319 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
NCX-950	Alpha'-[[(1,1-dimethylethyl)amino]methyl]-4 hydroxyl-1,3-benzenedimethanol nitrate				Antiasthma	Asthma
n-Docosanol		661-19-8				
NE-100	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO	9307113	Neuroleptic	Schizophrenia
N albarbital		561-83-1				
nebivolol	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro]-, (2R*(R*(R*(S*))))-(1+)-[CAS]	118457-14-0 99200-09-6	EP	145067	Antihypertensive, adrenergic	Hypertension, general
nebostinel	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP	0688312	Cognition enhancer	Unspecified
Nebracetam		97205-34-0				
nedaplatin	Platinum, diammine[hydroxyacetato(2-)-O1,O2]-, (SP-4-3)- [CAS]	95734-82-0	EP	216362	Anticancer, alkylating	
nedocromil	4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP	555718	Antiasthma, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nefazodone	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, [CAS]	82752-99-6 83366-66-9	US	4338317	Antidepressant	Depression, general
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US	4341790	Cognition enhancer	Dementia, senile, general
nefopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13669-70-0 23327-57-3	US	3487153	Analgesic, NSAID	
Negamycin		33404-78-3				
nelfinavir	3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S*,3S*),3Alpha,4aß,8aß))-, [CAS]	159989-65-8 159989-64-7			Antiviral, anti-HIV	Infection, HIV/AIDS
Nemonapride		75272-39-8				
Neostigmine		59-99-4				

NPC-UNIV-000004698

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 320 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-ß-D-glucopyranosyl]-L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO	9628467	Antiasthma	Asthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0			Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9			Musculoskeletal	Osteogenesis imperfecta
Neriifolin		466-07-9				
N-Ethylamphetamine		457-87-4				
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3 130726-68-0	EP	445540	Antifungal	Infection, Candida, general
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-ß-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB	1473733	Aminoglycoside antibiotic	Infection, general
nevirapine	6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	129618-40-2	EP	429987	Antiviral, anti-HIV	Infection, HIV/AIDS
NGD-98-2			WO	9635689	Anxiolytic	Anxiety, general
Nialamide		51-12-7				
Niaprazine		27367-90-4				
Nicametate		3099-52-3				
nicaraven	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis- [CAS]	79455-30-4	EP	29602	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US	3985758	Neuroprotective	Hypertension, general
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8/b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6			Formulation, modified-release, other	Unspecified

NPC-UNIV-000004699

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 321 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Niceritrol		5868053				
Niclosamide		50-65-7				
Nicoclonate		10571-59-2				
Nicofuranose		15351-13-0				
Nicomol		27959-26-8				
Nicomorphine		639-48-5				
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]- [CAS]	65141-46-0	US	4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0				
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5			Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6				
Nicotinic Acid Benzyl Ester		94-44-0				
Nicotinyl Alcohol		100-55-0				
nifedipine	4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB	1173862	Vasodilator, coronary	Hypertension, general
nifekalant	2,4(1H,3H)-Pyrimidinedione, 6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, [CAS]	130636-43-0 130656-51-8	EP	369627	Antiarrhythmic	Arrhythmia, general
Nifenalol		7413-36-7				
Niflumic Acid		4394-00-7				
Nifuratel		4936-47-4				
Nifurfoline		3363-58-4				
Nifuroxazide		965-52-6				
Nifuroxime		6236051				
Nifurpirinol		13411-16-0				
Nifurprazine		1614-20-6				
Nifurtimox		23256-30-6				
Nifurtoinol		1088-92-2				

NPC-UNIV-000004700

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 322 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
nifurzide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-furanyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US	3847911	Antidiarrhoeal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0			Formulation, other	Infection, general
Nikethamide		59-26-7				
nilutamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]	63612-50-0	US	4472382	Anticancer, hormonal	Cancer, prostate
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	US	4338322	Antihypertensive, other	Hypertension, general
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US	3840597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8				
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	EP	533014	Neuroprotective	
Nimorazole		6506-37-2				
nimustine	Urea, N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	GB	1374344	Anticancer, alkylating	Cancer, brain
Ninopterin		2179-16-0				
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide		WO	9804542	Antiarrhythmic	Fibrillation, atrial
NIP-531	N'-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N-[1-(4-fluorobenzyl)benzimidazol-2-yl]-amino]propyl-N-methylurea hydrochloride				Antipruritic/inflamm, allergic	Eczema, atopic
niperotidine	N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine	84845-75-0	GB	2104071	Antiulcer	Ulcer, GI, general

NPC-UNIV-000004701

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 323 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
nipradilol	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP	42299	Formulation, mucosal, topical	Glaucoma
Niridazole		61-57-4				
nisoldipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63675-72-9	GB	1516793	Antihypertensive, other	Hypertension, general
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	55981-09-4	US	5387598	Protozoacide	Infection, GI tract
nitisinone	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104206-65-7	EP	186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
nitracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4533-39-5 6514-85-8	FR	1458183	Anticancer, other	Cancer, ovarian
Nitrazepam		146-22-5				
nitrendipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB	1358951	Antihypertensive, other	Hypertension, general
nitroflurbiprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	158836-71-6	EP	670825	Urological	Incontinence
Nitrofurantoin		67-20-9				
Nitrofurazone		59-87-0				
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0			Formulation, transdermal, patch	Angina, general
Nitromersol		133-58-4				
nitronaproxen	2-Napthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO	9509831	Analgesic, NSAID	Pain, post-operative
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL	6608671	Antidepressant	
Nitroxoline		4008-48-4				
nizatidine	1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	76963-41-2	EP	49618	Antiulcer	Ulcer, duodenal

NPC-UNIV-000004702

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 324 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Nizofenone		54533-85-6				
NM-3	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin		JP	08176138	Anticancer, other	Cancer, general
NM-702	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride				Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4				
N-Methylepinephrine		554-99-4				
N-Methylglucamine		6284-40-8				
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide				Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid				Symptomatic antidiabetic	Neuropathy, diabetic
Nogalamycin		1404-15-5				
nolatrexed	4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio)-, [CAS]	152946-68-4 147149-76-6	WO	9320055	Anticancer, antimetabolite	Cancer, liver
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-)-[CAS]	138531-51-8	WO	9529147	Cardiostimulant	Heart failure
nolpitantium	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)-[CAS]	153050-21-6	EP	591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
nomegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- [CAS]	58652-20-3	DE	2522533	Menstruation disorders	Menstrual disorder, general
Nomifensine		24526-64-5				
Noprylsulfamide		576-97-6				
Norbolethone		1235-15-0				

NPC-UNIV-000004703

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 325 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5				
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (*R*,S**)-(±)-form				
Nordihydroguaiaretic Acid		27686-84-6 (*meso*-form); 500-38-9 (unspecified)				
Norelgestromin, Ethinyl Estradiol						
Norepinephrine		51-41-2				
Norethandrolone		52-78-8				
Norethindrone		68-22-4				
Norethynodrel		68-23-5				
Norfenefrine		536-21-0				
norfloxacin	3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US	4146719	Quinolone antibacterial	Infection, general
Norgesterone		13563-60-5				
Norgestimate		35189-28-7				
Norgestrel		6533-00-2				
Norgestrienone		848-21-5				
Norlevorphanol		1531-12-0				
Normethadone		467-85-6				
Normethandrone		514-61-4				
Normorphine		466-97-7				
Norphenazone		89-25-8				
Norpipanone		561-48-8				
Norpseudoephedrine		492-39-7				
Nortriptyline		72-69-5				
Norvinisterone		6795-60-4				

NPC-UNIV-000004704

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 326 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1				
Novembichin		1936-40-9				
Novobiocin		303-81-1				
Noxiptilin		3362-45-6				
Noxythiolin		15599-39-0				
NS-1209	Butanoic acid, 2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy- [CAS]	254751-28-5	WO	9426747	Antiepileptic	Epilepsy, general
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrolo-(3,2-h]naphthalene-2,3-dione-3-oxime				Neuroprotective	Ischaemia, cerebral
NS-126			US	5063222	Antiallergic, non-asthma	Rhinitis, allergic, general
NS-220	2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid				Hypolipaemic/Antiatherosclerosis	Atherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2			Cognition enhancer	Alzheimer's disease
NS5A inhibitors			US	6030785	Antiviral, other	Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-, monohydrochloride [CAS]	178429-67-9	WO	9607641	Neuroprotective	Ischaemia, cerebral
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile				Urological	Incontinence
NSC-330507	17-Allylaminogeldanamycin				Anticancer, antibiotic	Cancer, general
NSC-619534	2-chloroethyl phenyl selenone				Anticancer, alkylating	Cancer, general
NSC-697726	2,5-diazinidinyl-3-[hydroxymethyl]6-methyl-1,4-benzoquinone				Anticancer, antibiotic	Cancer, general
N-Sulfanilyl-3,4-xylamide		120-34-3				

NPC-UNIV-000004705

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 327 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
NU-6027	2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8			Anticancer, other	Cancer, general
NV-07	2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US	6455032	Antipruritic/inflamm, non-allergic	Keratosis
NVP-SRA880	([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate				Neurological	Unspecified
NW-1029	(S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide methansulfonate				Analgesic, other	Pain, general
NXY-059	CPI 22 [CAS]	168021-79-2	US	5780510	Neuroprotective	Ischaemia, cerebral
Nylidrin		447-41-6				
NZ-314	1-Imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP	353198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP	412940	Urological	Renal failure
Obidoxime Chloride		114-90-9				
OC-108	OC 108 [CAS]	162602-62-2			Vasoprotective, topical	Venous insufficiency
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	96604-21-6	EP	129847	Anxiolytic	Generalized anxiety disorder
Octabenzone		1843-05-6				
Octacaine		13912-77-1				
Octamoxin		4684-87-1				
Octav rine		549-68-8				
octenidine	1-Octanamine, N,N'-(1,10-decanediyldi-1(4H)-pyridinyl-4-ylidene)bis- [CAS]	70775-75-6 71251-02-0 86767-75-1	WO	8705501	Stomatological	Periodontitis
Octodrine		543-82-8				
Octopamine		104-14-3				
Octotiamine		137-86-0				

NPC-UNIV-000004706

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 328 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
octreotide	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*,R*)]- [CAS]	83150-76-9			Formulation, fixed-dose combinations	Cancer, general
Octyl Methoxycinnamate		5466-77-3				
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)- [CAS]	82419-36-1	EP	47005	Quinolone antibacterial	
o-Iodohippurate		133-17-5				
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-06-1	EP	454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7				
Oleic Acid		112-80-1				
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP	503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP	235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO	9619998	Osteoporosis treatment	Osteoporosis
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	US	4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
oltipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	64224-21-1	DE	2705641	Anticancer, other	Cancer, general

NPC-UNIV-000004707

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 329 of 1101

Table IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]-5-(phosphonooxy)pentyl]-4-(phosphonooxy)butyramide				Anticancer, immunological	Unspecified
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6			Hypolipaemic/Antiatherosclerosis	Hypertriglyceridaemia
omapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10aß))- [CAS]	167305-00-2	US	5508272	Antihypertensive, renin system	Hypertension, general
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- [CAS]	73590-58-6	US	4255431	Antiulcer	Ulcer, GI, general
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]	176894-09-0			Antidepressant	Depression, general
omoconazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP	8804	Antifungal	Infection, dermatological
Onapristone		96346-61-1				
ondansetron	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	99614-01-4 99614-02-5	US	4847281	Antiemetic	Chemotherapy-induced nausea and vomiting
ONO-3403	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminoiminomethyl)phenyl ester, monomethanesulfonate [CAS]	181586-07-2			GI inflammatory/bowel disorders	Unspecified

NPC-UNIV-000004708

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 330 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ONO-4128	1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl- [CAS]	342394-93-8			Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate				Labour inhibitor	Labour, preterm
ONT-093			US	5756527	Radio/chemosensitizer	Cancer, general
OPC-14523	2(1H)-Quinolinone, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP	512525	Antidepressant	Depression, general
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO	9105549	Urological	Unspecified
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide				Antidiabetic	Diabetes, insipidus
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO	9209586	GI inflammatory/bowel disorders	Inflammatory bowel disease
Opiniazide		2779-55-7				
opioid analgesics	2-(4-trifluoromethylphenyl)-N-methyl-[1-phenyl-2-(1-pyrolidinyl)ethylacetamide				Analgesic, other	Pain, general
Opipramol		315-72-0				
Orazamide		2574-78-9				
orazipone	2,4-Pentanedione, 3-((4-methylsulfonyl)phenyl)methylene)- [CAS]	137109-78-5	EP	440324	Antiasthma	Unspecified
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9			Antidepressant	Depression, general
Org-24448			US	6166008	Neuroleptic	Schizophrenia

NPC-UNIV-000004709

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 331 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-,(4''R)- [CAS]	171099-57-3	US	5840684	Peptide antibiotic	Infection, dermatological
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3ß]]- [CAS]	96829-58-2	EP	129748	Anorectic/Antiobesity	Obesity
ormeloxifene	Pyrrolidine, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE	2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5				
Ornipressin		3397-23-7				
Ornithine		70-26-8				
ornoprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US	4278688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1				
Orphenadrine		83-98-7				
Orthocaine		536-25-4				
Osalmid		526-18-1				
osanetant	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-56-8	EP	673928	Neuroleptic	Schizophrenia
osaterone	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- [CAS]	105149-00-6	EP	193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha,(4ß,5Alpha))-[CAS]	196618-13-0	WO	9626933	Antiviral, other	Infection, influenza virus
OSI-7836	4'-Thio-ß-D-arabinofuranosylcytosine				Anticancer, antimetabolite	Cancer, general

NPC-UNIV-000004710

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 332 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
OSI-7904	Pentanedioic acid, 2-[5-[[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-, (S)- [CAS]	139987-54-5	WO	9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO	9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-, bromide [CAS]	26095-59-0	GB	1181406	Antispasmodic	Irritable bowel syndrome
Ouabain		630-60-4				
Oxaceprol		33996-33-7				
Oxacillin		66-79-5				
Oxaflozane		26629-87-8				
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')[ethanedioato(2-)-O,O']-, [SP-4-2-(1R-trans)]- [CAS]	61825-94-3	EP	393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE	2249274	Urological	
Oxamarin		15301-80-1				
Oxametacine		27035-30-9				
Oxamniquine		21738-42-1				
oxandrolone	2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5Alpha,17ß)- [CAS]	53-39-4	US	3128283	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36531-26-7				
Oxapropanium		541-66-2				
oxaprozin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB	1206403	Antiarthritic, other	Arthritis, osteo
oxatomide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	60607-34-3	GB	1579365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1			Formulation, oral, orally-disintegrating	Anxiety, general

NPC-UNIV-000004711

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 333 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
oxazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US	3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE	2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1				
Oxendolone		33765-68-3				
Oxethazaine		126-27-2				
Oxetoron		26020-55-3				
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB	1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7				
Oxiniacic Acid		2398-81-4				
Oxiracetam		62613-82-5				
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1Alpha,2ß,4ß,5Alpha,7ß)]- [CAS]	30286-75-0	GB	1178305	Antiasthma	
Oxolamin		959-14-8				
Oxolinic Acid		14698-29-4				
Oxophenarsine		538-03-4				
Oxprenolol		6452-71-7				
Oxybenzone		131-57-7				
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester- [CAS]	5633-20-5			Formulation, modified-release, other	Incontinence
Oxycinchophen		485-89-2				
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5Alpha)-	76-42-6			Formulation, transmucosal, nasal	Pain, general

NPC-UNIV-000004712

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 334 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Oxyfedrine		15687-41-9				
Oxygent	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro- [CAS]	423-55-2			Haematological	Surgery adjunct
Oxymesterone		145-12-0				
Oxymetazoline		1491-59-4				
oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5Alpha,17ß)- [CAS]	434-07-1			Hormone	Anaemia, general
Oxymethurea		140-95-4				
oxymorphone	(5Alpha)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5			Formulation, modified-release, immediate	Pain, general
Oxypendyl		5585-93-3				
Oxypertine		153-87-7				
Oxyphenbutazone		129-20-4				
Oxyphencyclimine		125-53-1				
Oxyphenisatin		115-33-3				
Oxyphenonium		50-10-2				
Oxypinocamphone		10136-65-9				
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0			Antigout	Hyperuricaemia
Oxytetracycline		79-57-2				
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3 82571-53-7	GB	2025946	Antithrombotic	Vasospasm, cerebral
p-(Benzylsulfonamido)benzoic Acid		536-95-8				
P-100			US	6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US	6034267	Dermatological	Keratosis
P32/98	Di-(3N-[(2S,3S)-2-amino-3-methyl-pentanoyl]-1,3-thiazolidine)fumarate				Antidiabetic	Diabetes, Type II
PA-824			WO	9701562	Antimycobacterial	Infection, tuberculosis

NPC-UNIV-000004713

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 335 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US	5128242	Neuroprotective	Nerve injury, general
paclitaxel	5ß,20-Epoxy-1,2Alpha,4,7ß,10ß,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenylhippurate)	33069-62-4			Formulation, optimized, nanoparticles	Cancer, breast
PADRE			US	6413935	Immunostimulant, other	Vaccine adjunct
pagoclone	1H-Isoindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]	133737-32-3	US	4960779	Anxiolytic	Panic disorder
PAI inhibs			WO	9404512	Antithrombotic	Thrombosis, venous
palindore	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl]-, 2(S)-, (2E)-2-butendioate (1:1)	189681-71-8			Neuroleptic	Schizophrenia
Palivizumab		188039-54-5				
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US	5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		606-04-2				
Pamaquine		491-92-9				
pamicogrel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP	159677	Antithrombotic	Thrombosis, cerebral
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid-[CAS]	40391-99-9			Formulation, implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0				
p-Aminohippuric Acid		61-78-9				
p-Aminopropiophenone		70-69-9				
p-Aminosalicylic Acid		65-49-6				

NPC-UNIV-000004714

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 336 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Panavir	4,4'-isopropylidenedithiobis-2,6-di-t-butylphenol				Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0				
Panipenem		87726-17-8				
Pantethine		16816-67-4				
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- [CAS]	102625-70-7	EP	166287	Antiulcer	Ulcer, duodenal
Pantothenic Acid		79-83-4				
Papain						
Papaverine		58-74-2				
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2			Formulation, oral, other, modified-release	Pain, general
Paraflutizide		1580-83-2				
Paraldehyde		123-63-7				
Paramethadione		115-67-3				
Paramethasone		53-33-8				
Paranyline		1729-61-9				
Parathyroid Hormone		9002-64-6				
parecoxib	Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-, sodium salt [CAS]	198470-85-8	WO	9738986	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5				
Pargyline		555-57-7				
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1Alpha,3ß,7E,22E)- [CAS]	131918-61-1	EP	387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6-dideoxy-ß-L-idopyranosyl-(1-3)-ß-D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2			Protozoacide	Infection, leishmaniasis
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]	61869-08-7	EP	223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general

NPC-UNIV-000004715

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 337 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Paroxypropione		70-70-2				
Parsalmide		30653-83-9				
PaTrin-2	4-Bromothenylguanine				Radio/chemosensitizer	Cancer, melanoma
Pazinaclone		103255-66-9				
pazufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- [CAS]	127045-41-4 127046-45-1 136905-87-8	DE	3913245	Quinolone antibacterial	Infection, general
p-Bromoacetanilide		103-88-8				
PC-NSAIDs			US	4918063	Formulation, other	Arthritis, general
PD-0166285	6-(2,6-Dichlorophenyl)-2-[4-(diethylamino-ethoxy)-phenylamino]-8-pyrido[2,3-D]pyrimidine-7-one				Anticancer, other	Cancer, general
Pecilocin		19504-77-9				
pefloxacin	3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70458-92-3	GB	1598915	Quinolone antibacterial	Infection, urinary tract
pegvisomant	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9			Somatostatin	Acromegaly
Pelletierine		4396-1-4				
pemetrexed	L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]	137281-23-3 150399-23-8	US	5248775	Anticancer, antimetabolite	Cancer, mesothelioma
pemirolast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6	US	4457932	Antiasthma	Asthma
Pemoline		2152-34-3				
Pempidine		79-55-0				
PEN-203			US	5955446	Antiviral, other	Infection, human papilloma virus
Penamecillin		983-85-7				

NPC-UNIV-000004716

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 338 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-,(S)-, sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB	1215751	Antihypertensive, adrenergic	
penciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP	60058982	Antiviral, other	Infection, herpes simplex virus
Penethamate		808-71-9				
penfluridol	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	26864-56-2	DE	2040231	Neuroleptic	
Penicillamine		52-67-5				
Penicillin G		61-33-6				
Penicillin G Benzathine		1538-09-6				
Penicillin G Procaine		6130-64-9				
Penicillin N		525-94-0				
Penicillin O		87-09-2				
Penicillin V		87-08-1				
Penimepicycline		4599-60-4				
Penntuss			US	4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6				
Pentaerythritol Dichlorohydrin		2209-86-1				
Pentaerythritol		597-71-7				
Pentagastrin		5534-95-2				
Pentagestrone		7001-56-1				
PentaLyte	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US	5407428	Plasma substitute	Surgery adjunct
Pentam thonium		541-20-8				
pentamidine	Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis- [CAS]	100-33-4			Formulation, inhalable, systemic	Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1				
Pentetate		12111-24-9				
Pentetic Acid		67-43-6				
Pentetreotide		138661-02-6				

NPC-UNIV-000004717

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 339 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Penthienate		60-44-6				
Pentifyllin		1028-33-7				
Pentigetide		62087-72-3				
Pentisomide		78833-03-1				
Pentobarbital		76-74-4				
Pentolinium		52-62-0				
Pentorex		434-43-5				
pentosan	Xylan, [CAS]	37319-17-8	US	5180715	Urological	Inflammation, urinary tract
pentostatin	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-ß-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US	3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]				Neuroprotective	Amyotrophic lateral sclerosis
Pentoxyl		147-61-5				
Pentrinitrol		1607-17-6				
Pentylenetetrazole		54-95-5				
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US	4195018	Anticancer, antibiotic	
Perazine		84-97-9				
Perflubron		423-55-2				
Perfosfamide		62435-42-1; 39800-16-3 (unspecified)				
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8ß)-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	US	4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2				
Pericyazine		2622-26-6				
perifosine	Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP	594999	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	536-59-4	US	5110832	Anticancer, other	Cancer, breast
Perimethazine		13093-88-4				

NPC-UNIV-000004718

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 340 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl],amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aß,7aß]]-, compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-16-0 95153-31-4	EP	49658	Antihypertensive, renin system	Hypertension, general
Periodyl		53586-99-5				
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5 2055-44-9	JP	04217925	Anti-inflammatory	
Perlapine		1977-11-3				
Permethrin		52645-53-1				
perospirone	1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA	2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9				
Petroleum Benzin		8030-30-6				
PH-10			US	6331286	Antipsoriasis	Psoriasis
Phanquinone		84-12-8				
Pharmaprojects No. 4994			WO	9638482	Immunological	Unspecified
Pharmaprojects No. 5325			WO	9703986	Neuroleptic	Schizophrenia
Pharmaprojects No. 5972			WO	0204426	Antiasthma	Asthma
Pharmaprojects No. 6362			US	6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
Pharmaprojects No. 6446	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide				Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6590			WO	0206223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6656			US	6455026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6691			US	6299900	Formulation, other	Pain, general
Pharmaprojects No. 6743	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide				Antibacterial, other	Infection, general

NPC-UNIV-000004719

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 341 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Pharmaprojects No. 6748	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin				Antidepressant	Depression, general
Phenacaine		620-99-5				
Phenacemide		63-98-9				
Phenacetin		62-44-2				
Phenadoxone		467-84-5				
Ph nallymal		115-43-5				
Phenamet		3819-34-9				
Phenazocine		127-35-5				
Phenazopyridine		136-40-3				
Phenbutamide		3149-00-6				
Phencyclidine		77-10-1				
Phendimetrazine		634-03-7				
Phenelzine		51-71-8				
Phenesterine		3546-10-9				
Phenetharbital		357-67-5				
Phenethicillin		132-93-4				
Pheneturide		90-49-3				
Phenformin		114-86-3				
Phenglutarimide		1156-05-4				
Phenindamine		82-88-2				
Phenindione		83-12-5				
Pheniprazine		55-52-7				
Pheniramine		86-21-5				
Phenmetrazine		134-49-6				
Phenobarbital		50-06-6				
Phenobutiodil		554-24-5				
Phenocoll		103-97-9				
Phenoctide		78-05-7				
Phenolphthalein		77-09-8				
Phenolphthalol		81-92-5				

NPC-UNIV-000004720

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 342 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Phenolsulfonphthalein		143-74-8				
Phenoltetrachlorophthalein		639-44-1				
Phenoperidine		562-26-5				
Phenosulfazole		515-54-8				
Phenoxybenzamine		59-96-1				
Phenoxypropazine		3818-37-9				
Phenprobamate		673-31-4				
Phenprocoumon		435-97-2				
phenserine	Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS]	101246-66-6			Cognition enhancer	Alzheimer's disease
Phensuximide		86-34-0				
Phentermine		122-09-8				
Phentetiothalein		18265-54-8				
phentolamine	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1 50-60-2			Formulation, oral, other	Impotence
Phenyl Acetylsalicylate		134-55-4				
Phenyl Aminosalicylate		133-11-9				
Phenyl Salicylate		118-55-8				
Phenylbutazone		50-33-9				
Phenylephrine		61-76-7				
Phenylethanolamine		7568-93-6				
Phenylmercury		102-98-7				
Phenylmethylbarbituric Acid		76-94-8				
phenylpropanolamine	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4			Anorectic/Antiobesity, formulation, optimized, microparticles	
Phenylpropylmethylamine		93-88-9				

NPC-UNIV-000004721

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 343 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Phenyltoloxamine		92-12-6				
Phenyramidol		553-69-5				
phenytoin	2,4-Imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0			Formulation, oral, other	Epilepsy, general
Phethenylate		510-34-9				
Phloroglucinol		108-73-6				
Pholcodine		509-67-1				
Pholedrine		370-14-9				
Phosphocreatine		67-07-2				
Phosphocysteamine		5746-40-7				
Phosphorylcholine		107-73-3				
Phthalylsulfacetamide		131-69-1				
Phthalylsulfathiazole		85-73-4				
p-Hydroxyephedrine		365-26-4				
Phylloquinone		84-80-0				
Physostigmine		57-47-6				
Phytic Acid		83-86-3				
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)- hydrogen sulphate [CAS]	185077-23-0			Anticancer, other	Cancer, melanoma
Piberaline		39640-15-8				
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO	9318036	Antiarrhythmic	Fibrillation, atrial
Picilorex		62510-56-9				
Picloxydine		5636-92-0				
Picoperine		21755-66-8				
Picosulfate		10040-45-6				
Picotamide		32828-81-2				
Picumast		39577-19-0				

NPC-UNIV-000004722

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 344 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]- [CAS]	121808-62-6	EP	276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifarnine		56208-01-6				
piketoprofen	Benzeneacetamide, 3-benzoyl-Alpha-methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB	1436502	Anti-inflammatory, topical	
Pildralazine		64000-73-3				
pilocarpine	2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7			Formulation, implant, Stomatological	
Piloplex	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoicacid, compd. with (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE	2636559	Formulation, mucosal, topical	Glaucoma
pilsicainide	1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US	4564624	Antiarrhythmic	Arrhythmia, general
Pimeclone		534-84-9				
pimecrolimus	15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methyletheny)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R*E(1S*,3S*,4R*)), 4S*,5R*,8S*,9E*,12R*,14R*,5S*,16R*,18S 8,19S*,26aR*))- [CAS]	137071-32-0	EP	626385	Antipruritic/inflamm, allergic	Eczema, atopic
Pimefylline		10001-43-1				
pimilprost	Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha(1E,3S*,5S*),5ß,6a Alpha]]- [CAS]	139403-31-9			Dermatological	Ulcer, general
Piminodine		13495-09-5				
Pimobendan		74150-27-9				

NPC-UNIV-000004723

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 345 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
pimozide	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- [CAS]	2062-78-4	FR	M3695	Neuroleptic	
Pinacidil		85371-64-8				
pinaverium	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, [CAS]	53251-94-8 59995-65-2	EP	406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE	2339790	Anxiolytic	
Pindolol		13523-86-9				
pioglitazone	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-)- [CAS]	111025-46-8 112529-15-4	EP	193256	Antidiabetic	Diabetes, Type II
Pipacycline		1110-80-1				
Pipamazine		84-04-8				
Pipamperone		1893-33-0				
Pipazethate		2167-85-3				
Pipebuzone		27315-91-9				
Pipecurium		52212-02-9				
pipecuronium	Piperazinium, 4,4'-[(2ß,3Alpha,5Alpha,16ß,17ß)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1,1]-dimethyl-, [CAS]	52212-02-9 68399-57-5	GB	1398050	Muscle relaxant	Anaesthesia, adjunct
pipemidic acid	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	51940-44-4	GB	1451911	Antibacterial, other	Infection, urinary tract
Pipenzolate Bromide		125-51-9				
Piperacetazine		3819-00-9				
piperacillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-,[2S-[2Alpha,5Alpha,6ß(S*)]]- [CAS]	59703-84-3 61477-96-1	GB	1508062	Penicillin, injectable	Infection, general

NPC-UNIV-000004724

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 346 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Piperazine Adipate		142-88-1				
Piperidione		77-03-2				
Piperidolate		82-98-4				
Piperilate		4546-39-8				
piperine analogues			WO	002544	Dermatological	Vitiligo
Piperocaine		136-82-3				
Piperonal		120-57-0				
Piperoxan		59-39-2				
Piperylone		25 31-4-6				
Pipobroman		54-91-1				
Piposulfan		2608-24-4				
pipotiazine	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US	4782077	Neuroleptic	
Pipoxolan		18174-58-8				
Pipradrol		467-60-7				
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene]-, ethyl ester [CAS]	17243-64-0	US	3971794	GI inflammatory/bowel disorders	*Motility dysfunction*, GI, general
Piracetam		7491-74-9				
pirarubicin	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8Alpha,10Alpha(S*)]]- [CAS]	72496-41-4	US	4303785	Anticancer, antibiotic	Cancer, breast
Pirazolac		71002-09-0				
pirbuterol	2,6-Pyridinedimethanol, Alpha6-[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-, monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	US	3786160	Antiasthma	Asthma
Pirenoxine		1043-21-6				

NPC-UNIV-000004725

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 347 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	FR	1505795	Antiulcer	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US	4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8			Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US	3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8				
Pirifibrate		55285-45-5				
Piritramide		302-41-0				
Piritrexim		72732-56-0				
pirlindole	1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU	276060	Antidepressant	Depression, general
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.Alpha.phenyl-, cis-(+)- [CAS]	61477-94-9 68252-19-7	US	4112103	Antiarrhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5				
Piroheptine		16378-21-5				
Piromidic Acid		19562-30-2				
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US	3862319	Anti-inflammatory	
piroxicam betadex	ß-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	EP	153998	Formulation, other	Pain, musculoskeletal
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP	79639	Antiarthritic, other	Inflammation, general
Pirozadil		54110-25-7				
Pirprofen		31793-07-4				

NPC-UNIV-000004726

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 348 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-[R*,S*-(E)]]- [CAS]	147526-32-7	EP	304063	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4			Neurological	Anxiety, general
pivaloyloxymethyl	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP	302349	Anticancer, other	Cancer, lung, non-small cell
Pivalylbenzhydrazine		306-19-4				
Pivampicillin		33817-20-8				
pivampicillin/pivmecillinam		98445-47-7			Penicillin, oral	Infection, general
Pivcefalexin		63836-75-9				
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6ß)]- [CAS]	32886-97-8	GB	1293590	Penicillin, oral	Infection, general
pixantrone	Benz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate(1:2) [CAS]	144675-97-8	EP	503537	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine	15574-96-6	DE	2346747	Antimigraine	
Pizotyline		15574-96-6				
PKI-166	Phenol, 4-(4-(((1R)-1-phenylethyl)amino)-1H-pyrrolo(2,3-d)pyrimidin-6-yl)- [CAS]	187724-61-4			Anticancer, other	Cancer, general
p-Lactoph netide		539-08-2				
Plafibride		63394-05-8				
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP	151996	Fibrinolytic	Infarction, myocardial
Plasmocid		551-01-9				
Platonin		3571-88-8				
Plaunotol		64218-02-6				
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP	805145	Antifungal	Infection, Candida, general

NPC-UNIV-000004727

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 349 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
PLD-147	(OC-6-43)-Bis(acetato)(1-adamantylamine)ammine-dichloro-platinum (IV)				Anticancer, alkylating	Cancer, general
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US	5464848	Antiviral, other	Infection, respiratory tract, general
Plicamycin		18378-89-7				
p-Methyldiphenhydramine		19804-27-4				
PMS-601			WO	0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
Pneumococcal Vaccine, Diphtheria Conjugate						
Pneumococcal Vaccine, Polyvalent						
PNU-288034	N-[[(5s)-3[4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide]				Antibiotic, other	Infection, general
Podophyllotoxin		518-28-5				
polaprezinc	Zinc, bis(N-ß-alanyl-L-histidinato-N3,OAlpha)-, (T-4)- [CAS]	107667-60-7	EP	303380	Antiulcer	Ulcer, duodenal
Poldine Methylsulfate		545-80-2				
Policresulen		9011-2-3				
Polidexide		9064-92-0				
polidocanol	Polyethylene glycol monododecyl ether	3055-99-0 9002-92-0			Vasoprotective, systemic	Venous insufficiency
Poliovirus Vaccine Inactivated						

NPC-UNIV-000004728

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 350 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
poly-ADPRT inhibitors			WO	9845253	Anticancer, other	Cancer, general
Polyestradiol Phosphate		28014-46-2				
Polyphenon E	Polyphenon E [CAS]	188265-33-0			Antiviral, other	Infection, human papilloma virus
Polythiazide		346-18-9				
porfimer	Photofrin [CAS]	87806-31-3	US	4882234	Anticancer, other	Cancer, lung, non-small cell
P rfiromycin		801-52-5				
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1(1S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US	5714490	Antifungal	Infection, fungal, general
Posatirelin		78664-73-0				
potassium chloride	Potassium chloride (KCl) [CAS]	7447-40-7			Formulation, oral, enteric-coated	
Potassium Gluconate		299-27-4				
Potassium Guaiacolsulfonate		1321-14-8				
Potassium p-Aminobenzoate		138-84-1				
Potassium Permanganate		7722-64-7				
Povidone		9003-39-8				
Povidone-Iodine		25655-41-8				
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE	2633028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile				Antifungal	Infection, fungal, general

NPC-UNIV-000004729

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 351 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride				Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4				
Prajmaline		35080-11-6				
Pralidoxime		51-15-0				
pralnacasan	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1S,9S)- [CAS]	192755-52-5			Antiarthritic, immunological	Arthritis, rheumatoid
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP	186087	Antiparkinsonian	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US	4145347	Cognition enhancer	Amnesia
Pramiv rin		14334-40-8				
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv. [CAS]	151126-32-8	US	5124314	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8				
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP	173126	Antihypertensive, other	Hypertension, general
Pranlukast		103177-37-3				
pranoprofen	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4			Formulation, mucosal, topical	Ocular disorder, general
prasterone	Androst-5-en-17-one, 3-hydroxy-, (3ß)- [CAS]	53-43-0			Labour inducer	
pratosartan	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- [CAS]	153804-05-8	US	5409947	Antihypertensive, renin system	Hypertension, general

NPC-UNIV-000004730

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 352 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-ß,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1Alpha(ßS*,deltaS*),2Alpha,6Alpha,8ß(R*),8aAlpha]]- [CAS]	81093-37-0 81131-70-6	US	4346227	Hypolipaemic/Antiatherosclerosis	Atherosclerosis
Prazepam		2955-38-6				
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US	4001411	Schistosomicide	
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9 19237-84-4	US	4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate		73771-04-7				
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11ß)- [CAS]	29069-24-7	GB	1272841	Anticancer, alkylating	
Prednisolone		50-24-8				
Prednisolone 21-Diethylaminoacetate		5626-34-6				
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-, [11ß,21(2E,6E)]- [CAS]	118244-44-3	EP	332143	Antiarthritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0				
Prednisone		53-03-2				
Prednival		15180-00-4				
Pr dnylidene		599-33-7				
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8			Antiepileptic	Epilepsy, general
Pregnan-3α-ol-20-one		128-20-1				
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17ß (S)]- [CAS]	74513-62-5			Menopausal disorders	Hormone replacement therapy

NPC-UNIV-000004731

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 353 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB	1470039	Cardiostimulant	
Prenoxdiazine		982-43-4				
Prenylamine		390-64-7				
prezatide	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinato)(N2-(N-glycyl-L-histidyl)-L-lysinato(2-))-, hydrogen, [CAS]	130120-57-9			Vulnerary	Wound healing
Pridinol		511-45-5				
Prifinium		4630-95-9				
Prilocaine		721-50-6				
Primaquine		90-34-6				
Primidone		125-33-7				
Prinomastat		192329-42-3				
PRO-2000			US	5614599	Antiviral, anti-HIV	Infection, HIV prophylaxis
Probenecid		57-66-9				
Probucol		23288-49-5				
procainamide	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-06-9 614-39-1			Formulation, other	Arrhythmia, general
Procaine		59-46-1				
Procarbazine		671-16-9				
procaterol	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy 2-[(1-methylethyl)amino]butyl]-, monohydrochloride [CAS]	59828-07-8 60443-17-6 72332-33-3	GB	1496766	Antiasthma	
prochlorperazine	10H-Phenothiazine,2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6			Formulation, oral, other	Nausea and vomiting, general
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES	407882	Anticancer, immunological	Cancer, general
Procyclidine		77-37-2				
Procymate		13931-64-1				
Prodipine		31314-38-2				
Proflavine		92-62-6				
Progabide		62666-20-0				

NPC-UNIV-000004732

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 354 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-83-0			Formulation, transmucosal, systemic	Amenorrhoea
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethylester, (+/-)- [CAS]	57132-53-3 59209-40-4	GB	1467568	Anti-inflammatory	Inflammation, general
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-)- [CAS]	6620-60-6	DE	1518125	Antiulcer	Ulcer, gastric
Proheptazine		77-14-5				
Prolactin		9002-62-4				
Prolintane		493-92-5				
Prolonium		123-47-7				
Promazine		58-40-2				
Promedol		64-39-1				
Promegestone		34184-77-5				
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17ß)- [CAS]	39219-28-8	GB	1337198	Reproductive/gonadal, general	Acne
Promethazine		60-87-7				
Pronethalol		54-80-8				
propacetamol	Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester [CAS]	66532-85-2 66532-86-3	US	4127671	Formulation, parenteral, other	
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54063-53-5	GB	1307455	Antiarrhythmic	Fibrillation, ventricular
Propagermanium		12758-40-6				
Propallylonal		545-93-7				
Propamidine		104-32-5				
propane-1,2-diol	1,2-propanediol	57-55-6			Formulation, dermal, topical	Infection, fungal, general
Propanidid		1421-14-3				
Propantheline		50-34-0				
Proparacaine		499-67-2				
Propatyl		2921-92-8				
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2			Antifungal	Infection, trichomoniasis

NPC-UNIV-000004733

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 355 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB	1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9				
Propiomazine		362-29-8				
Propionic Acid		79-09-4				
propionyl L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB	2008578	Vasodilator, peripheral	Peripheral vascular disease
Propipocaine		3670-68-6				
Propiram		15686-91-6				
propiverine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9			Urological	Incontinence
Propizepine		10321-12-7				
propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	US	4056635	Anaesthetic, injectable	Anaesthesia
Propoxycaine		550-83-4				
Propoxyphene		469-62-5				
propranolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-98-9 525-66-6			Formulation, modified-release, <=24hr	Hypertension, general
Propylhexedrine		101-40-6				
Propyliodone		587-61-1				
Propylthiouracil		51-52-5				
Propyphenazone		479-92-5				
Proquazone		22760-18-5				
Proscillaridin		466-06-8				
Prostacyclin		35121-78-9				
Prostaglandin E_1		745-65-3				
Prostaglandin E_2		363-24-6				
Prostaglandin $F_{2\alpha}$		551-11-1				
Prosultiamine		59-58-5				
Protein C		60202-16-6				
Protheobromine		50-39-5				
Prothipendyl		303-69-5				
Protiofate		58416-00-5				

NPC-UNIV-000004734

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 356 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Protionamide		14222-60-7				
protizinic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha,10-dimethyl-, (+/-)- [CAS]	13799-03-6	US	3450698	Anti-inflammatory	
Protoanemonin		108-28-1				
Protokylol		136-70-9				
Protoporphyrin IX		553-12-8				
Protriptyline		438-60-8				
Pro-Urokinase		82657-92-9				
Proxazole		5696-9-3				
Proxibarbal		2537-29-3				
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]	12758-40-6	FR	2005110	Antiviral, other	Infection, hepatitis-B virus
Proxyphylline		603-00-9				
Prozapine		3426-8-2				
Prucalopride		179474-81-8				
prulifloxacin	1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP	315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		478-73-9				
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]				Formulation, modified-release, other	Rhinitis, allergic, general
pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- [CAS]	90-82-4, 8054-27-1, 345-78-8			Formulation, oral, other	Infection, respiratory tract, general
Psilocybin		520-52-5				
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2			Dermatological	Alopecia, general
p-Sulfanilylbenzylamine		4393-19-5				

NPC-UNIV-000004735

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 357 of 1101

Table IV

API G n ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
PT-141			US	6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3				
Puromycin		53-79-2				
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide				Anticancer, other	Cancer, general
Pyrantel		15686-83-6				
Pyrazinamide		98-96-4				
Pyridinol Carbamate		1882-26-4				
Pyridostigmine Bromide		101-26-8				
Pyridoxal 5-Phosphate		54-47-7				
Pyridoxine		58-56-0				
Pyrilamine		91-84-9				
Pyrimethamine		58-14-0				
Pyrinoline		1740-22-3				
Pyrisuccideanol		33605-94-6				
Pyrithione		1121-30-8				
Pyrithyldione		77-04-3				
Pyritinol		1098-97-1				
Pyrocatechol		120-80-9				
Pyrogallol		87-66-1				
Pyronaridine		74847-35-1				
Pyrovalerone		3563-49-3				
Pyroxylin		9004-70-0				
Pyrrobutamine		91-82-7				
Pyrrocaine		2210-77-7				
Pyrrolnitrin		1018-71-9				
Pyrvinium Pamoate		3546-41-6				
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US	3845039	Hypnotic/Sedative	Insomnia
Quercetin		117-39-5				

NPC-UNIV-000004736

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 358 of 1101

Table IV

API G n ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
quetiapine	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP	240228	Neuroleptic	Schizophrenia
Quinacillin		1596-63-0				
quinacrine	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl	83-89-6			Neurological	Creutzfeldt-Jakob disease
quinagolide	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3Alpha,4aAlpha,10aß)- (+/-)- [CAS]	87056-78-8 94424-50-7 97805-49-7	EP	77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP	49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]- [CAS]	82768-85-2	EP	46953	Antihypertensive, renin system	Hypertension, general
Quinapyramine		20493-41-8				
Quinbolone		2487-63-0				
Quinestradiol		1169-79-5				
Quinestrol		152-43-2				
Quinethazone		73-49-4				
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	US	3997542	Amoebicide	
quinidine	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5 56-54-2			Formulation, modified-release, other	Arrhythmia, general
Quinine		130-95-0				
Quinocide		525-61-1				
Quinupramine		31721-17-2				

NPC-UNIV-000004737

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 359 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Quinupristin		120138-50-3				
R-107500	cis-2,3,3a,8-tetrahydro-N,N-dimethyldibenz[c,f]isoxazolo[2,3-a]azepine-2-methanamine		WO	9614320	Anxiolytic	Anxiety, general
R-667			WO	0204439	COPD treatment	Emphysema, general
rabeprazole	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt- [CAS]	117976-89-3 117976-90-6	EP	268956	Antiulcer	Ulcer, gastric
racecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP	38758	Antidiarrhoeal	Diarrhoea, general
Racemethorphan		510-53-2				
raloxifene	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride [CAS]	82640-04-8 84449-90-1	EP	62503	Osteoporosis treatment	Osteoporosis
raltitrexed	L-glutamic acid, N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- [CAS]	112887-68-0	EP	239362	Anticancer, antimetabolite	Cancer, colorectal
ramatroban	9H-Carbazole-9-propanoic acid, 3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP	242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramifenazone		3615-24-5				
ramipril	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aß,6aß]]-[CAS]	87269-97-4 87333-19-5	EP	79022	Antihypertensive, renin system	Heart failure
ramosetron	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP	381422	Antiemetic	Nausea and vomiting, general
Ramot project No. 1097			US	5730992	Dermatological	Unspecified
Ranimustine		58994-96-0				

NPC-UNIV-000004738

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 360 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ranitidine	1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	66357-35-5	US	4128658	Antiulcer	Ulcer, duodenal
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-ni1-ethenediamine (1:1)- [CAS]	128345-62-0	EP	533281	Antiulcer	Ulcer, duodenal
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]	95635-55-5 95635-56-6	EP	126449	Antianginal	Angina, general
Ranpirnase		133737-96-9				
Rapacuronium		156137-99-4				
rasagiline	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, [CAS]	161735-79-1	US	5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5				
ravuconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- [CAS]	182760-06-1			Antifungal	Infection, meningitis, general
raxofelast	2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US	4999350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis- [CAS]	21416-67-1, 21416-87-5	GB	1234935	Anticancer, other	Cancer, general
RC-529	Tetradecanoic acid (1R)-1-(2-((2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-ß-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethanamine (1:1) [CAS]	216014-46-9			Immunostimulant, other	Vaccine adjunct
rebamipide	4-Quinolinepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE	3324034	Antiulcer	

NPC-UNIV-000004739

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 361 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
rebimastat	L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0			Anticancer, other	Cancer, lung, non-small cell
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,S*)- [CAS]	71620-89-8, 98769 81-4	US	4229449	Antidepressant	Depression, general
Remacemide		128298-28-2				
remifentanil	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-methyl ester- [CAS]	132539-07-2, 132875-61-7	EP	383579	Analgesic, other	Pain, general
reminertant	Tricyclo[3.3.1.13,7]decane-2-carboxylic acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP	699438	Neuroleptic	Schizophrenia
Remoxipride		80125-14-0				
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5 88721-77-1	JP	58188885	Gastroprokinetic	Irritable bowel syndrome
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO	9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	2(R)-4-Isobutylphenylpropionyl methanesulfonamide L-lysine salt		WO	0024710	Cardiovascular	Reperfusion injury
repinotan	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-29-0 144980-77-8	US	5137901	Neuroprotective	Ischaemia, cerebral
repirinast	4H-Pyrano[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0	US	4298610	Antiasthma	
Reposal		3625-25-0				

NPC-UNIV-000004740

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 362 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
reproterol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR	M5969	Antiasthma	Asthma
Rescimetol		73573-42-9				
Rescinnamine		24815-24-5				
Reserpiline		131-02-2				
Reserpine		50-55-5				
Resibufogenin		465-39-4				
resiquimod	1H-Imidazo(4,5-c)quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US	5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3				
Reteplase		133652-38-7				
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE	4200259	Antiepileptic	Epilepsy, general
retinoic acid	Retinoic acid [CAS]	302-79-4			Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Revimid			US	6281230	Anticancer, other	Cancer, myeloma
R-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4			Anticancer, other	Cancer, prostate
Rho (D) Immune Globulin (Human)						
Rho-kinase inhibitors			WO	0156988	Antiasthma	Unspecified
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-ß-D-ribofuranosyl- [CAS]	36791-04-5	US	4211771	Antiviral, other	Infection, haemorrhagic fever
Riboflavin		146-17-8				
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-[ß-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB	1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0				
Ridogrel		110140-89-1				

NPC-UNIV-000004741

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 363 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US	4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo- [CAS]	129791-92-0 129791-94-2 133633-12-2	EP	366914	Antimycobacterial	Infection, tuberculosis
rifametane	Rifamycin, 3-[[[1-(diethylamino)ethylidene]hydrazono]methyl]- [CAS]	94168-98-6	EP	119571	Antimycobacterial	Infection, general
Rifamide		2750-76-7				
rifampicin + trimethoprim	Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	61498-94-0			Formulation, fixed-dose combinations	Infection, general
Rifampin		13292-46-1				
Rifamycin SV		6998-60-3				
rifapentine	Rifamycin, 3-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]- [CAS]	61379-65-5	DE	2608218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]-pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB	2079270	Antibiotic, other	Infection, GI tract
rifaximine cream	4-deoxy-4'-methylpyrido[1',2'-1,2]imidoazo[5,4-c]rifamycin SV	80621-81-4	BE	888895	Formulation, dermal, topical	Infection, dermatological
Rilmazafone		99593-25-6				
rilmenidine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1 54249-57-9	DE	2362754	Antihypertensive, adrenergic	Hypertension, general
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)- [CAS]	1744-22-5	EP	50551	Neuroprotective	Amyotrophic lateral sclerosis
Rimantadine		13392-28-4				

NPC-UNIV-000004742

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 364 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
rimazolium	4H-Pyrido[1,2-a]pyrimidinium, 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-6 35615-72-6	DE	2461349	Analgesic, NSAID	
rimexolone	Androsta-1,4-dien-3-one,11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11ß,16Alpha,17ß)- [CAS]	49697-38-3	DE	2301317	Ophthalmological	Inflammation, ocular
Rimiterol		32953-89-2				
rimonabant	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US	5624941	Anorectic/Antiobesity	Obesity
riodoxol	1,3-Benzenediol, 2,4,6-triiodo- [CAS]	19403-92-0	US	3755251	Antiviral, other	
Rioprostil		77287-05-9				
risedronate	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1	EP	304961	Osteoporosis treatment	Paget's disease
Risedronic Acid		105462-24-6				
risperidone	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2	EP	196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanserin		87051-43-2				
Ritipenem		84845-57-8				
ritodrine	Benzenemethanol, 4-hydroxy-Alpha-[1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R*,S*)- [CAS]	23239-51-2 26652-09-5	US	3410944	Labour inhibitor	Labour, preterm
ritonavir	2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))- [CAS]	155213-67-5	WO	9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab		174722-31-7				
rivastigmine	Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester, (S)- [CAS]	123441-03-2 129101-54-8	DE	3805744	Cognition enhancer	Alzheimer's disease

NPC-UNIV-000004743

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 365 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
rizatriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	145202-66-0 159776-67-7 144034-80-0	EP	497512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5			Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine				Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine				Anticancer, antimetabolite	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl- [CAS]	180384-56-9	WO	9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine		53716-44-2				
rocuronium	Pyrrolidinium, 1-[(2ß,3Alpha,5Alpha,16ß,17ß)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide- [CAS]	104855-17-6 104884-91-5 119302-91-9 143558-00-3	EP	287150	Muscle relaxant	Muscle spasm, general
rofecoxib	2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl- [CAS]	162011-90-7	US	5474995	Analgesic, NSAID	Arthritis, osteo
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)- [CAS]	162401-32-3	WO	9501338	COPD treatment	Chronic obstructive pulmonary disease
rokitamycin	Leucomycin V, 4B-butanoate 3B-propanoate [CAS]	74014-51-0	US	4242504	Macrolide antibiotic	Infection, general
Rolipram		61413-54-5				
Rolitetracycline		751-97-3				
Romurtide		78113-36-7				
Ronifibrate		42597-57-9				
ropinirole	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9	EP	266033	Antiparkinsonian	Parkinson's disease

NPC-UNIV-000004744

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 366 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	EP	239710	Anaesthetic, local	Anaesthesia
Roquinimex		84088-42-6				
rosaprostol	Cyclopentaneheptanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB	1523355	Prostaglandin	
Rosaramicin		35834-26-5				
Rose Bengal		632-68-8				
rosiglitazone	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-2-butenedioate (1:1) [CAS]	122320-73-4 155141-29-0	US	5002953	Antidiabetic	Diabetes, Type II
rosoxacin	3-Quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US	3753993	Quinolone antibacterial	Infection, gonorrhoea
rostaporfin	Tin, dichloro[ethyl 3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26]-, (OC-6-13)- [CAS]	114494-17-6			Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimdinyl)-3,5-dihydroxy- (S-(R*, S*-(E))) [CAS]	147098-20-2	JP	2648897	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
rotigotine	1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]	99755-59-6	US	4564628	Antiparkinsonian	Parkinson's disease
Rotraxate		92071-51-7				
Roxarsone		121-19-7				
roxatidine	Acetamide, 2-(acetyloxy)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, [CAS]	78628-28-1 93793-83-0	EP	24510	Antiulcer	Ulcer, gastric
roxifiban	L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, [CAS]	176022-59-6	US	5849736	Antithrombotic	Thrombosis, general
Roxindol		112192-04-8				

NPC-UNIV-000004745

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 367 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP	33255	Macrolide antibiotic	Infection, general
RPR-109881A	Benzenepropanoic acid, ß-(((1,1-dimethylethoxy)carbonyl)amino)-Alpha-hydroxy-(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,47,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4) cyclopropa (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, betaS [CAS]	192573-38-9			Anticancer, other	Cancer, lung, general
RPR-130401	4,9-Ethano-3aH-benz[f]isoindole-3a-carboxylicacid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO	9829390	Anticancer, other	Cancer, general
R-roscovitine			US	6316456	Anticancer, other	Cancer, lung, non-small cell
RS-0406	N'N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine				Neuroprotective	Alzheimer's disease
RSR-13		131179-95-8				
Rubijervine		79-58-3				
rubitecan	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US	6485514	Anticancer, other	Cancer, pancreatic
ruboxistaurin	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione,9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	169939-94-0			Symptomatic antidiabetic	Retinopathy, diabetic
Rufinamide		106308-44-5				

NPC-UNIV-000004746

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 368 of 1101

Table IV

API G neric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
rufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP	165375	Quinolone antibacterial	Infection, general
rupatadine	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, trihydrochloride- [CAS]	156611-76-6	EP	0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		153-18-4				
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]	189448-35-9	WO	9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-oic acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO	9727314	Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7			Cognition enhancer	Cognitive disorder, general
S-18886	1-Napthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5			Antithrombotic	Thrombosis, general
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid				Neuroprotective	Unspecified
S-3578	7ß-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate				Cephalosporin, injectable	Infection, general

NPC-UNIV-000004747

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 369 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
S-36496	2-{N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-{3-[(4-isopropylthiazol-2-yl)methyloxy]benzyl}sulfamoyl}benzoic acid				Antiasthma	Asthma
S-36527	2-{N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-{3-[2-(4-cyclobutylthiazol-2-yl)ethyl]benzyl}sulfamoyl}benzoic acid				Antiasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3yl]-5(Z)-heptenoic acid				Antiallergic, non-asthma	Allergy, general
S-8510	Imidazo[4,5-d]pyrano[4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP	556008	Cognition enhancer	Alzheimer's disease
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO	9308155	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
Sabcomeline		159912-53-5				
Sabeluzole		104383-17-7				
S-Adenosylmethionine		29908-03-0				
safinamide	(S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU	711309	Antiepileptic	Epilepsy, general
Salacetamide		487-48-9				
Salazosulfadimidine		2315-8-4				
salbutamol	1,3-Benzenedimethanol,Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9	EP	451745	Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3				
Salicyl Alcohol		90-01-7				

NPC-UNIV-000004748

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 370 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Salicylamide		65-45-2				
Salicylamide O-Acetic Acid		25395-22-6				
Salicylanilide		87-17-2				
Salicylic Acid		69-72-7				
Salicylsulfuric Acid		89-45-2				
Salinazid		495-84-1				
salmeterol	1,3-Benzenedimethanol, 4-hydroxy-Alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (±)- 1-hydroxy-2-naphthalenecarboxylate [CAS]	89365-50-4 94749-08-3	WO	9006775	Antiasthma	Asthma
Salsalate		552-94-3				
Salverine		6376-26-7				
Samarium ^{153}Sm Lexidronam		154427-83-5				
sampatrilat	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1-[(2S)-3-amino-2-carboxypropyl]cyclopentanecarbonyl- [CAS]	129981-36-8	EP	358398	Antihypertensive, renin system	Hypertension, general
Sancycline		808-26-4				
Saperconazole		110588-57-3				
sapropterin	4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-, dihydrochloride, [6R-[6R*(1R*,2S*)]]- [CAS]	69056-38-8 62989-33-7	EP	191335	Antidepressant	Hyperphenylalaninaemia
saquinavir	Butanediamide, N1-[3-[3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2[1R*(R*),2S*],3Alpha,4aß,8aß]]- [CAS]	127779-20-8	EP	432695	Antiviral, anti-HIV	Infection, HIV/AIDS
Saralasin		34273-10-4				

NPC-UNIV-000004749

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 371 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
saredutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)- [CAS]	142001-63-6	EP	474561	Antiasthma	Asthma
sarizotan	3-Pyridinemethanamine, N-((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)- [CAS]	177975-08-5			Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester [CAS]	125926-17-2	EP	398326	Antithrombotic	
Satigrel		111753-73-2				
satraplatin	Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	129580-63-8	EP	328274	Anticancer, alkylating	Cancer, prostate
Satumomab		144058-40-2				
SB-237376	N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide, HCl				Antiarrhythmic	Fibrillation, atrial
SB-238039	(5(-2-phenylamino-4-pyrimidinyl)-4-)(4-fluorophenyl)-1-(4-piperidinyl)imidazole				Anticancer, other	Cancer, general
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide				Neuroleptic	Schizophrenia
Scarlet Red		85-83-6				
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]- [CAS]	217963-18-3	EP	618204	Cardiostimulant	Heart failure
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo [a,d] cyclohepten-S-yl]-N, N-dimethyl-ethanamine				Immunosuppressant	Inflammation, general

NPC-UNIV-000004750

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 372 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Sch-57790	1-Piperazineacetonitrile, 4-cyclohexyl-alpha-[4-[(S)-(4-methoxyphenyl)sulfinyl]phenyl]- [CAS]	221660-80-6			Cognition enhancer	Alzheimer's disease
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4			Antiparkinsonian	Parkinson's disease
Scillarenin		465-22-5				
Scopolamine		51-34-3				
Scopolamine N-Oxide		97-75-6				
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester, [7(S)-(1Alpha,2ß,4ß,5Alpha,7ß)]- [CAS]	51-34-3	US	4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology			US	6046188	Antiasthma	Unspecified
secalciferol	9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3ß,5Z,7E,24R)- [CAS]	55721-11-4	EP	301167	Osteoporosis treatment	Osteodystrophy
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	FR	M3270	Protozoacide	Infection, trichomoniasis
Secobarbital		309-43-3				
selegiline	Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-, (R)- [CAS]	14611-51-9	GB	1153578	Antiparkinsonian	
Selenomethionine		1464-42-2				
Sematilide		101526-83-4				
Semotiadil		116476-13-2				
seocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1R-(1Alpha(1R*,2E,4E),3aß,4E(1R*,3S*,5Z),7aAlpha))- [CAS]	134404-52-7	WO	9100855	Anticancer, other	Cancer, liver
Sepimostat		103926-64-3				
seratrodast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+/-)- [CAS]	103187-07-1 112665-43-7	EP	232089	Antiasthma	Asthma

NPC-UNIV-000004751

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 373 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
sertaconazole	1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	99592-32-2	EP	151477	Antifungal	Infection, dermatological
sertindole	2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]	106516-24-9	EP	392959	Neuroleptic	Schizophrenia
sertraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79559-97-0 79617-96-2 79617-97-3	EP	30081	Antidepressant	Depression, general
Setastine		64294-95-7				
sevelamer	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US	5496545	Urological	Renal failure
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE	1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluro-2-benzothiazolyl)methyl)- [CAS]	143162-65-6			Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	106650-56-0 84485-00-7	GB	2098602	Anorectic/Antiobesity	Obesity
siccanin	(4aS-(4aAlpha,6aAlpha,11bAlpha,13aR*,13bAlpha))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzo[a]furo[2,3,4-mn]xanthen-11-ol	22733-60-4	JP	37003548	Antifungal	
sildenafil	Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0 139755-83-2	WO	9428902	Male sexual dysfunction	Impotence
silodosin	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]- [CAS]	160970-54-7	EP	600675	Urological	Dysuria
Silver Lactate		128-00-7				

NPC-UNIV-000004752

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 374 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Silver Picrate		146-84-9				
silver sulfadiazine	N'-2-pyrimidinylsulfanilamide monosilver salt	22199-08-2 68-35-9			Anti-infective, other	Infection, general
Simetride		154-82-5				
Simfibrate		14929-11-4				
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7ß,8ß(2S*,4S*),8aß]]-[CAS]	79902-63-9	US	4444784	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
Sincalide		25126-32-3				
Sintropium Bromide		79467-19-9				
Sisomicin		32385-11-8				
sitafloxacin	3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1Alpha(S*),2Alpha]]-, hydrate	127254-12-0	EP	341493	Quinolone antibacterial	Infection, general
sitamaquine	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)- [CAS]	5330-29-0 57695-04-2			Protozoacide	Infection, leishmaniasis
sitaxsentan	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-o-toly]acetyl]-3-thiophenesulfonamide	184036-34-8	US	5464853	Antihypertensive, other	Hypertension, pulmonary
sivelestat	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]- [CAS]	127373-66-4	EP	347168	Respiratory	Systemic inflammatory response syndrome
SJA-6017	Butanamide, 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl.).-3-methyl-, (2S)-[CAS]	190274-53-4	EP	771565	Ophthalmological	Cataract
SL-65-1498	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one		EP	607076	Anxiolytic	Anxiety, general

NPC-UNIV-000004753

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 375 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2'R)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenyl-butyl-]-cyclopentan-1-carbonylamino]-2,3,4,5-tetra-hydro-2-oxo-1H-benzapin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sm153 lexidronam	Samarate(5-)-153Sm, (((1,2-ethanediylbis(nitrilobis(methylene)))tetrakis(phosphonato))(8-)-N,N',OP,OP',OP'',OP''')-, pentasodium, (OC-6-21)- [CAS]	160369-78-8		Analgesic, other	Pain, cancer
S-Methylmethionine		4727-40-6			
SMP-300	N-(Aminoiminomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo[3,2,1-kl][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate			Antianginal	Angina, general
SN-38	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl	100286-90-6		Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	((+)-methyl (4S)-3-{[(3-{4-[3-(acetylamino)phenyl]-1-piperidinyl}propyl)amino] carbonyl}-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride)			Anxiolytic	Anxiety, general
SOA-132	2-Naphthalenecarboxamide, N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1		Formulation, inhalable, topical	Asthma

NPC-UNIV-000004754

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 376 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
soblidotin	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*(1S*,2S*)]]- [CAS]	149606-27-9	WO	9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrerol		498-71-5				
sobuzoxane	Carbonic acid, 1,2-ethanediylbis[(2,6-dioxo 4,1-piperazinediyl)methylene]bis(2-methylpropyl) ester [CAS]	98631-95-9	EP	140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5				
Sodium Arsphenamine		1936-28-3				
Sodium Chloride						
Sodium Dibunate		14992-59-7				
Sodium Folate		6484-89-5				
Sodium Formaldehydesulfoxylate		149-44-0				
Sodium Glycerophosphate		1334-74-3				
Sodium Hyaluronate						
Sodium Iodomethamate		519-26-6				
Sodium Nitrite		7632-00-0				
Sodium Nitroprusside		14402-89-2				
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2			Psychostimulant	Narcolepsy
Sodium Ph nolsulfonate		1300-51-2				
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7			Formulation, other	Hyperammonaemia

NPC-UNIV-000004755

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 377 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous		US	6162464	Formulation, oral, other	Surgery adjunct
sodium prasterone sulfate	3ß-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP	380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate		137-40-6				
sodium salicylate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7			Formulation, oral, solubility-enhanced	Pain, general
Sodium Tetradecyl Sulfate		139-88-8				
sofalcone	Acetic acid, [5-[(3-methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]	64506-49-6	GB	1523241	Antiulcer	
Solasulfone		133-65-3				
solifenacin	*Butanedioic acid compd with* (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1) [CAS]	242478-38-2			Urological	Overactive bladder
Sorbinicate	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE	883352	Hypolipaemic/Antiatherosclerosis	
Sorbitol		50-70-4				
Sorivudine		77181-69-2				
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- [CAS]	3930-20-9 959-24-0			Antiarrhythmic	
Soterenol		13642-52-9				
Sozoiodolic Acid		554-71-2				
spaglumic acid	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS]	3106-85-2 80619-64-3			Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-*Quinolinecarboxylic acid*, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP	221463	Quinolone antibacterial	Infection, respiratory tract, general
Sparteine		90-39-1				

NPC-UNIV-000004756

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 378 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
SPA-S-843	Candicin D, 18-decarboxy-40-demethyl-3,7-*dideoxo*-N3'-((dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N47-methyl-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]	202748-83-2	US	5298495	Antifungal	Infection, fungal, general
Spasmolytol		25333-96-4				
SPD-754	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl- (2R-cis)-	160707-69-7	US	6228860	Antiviral, anti-HIV	Infection, HIV/AIDS
Spectinomycin		1695-77-8				
SPI-339	4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-yl)propionylamino]benzoic acid ethyl ester				Cognition enhancer	Alzheimer's disease
Spiperone		749-02-0				
spirapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7[R*(R*)],8R*]]- [CAS]	83647-97-6	EP	50800	Antihypertensive, renin system	Hypertension, general
Spirogermanium		41992-23-8				
spironolactone	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-,Gamma-lactone,(7Alpha,17Alpha)- [CAS]	52-01-7	EP	124147	Formulation, dermal, topical	Acne
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy- [CAS]	185913-78-4	WO	9715556	Cardiostimulant	Heart failure
SR-144190	Morpholine, 4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]-, (2R)- [CAS]	201152-86-5	WO	9623787	Anxiolytic	Anxiety, general

NPC-UNIV-000004757

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 379 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]	221671-61-0	WO	9915525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide				Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]- [CAS]	136381-85-6	EP	432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP	376850	Anticancer, other	Cancer, myeloma
SR-58611	Acetic acid, [[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride [CAS]	121524-09-2	EP	303546	GI inflammatory/bowel disorders	Irritable bowel syndrome
SS732			US	5385900	Formulation, mucosal, topical	Infection, ocular
SS-750	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US	6083968	Antifungal	Infection, fungal, general
ß-alethine	Propanamide, N, N'(dithiodi-2,1-ethanediyl)bis(3-amino)- [CAS]	646-08-2			Anticancer, immunological	Cancer, myeloma
SSR-149415	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide		WO	0155130	Antidepressant	Depression, general
SSR-180575	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-6]indol-1-yl)-N,N-dimethylacetamide				Neuroprotective	Unspecified

NPC-UNIV-000004758

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 380 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US	6221879	Neuroleptic	Schizophrenia
SSR-591813	(5aS,8S,10aR)-5a,6,9,10-tetrahydro, 7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine				Dependence treatment	Addiction, nicotine
SST-101	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2			Formulation, transdermal, other	Angina, general
SSY-726	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US	5147886	Antifungal	Infection, fungal, general
ST-200	1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	DE	3015635	Cognition enhancer	Dementia, senile, general
stachyflin			WO	9711947	Antiviral, other	Infection, influenza virus
Stallimycin		636-47-5				
Stampidine			US	6350736	Antiviral, anti-HIV	Infection, HIV/AIDS
Stannous Pyrophosphate		15578-26-4				
stannsoporfin	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24]stannate(2-)	106344-20-1			Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6				
Stanozolol		10418-03-8 (2'*H* form); 302-96-5 (1'*H* form)				
Staph aureus ther			US	6376652	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO	9629341	Immunosuppressant	Unspecified

NPC-UNIV-000004759

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 381 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
stavudine	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS]	3056-17-5	EP	501511	Antiviral, anti-HIV	Infection, HIV/AIDS
Stenbolone		5197-58-0				
stepronin	Glycine, N-[1-oxo-2-[(2-thienylcarbonyl)thio]propyl]- [CAS]	72324-18-6	US	4242354	Antitussive	Cough
Stibocaptate		27279-76-1				
Stibophen		15489-16-4				
Stilbamidine		122-06-5				
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4			Antiepileptic	Epilepsy, general
Streptodornase		37340-82-2				
Streptomycin		57-92-1				
Streptonicozid		5667-71-0				
Streptonigrin		3930-19-6				
Streptozocin		18883-66-4				
strontium ranelate	3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP	415850	Osteoporosis treatment	Osteoporosis
strontium-89 chloride	*Strontium chloride (89SrCl2) [CAS]*	38270-90-5			Analgesic, other	Pain, cancer
Succimer		304-55-2				
Succinimide		123-56-8				
Succinylcholine		55-94-7				
Succinylcholine		71-27-2				
Succinylsulfathiazole		116-43-8				
Succisulfone		5934-14-5				
Suclofenide		30279-49-3				
sucralfate	Aluminium, hexadeca-μ-hydroxytetracosahydroxy(μ8-(1,3,4,6-tetra-O-sulfo-ß-D-fructofuranosyl-Alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca- [CAS]	54182-58-0	JP	58208233	Antiulcer, Formulation, oral, other	Ulcer, general
sufentanil	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US	3998834	Analgesic, other, formulation implant	Pain, general

NPC-UNIV-000004760

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 382 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
sulbactam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	GB	2000138	Antibiotic, other	Infection, general
sulbactam + ampicillin		117060-71-6	US	4234579	Antibiotic, other	Infection, general
sulbenicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6ß(S*)]]- [CAS]	28002-18-8 41744-40-5	GB	1289358	Penicillin, injectable	Infection, pseudomonal
Sulbentine		350-12-9				
sulbutiamine	Propanoic acid, 2-methyl-, dithiobis[3-[1-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3			Neurological	Unspecified
sulconazole	1H-Imidazole, 1-[2-[[(4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-, (+/-)- [CAS]	61318-90-9 61318-91-0	US	4055652	Antifungal	Infection, fungal, general
Sulesomab		167747-19-5				
Sulfabenzamide		127-71-9				
Sulfacetamide		144-80-9				
Sulfachlorpyridazine		80-32-0				
Sulfachrysoidine		485-41-6				
Sulfacytine		17784-12-2				
Sulfadiazine		68-35-9				
Sulfadicramide		115-68-4				
Sulfadimethoxine		122-11-2				
Sulfadoxine		2447-57-6				
Sulfaethidole		94-19-9				
Sulfaguanidine		57-67-0				
Sulfaguanole		27031-08-9				
Sulfalene		152-47-6				
Sulfaloxic Acid		14376-16-0				
Sulfamerazine		127-79-7				
Sulfameter		651-06-9				
Sulfamethazine		57-68-1				

NPC-UNIV-000004761

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 383 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1				
Sulfamethomidine		3772-76-7				
Sulfamethoxazole		723-46-6				
Sulfamethoxypyridazine		80-35-3				
Sulfametrole		32909-92-5				
Sulfamidochrysoidine		103-12-8				
Sulfamoxole		729-99-7				
Sulfanilamide		63-74-1				
Sulfanilic Acid		121-57-3				
Sulfanilylurea		547-44-4				
Sulfaperine		599-88-2				
Sulfaphenazole		526-08-9				
Sulfaproxyline		116-42-7				
Sulfapyrazine		116-44-9				
Sulfapyridine		144-83-2				
Sulfarside		1134-98-1				
Sulfarsphenamine		618-82-6				
sulfasalazine	Benzoic acid, 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]- [CAS]	599-79-1			Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8				
Sulfasymazine		1984-94-7				
Sulfathiazole		72-14-0				
Sulfathiourea		515-49-1				
Sulfinalol		66264-77-5				
Sulfinpyrazone		57-96-5				
Sulfiram		95-05-6				
Sulfisomidine		515-64-0				
Sulfisoxazole		127-69-5				
Sulfobromophthalein		71-67-0				
Sulfonethylmethane		76-20-0				
Sulfoniazide		3691-81-4				

NPC-UNIV-000004762

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 384 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Sulfonmethane		115-24-2				
Sulforidazine		14759-06-9				
Sulfoxone		144-75-2				
sulindac	cis-5-fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]indene-3-acetic acid	38194-50-2	US	3725548	Anti-inflammatory	Inflammation, general
Sulisatin		54935-03-4				
Sulisobenzone		4065-45-6				
Sulmarin		29334-07-4				
Sulmazole		73384-60-8				
Suloctidil		54063-56-8				
Sulphan Blue		129-17-9				
sulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1			Alimentary/Metabolic, other	
sulprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),2ß(1E,3R*),3Alpha]]- [CAS]	60325-46-4	US	4024179	Prostaglandin	Abortion
sultamicillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5,alpha.,6.beta.(S*)))-[CAS]	117060-71-6 76497-13-7	GB	2044255	Penicillin, oral	Infection, general
Sulthiame		61-56-3				
sultopride	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR	M5916	Neuroleptic	Psychosis, general
Sultosilic Acid		57775-26-5				

NPC-UNIV-000004763

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 385 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
sumanirole	4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) [CAS]	179386-44-8	WO	9514020	Antiparkinsonian	Parkinson's disease
sumatriptan	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP	147107	Antimigraine	Migraine
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-{4-[4-(4-fluorobenzyl)phenyl]piperazin-1-yl}propan-2(s)-ol dimethanesulfonate				Neuroprotective	Infarction, cerebral
suplatast	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP	59167564	Antiasthma	Asthma
Suprofen		40828-46-4				
Suramin		129-46-4				
surfactant TA	Beractant [CAS]	108778-82-1	WO	9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5				
Suxibuzone		27470-51-5				
SYM-1010			US	5830998	Antiepileptic	Epilepsy, general
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3			Analgesic, other	Pain, general
SYM-2207	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide				Neuroprotective	Ischaemia, cerebral
Symclosene		87-90-1				
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid				Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azetidinesulfonic acid, 3-[[(2E)-[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]-2-thienylacetyl]amino]-2-methyl-4-oxo, (2S,3S)- [CAS]	214963-75-4	WO	9847895	Antibacterial, other	Infection, general

NPC-UNIV-000004764

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 386 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US	6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5				
Syrosingopine		84-36-6				
T-1095	1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-ß-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP	850948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-l-trytophyl-L-ananyl-L-seryl-L-leucyl-L-trytophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO	9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid				Quinolone antibacterial	Infection, dermatological
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP	565965	Cognition enhancer	Alzheimer's disease
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0			Anticancer, other	Cancer, liver
T-82			US	5190951	Cognition enhancer	Alzheimer's disease

NPC-UNIV-000004765

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 387 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
TA-2005	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy 2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]	137888-11-0	US	4579854	Antiasthma	Asthma
TA-2005	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy 2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]		WO	189480	Formulation, inhalable, solution	Asthma
TA-993	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel-(-)-, (2Z)-2-butenedioate [CAS]	122024-98-0	JP	01045376	Antithrombotic	Peripheral vascular disease
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-napthalenepropionamide	170851-70-4 193079-69-5			Releasing hormones	Growth hormone deficiency
tacalcitol	9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3ß,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP	129003	Antipsoriasis	Keratosis
tacedinaline	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2	DE	3613571	Anticancer, other	Cancer, pancreatic
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	1684-40-8 321-64-2	EP	332147	Cognition enhancer	Alzheimer's disease
Tacrolimus		104987-11-3				
tadalafil	Pyrazino(1',2':1,6)pyrido(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	171596-29-5	US	6143746	Male sexual dysfunction	Impotence
tafenoquine	1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- [CAS]	106635-80-7 106635-81-8 80065-55-0	US	4617394	Antimalarial	Infection, malaria
tafluposide		179067-42-6	WO	9612727	Anticancer, other	Cancer, general
TAK-375	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide				Hypnotic/Sedative	Insomnia

NPC-UNIV-000004766

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 388 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[[3-[4-(Diphenylmethoxy)-piperidino]imidazo[1,2-b]pyridazin-2-yl-2-methylpropionic acid dihydrate				Antipruritic/inflamm, allergic	Eczema, atopic
TAK-559	(E)-4-{4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid				Antidiabetic	Diabetes, general
Taka-Diastase		9001-19-8				
talampanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine,7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-,(8R)- [CAS]	161832-65-1	US	5639751	Antiepileptic	Epilepsy, general
Talampicillin		47747-56-8				
talaporfin	N-[[(2S,3S)-18-Carboxy-2-(2-carboxy-ethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl]-L-aspartic acid	220201-34-3			Radio/chemosensitizer	Cancer, lung, general
Talastine		16188-61-7				
Talbutal		115-44-6				
Talinolol		57460-41-0				
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4 36085-73-1	DE	3503963	Antiparkinsonian	Schizophrenia
talnetant	4-Quinolinecarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	174636-32-9	WO	9532948	GI inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester [CAS]	66898-62-2	BE	858864	Anti-inflammatory	Inflammation, ocular
taltirelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6 dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	JP	61033197	Neurological	Dyskinesia, general
tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	US	4536516	Anticancer, hormonal	

NPC-UNIV-000004767

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 389 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tamsulosin	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP	34432	Prostate disorders	Benign prostatic hyperplasia
tandospirone	4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3aAlpha,4ß,7ß,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP	82402	Anxiolytic	Anxiety, general
Tannoform		9010-29-1				
Taprostene		108945-35-3				
tariquidar	3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]- [CAS]	206873-63-4	WO	9817648	Radio/chemosensitizer	Cancer, lung, non-small cell
TAS-103	6-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	174634-09-4	WO	9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		145733-36-4				
Taurocholic Acid		81-24-3				
Taurolidine		19388-87-5				
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	US	4778816	Antiasthma	
tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester [CAS]	118292-40-3	EP	284288	Antipsoriasis	Psoriasis
Tazobactam		89786-04-9				
tazobactam + piperacillin			JP	58225091	Antibiotic, other	Infection, general
TBC-3711		374680-51-0			Cardiovascular	Heart failure
TCH-346	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin				Neuroprotective	Amyotrophic lateral sclerosis
tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]	82200-24-6			Beta-lactam antibiotic	Infection, streptococcal

NPC-UNIV-000004768

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 390 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tecadenoson	Adenosine, N-[(3R)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO	9808855	Antiarrhythmic	Tachycardia, supraventricular
tecastemizole	1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl- [CAS]	75970-99-9	US	4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium ^{99m}Tc Bicisate		121281-41-2				
Technetium ^{99m}Tc Mertiatide		125224-05-7; 104348-91-6				
Technetium ^{99m}Tc Sestamibi		109581-73-9				
Technetium ^{99m}Tc Teboroxime		104716-22-5				
Teclothiazide		4267-5-4				
Teclozan		5560-78-1				
tedisamil	Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]	90961-53-8	EP	102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1				
tegafur	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB	1168391	Anticancer, antimetabolite	Cancer, general
tegafur + uracil	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP	224885	Anticancer, antimetabolite	Cancer, breast
tegaserod	Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-pentyl-, (Z)-2-butenedioate [CAS]	189188-57-6 145158-71-0			GI inflammatory/bowel disorders	Irritable bowel syndrome
Teicoplanin		61036-64-4				
telbivudine	ß-L-2'-deoxythymidine	3424-98-4			Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6				

NPC-UNIV-000004769

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 391 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
telithromycin	3-De((2,6-dideoxy-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	EP	680967	Macrolide antibiotic	Infection, respiratory tract, general
telmesteine	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4			COPD treatment	Bronchitis, chronic
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	144701-48-4	EP	502314	Antihypertensive, renin system	Hypertension, general
telomerase inhibs			WO	9941261	Anticancer, other	Cancer, general
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US	3197467	Hypnotic/Sedative	Insomnia
temiverine	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butynyl ester, [CAS]	129927-33-9	GB	2222828	Urological	Pollakisuria
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2Alpha,6ß(R*)]]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US	4495188	Antihypertensive, renin system	Hypertension, general
Temocillin		66148-78-5				
temoporfin	Phenol, 3,3',3'',3'''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP	337601	Radio/chemosensitizer	Cancer, head and neck
temozolomide	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE	3231255	Anticancer, alkylating	Cancer, brain, general
tenatoprazole	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-98-4	US	4808596	Antiulcer	Ulcer, gastric
Tenecteplase		191588-94-0				
Tenidap		120210-48-2				

NPC-UNIV-000004770

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 392 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-ß-D-glucopyranosyl]oxy]-, [5R-[5Alpha,5aß,8aAlpha,9ß(R*)]]- [CAS]	29767-20-2	US	3524844	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS]	147127-20-6			Antiviral, anti-HIV	Infection, HIV/AIDS
tenofovir disoproxil	2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxymethyl) bis(1-methylethyl)ester, 5-oxide (R)-, (E)-2-butenedioate	202138-50-9			Antiviral, anti-HIV	Infection, HIV/AIDS
Tenonitrozole		3810-35-3				
tenoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	59804-37-4	GB	1519811	Antiarthritic, other	
Tenuazonic Acid		610-88-8				
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	3796-63-2 6809-52-5			Antiulcer	
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- [CAS]	63074-08-8 63590-64-7 70024-40-7	US	4112097	Antihypertensive, adrenergic	Hypertension, general
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-80-5 91161-71-6	EP	24587	Antifungal	Infection, dermatological
terbutaline	1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS]	23031-25-6			Formulation, mucosal, topical	Dysmenorrhoea
terconazole	Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS]	67915-31-5	US	4358449	Antifungal	Vaginitis

NPC-UNIV-000004771

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 393 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]	50679-08-8	US	3878217	Antiallergic, non-asthma	
terguride	Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]- [CAS]	37686-84-3	EP	159522	Antiprolactin	Hyperprolactinaemia
Terlipressin		14636-12-5				
Terodiline		15793-40-5				
Terofenamate		29098-15-5				
Terpin		80-53-5				
tertatolol	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+\-)- [CAS]	33580-30-2 83688-84-0 34784-64-0	GB	1308191	Antihypertensive, adrenergic	Hypertension, general
tert-Pentyl Alcohol		75-85-4				
tesaglitazar	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl] propanoic acid				Antidiabetic	Diabetes, Type II
tesmilifene	Ethanamine, N,N-Diethyl-2-(4-(phenylmethyl)phenoxy)- [CAS]	92981-78-7			Radio/chemosensitizer	Cancer, breast
Testolactone		968-93-4				
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17ß) - [CAS]	58-22-0 5949-44-0			Formulation, transdermal, systemic	Hormone replacement therapy
tetrabamate		60763-47-5	DE	2748794	Anxiolytic	Addiction, alcohol
Tetrabarbital		76-23-3				
Tetrabenazine		58-46-8				
Tetracaine		136-47-0				
Tetrachloroethylene		127-18-4				
tetracine	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6			Formulation, transdermal, systemic	Pain, general
tetracycline	2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6ß,12aAlpha)]- [CAS]	60-54-8			Formulation, oral, other	Infection, oral

NPC-UNIV-000004772

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 394 of 1101

Tabl IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0				
Tetrandrine		518-34-3				
T trantoin		52094-70-9				
Tetrazepam		10379-14-3				
Tetrofosmin		127502-06-1				
tetroxoprim	2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl]-[CAS]	53808-87-0 74515-38-1	US	3992379	Trimethoprim and analogues	Infection, general
Tevenel®		4302-95-8				
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	130306-02-4	US	5616702	Anticancer, antimetabolite	Cancer, colorectal
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0			Cardiostimulant	Oedema, general
thalidomide	1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1			Dermatological	Infection, dermatological
Thenaldine		86-12-4				
Thenyldiamine		91-79-2				
Theobromine		83-67-0				
Theofibrate		54504-70-0				
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9 5967-84-0			Formulation, modified-release, other	Asthma
Thiabendazole		148-79-8				
Thiacetazone		104-06-3				
thiacymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4			Cognition enhancer	Alzheimer's disease
Thialbarbital		467-36-7				
Thiamine		59-43-8				
Thiamine		154-87-0				
Thiamine		67-16-3				
Thiamiprine		5581-52-2				

NPC-UNIV-000004773

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 395 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolinobutazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbarsone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thioimreg	L-Thiotyrosinyl-glycinyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thioproperazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphonoformic acid			Antiviral, anti-HIV	Infection, HIV/AIDS
Thiphenamil		82-99-5			
Thiram		137-26-8			
Thonzylamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			

NPC-UNIV-000004774

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 396 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Thurfyl Nicotinate		70-19-9				
thymectacin			US	6245750	Anticancer, other	Cancer, colorectal
Thymol		89-83-8				
Thymopentin		69558-55-0				
Thymyl N-Isoamylcarbamate		578-20-1				
Thyropropic Acid		51-26-3				
Thyroxine		51-48-9				
Tiadenol		6964-20-1				
tiagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (R)- [CAS]	115103-54-3	WO	8700171	Antiepileptic	Epilepsy, general
Tiamenidine		31428-61-2				
tianeptine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]-, S,S-dioxide [CAS]	72797-41-2 66981-73-5	GB	1269551	Antidepressant	Depression, general
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB	1394563	Neuroleptic	
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl-Alpha-methyl- [CAS]	33005-95-7	GB	1331505	Antiarthritic, other	
Tiaramide		32527-55-2				
tiazofurin	4-Thiazolecarboxamide, 2-ß-D-ribofuranosyl- [CAS]	60084-10-8	EP	54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium		54663-47-7				
tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7Alpha,17Alpha)- [CAS]	5630-53-5	EP	389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin		34787-01-4				
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB	1554424	Antithrombotic	
Ticrynafen		40180-04-9				
tiemonium	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	6252-92-2 144-12-7			Antispasmodic	

NPC-UNIV-000004775

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 397 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tigecycline	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP	582829	Tetracycline	Infection, general
Tigemonam		102507-71-1				
Tigloidine		495-83-0				
Tilidine		20380-58-9				
Tilisolol		85136-71-6				
tilmacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO	9619463	Alimentary/Metabolic, other	Polyp
tiludronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis- [CAS]	89987-06-4	EP	100718	Osteoporosis treatment	Paget's disease
Timentin		86482-18-0			Antibiotic, other	Infection, general
timepidium	*Piperidinium*, 3-(di-2-thienylmethylene)-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB	1358446	Antispasmodic	
Timiperone		57648-21-2				
timolol	(-)-1-(t-butylamino)-3-[(4-morpholino-1,2,5-*thiadiazol*-3-yl)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB	1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacic		444-27-9				
Tin Ethyl Etiopurpurin		113471-15-1				
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US	3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8				
Tinoridine		24237-54-5				
Tiocarlide		910-86-1				
Tioclomarol		22619-35-8				
tioconazole	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	61675-64-7 65899-73-2	US	4062966	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US	3246025	Urological	Homocystinuria

NPC-UNIV-000004776

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 398 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tiotropium	3-Oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-, [CAS]	136310-93-5	EP	418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4991-65-5				
Tipepidine		5169-78-8				
tipifarnib	2(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO	9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-[1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4			Antiviral, anti-HIV	Infection, HIV/AIDS
tiquizium	2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, [CAS]	71731-58-3	US	4205074	Antispasmodic	
tirapazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE	2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tiratricol		51-24-1				
tirilazad	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2 110101-66-1	WO	8701706	*Neuroprotective*	*Haemorrhage, subarachnoid*
tirofiban	L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, [CAS]	142373-60-2 144494-65-5	EP	478363	Antithrombotic	Infarction, myocardial
tiropramide	Benzenepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+\-)- [CAS]	55837-29-1	DE	2503992	Antispasmodic	Muscle spasm, general
Titanium Sulfate		13825-74-6				
tixocortol	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11ß)- [CAS]	55560-96-8 61951-99-3	GB	1475795	Antiallergic, non-asthma, mucosal, topical	Rhinitis, allergic, general

NPC-UNIV-000004777

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 399 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB	1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	US	5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[[2-([bis[bis(2-chloroethyl)amino]phosphinyl]oxy)ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	US	5545621	Anticancer, other	Cancer, ovarian
TNF-ß analogue			RU	2035185	Anticancer, immunological	Cancer, general
TNP-470		129298-91-5				
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro-11ß,17,21-trihydroxy-16.beta.-methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1			Antipruritic/inflamm, allergic	
tobramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4)-2-deoxy- [CAS]	32986-56-4			Formulation, inhalable, topical	Infection, respiratory tract, general
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US	4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyl		5634-42-4				
tocladesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4			Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1				
Todralazine		14679-73-3				
Tofenacin		15301-93-6				
tofimilast	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-	185954-27-2			Antiasthma	Asthma
tofisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB	1334271	Anxiolytic	Anxiety, general
Tolazamid		1156-19-0				

NPC-UNIV-000004778

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 400 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Tolazolin		59-98-3				
Tolbutamide		64-77-7				
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP	237929	Antiparkinsonian	Parkinson's disease
tolciclate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3	GB	1364407	Antifungal	Infection, dermatological
Tolcyclamide		664-95-9				
tolevamer	Benzenesulfonic acid, 4-ethenyl-, homopolymer,	28038-50-8			Antibacterial, other	Infection, Clostridium, general
tolfenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	13710-19-5	DE	1543295	Anti-inflammatory	Inflammation, general
Tolindate		27877-51-6				
Toliprolol		2933-94-0				
Tolmetin		26171-23-3				
Tolnaftate		2398-96-1				
Tolonidine		4201-22-3				
Tolonium		92-31-9				
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB	1250538	Antidepressant	
Tolperisone		728-88-1				
Tolpropamine		5632-44-0				
Tolrestat		82964-04-3				
tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9			Cognition enhancer	Alzheimer's disease
tolterodine	Phenol, 2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP	325571	Urological	Incontinence
tolvaptan	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP	450097	Cardiovascular	Heart failure

NPC-UNIV-000004779

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 401 of 1101

Tabl IV

API G n ric Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Tolycaine		3686-58-6				
Topiramate	Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate [CAS]	97240-79-4	EP	533483	Antiepileptic	Epilepsy, generalized, tonic-clonic
topoisomerase inhibitors			US	5733880	Anticancer, other	Cancer, general
topotecan	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP	321122	Anticancer, other	Cancer, ovarian
torasemide	3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	US	4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl) benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0			Hypolipaemic/Antiatherosclerosis	Atherosclerosis
torcitabine	ß-L-2'Deoxycytidine				Antiviral, other	Infection, hepatitis-B virus
toremifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8	EP	95875	Anticancer, hormonal	Cancer, breast
Torsemide		56211-40-6				
Tositumomab		208921-02-2				
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US	4704459	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)-[CAS]	27203-92-5 36282-47-0			Analgesic, other	Pain, general
Tramazoline		1082-57-1				
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aAlpha,7aß]]- [CAS]	87679-71-8 87679-37-6 52-53-9	DE	3151690	Antihypertensive, renin system	Hypertension, general

NPC-UNIV-000004780

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 402 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US	3950405	Antifibrinolytic	Menstrual disorder, general
tranilast	Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US	3940422	Vulnerary	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4			Anticancer, other	Cancer, general
Tranylcypromine		155-09-9				
trapidil	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD	55956	Vasodilator, coronary	
Trastuzumab		180288-69-1				
travoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R(1Alpha(Z),2ß(1E,3R*),3Alpha,5Alpha) [CAS]	157283-68-6			Formulation, mucosal, topical	Glaucoma
Traxanox		58712-69-9				
traxoprodil	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-ß-methyl-4-phenyl-, (AlphaS,ßS)- [CAS]	134234-12-1 188591-67-5			Analgesic, other	Pain, general
trazodone	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- [CAS]	19794-93-5 25332-39-2	US	4215104	Antidepressant	
Tremacamra		155576-45-7				
Trenbolone		10161-33-8				
Trengestone		5192-84-7				
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)]- [CAS]	299-75-2	WO	8401506	Anticancer, alkylating	
trepibutone	Benzenebutanoic acid, 2,4,5-triethoxy-Gamma-oxo- [CAS]	41826-92-0	GB	1387733	Antispasmodic	
treprostinol	Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US	6054486	Formulation, parenteral, other	Hypertension, pulmonary
tretinoin	Retinoic acid [CAS]	302-79-4			Formulation, dermal, topical	Acne

NPC-UNIV-000004781

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 403 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
tretoquinol	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, (S)-[CAS]	18559-59-6 30418-38-3 21650-42-0	ZA	6802416	Antiasthma	
TRH		24305-27-9				
TRI-50b	TRI 50b [CAS]	226214-49-9			Antithrombotic	Thrombosis, general
Triacetin		102-76-1				
Triamcinolone Acetonide		76-25-5				
Triamcinolone Benetonide		31002-79-6				
Triamcinolone Hexacetonide		5611-51-8				
triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-*methylethylidene)bis(oxy)*]-, (11ß,16Alpha)-[CAS]	76-25-5 124-94-7			Formulation, inhalable, topical	Asthma
Triamterene		396-01-0				
triapine	Triapine [CAS]	236392-56-6	US	6458816	Anticancer, antimetabolite	Cancer, leukaemia, general
Triaziquone		68-76-8				
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US	3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4				
Trichlorfon		52-68-6				
Trichlormethiazide		133-67-5				
Trichlormethine		555-77-1				
Trichloroethylene		79-01-6				
Triclobisonium		79-90-3				
Triclocarban		101-20-2				
Triclofenol Piperazine		5714-82-9				
Triclofos		306-52-5				
Triclosan		3380-34-5				
Tricromyl		85-90-5				
Tridihexethyl Iodide		125-99-5				

NPC-UNIV-000004782

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 404 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
trientine	1,2-Ethanediamine, N,N2-bis(2aminoethyl)-, [CAS]	38260-01-4 112-24-3			Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6				
Triethylenemelamine		51-18-3				
Triethylenephosphoramide		545-55-1				
Triethylenethiophosphoramide		52-24-4				
Trifluoperazine		117-89-5				
Trifluperidol		749-13-3				
Triflupromazine		146-54-3				
trifluridine	Thymidine, Alpha,Alpha,Alpha-trifluoro- [CAS]	70-00-8	US	3201387	Antiviral, other	Infection, herpes virus, general
triflusal	Benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US	4096252	Antithrombotic	Thrombosis, general
Trihexyphenidyl		52-49-3				
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17ß)- [CAS]	13647-35-3	US	3296255	Anticancer, hormonal	Cancer, breast
Trimazosin		35795-16-5				
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5 39133-31-8	DE	2151716	Antispasmodic	
Trimecaine		616-68-2				
Trimeprazine		84-96-8				
Trimetazidine		5011-34-7				
Trimethadione		127-48-0				
Trimethaphan		68-91-7				
Trimethobenzamide		138-56-7				
Trimethoprim		738-70-5				
Trimetozine		635-41-6				
trimetrexate	2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]- [CAS]	52128-35-5 82952-64-5	US	4391809	Antifungal	Infection, Pneumocystis jiroveci

NPC-UNIV-000004783

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 405 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
trimipramine	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,ß-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9			Antidepressant	
Trimoprostil		69900-72-7				
Trioxsalen		3902-71-4				
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3aAlpha,4Alpha,7Alpha,7aAlpha)- [CAS]	73803-48-2	JP	7305585	Antihypertensive, diuretic	Hypertension, general
Triparanol		78-41-1				
Tripelennamine		91-81-6				
Triprolidine		486-12-4				
triptorelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan- [CAS]	124508-66-3 57773-63-4	US	4010125	Releasing hormones	Cancer, prostate
tritiozine	Morpholine, 4-[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US	3862138	Antiulcer	
Tritoqualine		14504-73-5				
TRK-530	Phosphonic acid, [[[4-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	151425-92-2	WO	9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propenamide, N-[(5Alpha,6ß)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO	9315081	Antipruritic/inflamm, non-allergic	Pruritus
Troclosene		2244-21-5				
trofosfamide	3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB	1188159	Anticancer, alkylating	
Troglitazone		97322-87-7				
Troleandomycin		2751-9-9				
Trolnitrate		588-42-1				
tromantadine	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE	1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1				

NPC-UNIV-000004784

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 406 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Tropacine		6878-98-4				
Tropesin		65189-78-8				
Tropicamide		1508-75-4				
tropine	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-)- [CAS]	65189-78-8			Antiarthritic, other	
tropisetron	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]	89565-68-4	GB	2125398	Antiemetic	Chemotherapy-induced nausea and vomiting
Trospectomycin		88669-04-9				
trospium	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] benzilate	10405-02-4			Urological	Pollakisuria
trovafloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1Alpha,5Alpha,6Alpha)-, [CAS]	147059-72-1 147059-75-4	US	5164402	Quinolone antibacterial	Infection, respiratory tract, general
troxacitabine	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-[CAS]	145918-75-8			Anticancer, other	Cancer, leukaemia, acute myelogenous
Troxerutin		7085-55-4				
troxipide	Benzamide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-)- [CAS]	30751-05-4 99777-81-8	US	3647805	Antiulcer	Ulcer, gastric
Trypan Red		574-64-1				
Tryparsamide		554-72-3				
Tryptophan		73-22-3				
TSH		9002-71-5				
TSN-09	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]- [CAS]	52485-79-7			Formulation, transdermal, patch	Pain, cancer
TU-2100	Nonanedioic acid, bis[(2-(ethoxycarbonyl)phenyl] ester		US	6180669	Antiacne	Acne

NPC-UNIV-000004785

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 407 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0				
Tubercidin		69-33-0				
Tubocurarine Chloride		57-94-3				
tulobuterol	Benzenemethanol, 2-chloro-Alpha-[[(1,1-dimethylethyl)amino]methyl]- [CAS]	41570-61-0	DE	2244737	Antiasthma	Asthma
TV-3326	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate				Cognition enhancer	Alzheimer's disease
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadiynyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2ß,3aAlpha,7aAlpha]]- [CAS]	140694-43-5	US	4837342	Antithrombotic	Unspecified
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate		US	6258829	Antiarrhythmic	Unspecified
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2			Formulation, modified-release, other	Angina, general
Tybamate		4268-36-4				
tyloxapol	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4			Formulation, inhalable, topical	Cystic fibrosis
Tymazoline		24243-97-8				
Tyramine		51-67-2				
Tyropanoate		7246-21-1				
Ubenimex		58970-76-6				
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, butyl ester [CAS]	67330-25-0	BE	861852	Antipruritic/inflamm, non-allergic	
Undecylenic Acid		112-38-9				
Unoprostone		120373-36-6				

NPC-UNIV-000004786

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 408 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl]benzenesulfonamide- [CAS]				Anti-inflammatory	Inflammation, general
Uracil Mustard		66-75-1				
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US	4400535	Urological	
urapidil	2,4(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB	1309324	Antihypertensive, adrenergic	Hypertension, general
urea	Urea [CAS]	57-13-6			Antipsoriasis	
Uredepa		302-49-8				
Urethan		51-79-6				
Uridine 5'-Triphosphate		63-39-8				
Urinastatin		80449-31-6				
ursodeoxycholic acid	3Alpha,7ß-dihydroxy-5ß-cholan-24-oic acid [CAS]	128-13-2			Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calcalus	Cirrhosis, primary biliary
Ursodiol		128-13-2				
Ushercell			US	6063773	Formulation, mucosal, topical	Contraceptive, female
Uzarin		20231-81-6				
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP	308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4				
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US	5859257	Antiarthritic, other	Arthritis, rheumatoid
Valdetamide		512-48-1				
Valethamate		90-22-2				
valganciclovir	L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8	EP	694547	Antiviral, other	Infection, cytomegalovirus
Valnoctamide		4171-13-5				

NPC-UNIV-000004787

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 409 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
valomaciclovir	L-Valine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl)-4-((1-oxooctadecyl)oxy)butyl ester [CAS]	195156-77-5			Antiviral, other	Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	76584-70-8 1069-66-5	US	4988731	Antiepileptic	Epilepsy, generalized, tonic-clonic
Valproic Acid		99-66-1				
Valpromide		2430-27-5				
valrocemide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92262-58-3	US	5585358	Antiepileptic	Epilepsy, general
valrubicin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl ester (2S-cis)- [CAS]	56124-62-0	US	4035566	Anticancer, antibiotic	Cancer, bladder
valsartan	L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- [CAS]	137862-53-4	EP	443983	Antihypertensive, renin system	Hypertension, general
Valspodar		121584-18-7				
vardenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl(-4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	224785-90-4			Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	172732-68-2 172733-42-5	EP	675110	Septic shock treatment	Sepsis
Varicella Virus Vaccine						
vatanidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester, [CAS]	116308-55-5 133743-71-2	EP	257616	Neuroprotective	Hypertension, general
VEA			US	6007817	Radio/chemosensitizer	Cancer, general

NPC-UNIV-000004788

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 410 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
vecuronium	Piperidinium, 1-[(2ß,3Alpha,5Alpha,16ß,17ß)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, [CAS]	50700-72-6	US	4237126	Muscle relaxant	Anaesthesia, adjunct
Velnacrine		104675-29-8				
venlafaxine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]	93413-69-5 99300-78-4	GB	2227743	Antidepressant	Depression, general
Veralipride		66644-81-3				
verapamil	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)- [CAS]	52-53-9			Formulation, modified-release, other	Hypertension, general
verteporfin	23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans- [CAS]	129497-78-5	US	5238940	Ophthalmological	Macular degeneration
vesnarinone	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- [CAS]	81840-15-5	GB	2086896	Cardiostimulant	Heart failure
Vetrabutine		3735-45-3				
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydroxy- [CAS]	95933-74-7	US	4623659	Cardiovascular	Reperfusion injury
VI-0134			US	6403597	Male sexual dysfunction	Premature ejaculation
vidarabine	9H-Purin-6-amine, 9-ß-D-arabinofuranosyl- [CAS]	24356-66-9 5536-17-4	GB	1159290	Antiviral, other	Infection, herpes virus, general
vigabatrin	5-Hexenoic acid, 4-amino- [CAS]	68506-86-5 60643-86-9	GB	1472525	Antiepileptic	Epilepsy, partial (focal, local)
vilazodone	2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]- [CAS]	163521-12-8	EP	648767	Antidepressant	Depression, general
Viloxazine		46817-91-8				
Viminol		21363-18-8				
Vinbarbital		125-44-0				
Vinblastine		865-21-4				
vinburnine	Eburnamenin-14(15H)-one, (3Alpha,16Alpha)- [CAS]	474-00-0 4880-88-0	DE	1932245	Cognition enhancer	

NPC-UNIV-000004789

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 411 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9				
Vinconate		70704-03-9				
vincristine	Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP	207831	Formulation, parenteral, other	Cancer, general
vindesine	Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB	1463575	Anticancer, other	Cancer, leukaemia, acute lymphocytic
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2ß,3ß,4ß,5Alpha,12ß,19Alpha) - [CAS]	162652-95-1	FR	2707988	Anticancer, other	Cancer, general
vinorelbine	C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP	10458	Anticancer, other	Cancer, lung, non-small cell
vinpocetine	Eburnamenine-14-carboxylic acid, ethyl ester, (3Alpha,16Alpha)- [CAS]	42971-09-5	GB	1405127	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3				
Vinylbital		2430-49-1				
Viquidil		84-55-9				
Viridin		3306-52-3				
Visnadine		477-32-7				
Vitamin A		68-26-8				
vitamin B12	Vitamin B12 [CAS]	68-19-9			Formulation, transmucosal, nasal	Anaemia, general
vitamin C	L-Ascorbic acid [CAS]	50-81-7			Formulation, modified-release, <=24hr	Nutrition
Vitamin D_2		50-14-6				
Vitamin D_3		67-97-0				
Vitamin K_5		83-70-5				
Vitamins, Prenatal						

NPC-UNIV-000004790

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 412 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenylyl)-methyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP	842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US	6040338	Anticancer, alkylating	Cancer, general
voglibose	D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	EP	56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-ß-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))- [CAS]	137234-62-9	EP	440372	Antifungal	Infection, fungal, general
Vorozole		129731-10-8				
VUF-K-8788	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one				Antiasthma	Asthma
Warfarin		81-81-2				
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2			Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, general
WMC-79	2-(3-[4-[3-(6-oxo-6H-2,10b-diaza-aceanthrenylen-5-ylamino)propyl]-piperazin-1-yl]propyl)-5-nitro-2-aza-phenalene-1,3-dione				Anticancer, other	Cancer, colorectal
wound healing matrix			US	5897880	Formulation, transdermal, patch	Ulcer, diabetic
WP-170			US	6531121	Cytokine	Unspecified
xaliproden	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, [CAS]	90494-79-4 135354-020-8	EP	101381	Neuroprotective	Amyotrophic lateral sclerosis
xamoterol	4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-, (+/-)- [CAS]	73210-73-8 81801-12-9	GB	2002748	Cardiostimulant	Heart failure

NPC-UNIV-000004791

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 413 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3				
Xanthinol Niacinate		437-74-1				
Xemilofiban		149820-74-6				
Xenbucin		959-10-4				
Xibenolol		81584-06-7				
xibornol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo- [CAS]	13741-18-9	GB	1206774	Antibacterial, other	Infection, general
ximelagatran	Glycine, N-((R)-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl ethyl ester [CAS]	192939-46-1			Antithrombotic	Thrombosis, venous
Ximoprofen		56187-89-4				
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US	3567777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8ß)- [CAS]	77287-89-9			Analgesic, other	Pain, cancer
XR-5118	2,5-Piperazinedione, 3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO	9532190	Anticancer, other	Cancer, general
XR-5944	N,N'-(1,2-Ethanediyl)bis(imino-2,1-ethanediyl)bis(9-methylphenazine-1-carboxamide)		EP	934278	Anticancer, other	Cancer, general
Xylometazoline		526-36-3				
Xylose		58-86-6				
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO	9605177	Antiulcer	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO	9305027	Anticancer, hormonal	Cancer, breast

NPC-UNIV-000004792

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 414 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamidate				Anticancer, other	Cancer, prostate
Yohimbine		146-48-5				
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	90596-75-1	US	5270304	Anti-inflammatory	Inflammation, general
Z-321	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]	130849-58-0	EP	372484	Cognition enhancer	Dementia, senile, general
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonyl]amino]methyl]-2,3-dihydro, monosodium salt) [CAS]	146731-14-8	JP	92506077	Antithrombotic	Peripheral vascular disease
zafirlukast	Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester [CAS]	107753-78-6	EP	199543	Antiasthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US	4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zaldaride		109826-26-8				
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP	776898	Hypnotic/Sedative	Insomnia
zaltoprofen	Dibenzo[b,f]thiepin-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP	55053282	Anti-inflammatory	
zanamivir	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO	9116320	Antiviral, other	Infection, influenza virus
zanapezil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP	487071	Cognition enhancer	Alzheimer's disease
Zatebradine		85175-67-3				
ZD-0473	Platinum, amminedichloro(2-methylpyridine)- (SP-4-3)- [CAS]	181630-15-9	EP	727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947			WO	9528388	Urological	Overactive bladder
ZD-6126	N-acetylcolchinol-O-phosphate				Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanoic acid, Alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB	2264946	Anticancer, antimetabolite	Cancer, pancreatic

NPC-UNIV-000004793

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 415 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
zebularine	2(1H)-Pyrimidinone, 1-ß-D-ribofuranosyl- [CAS]	3690-10-6			Anticancer, other	Cancer, general
zelandopam	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]	138086-00-7	JP	03190818	Vasodilator, renal	Hypertension, general
Zenarestat		112733-06-9				
Ziconotide		107452-89-1				
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US	4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
zileuton	Urea, N-(1-benzo[b]thien-2-ylethyl)-N-hydroxy- [CAS]	111406-87-2	EP	279263	Antiasthma	Asthma
Zimeldine		56775-88-3				
zinc acetate	hexakis(\m-acetato)-\m4-oxotetrazinc	12129-82-7			Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc acexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	70020-71-2	EP	369088	Antiulcer	Ulcer, duodenal
zinc ibuprofenate		78416-80-5			Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2				
Zinc Salicylate		16283-36-6				
Zinostatin		9014-2-2				
zinostatin stimalamer		123760-07-6	EP	136791	Anticancer, antibiotic	Cancer, liver
Zipeprol		34758-83-3				
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP	281309	Neuroleptic	Schizophrenia
zofenopril	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-,[1(R*),2Alpha,4Alpha]- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB	2028327	Antihypertensive, renin system	Hypertension, general
zofenopril + HCTZ	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-,[1(R*),2Alpha,4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]				Formulation, fixed-dose combinations	Hypertension, general
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8 165800-06-6	EP	531253	Osteoporosis treatment	Hypercalcaemia of malignancy

NPC-UNIV-000004794

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 416 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
zolimidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US	3318880	Antiulcer	Gastritis
zolmitriptan	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)- [CAS]	139264-17-8	WO	9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*,R*))-2,3-dihydroxybutanediotade (2:1) [CAS]	99294-93-6 82626-48-0	EP	50563	Hypnotic/Sedative	Insomnia
Zomepirac		33369-31-2				
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	210245-80-0			Neuroprotective	Ischaemia, cerebral
zoniporide	1H-pyrazole-4-carboxamide,N-(aminoimino methyl)-5-cyclopropyl-1-(5-quinolinyl)-,	249296-45-5			Cardiovascular	Unspecified
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB	2025931	Antiepileptic	Epilepsy, generalized, tonic-clonic
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB	1358680	Hypnotic/Sedative	Insomnia
Zopolrestat		110703-94-1				
Zorubicin		54083-22-6				
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cycloheptene-6-yl)-Alpha-[(5-quinolinyloxy)methyl]-, [6(R)-(1aAlpha,6Alpha,10bAlpha)]- [CAS]	167465-36-3			Radio/chemosensitizer	Cancer, leukaemia, acute myelogenous
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl- [CAS]	26615-21-4	GB	1247067	Neuroleptic	Schizophrenia
ZP-123			WO	0162775	Antiarrhythmic	Arrhythmia, general
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1			Anticancer, hormonal	Cancer, colorectal

NPC-UNIV-000004795

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 417 of 1101

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1 982-24-1 85721-05-7 64053-00-5	EP	270282	Neuroleptic	Psychosis, general

NPC-UNIV-000004796

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 418 of 1101

CLAIMS:

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.

2. The pharmaceutical co-crystal composition according to claim 1, wherein:

(a) the co-crystal former is selected from a co-crystal former of Table I or Table II;

(b) the API is selected from an API of Table IV;

(c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) the API is a liquid at room temperature;

(e) the API is a solid at room temperature;

(f) the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) the co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(h) the difference in pK_a between the API and the co-crystal former does not exceed 2;

(i) the solubility of the co-crystal is increased as compared to the API;

(j) the dose response of the co-crystal is increased as compared to the API;

(k) the dissolution of the co-crystal is increased as compared to the API;

(l) the bioavailability of the co-crystal is increased as compared to the API;

(m) the stability of the co-crystal is increased as compared to the API;

(n) a difficult to salt or unsaltable API is incorporated into the co-crystal;

(o) the hygroscopicity of the co-crystal is decreased as compared to the API;

(p) an amorphous API is crystallized as a component of the co-crystal;

(q) the form diversity of the co-crystal is decreased as compared to the API; or

(r) the morphology of the co-crystal is modulated as compared to the API.

3. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule; wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

4. The pharmaceutical co-crystal composition according to claim 3, wherein:

(a) the co-crystal former is selected from a co-crystal former of Table I or Table II;

(b) the API is selected from an API of Table IV;

(c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) the API is a liquid at room temperature;

(e) the API is a solid at room temperature;

(f) the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone,

thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) the co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or

(h) the difference in pK_a between the API and the co-crystal former does not exceed 2;

(i) the solubility of the co-crystal is increased as compared to the API;

(j) the dose response of the co-crystal is increased as compared to the API;

(k) the dissolution of the co-crystal is increased as compared to the API;

(l) the bioavailability of the co-crystal is increased as compared to the API;

(m) the stability of the co-crystal is increased as compared to the API;

(n) a difficult to salt or unsaltable API is incorporated into the co-crystal;

(o) the hygroscopicity of the co-crystal is decreased as compared to the API;

(p) an amorphous API is crystallized as a component of the co-crystal;

(q) the form diversity of the co-crystal is decreased as compared to the API; or

(r) the morphology of the co-crystal is modulated as compared to the API.

5. A pharmaceutical co-crystal composition, comprising: a first and a second API, wherein each API is either a liquid or a solid at room temperature, and wherein the APIs are hydrogen bonded to a molecule.

6. The pharmaceutical co-crystal composition according to claim 5, wherein:

(a) the first API is hydrogen bonded to the second API;

(b) an API is selected from an API of Table IV;

(c) each API is selected from an API of Table IV;

(d) an API is a liquid at room temperature and the other API is a solid at room temperature;

(e) each API is a solid at room temperature;

(f) an API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) each API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(h) the difference in pK_a between the first API and the second API does not exceed 2;

(i) the solubility of the co-crystal is increased as compared to the API;

(j) the dose response of the co-crystal is increased as compared to the API;

(k) the dissolution of the co-crystal is increased as compared to the API;

(l) the bioavailability of the co-crystal is increased as compared to the API;

(m) the stability of the co-crystal is increased as compared to the API;

(n) a difficult to salt or unsaltable API is incorporated into the co-crystal;

(o) the hygroscopicity of the co-crystal is decreased as compared to the API;

(p) an amorphous API is crystallized as a component of the co-crystal;

(q) the form diversity of the co-crystal is decreased as compared to the API; or

(r) the morphology of the co-crystal is modulated as compared to the API.

7. A pharmaceutical co-crystal composition, comprising: a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature, and wherein both co-crystal formers are hydrogen bonded to a molecule.

8. The pharmaceutical co-crystal composition according to claim 7, wherein:

(a) the first co-crystal former is hydrogen bonded to the second co-crystal former;

(b) a co-crystal former is selected from a co-crystal former of Table I or Table II;

(c) each co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) a co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(e) each co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(f) the difference in pK_a between the first co-crystal former and the second co-crystal former does not exceed 2;

(g) the solubility of the co-crystal is increased as compared to the API;

(h) the dose response of the co-crystal is increased as compared to the API;

(i) the dissolution of the co-crystal is increased as compared to the API;

(j) the bioavailability of the co-crystal is increased as compared to the API;

(k) the stability of the co-crystal is increased as compared to the API;

(l) a difficult to salt or unsaltable API is incorporated into the co-crystal;

(m) the hygroscopicity of the co-crystal is decreased as compared to the API;

(n) an amorphous API is crystallized as a component of the co-crystal;

(o) the form diversity of the co-crystal is decreased as compared to the API; or

(p) the morphology of the co-crystal is modulated as compared to the API.

9. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.

10. The pharmaceutical co-crystal composition according to claim 1, further comprising a pharmaceutically acceptable diluent, excipient, or carrier.

11. A co-crystal comprising an API and a co-crystal former selected from:

(a) carbamazepine and saccharin;

(b) carbamazepine and nicotinamide;

(c) carbamazepine and trimesic acid;

(d) celecoxib and nicotinamide;

(e) olanzapine and nicotinamide;

(f) celecoxib and 18-crown-6;

(g) itraconazole and succinic acid;

(h) itraconazole and fumaric acid;

(i) itraconazole and tartaric acid;

(j) itraconazole and malic acid;

(k) itraconazoleHCl and tartaric acid;

(l) modafinil and malonic acid;

(m) modafinil and benzamide;

(n) modafinil and mandelic acid;

(o) modafinil and glycolic acid;

(p) modafinil and fumaric acid;

(q) modafinil and maleic acid;

(r) topiramate and 18-crown-6;

(s) 5-fluorouracil and urea;

(t) hydrochlorothiazide and nicotinic acid;

(u) hydrochlorothiazide and 18-crown-6;

(v) hydrochlorothiazide and piperazine;

(w) acetaminophen and 4,4'-bipyridine;

(x) phenytoin and pyridone;

(y) aspirin and 4,4'-bipyridine;

(z) ibuprofen and 4,4'-bipyridine;

(aa) flurbiprofen and 4,4'-bipyridine;

(bb) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;

(cc) carbamazepine and p-phthalaldehyde;

(dd) carbamazepine and 2,6-pyridinecarboxylic acid;

(ee) carbamazepine and 5-nitroisophthalic acid;

(ff) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or

(gg) carbamazepine and benzoquinone.

12. A process for preparing a pharmaceutical co-crystal composition comprising an API and a co-crystal former, comprising:

(a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;

(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and co-crystal former are hydrogen bonded to each other;

(c) isolating co-crystals formed thereby; and

(d) incorporating the co-crystals into a pharmaceutical composition.

13. The process of claim 12, wherein:

(a) the co-crystal former is selected from a co-crystal former of Table I or Table II;

(b) the API is selected from an API of Table IV;

(c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) the API is a liquid at room temperature;

(e) the API is a solid at room temperature;

(f) the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) the co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester,

NPC-UNIV-000004804

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 426 of 1101

ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or

(h) the difference in pK_a between the API and the co-crystal former does not exceed 2.

14. A process for preparing a pharmaceutical co-crystal composition comprising an API, a co-crystal former, and a third molecule, comprising:

(a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;

(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other;

(c) isolating co-crystals formed thereby; and

(d) incorporating the co-crystals into a pharmaceutical composition.

15. The process of claim 14, wherein:

(a) the co-crystal former is selected from a co-crystal former of Table I or Table II;

(b) the API is selected from an API of Table IV;

(c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) the API is a liquid at room temperature;

(e) the API is a solid at room temperature;

(f) the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic

acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) the co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or

(h) the difference in pK_a between the API and the co-crystal former does not exceed 2.

16. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second API, comprising:

(a) providing a first and a second API, wherein each API is either a liquid or a solid at room temperature;

(b) grinding, heating, or contacting in solution the APIs under crystallization conditions, so as to form a solid phase, wherein the APIs are hydrogen bonded to a molecule;

(c) isolating co-crystals formed thereby; and

(d) incorporating the co-crystals into a pharmaceutical composition.

17. The process of claim 16, wherein:

(a) the first API is hydrogen bonded to the second API;

(b) an API is selected from an API of Table IV;

(c) each API is selected from an API of Table IV;

(d) an API is a liquid at room temperature and the other API is a solid at room temperature;

(e) each API is a solid at room temperature;

(f) an API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(g) each API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or

(h) the difference in pK_a between the first API and the second API does not exceed 2.

18. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second co-crystal former, comprising:

(a) providing a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature;

(b) grinding, heating, or contacting in solution the co-crystal formers under crystallization conditions, so as to form a solid phase, wherein both co-crystal formers are hydrogen bonded to a molecule;

(c) isolating co-crystals formed thereby; and

(d) incorporating the co-crystals into a pharmaceutical composition.

19. The process of claim 18, wherein:

(a) the first co-crystal former is hydrogen bonded to the second co-crystal former;

NPC-UNIV-000004807

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 429 of 1101

(b) a co-crystal former is selected from a co-crystal former of Table I or Table II;

(c) each co-crystal former is selected from a co-crystal former of Table I or Table II;

(d) a co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(e) each co-crystal former has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or

(f) the difference in pK_a between the first co-crystal former and the second co-crystal former does not exceed 2.

20. The process of claim 12, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.

21. The process of claim 12, further comprising: incorporating a pharmaceutically acceptable diluent, excipient, or carrier.

22. A process of preparing a co-crystal comprising an API and a co-crystal former, comprising:

(a) providing an API and a co-crystal former;

(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase; and

(c) isolating co-crystals formed thereby;

wherein the API and the co-crystal former are selected from carbamazepine and saccharin, carbamazepine and nicotinamide, carbamazepine and trimesic acid, celecoxib and nicotinamide, olanzapine and nicotinamide, celecoxib and 18-crown-6, itraconazole and succinic acid, itraconazole and fumaric acid, itraconazole and tartaric acid, itraconazole and malic acid, itraconazoleHCl and tartaric acid, modafinil and malonic acid, modafinil and benzamide, modafinil and mandelic acid, modafinil and glycolic acid, modafinil and fumaric acid, modafinil and maleic acid, topiramate and 18-crown-6, 5-fluorouracil and urea, hydrochlorothiazide and nicotinic acid, hydrochlorothiazide and 18-crown-6, hydrochlorothiazide and piperazine, acetaminophen and 4,4'-bipyridine, phenytoin and pyridone, aspirin and 4,4'-bipyridine, ibuprofen and 4,4'-bipyridine, flurbiprofen and 4,4'-bipyridine, flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene, carbamazepine and p-phthalaldehyde, carbamazepine and 2,6-pyridinecarboxylic acid, carbamazepine and 5-nitroisophthalic acid, carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, or carbamazepine and benzoquinone.

23. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has a modulated solubility as compared to the API; and

(c) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

24. The process of claim 23, wherein the solubility of the co-crystal is increased as compared to the API.

25. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has a modulated dose response as compared to the API; and

(c) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

26. The process of claim 25, wherein the dose response of the co-crystal is increased as compared to the API.

27. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has a modulated dissolution as compared to the API; and

(c) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.

28. The process of claim 27, wherein the dissolution of the co-crystal is increased as compared to the API.

29. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has a modulated bioavailability as compared to the API; and

(c) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.

30. The process of claim 29, wherein the bioavailability of the co-crystal is increased as compared to the API.

31. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and

(c) incorporating the co-crystal having increased stability into a pharmaceutical composition.

32. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal;

(c) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.

33. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and

(c) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.

34. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal;

(c) incorporating the co-crystal into a pharmaceutical composition.

35. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has decreased form diversity as compared to the API; and

(c) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

36. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(b) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and

(c) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

37. The co-crystal of claim 1, specifically excluding a co-crystal selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid,

theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamidine:maleic acid, diglycine hydrochloride ($C_2H_5NO_2$:$C_2H_6NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-ylium)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine) succinate:succinic acid, bis(p-cyanophenyl)imidazolylmethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI_3, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid, barbital:N'-(p-cyanophenyl)-N-(p-iodophenyl)melamine, barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(p-chlorophenyl)melamine, N,N'-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(p-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(p-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-chlorophenyl)melamine, N,N'-Bis(m-methylphenyl)melamine:barbital, N,N'-bis(m-

chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(t-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(t-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-t-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(m-fluorophenyl)melamine:barbital, N,N'-bis(m-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(m-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF_3CSO_3, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid, 4,4'-bipyridyl:tricaballylic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N^{ε}-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid, isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester, isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid, isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid, isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline: 1,3,5-cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid, pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid, pyrazine:octanoic acid, pyrazine:nonanoic acid,

pyrazine:decanoic acid, diammine-(deoxy-quanyl-quanyl-N^7,N^7)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-phenylenediacetic acid, bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid, 2-aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic acid, 2-aminopyrimidine:thiophen-2-carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid, 2,4,6-Trinitrobenzoic acid: 2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic acid, 2-hexeneoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic acid:4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid, oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N',N'-dimethylhydrazino)-4-thiazolylmethylthio]-N^2-sulfamoylpropionamidine:maleic acid, 5-fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{[4-(1-imidazolylmethyl)cyclohexyl]methyl}imidazole:succinic acid, CGS18320B:succinic acid, sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-dinitrobenzoic acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid, isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid, benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol, betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic

NPC-UNIV-000004815

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 437 of 1101

acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.

NPC-UNIV-000004816

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 438 of 1101

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

NPC-UNIV-000004817
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 439 of 1101



Intensity(Counts)
6000
5000
4000
3000
2000
1000
0
Theta(°)
5
10
15
20
25
30
35
2T=4.990
2T=7.010
2T=8.650
2T=10.611
2T=12.070
2T=13.210
2T=14.090
2T=15.410
2T=18.470
2T=20.130
2T=21.230
2T=22.010
2T=22.731
2T=23.570
2T=24.410
2T=26.050
2T=28.310
2T=29.270
2T=31.010
2T=32.670
2T=34.270
2T=35.490
2T=36.730
2T=38.451

FIG. 1




FIG. 2

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 441 of 1101



Intensity(Counts)
7500
5000
2500
0
5
10
15
20
25
30
35
Theta(°)
2T=4.970
2T=6.670
2T=8.750
2T=10.250
2T=12.249
2T=13.250
2T=14.330
2T=14.949
2T=15.649
2T=16.750
2T=17.910
2T=18.490
2T=19.950
2T=20.490
2T=21.790
2T=22.731
2T=23.310
2T=24.390
2T=25.410
2T=26.490
2T=28.190
2T=29.210
2T=30.069
2T=30.630
2T=30.930
2T=31.951
2T=32.529
2T=33.310
2T=34.870
2T=35.430
2T=37.810
2T=38.490

FIG. 3




FIG. 4

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 443 of 1101



Intensity(Counts)
0
100
200
300
400
500
2-Theta(°)
5
10
15
20
25
30
35
2T=5.009
2T=7.250
2T=8.433
2T=10.890
2T=12.230
2T=13.872
2T=14.828
2T=16.248
2T=16.790
2T=17.050
2T=18.130
2T=18.469
2T=18.829
2T=19.395
2T=20.427
2T=21.470
2T=21.951
2T=22.531
2T=24.569
2T=25.110
2T=26.050
2T=26.470
2T=26.831
2T=27.408
2T=27.991
2T=29.450
2T=30.729
2T=37.708

FIG. 5



Intensity(Counts)
3000
2500
2000
1500
1000
500
0
5
10
15
20
25
30
35
2-Theta(°)
2T=10.790
2T=11.069
2T=12.167
2T=12.650
2T=13.827
2T=16.129
2T=18.028
2T=18.509
2T=19.210
2T=20.870
2T=21.430
2T=21.830
2T=22.250
2T=22.707
2T=24.112
2T=28.110

FIG. 6




FIG. 7

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 446 of 1101



Intensity(Counts)
0
100
200
300
400
500
600
2-Theta(°)
5
10
15
20
25
30
35
2T=4.890
2T=8.650
2T=12.510
2T=14.190
2T=15.590
2T=17.150
2T=19.710
2T=21.049
2T=21.491
2T=22.251
2T=23.950
2T=24.590
2T=25.530
2T=26.710
2T=27.790
2T=28.410
2T=29.690
2T=34.589

FIG. 8




FIG. 9

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 448 of 1101



Intensity(Counts)
0
50
100
150
200
250
300
350
2-Theta(°)
5
10
15
20
25
30
35
2T=8.730
2T=11.891
2T=12.570
2T=13.130
2T=15.008
2T=16.369
2T=17.027
2T=17.749
2T=18.450
2T=19.451
2T=20.329
2T=20.750
2T=22.370
2T=23.110
2T=24.329
2T=24.970
2T=26.609
2T=28.150

FIG. 10




FIG. 11

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 450 of 1101



Intensity(Counts)
0
500
1000
1500
2-Theta(°)
5
10
15
20
25
30
35
40
2T=3.010
2T=6.011
2T=8.130
2T=9.050
2T=12.910
2T=15.870
2T=16.170
2T=17.290
2T=18.030
2T=19.029
2T=19.470
2T=20.410
2T=21.670
2T=22.270
2T=23.330
2T=23.689
2T=24.470
2T=25.030
2T=25.830
2T=26.649
2T=27.450
2T=27.710
2T=28.750
2T=30.808
2T=31.289
2T=32.547
2T=36.490

FIG. 12




FIG. 13

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 452 of 1101



Intensity(Counts)
1000
750
500
250
0
2-Theta(°)
0
5
10
15
20
25
30
35
40
2T=4.609
2T=5.890
2T=9.230
2T=10.570
2T=13.930
2T=14.544
2T=15.171
2T=15.511
2T=16.230
2T=16.931
2T=17.750
2T=19.050
2T=19.690
2T=20.790
2T=21.329
2T=22.010
2T=22.950
2T=23.388
2T=24.070
2T=25.150
2T=25.510
2T=27.230
2T=28.450
2T=29.350
2T=29.749
2T=32.471

FIG. 14



DSC
179.58°C
Heat Flow (W/g)
Temperature (°C)
Exo Up
2
0
-2
-4
-6
0
50
100
150
200
250
300

FIG. 15



Intensity(%)
2-Theta(°)
2T=4.130
2T=6.190
2T=8.490
2T=11.749
2T=12.368
2T=16.130
2T=17.230
2T=18.070
2T=19.130
2T=20.789
2T=21.710
2T=22.850
2T=23.969
2T=24.749
2T=26.170

FIG. 16



DSC
177.83°C
78.53J/g
180.74°C
Heat Flow (W/g)
Temperature (°C)
Exo Up
0
-1
-2
-3
-4
-5
0
50
100
150
200
250
300

FIG. 17



Intensity(%)
2-Theta(°)
2T=4.430
2T=6.070
2T=8.850
2T=11.330
2T=12.112
2T=12.590
2T=13.449
2T=14.589
2T=15.930
2T=17.050
2T=17.629
2T=19.171
2T=19.570
2T=20.490
2T=21.270
2T=22.849
2T=23.169
2T=24.611
2T=25.291
2T=26.171
2T=27.590
2T=30.250

FIG. 18




FIG. 19

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 458 of 1101



I(%)
80
0
5
10
15
20
25
30
35
Theta(°)
2T=3.729
2T=10.950
2T=12.350
2T=13.830
2T=14.191
2T=15.470
2T=16.529
2T=17.150
2T=17.750
2T=18.991
2T=19.649
2T=20.392
2T=21.110
2T=22.110
2T=23.950
2T=24.850
2T=26.750
2T=27.650
2T=34.471

FIG. 20



DSC
Heat Flow (W/g)
Exo Up
Temperature (°C)
167.87°C
161.80°C
1
0
-1
-2
-3
0
50
100
150
200
250
300

FIG. 21



Lin (Counts)
0
10
20
30
40
50
60
70
80
90
3
10
20
30
2-Theta - Scale
2T-5.003°, d-17.64
2T-9.169°, d-9.637
2T-10.079°, d-8.769
2T-16.808°, d-5.270
2T-18.258°, d-4.855
2T-19.430°, d-4.565
2T-21.356°, d-4.157
2T-21.944°, d-4.047
2T-22.773°, d-3.902
2T-23.403°, d-3.798
2T-24.490°, d-3.632
2T-25.001°, d-3.559
2T-25.629°, d-3.473
2T-26.372°, d-3.377
2T-28.453°, d-3.134
2T-33.901°, d-2.642

FIG. 22



Intensity(Counts)
0
500
1000
1500
2-Theta(°)
5
10
15
20
25
30
35
2T=5.111
2T=9.349
2T=10.251
2T=10.790
2T=14.073
2T=16.869
2T=18.330
2T=19.530
2T=21.375
2T=22.050
2T=22.890
2T=23.571
2T=24.729
2T=25.190
2T=25.811
2T=26.510
2T=28.589
2T=31.090
2T=34.052
2T=37.209

FIG. 23




FIG. 24

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 463 of 1101



Intensity(Counts)
0
100
200
300
400
500
5
10
15
20
25
30
35
2-Theta(°)
2T=4.069
2T=6.088
2T=9.511
2T=11.831
2T=14.911
2T=15.970
2T=19.012
2T=20.030
2T=21.591
2T=22.432
2T=22.750
2T=23.751
2T=25.030
2T=25.710
2T=27.330
2T=28.849
2T=29.310
2T=30.430
2T=34.891

FIG. 25



Intensity(Counts)
1250
1000
750
500
250
0
5
10
15
20
25
30
35
2-Theta(°)
2T=5.870
2T=7.189
2T=8.951
2T=10.411
2T=12.490
2T=13.991
2T=16.130
2T=17.090
2T=18.189
2T=19.991
2T=21.568
2T=23.481
2T=25.011
2T=25.791
2T=28.172
2T=28.872
2T=29.691
2T=32.185
2T=35.569

FIG. 26





FIG. 27

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 466 of 1101



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase) (Rectangle)
l-Malate (Inverted triangle)
l-Tartrate (Oval)
Succinate (Triangle)
Crystalline Freebase (Diamond)

FIG. 28

NPC-UNIV-000004845
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 467 of 1101




FIG. 29

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 468 of 1101



Intensity(Counts)
3500
3000
2500
2000
1500
1000
500
0
5
10
15
20
25
30
35
2-Theta(°)
2T=6.411
2T=9.550
2T=12.850
2T=14.231
2T=14.910
2T=15.350
2T=16.310
2T=16.728
2T=17.591
2T=18.091
2T=18.670
2T=19.310
2T=19.810
2T=20.330
2T=21.850
2T=23.230
2T=23.890
2T=24.370
2T=25.950
2T=26.890
2T=27.589
2T=28.670
2T=30.109
2T=31.890
2T=32.790
2T=34.631
2T=37.930
2T=38.549
2T=39.231

FIG. 30



Intensity(Counts)
3000
2500
2000
1500
1000
500
0
5
10
15
20
25
30
35
2-Theta(°)
2T=6.411
2T=9.550
2T=12.850
2T=14.231
2T=14.910
2T=15.350
2T=16.310
2T=16.728
2T=17.591
2T=18.091
2T=18.670
2T=19.310
2T=19.810
2T=20.330
2T=21.850
2T=23.230
2T=23.890
2T=24.370
2T=25.950
2T=26.890
2T=27.589
2T=28.670
2T=30.109
2T=31.890
2T=32.790
2T=34.631
2T=37.930
2T=38.549
2T=39.231

FIG. 31

FIG. 32A

FIG. 32B




FIG. 32C




FIG. 32D

NPC-UNIV-00

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 473 of 1101



DSC
234 .91 °C
259 .86 °C
207 .60 °C
Heat Flow (W/g)
Exo Up
Temperature (°C)
5
0
-5
-10
-15
-20
0
50
100
150
200
250
300

FIG. 33



TGA
32.17 %
(0.7838 mg)
Weight (%)
120
100
80
60
40
20
0
-20
0
50
100
150
200
250
300
Temperature (°C)

FIG. 34



Int
70000
65000
60000
55000
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
-0
1500
1000
500
Raman shift (cm-1)
1680.10
1522.41
1440.42
1347.08
1261.49
1225.05
1024.43
818.70
756.89
643.67
610.13
545.34
471.61
413.47
369.08
132.85

FIG. 35



Intensity(Counts)
2-Theta(°)
2T=11.230
2T=12.691
2T=13.270
2T=15.931
2T=16.930
2T=17.930
2T=19.891
2T=20.370
2T=23.650
2T=24.590
2T=25.550
2T=26.869
2T=27.289
2T=29.231
2T=29.670
2T=30.170
2T=31.410
2T=32.120
2T=32.490
2T=33.071
2T=34.250
2T=34.710
2T=36.410
2T=38.430

FIG. 36



Intensity(Counts)
0
100
200
300
400
500
5
10
15
20
25
30
35
2-Theta(°)
2T=8.570
2T=12.733
2T=13.229
2T=14.310
2T=15.390
2T=16.271
2T=17.891
2T=18.750
2T=20.411
2T=21.130
2T=21.450
2T=22.810
2T=23.920
2T=24.409
2T=25.730
2T=26.570
2T=27.429
2T=28.490
2T=30.130
2T=32.968
2T=33.610
2T=35.430
2T=37.650

FIG. 37



Intensity(Counts)
0
100
200
300
400
500
5
10
15
20
25
30
35
2-Theta(°)
2T=9.969
2T=10.431
2T=11.670
2T=12.831
2T=14.530
2T=14.951
2T=15.670
2T=16.610
2T=19.050
2T=19.550
2T=20.310
2T=20.650
2T=21.090
2T=21.851
2T=22.450
2T=23.630
2T=24.209
2T=25.331
2T=25.810
2T=26.730
2T=27.288
2T=27.838
2T=28.531
2T=29.270

FIG. 38



Intensity(Counts)
2-Theta(°)
2T=6.850
2T=10.150
2T=15.191
2T=15.931
2T=18.171
2T=18.710
2T=19.689
2T=20.271
2T=20.671
2T=22.691
2T=23.271
2T=24.189
2T=24.569
2T=25.270
2T=27.750
2T=28.329
2T=28.870
2T=29.811
2T=30.890
2T=31.391
2T=32.890
2T=33.311
2T=34.450
2T=36.171
2T=36.850
2T=37.651

FIG. 39




FIG. 40

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 481 of 1101




FIG. 41

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 482 of 1101



Raman intensity
45000
40000
35000
30000
25000
20000
15000
10000
5000
3000
2500
2000
1500
1000
500
Raman shift (cm-1)

FIG. 42A

FIND PEAKS:
Spectrum: MO-157-72C_Modafinil-Malonic
Region: 3432 200
Absolute threshold: 586.428
Sensitivity: 66
Peak list:

Position:	1004	Intensity:	48530.113
Position:	222	Intensity:	41931.176
Position:	633	Intensity:	30431.455
Position:	265	Intensity:	27932.348
Position:	1032	Intensity:	25424.109
Position:	1183	Intensity:	23455.441
Position:	814	Intensity:	21886.129
Position:	1601	Intensity:	20374.211
Position:	490	Intensity:	18917.469
Position:	718	Intensity:	18779.322
Position:	767	Intensity:	16891.541
Position:	361	Intensity:	15080.872
Position:	917	Intensity:	12851.293
Position:	1104	Intensity:	11706.740
Position:	889	Intensity:	11172.833
Position:	412	Intensity:	11137.415
Position:	1225	Intensity:	9027.109
Position:	1251	Intensity:	8644.633
Position:	1398	Intensity:	8252.702
Position:	1442	Intensity:	6738.894
Position:	1731	Intensity:	5730.559
Position:	1298	Intensity:	5700.056
Position:	3065	Intensity:	1935.514
Position:	2949	Intensity:	1912.835

FIG. 42B

NPC-UNIV-000004862
NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 484 of 1101



[MO-157-72G_Modafinil-Maleic.txt]
Intensity(Counts)
2 Theta (°)
d=18.8259/2T=4.690
d=14.3587/2T=6.150
d=9.1950/2T=9.611
d=8.6393/2T=10.231
d=7.1727/2T=12.330
d=5.6574/2T=15.651
d=5.3587/2T=16.529
d=5.1539/2T=17.191
d=4.9212/2T=18.010
d=4.6022/2T=19.220
d=4.4425/2T=19.970
d=4.3183/2T=20.550
d=4.0680/2T=21.830
d=3.9571/2T=22.450
d=3.6790/2T=24.171
d=3.5050/2T=25.390
d=3.4701/2T=25.650
d=3.2258/2T=27.630
d=3.0488/2T=29.269
d=2.8386/2T=31.490
d=2.7372/2T=32.689

FIG. 43




Figure 44A




Figure 44B




Figure 45A




Figure 45B




Figure 46A




Figure 46C




Figure 46B




Figure 46D

Figure 47A





Figure 47C






Figure 47B




Figure 47D

Figure 48A





Figure 48C






Figure 48B




Figure 48D




Figure 49A




Figure 49B

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 492 of 1101




Figure 50A




Figure 50B




Figure 51




Figure 52




Figure 53A




Figure 53B




Figure 53C




Figure 54A




Figure 54B




Figure 55A




Figure 55B

NPC-UNIV-




Figure 56A




Figure 56B




Figure 57A




Figure 57B




Figure 58A




Figure 58B



Intensity(Counts)
x10^3
100
75
50
25
2-Theta(°)
5
10
15
20
25
30
35
40
2T=3.773
2T=7.563
2T=9.629
2T=14.760
2T=15.207
2T=16.014
2T=17.779
2T=18.677
2T=19.306
2T=20.435
2T=21.194
2T=22.099
2T=23.396
2T=23.804
2T=24.703
2T=25.295
2T=26.321
2T=26.727
2T=29.517
2T=30.100

FIG. 59



DSC
129.68°C
Heat Flow (W/g)
Temperature (°C)
Exo Up
0
-2
-4
-6
-8
0
50
100
150
200
250
300

FIG. 60




FIG. 61

NOVARTIS EXHIBIT 1023
Novartis v. Regents, IPR2023-01346
Page 503 of 1101





Raman intensity
65000
60000
55000
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
-0
1500
1000
500
Raman shift (cm-1)
1612.52
1598.74
1452.05
1370.29
1162.52
1044.32
972.92
796.38
631.84
392.51
205.90
121.53

FIG. 62


1. One-dimentional (linear) hydrogen-bonded chains:



2. Isolated rings:



3. Extended Networks:



4. Isolated triads:




FIG. 63